id	sid	tid	token	lemma	pos
gsrj-11	1	1	evaluating	evaluate	VERB
gsrj-11	1	2	the	the	DET
gsrj-11	1	3	efficacy	efficacy	NOUN
gsrj-11	1	4	of	of	ADP
gsrj-11	1	5	targeted	target	VERB
gsrj-11	1	6	inhibitor	inhibitor	NOUN
gsrj-11	1	7	therapeutics	therapeutic	NOUN
gsrj-11	1	8	for	for	ADP
gsrj-11	1	9	sonic	sonic	ADJ
gsrj-11	1	10	hedgehog	hedgehog	ADJ
gsrj-11	1	11	medulloblastoma	medulloblastoma	NOUN
gsrj-11	1	12	:	:	PUNCT
gsrj-11	1	13	significant	significant	ADJ
gsrj-11	1	14	milestones	milestone	NOUN
gsrj-11	1	15	and	and	CCONJ
gsrj-11	1	16	current	current	ADJ
gsrj-11	1	17	limitations	limitation	NOUN
gsrj-11	1	18	maria	maria	PROPN
gsrj-11	1	19	victoria	victoria	PROPN
gsrj-11	1	20	dias	dias	PROPN
gsrj-11	1	21	,	,	PUNCT
gsrj-11	1	22	bridgitte	bridgitte	NOUN
gsrj-11	1	23	isom	isom	NOUN
gsrj-11	1	24	,	,	PUNCT
gsrj-11	1	25	katherine	katherine	PROPN
gsrj-11	1	26	poole	poole	PROPN
gsrj-11	1	27	,	,	PUNCT
gsrj-11	1	28	sofia	sofia	PROPN
gsrj-11	1	29	triplett	triplett	PROPN
gsrj-11	1	30	,	,	PUNCT
gsrj-11	1	31	nadia	nadia	PROPN
gsrj-11	1	32	sadanandan	sadanandan	PROPN
gsrj-11	1	33	volume	volume	PROPN
gsrj-11	1	34	one	one	NUM
gsrj-11	1	35	edition	edition	NOUN
gsrj-11	1	36	one	one	NUM
gsrj-11	1	37	february	february	PROPN
gsrj-11	1	38	2021	2021	NUM
gsrj-11	1	39	georgetown	georgetown	PROPN
gsrj-11	1	40	scientific	scientific	PROPN
gsrj-11	1	41	research	research	PROPN
gsrj-11	1	42	journal	journal	PROPN
gsrj-11	1	43	84	84	NUM
gsrj-11	1	44	georgetown	georgetown	PROPN
gsrj-11	1	45	scientific	scientific	PROPN
gsrj-11	1	46	research	research	PROPN
gsrj-11	1	47	journal	journal	NOUN
gsrj-11	1	48	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	NOUN
gsrj-11	1	49	evaluating	evaluate	VERB
gsrj-11	1	50	the	the	DET
gsrj-11	1	51	efficacy	efficacy	NOUN
gsrj-11	1	52	of	of	ADP
gsrj-11	1	53	targeted	target	VERB
gsrj-11	1	54	inhibitor	inhibitor	NOUN
gsrj-11	1	55	therapeutics	therapeutic	NOUN
gsrj-11	1	56	for	for	ADP
gsrj-11	1	57	sonic	sonic	ADJ
gsrj-11	1	58	hedgehog	hedgehog	ADJ
gsrj-11	1	59	medulloblastoma	medulloblastoma	NOUN
gsrj-11	1	60	:	:	PUNCT
gsrj-11	1	61	significant	significant	ADJ
gsrj-11	1	62	milestones	milestone	NOUN
gsrj-11	1	63	and	and	CCONJ
gsrj-11	1	64	current	current	ADJ
gsrj-11	1	65	limitations	limitation	NOUN
gsrj-11	1	66	maria	maria	PROPN
gsrj-11	1	67	victoria	victoria	PROPN
gsrj-11	1	68	dias	dias	PROPN
gsrj-11	1	69	,	,	PUNCT
gsrj-11	1	70	bridgitte	bridgitte	NOUN
gsrj-11	1	71	isom	isom	NOUN
gsrj-11	1	72	,	,	PUNCT
gsrj-11	1	73	katherine	katherine	PROPN
gsrj-11	1	74	poole	poole	PROPN
gsrj-11	1	75	,	,	PUNCT
gsrj-11	1	76	sofia	sofia	PROPN
gsrj-11	1	77	triplett	triplett	PROPN
gsrj-11	1	78	and	and	CCONJ
gsrj-11	1	79	nadia	nadia	PROPN
gsrj-11	1	80	sadanandan	sadanandan	PROPN
gsrj-11	1	81	school	school	PROPN
gsrj-11	1	82	of	of	ADP
gsrj-11	1	83	nursing	nursing	NOUN
gsrj-11	1	84	and	and	CCONJ
gsrj-11	1	85	health	health	NOUN
gsrj-11	1	86	studies	study	NOUN
gsrj-11	1	87	,	,	PUNCT
gsrj-11	1	88	georgetown	georgetown	PROPN
gsrj-11	1	89	university	university	PROPN
gsrj-11	1	90	,	,	PUNCT
gsrj-11	1	91	washington	washington	PROPN
gsrj-11	1	92	dc	dc	PROPN
gsrj-11	1	93	,	,	PUNCT
gsrj-11	1	94	united	united	PROPN
gsrj-11	1	95	states	states	PROPN
gsrj-11	1	96	e	e	NOUN
gsrj-11	1	97	-	-	NOUN
gsrj-11	1	98	mail	mail	NOUN
gsrj-11	1	99	:	:	PUNCT
gsrj-11	1	100	nas146@georgetown.edu	nas146@georgetown.edu	PROPN
gsrj-11	1	101	,	,	PUNCT
gsrj-11	1	102	md1694@georgetown.edu	md1694@georgetown.edu	PROPN
gsrj-11	1	103	,	,	PUNCT
gsrj-11	1	104	krp60@georgetown.edu	krp60@georgetown.edu	PROPN
gsrj-11	1	105	,	,	PUNCT
gsrj-11	1	106	sft9@georgetown.edu	sft9@georgetown.edu	PROPN
gsrj-11	1	107	,	,	PUNCT
gsrj-11	1	108	bei5@georgetown.edu	bei5@georgetown.edu	PUNCT
gsrj-11	1	109	abstract	abstract	ADJ
gsrj-11	1	110	medulloblastoma	medulloblastoma	NOUN
gsrj-11	1	111	(	(	PUNCT
gsrj-11	1	112	mb	mb	NOUN
gsrj-11	1	113	)	)	PUNCT
gsrj-11	1	114	is	be	AUX
gsrj-11	1	115	the	the	DET
gsrj-11	1	116	most	most	ADV
gsrj-11	1	117	common	common	ADJ
gsrj-11	1	118	pediatric	pediatric	ADJ
gsrj-11	1	119	brain	brain	NOUN
gsrj-11	1	120	tumor	tumor	NOUN
gsrj-11	1	121	with	with	ADP
gsrj-11	1	122	the	the	DET
gsrj-11	1	123	sonic	sonic	ADJ
gsrj-11	1	124	hedgehog	hedgehog	NOUN
gsrj-11	1	125	(	(	PUNCT
gsrj-11	1	126	shh	shh	NOUN
gsrj-11	1	127	)	)	PUNCT
gsrj-11	1	128	subtype	subtype	NOUN
gsrj-11	1	129	accounting	account	VERB
gsrj-11	1	130	for	for	ADP
gsrj-11	1	131	30	30	NUM
gsrj-11	1	132	%	%	NOUN
gsrj-11	1	133	of	of	ADP
gsrj-11	1	134	all	all	DET
gsrj-11	1	135	diagnoses	diagnosis	NOUN
gsrj-11	1	136	.	.	PUNCT
gsrj-11	2	1	the	the	DET
gsrj-11	2	2	current	current	ADJ
gsrj-11	2	3	standard	standard	ADJ
gsrj-11	2	4	treatment	treatment	NOUN
gsrj-11	2	5	regimen	regiman	NOUN
gsrj-11	2	6	includes	include	VERB
gsrj-11	2	7	high	high	ADJ
gsrj-11	2	8	doses	dose	NOUN
gsrj-11	2	9	of	of	ADP
gsrj-11	2	10	toxic	toxic	ADJ
gsrj-11	2	11	chemotherapy	chemotherapy	NOUN
gsrj-11	2	12	and	and	CCONJ
gsrj-11	2	13	radiation	radiation	NOUN
gsrj-11	2	14	,	,	PUNCT
gsrj-11	2	15	as	as	ADV
gsrj-11	2	16	well	well	ADV
gsrj-11	2	17	as	as	ADP
gsrj-11	2	18	surgical	surgical	ADJ
gsrj-11	2	19	resection	resection	NOUN
gsrj-11	2	20	,	,	PUNCT
gsrj-11	2	21	motivating	motivate	VERB
gsrj-11	2	22	the	the	DET
gsrj-11	2	23	need	need	NOUN
gsrj-11	2	24	for	for	ADP
gsrj-11	2	25	alternative	alternative	ADJ
gsrj-11	2	26	therapies	therapy	NOUN
gsrj-11	2	27	which	which	PRON
gsrj-11	2	28	do	do	AUX
gsrj-11	2	29	not	not	PART
gsrj-11	2	30	generate	generate	VERB
gsrj-11	2	31	deleterious	deleterious	ADJ
gsrj-11	2	32	effects	effect	NOUN
gsrj-11	2	33	on	on	ADP
gsrj-11	2	34	patients	patient	NOUN
gsrj-11	2	35	.	.	PUNCT
gsrj-11	3	1	the	the	DET
gsrj-11	3	2	purpose	purpose	NOUN
gsrj-11	3	3	of	of	ADP
gsrj-11	3	4	this	this	DET
gsrj-11	3	5	literature	literature	NOUN
gsrj-11	3	6	review	review	NOUN
gsrj-11	3	7	was	be	AUX
gsrj-11	3	8	to	to	PART
gsrj-11	3	9	evaluate	evaluate	VERB
gsrj-11	3	10	the	the	DET
gsrj-11	3	11	most	most	ADV
gsrj-11	3	12	recent	recent	ADJ
gsrj-11	3	13	developments	development	NOUN
gsrj-11	3	14	in	in	ADP
gsrj-11	3	15	the	the	DET
gsrj-11	3	16	efficacy	efficacy	NOUN
gsrj-11	3	17	of	of	ADP
gsrj-11	3	18	targeted	target	VERB
gsrj-11	3	19	therapeutics	therapeutic	NOUN
gsrj-11	3	20	in	in	ADP
gsrj-11	3	21	treatment	treatment	NOUN
gsrj-11	3	22	of	of	ADP
gsrj-11	3	23	shh	shh	INTJ
gsrj-11	3	24	mb	mb	NOUN
gsrj-11	3	25	,	,	PUNCT
gsrj-11	3	26	specifically	specifically	ADV
gsrj-11	3	27	focusing	focus	VERB
gsrj-11	3	28	on	on	ADP
gsrj-11	3	29	small	small	ADJ
gsrj-11	3	30	molecule	molecule	NOUN
gsrj-11	3	31	inhibitors	inhibitor	NOUN
gsrj-11	3	32	targeting	target	VERB
gsrj-11	3	33	the	the	DET
gsrj-11	3	34	sonic	sonic	ADJ
gsrj-11	3	35	hedgehog	hedgehog	NOUN
gsrj-11	3	36	pathway	pathway	NOUN
gsrj-11	3	37	.	.	PUNCT
gsrj-11	4	1	the	the	DET
gsrj-11	4	2	sources	source	NOUN
gsrj-11	4	3	analyzed	analyze	VERB
gsrj-11	4	4	in	in	ADP
gsrj-11	4	5	this	this	DET
gsrj-11	4	6	review	review	NOUN
gsrj-11	4	7	include	include	VERB
gsrj-11	4	8	case	case	NOUN
gsrj-11	4	9	studies	study	NOUN
gsrj-11	4	10	,	,	PUNCT
gsrj-11	4	11	preclinical	preclinical	ADJ
gsrj-11	4	12	and	and	CCONJ
gsrj-11	4	13	clinical	clinical	ADJ
gsrj-11	4	14	studies	study	NOUN
gsrj-11	4	15	,	,	PUNCT
gsrj-11	4	16	and	and	CCONJ
gsrj-11	4	17	other	other	ADJ
gsrj-11	4	18	review	review	NOUN
gsrj-11	4	19	papers	paper	NOUN
gsrj-11	4	20	that	that	PRON
gsrj-11	4	21	investigate	investigate	VERB
gsrj-11	4	22	the	the	DET
gsrj-11	4	23	mechanism	mechanism	NOUN
gsrj-11	4	24	and	and	CCONJ
gsrj-11	4	25	value	value	NOUN
gsrj-11	4	26	of	of	ADP
gsrj-11	4	27	five	five	NUM
gsrj-11	4	28	shh	shh	NOUN
gsrj-11	4	29	inhibitors	inhibitor	NOUN
gsrj-11	4	30	:	:	PUNCT
gsrj-11	4	31	vismodegib	vismodegib	NOUN
gsrj-11	4	32	,	,	PUNCT
gsrj-11	4	33	sonidegib	sonidegib	NOUN
gsrj-11	4	34	,	,	PUNCT
gsrj-11	4	35	glasdegib	glasdegib	NOUN
gsrj-11	4	36	,	,	PUNCT
gsrj-11	4	37	temozolomide	temozolomide	NOUN
gsrj-11	4	38	,	,	PUNCT
gsrj-11	4	39	and	and	CCONJ
gsrj-11	4	40	gant-61	gant-61	PROPN
gsrj-11	4	41	.	.	PUNCT
gsrj-11	5	1	novel	novel	ADJ
gsrj-11	5	2	discoveries	discovery	NOUN
gsrj-11	5	3	have	have	AUX
gsrj-11	5	4	highlighted	highlight	VERB
gsrj-11	5	5	that	that	SCONJ
gsrj-11	5	6	inhibitor	inhibitor	NOUN
gsrj-11	5	7	therapeutics	therapeutic	NOUN
gsrj-11	5	8	effectively	effectively	ADV
gsrj-11	5	9	target	target	VERB
gsrj-11	5	10	aberrant	aberrant	ADJ
gsrj-11	5	11	activity	activity	NOUN
gsrj-11	5	12	of	of	ADP
gsrj-11	5	13	the	the	DET
gsrj-11	5	14	shh	shh	PROPN
gsrj-11	5	15	pathway	pathway	NOUN
gsrj-11	5	16	at	at	ADP
gsrj-11	5	17	various	various	ADJ
gsrj-11	5	18	stages	stage	NOUN
gsrj-11	5	19	,	,	PUNCT
gsrj-11	5	20	thereby	thereby	ADV
gsrj-11	5	21	diminishing	diminish	VERB
gsrj-11	5	22	tumor	tumor	NOUN
gsrj-11	5	23	progression	progression	NOUN
gsrj-11	5	24	and	and	CCONJ
gsrj-11	5	25	metastasis	metastasis	NOUN
gsrj-11	5	26	.	.	PUNCT
gsrj-11	6	1	through	through	ADP
gsrj-11	6	2	evaluation	evaluation	NOUN
gsrj-11	6	3	of	of	ADP
gsrj-11	6	4	the	the	DET
gsrj-11	6	5	inhibitors	inhibitor	NOUN
gsrj-11	6	6	,	,	PUNCT
gsrj-11	6	7	it	it	PRON
gsrj-11	6	8	was	be	AUX
gsrj-11	6	9	determined	determine	VERB
gsrj-11	6	10	that	that	SCONJ
gsrj-11	6	11	they	they	PRON
gsrj-11	6	12	are	be	AUX
gsrj-11	6	13	promising	promise	VERB
gsrj-11	6	14	targeted	targeted	ADJ
gsrj-11	6	15	therapeutics	therapeutic	NOUN
gsrj-11	6	16	for	for	ADP
gsrj-11	6	17	shh	shh	NOUN
gsrj-11	6	18	mb	mb	NOUN
gsrj-11	6	19	,	,	PUNCT
gsrj-11	6	20	despite	despite	SCONJ
gsrj-11	6	21	their	their	PRON
gsrj-11	6	22	limitations	limitation	NOUN
gsrj-11	6	23	.	.	PUNCT
gsrj-11	7	1	these	these	DET
gsrj-11	7	2	limitations	limitation	NOUN
gsrj-11	7	3	include	include	VERB
gsrj-11	7	4	drug	drug	NOUN
gsrj-11	7	5	resistance	resistance	NOUN
gsrj-11	7	6	,	,	PUNCT
gsrj-11	7	7	molecular	molecular	ADJ
gsrj-11	7	8	heterogeneity	heterogeneity	NOUN
gsrj-11	7	9	of	of	ADP
gsrj-11	7	10	shh	shh	NOUN
gsrj-11	7	11	-	-	PUNCT
gsrj-11	7	12	driven	drive	VERB
gsrj-11	7	13	tumors	tumor	NOUN
gsrj-11	7	14	,	,	PUNCT
gsrj-11	7	15	and	and	CCONJ
gsrj-11	7	16	poor	poor	ADJ
gsrj-11	7	17	drug	drug	NOUN
gsrj-11	7	18	properties	property	NOUN
gsrj-11	7	19	.	.	PUNCT
gsrj-11	8	1	more	more	ADJ
gsrj-11	8	2	research	research	NOUN
gsrj-11	8	3	will	will	AUX
gsrj-11	8	4	be	be	AUX
gsrj-11	8	5	needed	need	VERB
gsrj-11	8	6	to	to	PART
gsrj-11	8	7	overcome	overcome	VERB
gsrj-11	8	8	these	these	DET
gsrj-11	8	9	obstacles	obstacle	NOUN
gsrj-11	8	10	for	for	ADP
gsrj-11	8	11	clinical	clinical	ADJ
gsrj-11	8	12	use	use	NOUN
gsrj-11	8	13	,	,	PUNCT
gsrj-11	8	14	but	but	CCONJ
gsrj-11	8	15	the	the	DET
gsrj-11	8	16	investment	investment	NOUN
gsrj-11	8	17	is	be	AUX
gsrj-11	8	18	warranted	warrant	VERB
gsrj-11	8	19	given	give	VERB
gsrj-11	8	20	the	the	DET
gsrj-11	8	21	promise	promise	NOUN
gsrj-11	8	22	of	of	ADP
gsrj-11	8	23	these	these	DET
gsrj-11	8	24	inhibitors	inhibitor	NOUN
gsrj-11	8	25	.	.	PUNCT
gsrj-11	9	1	future	future	ADJ
gsrj-11	9	2	research	research	NOUN
gsrj-11	9	3	should	should	AUX
gsrj-11	9	4	seek	seek	VERB
gsrj-11	9	5	to	to	PART
gsrj-11	9	6	establish	establish	VERB
gsrj-11	9	7	optimal	optimal	ADJ
gsrj-11	9	8	dosage	dosage	NOUN
gsrj-11	9	9	and	and	CCONJ
gsrj-11	9	10	timing	timing	NOUN
gsrj-11	9	11	of	of	ADP
gsrj-11	9	12	intervention	intervention	NOUN
gsrj-11	9	13	,	,	PUNCT
gsrj-11	9	14	further	far	ADV
gsrj-11	9	15	delineate	delineate	VERB
gsrj-11	9	16	the	the	DET
gsrj-11	9	17	genetic	genetic	ADJ
gsrj-11	9	18	basis	basis	NOUN
gsrj-11	9	19	for	for	ADP
gsrj-11	9	20	shh	shh	INTJ
gsrj-11	9	21	mb	mb	NOUN
gsrj-11	9	22	,	,	PUNCT
gsrj-11	9	23	and	and	CCONJ
gsrj-11	9	24	investigate	investigate	VERB
gsrj-11	9	25	potential	potential	ADJ
gsrj-11	9	26	combination	combination	NOUN
gsrj-11	9	27	therapies	therapy	NOUN
gsrj-11	9	28	with	with	ADP
gsrj-11	9	29	shh	shh	PROPN
gsrj-11	9	30	inhibitors	inhibitor	NOUN
gsrj-11	9	31	.	.	PUNCT
gsrj-11	10	1	keywords	keyword	NOUN
gsrj-11	10	2	:	:	PUNCT
gsrj-11	10	3	medulloblastoma	medulloblastoma	ADJ
gsrj-11	10	4	,	,	PUNCT
gsrj-11	10	5	sonic	sonic	ADJ
gsrj-11	10	6	hedgehog	hedgehog	NOUN
gsrj-11	10	7	pathway	pathway	NOUN
gsrj-11	10	8	,	,	PUNCT
gsrj-11	10	9	inhibitor	inhibitor	NOUN
gsrj-11	10	10	therapeutics	therapeutic	NOUN
gsrj-11	10	11	,	,	PUNCT
gsrj-11	10	12	vismodegib	vismodegib	NOUN
gsrj-11	10	13	,	,	PUNCT
gsrj-11	10	14	sonidegib	sonidegib	NOUN
gsrj-11	10	15	,	,	PUNCT
gsrj-11	10	16	glasdegib	glasdegib	NOUN
gsrj-11	10	17	,	,	PUNCT
gsrj-11	10	18	temozolomide	temozolomide	NOUN
gsrj-11	10	19	,	,	PUNCT
gsrj-11	10	20	gant-61	gant-61	NOUN
gsrj-11	10	21	,	,	PUNCT
gsrj-11	10	22	pediatric	pediatric	NOUN
gsrj-11	10	23	,	,	PUNCT
gsrj-11	10	24	cancer	cancer	NOUN
gsrj-11	10	25	,	,	PUNCT
gsrj-11	10	26	shh	shh	NOUN
gsrj-11	10	27	,	,	PUNCT
gsrj-11	10	28	sonic	sonic	ADJ
gsrj-11	10	29	hedgehog	hedgehog	PROPN
gsrj-11	10	30	,	,	PUNCT
gsrj-11	10	31	smo	smo	PROPN
gsrj-11	10	32	,	,	PUNCT
gsrj-11	10	33	ptch	ptch	VERB
gsrj-11	10	34	85	85	NUM
gsrj-11	10	35	georgetown	georgetown	NOUN
gsrj-11	10	36	scientific	scientific	ADJ
gsrj-11	10	37	research	research	NOUN
gsrj-11	10	38	journal	journal	NOUN
gsrj-11	10	39	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	10	40	1	1	NUM
gsrj-11	10	41	.	.	PUNCT
gsrj-11	10	42	introduction	introduction	NOUN
gsrj-11	10	43	medulloblastoma	medulloblastoma	NOUN
gsrj-11	10	44	(	(	PUNCT
gsrj-11	10	45	mb	mb	NOUN
gsrj-11	10	46	)	)	PUNCT
gsrj-11	10	47	is	be	AUX
gsrj-11	10	48	a	a	DET
gsrj-11	10	49	malignant	malignant	ADJ
gsrj-11	10	50	brain	brain	NOUN
gsrj-11	10	51	tumor	tumor	NOUN
gsrj-11	10	52	first	first	ADV
gsrj-11	10	53	described	describe	VERB
gsrj-11	10	54	by	by	ADP
gsrj-11	10	55	harvey	harvey	PROPN
gsrj-11	10	56	cushing	cushing	PROPN
gsrj-11	10	57	and	and	CCONJ
gsrj-11	10	58	percival	percival	PROPN
gsrj-11	10	59	bailey	bailey	NOUN
gsrj-11	10	60	in	in	ADP
gsrj-11	10	61	their	their	PRON
gsrj-11	10	62	classification	classification	NOUN
gsrj-11	10	63	of	of	ADP
gsrj-11	10	64	central	central	ADJ
gsrj-11	10	65	nervous	nervous	ADJ
gsrj-11	10	66	system	system	NOUN
gsrj-11	10	67	(	(	PUNCT
gsrj-11	10	68	cns	cns	NOUN
gsrj-11	10	69	)	)	PUNCT
gsrj-11	10	70	tumors	tumor	NOUN
gsrj-11	10	71	in	in	ADP
gsrj-11	10	72	1925	1925	NUM
gsrj-11	10	73	.	.	PUNCT
gsrj-11	11	1	although	although	SCONJ
gsrj-11	11	2	it	it	PRON
gsrj-11	11	3	is	be	AUX
gsrj-11	11	4	the	the	DET
gsrj-11	11	5	most	most	ADV
gsrj-11	11	6	common	common	ADJ
gsrj-11	11	7	pediatric	pediatric	ADJ
gsrj-11	11	8	malignant	malignant	ADJ
gsrj-11	11	9	brain	brain	NOUN
gsrj-11	11	10	tumor	tumor	NOUN
gsrj-11	11	11	,	,	PUNCT
gsrj-11	11	12	representing	represent	VERB
gsrj-11	11	13	about	about	ADV
gsrj-11	11	14	20	20	NUM
gsrj-11	11	15	%	%	NOUN
gsrj-11	11	16	of	of	ADP
gsrj-11	11	17	all	all	DET
gsrj-11	11	18	pediatric	pediatric	ADJ
gsrj-11	11	19	brain	brain	NOUN
gsrj-11	11	20	tumors,1	tumors,1	NOUN
gsrj-11	11	21	it	it	PRON
gsrj-11	11	22	is	be	AUX
gsrj-11	11	23	very	very	ADV
gsrj-11	11	24	rare	rare	ADJ
gsrj-11	11	25	in	in	ADP
gsrj-11	11	26	adults	adult	NOUN
gsrj-11	11	27	,	,	PUNCT
gsrj-11	11	28	representing	represent	VERB
gsrj-11	11	29	0.4	0.4	NUM
gsrj-11	11	30	to	to	PART
gsrj-11	11	31	1	1	NUM
gsrj-11	11	32	%	%	NOUN
gsrj-11	11	33	of	of	ADP
gsrj-11	11	34	adult	adult	NOUN
gsrj-11	11	35	brain	brain	NOUN
gsrj-11	11	36	tumors.2	tumors.2	ADP
gsrj-11	11	37	most	most	ADJ
gsrj-11	11	38	cases	case	NOUN
gsrj-11	11	39	are	be	AUX
gsrj-11	11	40	diagnosed	diagnose	VERB
gsrj-11	11	41	under	under	ADP
gsrj-11	11	42	age	age	NOUN
gsrj-11	11	43	16	16	NUM
gsrj-11	11	44	and	and	CCONJ
gsrj-11	11	45	it	it	PRON
gsrj-11	11	46	is	be	AUX
gsrj-11	11	47	rarely	rarely	ADV
gsrj-11	11	48	seen	see	VERB
gsrj-11	11	49	after	after	ADP
gsrj-11	11	50	age	age	NOUN
gsrj-11	11	51	40	40	NUM
gsrj-11	11	52	.	.	PUNCT
gsrj-11	12	1	in	in	ADP
gsrj-11	12	2	the	the	DET
gsrj-11	12	3	united	united	PROPN
gsrj-11	12	4	states	states	PROPN
gsrj-11	12	5	,	,	PUNCT
gsrj-11	12	6	an	an	DET
gsrj-11	12	7	average	average	NOUN
gsrj-11	12	8	of	of	ADP
gsrj-11	12	9	500	500	NUM
gsrj-11	12	10	children	child	NOUN
gsrj-11	12	11	and	and	CCONJ
gsrj-11	12	12	200	200	NUM
gsrj-11	12	13	adults	adult	NOUN
gsrj-11	12	14	are	be	AUX
gsrj-11	12	15	diagnosed	diagnose	VERB
gsrj-11	12	16	with	with	ADP
gsrj-11	12	17	mb	mb	ADP
gsrj-11	12	18	every	every	DET
gsrj-11	12	19	year	year	NOUN
gsrj-11	12	20	,	,	PUNCT
gsrj-11	12	21	and	and	CCONJ
gsrj-11	12	22	it	it	PRON
gsrj-11	12	23	is	be	AUX
gsrj-11	12	24	more	more	ADV
gsrj-11	12	25	common	common	ADJ
gsrj-11	12	26	in	in	ADP
gsrj-11	12	27	males	male	NOUN
gsrj-11	12	28	than	than	ADP
gsrj-11	12	29	females.3	females.3	PROPN
gsrj-11	12	30	medulloblastoma	medulloblastoma	NOUN
gsrj-11	12	31	is	be	AUX
gsrj-11	12	32	part	part	NOUN
gsrj-11	12	33	of	of	ADP
gsrj-11	12	34	the	the	DET
gsrj-11	12	35	primitive	primitive	ADJ
gsrj-11	12	36	neuroectodermal	neuroectodermal	ADJ
gsrj-11	12	37	tumors	tumor	NOUN
gsrj-11	12	38	(	(	PUNCT
gsrj-11	12	39	pnet	pnet	PROPN
gsrj-11	12	40	)	)	PUNCT
gsrj-11	12	41	group	group	NOUN
gsrj-11	12	42	,	,	PUNCT
gsrj-11	12	43	which	which	PRON
gsrj-11	12	44	is	be	AUX
gsrj-11	12	45	classified	classify	VERB
gsrj-11	12	46	within	within	ADP
gsrj-11	12	47	the	the	DET
gsrj-11	12	48	embryonal	embryonal	ADJ
gsrj-11	12	49	subtype	subtype	NOUN
gsrj-11	12	50	of	of	ADP
gsrj-11	12	51	cns	cns	NOUN
gsrj-11	12	52	tumors	tumor	NOUN
gsrj-11	12	53	.	.	PUNCT
gsrj-11	13	1	it	it	PRON
gsrj-11	13	2	originates	originate	VERB
gsrj-11	13	3	in	in	ADP
gsrj-11	13	4	the	the	DET
gsrj-11	13	5	cerebellum	cerebellum	NOUN
gsrj-11	13	6	,	,	PUNCT
gsrj-11	13	7	in	in	ADP
gsrj-11	13	8	the	the	DET
gsrj-11	13	9	posterior	posterior	ADJ
gsrj-11	13	10	fossa	fossa	NOUN
gsrj-11	13	11	,	,	PUNCT
gsrj-11	13	12	and	and	CCONJ
gsrj-11	13	13	may	may	AUX
gsrj-11	13	14	spread	spread	VERB
gsrj-11	13	15	to	to	ADP
gsrj-11	13	16	other	other	ADJ
gsrj-11	13	17	regions	region	NOUN
gsrj-11	13	18	of	of	ADP
gsrj-11	13	19	the	the	DET
gsrj-11	13	20	brain	brain	NOUN
gsrj-11	13	21	and	and	CCONJ
gsrj-11	13	22	spinal	spinal	ADJ
gsrj-11	13	23	cord	cord	NOUN
gsrj-11	13	24	.	.	PUNCT
gsrj-11	14	1	the	the	DET
gsrj-11	14	2	world	world	PROPN
gsrj-11	14	3	health	health	PROPN
gsrj-11	14	4	organization	organization	NOUN
gsrj-11	14	5	classified	classify	VERB
gsrj-11	14	6	medulloblastoma	medulloblastoma	NOUN
gsrj-11	14	7	into	into	ADP
gsrj-11	14	8	four	four	NUM
gsrj-11	14	9	non	non	ADJ
gsrj-11	14	10	-	-	ADJ
gsrj-11	14	11	histological	histological	ADJ
gsrj-11	14	12	subgroups	subgroup	NOUN
gsrj-11	14	13	according	accord	VERB
gsrj-11	14	14	to	to	ADP
gsrj-11	14	15	molecular	molecular	ADJ
gsrj-11	14	16	profiling	profiling	NOUN
gsrj-11	14	17	of	of	ADP
gsrj-11	14	18	the	the	DET
gsrj-11	14	19	tumors	tumor	NOUN
gsrj-11	14	20	:	:	PUNCT
gsrj-11	14	21	wingless	wingless	NOUN
gsrj-11	14	22	(	(	PUNCT
gsrj-11	14	23	wnt	wnt	PROPN
gsrj-11	14	24	)	)	PUNCT
gsrj-11	14	25	,	,	PUNCT
gsrj-11	14	26	sonic	sonic	ADJ
gsrj-11	14	27	hedgehog	hedgehog	PROPN
gsrj-11	14	28	(	(	PUNCT
gsrj-11	14	29	shh	shh	NOUN
gsrj-11	14	30	)	)	PUNCT
gsrj-11	14	31	,	,	PUNCT
gsrj-11	14	32	and	and	CCONJ
gsrj-11	14	33	groups	group	NOUN
gsrj-11	14	34	3	3	NUM
gsrj-11	14	35	and	and	CCONJ
gsrj-11	14	36	4	4	NUM
gsrj-11	14	37	.	.	PUNCT
gsrj-11	15	1	this	this	DET
gsrj-11	15	2	review	review	NOUN
gsrj-11	15	3	will	will	AUX
gsrj-11	15	4	focus	focus	VERB
gsrj-11	15	5	on	on	ADP
gsrj-11	15	6	the	the	DET
gsrj-11	15	7	shh	shh	NOUN
gsrj-11	15	8	subtype	subtype	NOUN
gsrj-11	15	9	because	because	SCONJ
gsrj-11	15	10	it	it	PRON
gsrj-11	15	11	accounts	account	VERB
gsrj-11	15	12	for	for	ADP
gsrj-11	15	13	30	30	NUM
gsrj-11	15	14	%	%	NOUN
gsrj-11	15	15	of	of	ADP
gsrj-11	15	16	all	all	PRON
gsrj-11	15	17	mb	mb	ADP
gsrj-11	15	18	diagnoses	diagnosis	NOUN
gsrj-11	15	19	and	and	CCONJ
gsrj-11	15	20	is	be	AUX
gsrj-11	15	21	the	the	DET
gsrj-11	15	22	most	most	ADV
gsrj-11	15	23	prominent	prominent	ADJ
gsrj-11	15	24	subtype	subtype	NOUN
gsrj-11	15	25	in	in	ADP
gsrj-11	15	26	both	both	DET
gsrj-11	15	27	infants	infant	NOUN
gsrj-11	15	28	(	(	PUNCT
gsrj-11	15	29	<	<	X
gsrj-11	15	30	3	3	NUM
gsrj-11	15	31	years	year	NOUN
gsrj-11	15	32	of	of	ADP
gsrj-11	15	33	age	age	NOUN
gsrj-11	15	34	)	)	PUNCT
gsrj-11	15	35	and	and	CCONJ
gsrj-11	15	36	adults	adult	NOUN
gsrj-11	15	37	(	(	PUNCT
gsrj-11	15	38	>	>	X
gsrj-11	15	39	17	17	NUM
gsrj-11	15	40	years	year	NOUN
gsrj-11	15	41	of	of	ADP
gsrj-11	15	42	age).4	age).4	NOUN
gsrj-11	15	43	first	first	ADV
gsrj-11	15	44	introduced	introduce	VERB
gsrj-11	15	45	in	in	ADP
gsrj-11	15	46	the	the	DET
gsrj-11	15	47	1930s	1930	NOUN
gsrj-11	15	48	,	,	PUNCT
gsrj-11	15	49	surgery	surgery	NOUN
gsrj-11	15	50	was	be	AUX
gsrj-11	15	51	the	the	DET
gsrj-11	15	52	initial	initial	ADJ
gsrj-11	15	53	treatment	treatment	NOUN
gsrj-11	15	54	approach	approach	NOUN
gsrj-11	15	55	.	.	PUNCT
gsrj-11	16	1	however	however	ADV
gsrj-11	16	2	,	,	PUNCT
gsrj-11	16	3	the	the	DET
gsrj-11	16	4	mortality	mortality	NOUN
gsrj-11	16	5	rate	rate	NOUN
gsrj-11	16	6	following	follow	VERB
gsrj-11	16	7	the	the	DET
gsrj-11	16	8	operation	operation	NOUN
gsrj-11	16	9	exceeded	exceed	VERB
gsrj-11	16	10	30%.5	30%.5	NUM
gsrj-11	16	11	in	in	ADP
gsrj-11	16	12	1953	1953	NUM
gsrj-11	16	13	,	,	PUNCT
gsrj-11	16	14	craniospinal	craniospinal	ADJ
gsrj-11	16	15	irradiation	irradiation	NOUN
gsrj-11	16	16	was	be	AUX
gsrj-11	16	17	introduced	introduce	VERB
gsrj-11	16	18	following	follow	VERB
gsrj-11	16	19	surgery	surgery	NOUN
gsrj-11	16	20	,	,	PUNCT
gsrj-11	16	21	and	and	CCONJ
gsrj-11	16	22	although	although	SCONJ
gsrj-11	16	23	there	there	PRON
gsrj-11	16	24	was	be	VERB
gsrj-11	16	25	improvement	improvement	NOUN
gsrj-11	16	26	to	to	ADP
gsrj-11	16	27	a	a	DET
gsrj-11	16	28	3	3	NUM
gsrj-11	16	29	-	-	PUNCT
gsrj-11	16	30	year	year	NOUN
gsrj-11	16	31	survival	survival	NOUN
gsrj-11	16	32	rate	rate	NOUN
gsrj-11	16	33	of	of	ADP
gsrj-11	16	34	65	65	NUM
gsrj-11	16	35	%	%	NOUN
gsrj-11	16	36	,	,	PUNCT
gsrj-11	16	37	the	the	DET
gsrj-11	16	38	development	development	NOUN
gsrj-11	16	39	of	of	ADP
gsrj-11	16	40	significant	significant	ADJ
gsrj-11	16	41	motor	motor	NOUN
gsrj-11	16	42	and	and	CCONJ
gsrj-11	16	43	cognitive	cognitive	ADJ
gsrj-11	16	44	side	side	NOUN
gsrj-11	16	45	effects	effect	NOUN
gsrj-11	16	46	was	be	AUX
gsrj-11	16	47	observed	observe	VERB
gsrj-11	16	48	.	.	PUNCT
gsrj-11	17	1	non	non	ADJ
gsrj-11	17	2	-	-	ADJ
gsrj-11	17	3	specific	specific	ADJ
gsrj-11	17	4	cytotoxic	cytotoxic	ADJ
gsrj-11	17	5	chemotherapy	chemotherapy	NOUN
gsrj-11	17	6	complemented	complement	VERB
gsrj-11	17	7	with	with	ADP
gsrj-11	17	8	surgery	surgery	NOUN
gsrj-11	17	9	and/or	and/or	CCONJ
gsrj-11	17	10	radiation	radiation	NOUN
gsrj-11	17	11	was	be	AUX
gsrj-11	17	12	then	then	ADV
gsrj-11	17	13	introduced	introduce	VERB
gsrj-11	17	14	in	in	ADP
gsrj-11	17	15	the	the	DET
gsrj-11	17	16	1970s	1970	NOUN
gsrj-11	17	17	,	,	PUNCT
gsrj-11	17	18	and	and	CCONJ
gsrj-11	17	19	it	it	PRON
gsrj-11	17	20	is	be	AUX
gsrj-11	17	21	still	still	ADV
gsrj-11	17	22	the	the	DET
gsrj-11	17	23	standard	standard	ADJ
gsrj-11	17	24	treatment	treatment	NOUN
gsrj-11	17	25	today	today	NOUN
gsrj-11	17	26	.	.	PUNCT
gsrj-11	18	1	unfortunately	unfortunately	ADV
gsrj-11	18	2	,	,	PUNCT
gsrj-11	18	3	the	the	DET
gsrj-11	18	4	unforeseen	unforeseen	ADJ
gsrj-11	18	5	long	long	ADJ
gsrj-11	18	6	-	-	PUNCT
gsrj-11	18	7	term	term	NOUN
gsrj-11	18	8	use	use	NOUN
gsrj-11	18	9	of	of	ADP
gsrj-11	18	10	this	this	DET
gsrj-11	18	11	high	high	ADJ
gsrj-11	18	12	toxicity	toxicity	NOUN
gsrj-11	18	13	treatment	treatment	NOUN
gsrj-11	18	14	therapy	therapy	NOUN
gsrj-11	18	15	has	have	AUX
gsrj-11	18	16	caused	cause	VERB
gsrj-11	18	17	extensive	extensive	ADJ
gsrj-11	18	18	toxic	toxic	ADJ
gsrj-11	18	19	damage	damage	NOUN
gsrj-11	18	20	to	to	ADP
gsrj-11	18	21	patients	patient	NOUN
gsrj-11	18	22	,	,	PUNCT
gsrj-11	18	23	particularly	particularly	ADV
gsrj-11	18	24	in	in	ADP
gsrj-11	18	25	younger	young	ADJ
gsrj-11	18	26	patients.6	patients.6	PROPN
gsrj-11	18	27	cerebellar	cerebellar	ADJ
gsrj-11	18	28	mutism	mutism	NOUN
gsrj-11	18	29	,	,	PUNCT
gsrj-11	18	30	dysarthria	dysarthria	NOUN
gsrj-11	18	31	,	,	PUNCT
gsrj-11	18	32	and	and	CCONJ
gsrj-11	18	33	neurocognitive	neurocognitive	ADJ
gsrj-11	18	34	disorders	disorder	NOUN
gsrj-11	18	35	result	result	VERB
gsrj-11	18	36	in	in	ADP
gsrj-11	18	37	over	over	ADP
gsrj-11	18	38	25	25	NUM
gsrj-11	18	39	%	%	NOUN
gsrj-11	18	40	of	of	ADP
gsrj-11	18	41	patients	patient	NOUN
gsrj-11	18	42	following	follow	VERB
gsrj-11	18	43	treatment	treatment	NOUN
gsrj-11	18	44	,	,	PUNCT
gsrj-11	18	45	as	as	ADV
gsrj-11	18	46	well	well	ADV
gsrj-11	18	47	as	as	ADP
gsrj-11	18	48	the	the	DET
gsrj-11	18	49	growth	growth	NOUN
gsrj-11	18	50	of	of	ADP
gsrj-11	18	51	secondary	secondary	ADJ
gsrj-11	18	52	tumors	tumor	NOUN
gsrj-11	18	53	due	due	ADP
gsrj-11	18	54	to	to	ADP
gsrj-11	18	55	high	high	ADJ
gsrj-11	18	56	intensity	intensity	NOUN
gsrj-11	18	57	of	of	ADP
gsrj-11	18	58	radiation	radiation	NOUN
gsrj-11	18	59	and	and	CCONJ
gsrj-11	18	60	chemotherapy	chemotherapy	NOUN
gsrj-11	18	61	.	.	PUNCT
gsrj-11	19	1	moreover	moreover	ADV
gsrj-11	19	2	,	,	PUNCT
gsrj-11	19	3	the	the	DET
gsrj-11	19	4	current	current	ADJ
gsrj-11	19	5	standardized	standardized	ADJ
gsrj-11	19	6	treatment	treatment	NOUN
gsrj-11	19	7	fails	fail	VERB
gsrj-11	19	8	to	to	PART
gsrj-11	19	9	address	address	VERB
gsrj-11	19	10	the	the	DET
gsrj-11	19	11	root	root	NOUN
gsrj-11	19	12	cause	cause	NOUN
gsrj-11	19	13	of	of	ADP
gsrj-11	19	14	tumor	tumor	NOUN
gsrj-11	19	15	growth	growth	NOUN
gsrj-11	19	16	,	,	PUNCT
gsrj-11	19	17	and	and	CCONJ
gsrj-11	19	18	along	along	ADP
gsrj-11	19	19	with	with	ADP
gsrj-11	19	20	the	the	DET
gsrj-11	19	21	occurrence	occurrence	NOUN
gsrj-11	19	22	of	of	ADP
gsrj-11	19	23	serious	serious	ADJ
gsrj-11	19	24	adverse	adverse	ADJ
gsrj-11	19	25	effects	effect	NOUN
gsrj-11	19	26	,	,	PUNCT
gsrj-11	19	27	validates	validate	VERB
gsrj-11	19	28	the	the	DET
gsrj-11	19	29	need	need	NOUN
gsrj-11	19	30	for	for	ADP
gsrj-11	19	31	non	non	ADJ
gsrj-11	19	32	-	-	ADJ
gsrj-11	19	33	toxic	toxic	ADJ
gsrj-11	19	34	,	,	PUNCT
gsrj-11	19	35	individualized	individualized	ADJ
gsrj-11	19	36	therapy	therapy	NOUN
gsrj-11	19	37	which	which	PRON
gsrj-11	19	38	tackles	tackle	VERB
gsrj-11	19	39	the	the	DET
gsrj-11	19	40	substantial	substantial	ADJ
gsrj-11	19	41	variability	variability	NOUN
gsrj-11	19	42	of	of	ADP
gsrj-11	19	43	pathological	pathological	ADJ
gsrj-11	19	44	mechanisms	mechanism	NOUN
gsrj-11	19	45	among	among	ADP
gsrj-11	19	46	the	the	DET
gsrj-11	19	47	four	four	NUM
gsrj-11	19	48	subtypes	subtype	NOUN
gsrj-11	19	49	.	.	PUNCT
gsrj-11	20	1	currently	currently	ADV
gsrj-11	20	2	,	,	PUNCT
gsrj-11	20	3	a	a	DET
gsrj-11	20	4	substantial	substantial	ADJ
gsrj-11	20	5	amount	amount	NOUN
gsrj-11	20	6	of	of	ADP
gsrj-11	20	7	research	research	NOUN
gsrj-11	20	8	is	be	AUX
gsrj-11	20	9	focused	focus	VERB
gsrj-11	20	10	on	on	ADP
gsrj-11	20	11	developing	develop	VERB
gsrj-11	20	12	targeted	target	VERB
gsrj-11	20	13	therapeutics	therapeutic	NOUN
gsrj-11	20	14	for	for	ADP
gsrj-11	20	15	shh	shh	INTJ
gsrj-11	20	16	mb	mb	NOUN
gsrj-11	20	17	in	in	ADP
gsrj-11	20	18	order	order	NOUN
gsrj-11	20	19	to	to	PART
gsrj-11	20	20	meet	meet	VERB
gsrj-11	20	21	this	this	DET
gsrj-11	20	22	need	need	NOUN
gsrj-11	20	23	.	.	PUNCT
gsrj-11	21	1	since	since	SCONJ
gsrj-11	21	2	the	the	DET
gsrj-11	21	3	overactivation	overactivation	NOUN
gsrj-11	21	4	of	of	ADP
gsrj-11	21	5	the	the	DET
gsrj-11	21	6	shh	shh	PROPN
gsrj-11	21	7	pathway	pathway	NOUN
gsrj-11	21	8	may	may	AUX
gsrj-11	21	9	play	play	VERB
gsrj-11	21	10	a	a	DET
gsrj-11	21	11	critical	critical	ADJ
gsrj-11	21	12	role	role	NOUN
gsrj-11	21	13	in	in	ADP
gsrj-11	21	14	the	the	DET
gsrj-11	21	15	formation	formation	NOUN
gsrj-11	21	16	of	of	ADP
gsrj-11	21	17	this	this	DET
gsrj-11	21	18	mb	mb	ADJ
gsrj-11	21	19	subtype	subtype	NOUN
gsrj-11	21	20	,	,	PUNCT
gsrj-11	21	21	creating	create	VERB
gsrj-11	21	22	therapeutics	therapeutic	NOUN
gsrj-11	21	23	that	that	PRON
gsrj-11	21	24	can	can	AUX
gsrj-11	21	25	mitigate	mitigate	VERB
gsrj-11	21	26	aberrations	aberration	NOUN
gsrj-11	21	27	to	to	ADP
gsrj-11	21	28	the	the	DET
gsrj-11	21	29	shh	shh	PROPN
gsrj-11	21	30	pathway	pathway	NOUN
gsrj-11	21	31	serves	serve	VERB
gsrj-11	21	32	as	as	ADP
gsrj-11	21	33	a	a	DET
gsrj-11	21	34	putative	putative	ADJ
gsrj-11	21	35	treatment	treatment	NOUN
gsrj-11	21	36	strategy	strategy	NOUN
gsrj-11	21	37	.	.	PUNCT
gsrj-11	22	1	evidence	evidence	NOUN
gsrj-11	22	2	indicates	indicate	VERB
gsrj-11	22	3	that	that	SCONJ
gsrj-11	22	4	shh	shh	PROPN
gsrj-11	22	5	signaling	signal	VERB
gsrj-11	22	6	directs	direct	VERB
gsrj-11	22	7	developmental	developmental	ADJ
gsrj-11	22	8	processes	process	NOUN
gsrj-11	22	9	,	,	PUNCT
gsrj-11	22	10	such	such	ADJ
gsrj-11	22	11	as	as	ADP
gsrj-11	22	12	cell	cell	NOUN
gsrj-11	22	13	differentiation	differentiation	NOUN
gsrj-11	22	14	and	and	CCONJ
gsrj-11	22	15	morphogenesis	morphogenesis	NOUN
gsrj-11	22	16	,	,	PUNCT
gsrj-11	22	17	and	and	CCONJ
gsrj-11	22	18	has	have	AUX
gsrj-11	22	19	been	be	AUX
gsrj-11	22	20	implicated	implicate	VERB
gsrj-11	22	21	in	in	ADP
gsrj-11	22	22	several	several	ADJ
gsrj-11	22	23	cancers.7	cancers.7	NOUN
gsrj-11	22	24	importantly	importantly	ADV
gsrj-11	22	25	,	,	PUNCT
gsrj-11	22	26	proper	proper	ADJ
gsrj-11	22	27	shh	shh	NOUN
gsrj-11	22	28	signaling	signal	VERB
gsrj-11	22	29	is	be	AUX
gsrj-11	22	30	crucial	crucial	ADJ
gsrj-11	22	31	for	for	ADP
gsrj-11	22	32	neural	neural	ADJ
gsrj-11	22	33	tube	tube	NOUN
gsrj-11	22	34	formation	formation	NOUN
gsrj-11	22	35	and	and	CCONJ
gsrj-11	22	36	normal	normal	ADJ
gsrj-11	22	37	cerebellar	cerebellar	ADJ
gsrj-11	22	38	development	development	NOUN
gsrj-11	22	39	,	,	PUNCT
gsrj-11	22	40	as	as	SCONJ
gsrj-11	22	41	the	the	DET
gsrj-11	22	42	pathway	pathway	NOUN
gsrj-11	22	43	mediates	mediate	VERB
gsrj-11	22	44	the	the	DET
gsrj-11	22	45	proliferation	proliferation	NOUN
gsrj-11	22	46	of	of	ADP
gsrj-11	22	47	cerebellar	cerebellar	ADJ
gsrj-11	22	48	granule	granule	NOUN
gsrj-11	22	49	cells	cell	NOUN
gsrj-11	22	50	(	(	PUNCT
gsrj-11	22	51	gcs	gcs	PROPN
gsrj-11	22	52	)	)	PUNCT
gsrj-11	22	53	during	during	ADP
gsrj-11	22	54	embryonic	embryonic	ADJ
gsrj-11	22	55	development	development	NOUN
gsrj-11	22	56	.	.	PUNCT
gsrj-11	23	1	the	the	DET
gsrj-11	23	2	heightened	heighten	VERB
gsrj-11	23	3	activation	activation	NOUN
gsrj-11	23	4	of	of	ADP
gsrj-11	23	5	the	the	DET
gsrj-11	23	6	shh	shh	PROPN
gsrj-11	23	7	pathway	pathway	NOUN
gsrj-11	23	8	leads	lead	VERB
gsrj-11	23	9	to	to	ADP
gsrj-11	23	10	the	the	DET
gsrj-11	23	11	overproliferation	overproliferation	NOUN
gsrj-11	23	12	of	of	ADP
gsrj-11	23	13	cerebellar	cerebellar	PROPN
gsrj-11	23	14	gcs	gcs	PROPN
gsrj-11	23	15	,	,	PUNCT
gsrj-11	23	16	which	which	PRON
gsrj-11	23	17	may	may	AUX
gsrj-11	23	18	culminate	culminate	VERB
gsrj-11	23	19	in	in	ADP
gsrj-11	23	20	tumorigenesis.8	tumorigenesis.8	PROPN
gsrj-11	23	21	this	this	DET
gsrj-11	23	22	pathway	pathway	NOUN
gsrj-11	23	23	shows	show	VERB
gsrj-11	23	24	the	the	DET
gsrj-11	23	25	most	most	ADJ
gsrj-11	23	26	promise	promise	NOUN
gsrj-11	23	27	for	for	ADP
gsrj-11	23	28	developing	develop	VERB
gsrj-11	23	29	effective	effective	ADJ
gsrj-11	23	30	inhibitors	inhibitor	NOUN
gsrj-11	23	31	,	,	PUNCT
gsrj-11	23	32	as	as	SCONJ
gsrj-11	23	33	shown	show	VERB
gsrj-11	23	34	by	by	ADP
gsrj-11	23	35	the	the	DET
gsrj-11	23	36	extensive	extensive	ADJ
gsrj-11	23	37	amount	amount	NOUN
gsrj-11	23	38	of	of	ADP
gsrj-11	23	39	research	research	NOUN
gsrj-11	23	40	that	that	PRON
gsrj-11	23	41	has	have	AUX
gsrj-11	23	42	been	be	AUX
gsrj-11	23	43	dedicated	dedicate	VERB
gsrj-11	23	44	to	to	ADP
gsrj-11	23	45	understanding	understand	VERB
gsrj-11	23	46	its	its	PRON
gsrj-11	23	47	mechanism	mechanism	NOUN
gsrj-11	23	48	and	and	CCONJ
gsrj-11	23	49	the	the	DET
gsrj-11	23	50	role	role	NOUN
gsrj-11	23	51	of	of	ADP
gsrj-11	23	52	shh	shh	NOUN
gsrj-11	23	53	signaling	signal	VERB
gsrj-11	23	54	in	in	ADP
gsrj-11	23	55	generating	generate	VERB
gsrj-11	23	56	medulloblastoma	medulloblastoma	NOUN
gsrj-11	23	57	.	.	PUNCT
gsrj-11	24	1	the	the	DET
gsrj-11	24	2	purpose	purpose	NOUN
gsrj-11	24	3	of	of	ADP
gsrj-11	24	4	this	this	DET
gsrj-11	24	5	literature	literature	NOUN
gsrj-11	24	6	review	review	NOUN
gsrj-11	24	7	is	be	AUX
gsrj-11	24	8	to	to	PART
gsrj-11	24	9	evaluate	evaluate	VERB
gsrj-11	24	10	the	the	DET
gsrj-11	24	11	most	most	ADV
gsrj-11	24	12	notable	notable	ADJ
gsrj-11	24	13	recent	recent	ADJ
gsrj-11	24	14	developments	development	NOUN
gsrj-11	24	15	in	in	ADP
gsrj-11	24	16	targeted	target	VERB
gsrj-11	24	17	inhibitor	inhibitor	NOUN
gsrj-11	24	18	therapeutics	therapeutic	NOUN
gsrj-11	24	19	as	as	ADP
gsrj-11	24	20	a	a	DET
gsrj-11	24	21	possible	possible	ADJ
gsrj-11	24	22	treatment	treatment	NOUN
gsrj-11	24	23	for	for	ADP
gsrj-11	24	24	shh	shh	INTJ
gsrj-11	24	25	mb	mb	PROPN
gsrj-11	24	26	and	and	CCONJ
gsrj-11	24	27	suggest	suggest	VERB
gsrj-11	24	28	further	further	ADJ
gsrj-11	24	29	research	research	NOUN
gsrj-11	24	30	that	that	PRON
gsrj-11	24	31	would	would	AUX
gsrj-11	24	32	improve	improve	VERB
gsrj-11	24	33	the	the	DET
gsrj-11	24	34	efficacy	efficacy	NOUN
gsrj-11	24	35	of	of	ADP
gsrj-11	24	36	the	the	DET
gsrj-11	24	37	inhibitors	inhibitor	NOUN
gsrj-11	24	38	.	.	PUNCT
gsrj-11	25	1	the	the	DET
gsrj-11	25	2	sources	source	NOUN
gsrj-11	25	3	examined	examine	VERB
gsrj-11	25	4	describe	describe	VERB
gsrj-11	25	5	the	the	DET
gsrj-11	25	6	mechanism	mechanism	NOUN
gsrj-11	25	7	of	of	ADP
gsrj-11	25	8	action	action	NOUN
gsrj-11	25	9	and	and	CCONJ
gsrj-11	25	10	value	value	NOUN
gsrj-11	25	11	of	of	ADP
gsrj-11	25	12	five	five	NUM
gsrj-11	25	13	shh	shh	NOUN
gsrj-11	25	14	inhibitors	inhibitor	NOUN
gsrj-11	25	15	:	:	PUNCT
gsrj-11	25	16	vismodegib	vismodegib	NOUN
gsrj-11	25	17	,	,	PUNCT
gsrj-11	25	18	sonidegib	sonidegib	NOUN
gsrj-11	25	19	,	,	PUNCT
gsrj-11	25	20	glasdegib	glasdegib	NOUN
gsrj-11	25	21	,	,	PUNCT
gsrj-11	25	22	temozolomide	temozolomide	NOUN
gsrj-11	25	23	,	,	PUNCT
gsrj-11	25	24	and	and	CCONJ
gsrj-11	25	25	gant-61	gant-61	PROPN
gsrj-11	25	26	.	.	PUNCT
gsrj-11	26	1	significant	significant	ADJ
gsrj-11	26	2	work	work	NOUN
gsrj-11	26	3	has	have	AUX
gsrj-11	26	4	been	be	AUX
gsrj-11	26	5	recently	recently	ADV
gsrj-11	26	6	devoted	devote	VERB
gsrj-11	26	7	to	to	ADP
gsrj-11	26	8	the	the	DET
gsrj-11	26	9	development	development	NOUN
gsrj-11	26	10	of	of	ADP
gsrj-11	26	11	these	these	DET
gsrj-11	26	12	inhibitors	inhibitor	NOUN
gsrj-11	26	13	,	,	PUNCT
gsrj-11	26	14	and	and	CCONJ
gsrj-11	26	15	researchers	researcher	NOUN
gsrj-11	26	16	need	need	VERB
gsrj-11	26	17	to	to	PART
gsrj-11	26	18	understand	understand	VERB
gsrj-11	26	19	the	the	DET
gsrj-11	26	20	extent	extent	NOUN
gsrj-11	26	21	of	of	ADP
gsrj-11	26	22	this	this	DET
gsrj-11	26	23	recent	recent	ADJ
gsrj-11	26	24	progress	progress	NOUN
gsrj-11	26	25	in	in	ADP
gsrj-11	26	26	order	order	NOUN
gsrj-11	26	27	to	to	PART
gsrj-11	26	28	plan	plan	VERB
gsrj-11	26	29	their	their	PRON
gsrj-11	26	30	next	next	ADJ
gsrj-11	26	31	steps	step	NOUN
gsrj-11	26	32	.	.	PUNCT
gsrj-11	27	1	therefore	therefore	ADV
gsrj-11	27	2	,	,	PUNCT
gsrj-11	27	3	this	this	DET
gsrj-11	27	4	review	review	NOUN
gsrj-11	27	5	serves	serve	VERB
gsrj-11	27	6	as	as	ADP
gsrj-11	27	7	an	an	DET
gsrj-11	27	8	important	important	ADJ
gsrj-11	27	9	resource	resource	NOUN
gsrj-11	27	10	because	because	SCONJ
gsrj-11	27	11	it	it	PRON
gsrj-11	27	12	86	86	NUM
gsrj-11	27	13	georgetown	georgetown	PROPN
gsrj-11	27	14	scientific	scientific	PROPN
gsrj-11	27	15	research	research	PROPN
gsrj-11	27	16	journal	journal	PROPN
gsrj-11	27	17	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	27	18	presents	present	VERB
gsrj-11	27	19	a	a	DET
gsrj-11	27	20	summary	summary	NOUN
gsrj-11	27	21	and	and	CCONJ
gsrj-11	27	22	evaluation	evaluation	NOUN
gsrj-11	27	23	of	of	ADP
gsrj-11	27	24	findings	finding	NOUN
gsrj-11	27	25	regarding	regard	VERB
gsrj-11	27	26	the	the	DET
gsrj-11	27	27	efficacy	efficacy	NOUN
gsrj-11	27	28	of	of	ADP
gsrj-11	27	29	shh	shh	PROPN
gsrj-11	27	30	inhibitors	inhibitor	NOUN
gsrj-11	27	31	,	,	PUNCT
gsrj-11	27	32	as	as	ADV
gsrj-11	27	33	well	well	ADV
gsrj-11	27	34	as	as	ADP
gsrj-11	27	35	potential	potential	ADJ
gsrj-11	27	36	future	future	ADJ
gsrj-11	27	37	steps	step	NOUN
gsrj-11	27	38	to	to	PART
gsrj-11	27	39	eventually	eventually	ADV
gsrj-11	27	40	use	use	VERB
gsrj-11	27	41	these	these	DET
gsrj-11	27	42	therapeutics	therapeutic	NOUN
gsrj-11	27	43	in	in	ADP
gsrj-11	27	44	clinical	clinical	ADJ
gsrj-11	27	45	practice	practice	NOUN
gsrj-11	27	46	.	.	PUNCT
gsrj-11	28	1	overall	overall	ADJ
gsrj-11	28	2	,	,	PUNCT
gsrj-11	28	3	novel	novel	ADJ
gsrj-11	28	4	findings	finding	NOUN
gsrj-11	28	5	suggest	suggest	VERB
gsrj-11	28	6	that	that	SCONJ
gsrj-11	28	7	inhibitors	inhibitor	NOUN
gsrj-11	28	8	of	of	ADP
gsrj-11	28	9	the	the	DET
gsrj-11	28	10	shh	shh	PROPN
gsrj-11	28	11	pathway	pathway	NOUN
gsrj-11	28	12	exhibit	exhibit	PROPN
gsrj-11	28	13	efficacy	efficacy	NOUN
gsrj-11	28	14	in	in	ADP
gsrj-11	28	15	suppressing	suppress	VERB
gsrj-11	28	16	the	the	DET
gsrj-11	28	17	pathway	pathway	NOUN
gsrj-11	28	18	and	and	CCONJ
gsrj-11	28	19	diminishing	diminish	VERB
gsrj-11	28	20	tumor	tumor	NOUN
gsrj-11	28	21	growth	growth	NOUN
gsrj-11	28	22	in	in	ADP
gsrj-11	28	23	shh	shh	INTJ
gsrj-11	28	24	mb	mb	NOUN
gsrj-11	28	25	;	;	PUNCT
gsrj-11	28	26	however	however	ADV
gsrj-11	28	27	,	,	PUNCT
gsrj-11	28	28	further	further	ADJ
gsrj-11	28	29	investigation	investigation	NOUN
gsrj-11	28	30	is	be	AUX
gsrj-11	28	31	needed	need	VERB
gsrj-11	28	32	to	to	PART
gsrj-11	28	33	overcome	overcome	VERB
gsrj-11	28	34	the	the	DET
gsrj-11	28	35	limitations	limitation	NOUN
gsrj-11	28	36	that	that	PRON
gsrj-11	28	37	arise	arise	VERB
gsrj-11	28	38	with	with	ADP
gsrj-11	28	39	these	these	DET
gsrj-11	28	40	therapeutics	therapeutic	NOUN
gsrj-11	28	41	.	.	PUNCT
gsrj-11	29	1	2	2	X
gsrj-11	29	2	.	.	X
gsrj-11	29	3	the	the	DET
gsrj-11	29	4	hedgehog	hedgehog	PROPN
gsrj-11	29	5	pathway	pathway	NOUN
gsrj-11	29	6	shh	shh	PROPN
gsrj-11	29	7	-	-	PUNCT
gsrj-11	29	8	mb	mb	PROPN
gsrj-11	29	9	is	be	AUX
gsrj-11	29	10	named	name	VERB
gsrj-11	29	11	as	as	ADP
gsrj-11	29	12	such	such	ADJ
gsrj-11	29	13	because	because	SCONJ
gsrj-11	29	14	the	the	DET
gsrj-11	29	15	overactivation	overactivation	NOUN
gsrj-11	29	16	of	of	ADP
gsrj-11	29	17	the	the	DET
gsrj-11	29	18	shh	shh	PROPN
gsrj-11	29	19	pathway	pathway	NOUN
gsrj-11	29	20	is	be	AUX
gsrj-11	29	21	the	the	DET
gsrj-11	29	22	mechanism	mechanism	NOUN
gsrj-11	29	23	driving	drive	VERB
gsrj-11	29	24	the	the	DET
gsrj-11	29	25	formation	formation	NOUN
gsrj-11	29	26	of	of	ADP
gsrj-11	29	27	this	this	DET
gsrj-11	29	28	tumor	tumor	NOUN
gsrj-11	29	29	.	.	PUNCT
gsrj-11	30	1	evidence	evidence	NOUN
gsrj-11	30	2	suggests	suggest	VERB
gsrj-11	30	3	that	that	SCONJ
gsrj-11	30	4	mutations	mutation	NOUN
gsrj-11	30	5	in	in	ADP
gsrj-11	30	6	genes	gene	NOUN
gsrj-11	30	7	that	that	PRON
gsrj-11	30	8	contribute	contribute	VERB
gsrj-11	30	9	to	to	ADP
gsrj-11	30	10	the	the	DET
gsrj-11	30	11	shh	shh	PROPN
gsrj-11	30	12	pathway	pathway	NOUN
gsrj-11	30	13	may	may	AUX
gsrj-11	30	14	generate	generate	VERB
gsrj-11	30	15	tumorigenesis	tumorigenesis	NOUN
gsrj-11	30	16	.	.	PUNCT
gsrj-11	31	1	some	some	PRON
gsrj-11	31	2	of	of	ADP
gsrj-11	31	3	these	these	DET
gsrj-11	31	4	genes	gene	NOUN
gsrj-11	31	5	include	include	VERB
gsrj-11	31	6	the	the	DET
gsrj-11	31	7	patched	patch	VERB
gsrj-11	31	8	homologue	homologue	NOUN
gsrj-11	31	9	1	1	NUM
gsrj-11	31	10	gene	gene	NOUN
gsrj-11	31	11	(	(	PUNCT
gsrj-11	31	12	ptch1	ptch1	PROPN
gsrj-11	31	13	)	)	PUNCT
gsrj-11	31	14	,	,	PUNCT
gsrj-11	31	15	smoothened	smoothen	VERB
gsrj-11	31	16	homologue	homologue	NOUN
gsrj-11	31	17	gene	gene	NOUN
gsrj-11	31	18	(	(	PUNCT
gsrj-11	31	19	smo	smo	PROPN
gsrj-11	31	20	)	)	PUNCT
gsrj-11	31	21	,	,	PUNCT
gsrj-11	31	22	and	and	CCONJ
gsrj-11	31	23	the	the	DET
gsrj-11	31	24	suppressor	suppressor	NOUN
gsrj-11	31	25	of	of	ADP
gsrj-11	31	26	fused	fuse	VERB
gsrj-11	31	27	homologue	homologue	NOUN
gsrj-11	31	28	gene	gene	NOUN
gsrj-11	31	29	(	(	PUNCT
gsrj-11	31	30	sufu	sufu	PROPN
gsrj-11	31	31	)	)	PUNCT
gsrj-11	31	32	.	.	PUNCT
gsrj-11	32	1	heightened	heighten	VERB
gsrj-11	32	2	expression	expression	NOUN
gsrj-11	32	3	of	of	ADP
gsrj-11	32	4	the	the	DET
gsrj-11	32	5	gli	gli	NOUN
gsrj-11	32	6	zinc	zinc	NOUN
gsrj-11	32	7	finger	finger	NOUN
gsrj-11	32	8	transcription	transcription	NOUN
gsrj-11	32	9	factors	factor	NOUN
gsrj-11	32	10	(	(	PUNCT
gsrj-11	32	11	gli1	gli1	NOUN
gsrj-11	32	12	,	,	PUNCT
gsrj-11	32	13	gli2	gli2	PROPN
gsrj-11	32	14	,	,	PUNCT
gsrj-11	32	15	gli3	gli3	PROPN
gsrj-11	32	16	)	)	PUNCT
gsrj-11	32	17	and	and	CCONJ
gsrj-11	32	18	mycn	mycn	NOUN
gsrj-11	32	19	,	,	PUNCT
gsrj-11	32	20	an	an	DET
gsrj-11	32	21	oncogene	oncogene	NOUN
gsrj-11	32	22	,	,	PUNCT
gsrj-11	32	23	has	have	AUX
gsrj-11	32	24	also	also	ADV
gsrj-11	32	25	been	be	AUX
gsrj-11	32	26	associated	associate	VERB
gsrj-11	32	27	with	with	ADP
gsrj-11	32	28	the	the	DET
gsrj-11	32	29	formation	formation	NOUN
gsrj-11	32	30	of	of	ADP
gsrj-11	32	31	shh	shh	INTJ
gsrj-11	32	32	mb	mb	NOUN
gsrj-11	32	33	.	.	PROPN
gsrj-11	33	1	when	when	SCONJ
gsrj-11	33	2	the	the	DET
gsrj-11	33	3	ligand	ligand	NOUN
gsrj-11	33	4	for	for	ADP
gsrj-11	33	5	the	the	DET
gsrj-11	33	6	shh	shh	PROPN
gsrj-11	33	7	pathway	pathway	NOUN
gsrj-11	33	8	is	be	AUX
gsrj-11	33	9	not	not	PART
gsrj-11	33	10	present	present	ADJ
gsrj-11	33	11	,	,	PUNCT
gsrj-11	33	12	the	the	DET
gsrj-11	33	13	patched	patch	VERB
gsrj-11	33	14	1	1	NUM
gsrj-11	33	15	(	(	PUNCT
gsrj-11	33	16	ptch	ptch	NOUN
gsrj-11	33	17	)	)	PUNCT
gsrj-11	33	18	protein	protein	NOUN
gsrj-11	33	19	,	,	PUNCT
gsrj-11	33	20	a	a	DET
gsrj-11	33	21	12	12	NUM
gsrj-11	33	22	transmembrane	transmembrane	ADJ
gsrj-11	33	23	receptor	receptor	NOUN
gsrj-11	33	24	protein	protein	NOUN
gsrj-11	33	25	,	,	PUNCT
gsrj-11	33	26	represses	repress	VERB
gsrj-11	33	27	the	the	DET
gsrj-11	33	28	smoothened	smoothened	ADJ
gsrj-11	33	29	receptor	receptor	NOUN
gsrj-11	33	30	(	(	PUNCT
gsrj-11	33	31	smo	smo	PROPN
gsrj-11	33	32	)	)	PUNCT
gsrj-11	33	33	,	,	PUNCT
gsrj-11	33	34	thereby	thereby	ADV
gsrj-11	33	35	inhibiting	inhibit	VERB
gsrj-11	33	36	the	the	DET
gsrj-11	33	37	pathway	pathway	NOUN
gsrj-11	33	38	.	.	PUNCT
gsrj-11	34	1	as	as	SCONJ
gsrj-11	34	2	shown	show	VERB
gsrj-11	34	3	in	in	ADP
gsrj-11	34	4	figure	figure	NOUN
gsrj-11	34	5	1	1	NUM
gsrj-11	34	6	,	,	PUNCT
gsrj-11	34	7	when	when	SCONJ
gsrj-11	34	8	a	a	DET
gsrj-11	34	9	ptch	ptch	NOUN
gsrj-11	34	10	ligand	ligand	NOUN
gsrj-11	34	11	,	,	PUNCT
gsrj-11	34	12	such	such	ADJ
gsrj-11	34	13	as	as	ADP
gsrj-11	34	14	sonic	sonic	ADJ
gsrj-11	34	15	hedgehog	hedgehog	NOUN
gsrj-11	34	16	,	,	PUNCT
gsrj-11	34	17	is	be	AUX
gsrj-11	34	18	present	present	ADJ
gsrj-11	34	19	,	,	PUNCT
gsrj-11	34	20	it	it	PRON
gsrj-11	34	21	binds	bind	VERB
gsrj-11	34	22	to	to	ADP
gsrj-11	34	23	ptch1	ptch1	PROPN
gsrj-11	34	24	and	and	CCONJ
gsrj-11	34	25	activates	activate	VERB
gsrj-11	34	26	the	the	DET
gsrj-11	34	27	pathway	pathway	NOUN
gsrj-11	34	28	,	,	PUNCT
gsrj-11	34	29	as	as	SCONJ
gsrj-11	34	30	smo	smo	PROPN
gsrj-11	34	31	is	be	AUX
gsrj-11	34	32	no	no	ADV
gsrj-11	34	33	longer	long	ADV
gsrj-11	34	34	suppressed	suppress	VERB
gsrj-11	34	35	.	.	PUNCT
gsrj-11	35	1	next	next	ADV
gsrj-11	35	2	,	,	PUNCT
gsrj-11	35	3	smo	smo	PROPN
gsrj-11	35	4	is	be	AUX
gsrj-11	35	5	moved	move	VERB
gsrj-11	35	6	to	to	ADP
gsrj-11	35	7	the	the	DET
gsrj-11	35	8	primary	primary	ADJ
gsrj-11	35	9	cilium	cilium	NOUN
gsrj-11	35	10	,	,	PUNCT
gsrj-11	35	11	and	and	CCONJ
gsrj-11	35	12	it	it	PRON
gsrj-11	35	13	then	then	ADV
gsrj-11	35	14	activates	activate	VERB
gsrj-11	35	15	a	a	DET
gsrj-11	35	16	gli	gli	NOUN
gsrj-11	35	17	zinc	zinc	NOUN
gsrj-11	35	18	finger	finger	NOUN
gsrj-11	35	19	transcription	transcription	NOUN
gsrj-11	35	20	factor	factor	NOUN
gsrj-11	35	21	,	,	PUNCT
gsrj-11	35	22	which	which	PRON
gsrj-11	35	23	could	could	AUX
gsrj-11	35	24	be	be	AUX
gsrj-11	35	25	gli1	gli1	NOUN
gsrj-11	35	26	,	,	PUNCT
gsrj-11	35	27	gli2	gli2	NOUN
gsrj-11	35	28	,	,	PUNCT
gsrj-11	35	29	or	or	CCONJ
gsrj-11	35	30	gli3	gli3	PROPN
gsrj-11	35	31	.	.	PUNCT
gsrj-11	36	1	once	once	ADV
gsrj-11	36	2	a	a	DET
gsrj-11	36	3	gli	gli	NOUN
gsrj-11	36	4	factor	factor	NOUN
gsrj-11	36	5	is	be	AUX
gsrj-11	36	6	stimulated	stimulate	VERB
gsrj-11	36	7	,	,	PUNCT
gsrj-11	36	8	the	the	DET
gsrj-11	36	9	transcription	transcription	NOUN
gsrj-11	36	10	of	of	ADP
gsrj-11	36	11	target	target	NOUN
gsrj-11	36	12	genes	gene	NOUN
gsrj-11	36	13	for	for	ADP
gsrj-11	36	14	the	the	DET
gsrj-11	36	15	shh	shh	PROPN
gsrj-11	36	16	pathway	pathway	NOUN
gsrj-11	36	17	(	(	PUNCT
gsrj-11	36	18	e.g.	e.g.	ADV
gsrj-11	36	19	gli1	gli1	NOUN
gsrj-11	36	20	,	,	PUNCT
gsrj-11	36	21	ptchi1	ptchi1	NOUN
gsrj-11	36	22	,	,	PUNCT
gsrj-11	36	23	cyclin	cyclin	NOUN
gsrj-11	36	24	d1	d1	NOUN
gsrj-11	36	25	,	,	PUNCT
gsrj-11	36	26	bcl-2	bcl-2	NOUN
gsrj-11	36	27	,	,	PUNCT
gsrj-11	36	28	snail	snail	NOUN
gsrj-11	36	29	)	)	PUNCT
gsrj-11	36	30	is	be	AUX
gsrj-11	36	31	promoted	promote	VERB
gsrj-11	36	32	.	.	PUNCT
gsrj-11	37	1	anomalous	anomalous	ADJ
gsrj-11	37	2	activity	activity	NOUN
gsrj-11	37	3	at	at	ADP
gsrj-11	37	4	any	any	DET
gsrj-11	37	5	stage	stage	NOUN
gsrj-11	37	6	of	of	ADP
gsrj-11	37	7	this	this	DET
gsrj-11	37	8	pathway	pathway	NOUN
gsrj-11	37	9	may	may	AUX
gsrj-11	37	10	spur	spur	VERB
gsrj-11	37	11	the	the	DET
gsrj-11	37	12	formation	formation	NOUN
gsrj-11	37	13	of	of	ADP
gsrj-11	37	14	medulloblastoma	medulloblastoma	NOUN
gsrj-11	37	15	.	.	PUNCT
gsrj-11	38	1	the	the	DET
gsrj-11	38	2	most	most	ADV
gsrj-11	38	3	prominent	prominent	ADJ
gsrj-11	38	4	drivers	driver	NOUN
gsrj-11	38	5	of	of	ADP
gsrj-11	38	6	shh	shh	INTJ
gsrj-11	38	7	mb	mb	PART
gsrj-11	38	8	include	include	VERB
gsrj-11	38	9	aberrant	aberrant	ADJ
gsrj-11	38	10	expression	expression	NOUN
gsrj-11	38	11	of	of	ADP
gsrj-11	38	12	shh	shh	PROPN
gsrj-11	38	13	target	target	NOUN
gsrj-11	38	14	genes	gene	NOUN
gsrj-11	38	15	,	,	PUNCT
gsrj-11	38	16	ptch	ptch	VERB
gsrj-11	38	17	dysfunction	dysfunction	NOUN
gsrj-11	38	18	,	,	PUNCT
gsrj-11	38	19	and	and	CCONJ
gsrj-11	38	20	smo	smo	PROPN
gsrj-11	38	21	promotion.6	promotion.6	NOUN
gsrj-11	38	22	to	to	PART
gsrj-11	38	23	counter	counter	VERB
gsrj-11	38	24	the	the	DET
gsrj-11	38	25	deleterious	deleterious	ADJ
gsrj-11	38	26	effects	effect	NOUN
gsrj-11	38	27	of	of	ADP
gsrj-11	38	28	these	these	DET
gsrj-11	38	29	shh	shh	PROPN
gsrj-11	38	30	pathway	pathway	NOUN
gsrj-11	38	31	permutations	permutation	NOUN
gsrj-11	38	32	,	,	PUNCT
gsrj-11	38	33	targeted	target	VERB
gsrj-11	38	34	small	small	ADJ
gsrj-11	38	35	molecule	molecule	NOUN
gsrj-11	38	36	inhibitors	inhibitor	NOUN
gsrj-11	38	37	that	that	PRON
gsrj-11	38	38	prevent	prevent	VERB
gsrj-11	38	39	the	the	DET
gsrj-11	38	40	shh	shh	PROPN
gsrj-11	38	41	ligand	ligand	NOUN
gsrj-11	38	42	from	from	ADP
gsrj-11	38	43	binding	bind	VERB
gsrj-11	38	44	to	to	AUX
gsrj-11	38	45	ptch	ptch	VERB
gsrj-11	38	46	or	or	CCONJ
gsrj-11	38	47	antagonists	antagonist	NOUN
gsrj-11	38	48	of	of	ADP
gsrj-11	38	49	smo	smo	PROPN
gsrj-11	38	50	have	have	AUX
gsrj-11	38	51	risen	rise	VERB
gsrj-11	38	52	as	as	ADP
gsrj-11	38	53	potential	potential	ADJ
gsrj-11	38	54	therapeutics	therapeutic	NOUN
gsrj-11	38	55	against	against	ADP
gsrj-11	38	56	shh	shh	INTJ
gsrj-11	38	57	mb	mb	PROPN
gsrj-11	38	58	.	.	PROPN
gsrj-11	38	59	figure	figure	NOUN
gsrj-11	38	60	1	1	NUM
gsrj-11	38	61	.	.	PUNCT
gsrj-11	39	1	an	an	DET
gsrj-11	39	2	overview	overview	NOUN
gsrj-11	39	3	of	of	ADP
gsrj-11	39	4	the	the	DET
gsrj-11	39	5	hedgehog	hedgehog	NOUN
gsrj-11	39	6	signaling	signal	VERB
gsrj-11	39	7	pathway	pathway	NOUN
gsrj-11	39	8	.	.	PUNCT
gsrj-11	40	1	in	in	ADP
gsrj-11	40	2	the	the	DET
gsrj-11	40	3	absence	absence	NOUN
gsrj-11	40	4	of	of	ADP
gsrj-11	40	5	a	a	DET
gsrj-11	40	6	ptch	ptch	NOUN
gsrj-11	40	7	ligand	ligand	NOUN
gsrj-11	40	8	(	(	PUNCT
gsrj-11	40	9	e.g.	e.g.	ADV
gsrj-11	40	10	sonic	sonic	ADJ
gsrj-11	40	11	hedgehog	hedgehog	NOUN
gsrj-11	40	12	)	)	PUNCT
gsrj-11	40	13	,	,	PUNCT
gsrj-11	40	14	ptch	ptch	NOUN
gsrj-11	40	15	represses	repress	VERB
gsrj-11	40	16	smo	smo	PROPN
gsrj-11	40	17	.	.	PUNCT
gsrj-11	41	1	once	once	SCONJ
gsrj-11	41	2	sonic	sonic	ADJ
gsrj-11	41	3	hedgehog	hedgehog	NOUN
gsrj-11	41	4	binds	bind	NOUN
gsrj-11	41	5	,	,	PUNCT
gsrj-11	41	6	ptch	ptch	AUX
gsrj-11	41	7	no	no	ADV
gsrj-11	41	8	longer	long	ADV
gsrj-11	41	9	inhibits	inhibit	VERB
gsrj-11	41	10	smo	smo	PROPN
gsrj-11	41	11	,	,	PUNCT
gsrj-11	41	12	and	and	CCONJ
gsrj-11	41	13	smo	smo	PROPN
gsrj-11	41	14	is	be	AUX
gsrj-11	41	15	translocated	translocate	VERB
gsrj-11	41	16	to	to	ADP
gsrj-11	41	17	the	the	DET
gsrj-11	41	18	primary	primary	ADJ
gsrj-11	41	19	cilium	cilium	NOUN
gsrj-11	41	20	,	,	PUNCT
gsrj-11	41	21	where	where	SCONJ
gsrj-11	41	22	it	it	PRON
gsrj-11	41	23	subsequently	subsequently	ADV
gsrj-11	41	24	activates	activate	VERB
gsrj-11	41	25	gli	gli	NOUN
gsrj-11	41	26	transcription	transcription	NOUN
gsrj-11	41	27	factors	factor	NOUN
gsrj-11	41	28	that	that	PRON
gsrj-11	41	29	promote	promote	VERB
gsrj-11	41	30	target	target	NOUN
gsrj-11	41	31	gene	gene	NOUN
gsrj-11	41	32	expression	expression	NOUN
gsrj-11	41	33	of	of	ADP
gsrj-11	41	34	the	the	DET
gsrj-11	41	35	hedgehog	hedgehog	NOUN
gsrj-11	41	36	pathway	pathway	NOUN
gsrj-11	41	37	.	.	PUNCT
gsrj-11	42	1	3	3	X
gsrj-11	42	2	.	.	X
gsrj-11	42	3	mechanism	mechanism	NOUN
gsrj-11	42	4	of	of	ADP
gsrj-11	42	5	action	action	NOUN
gsrj-11	42	6	for	for	ADP
gsrj-11	42	7	small	small	ADJ
gsrj-11	42	8	molecule	molecule	NOUN
gsrj-11	42	9	inhibitors	inhibitor	NOUN
gsrj-11	42	10	of	of	ADP
gsrj-11	42	11	the	the	DET
gsrj-11	42	12	sonic	sonic	ADJ
gsrj-11	42	13	hedgehog	hedgehog	NOUN
gsrj-11	42	14	pathway	pathway	NOUN
gsrj-11	42	15	the	the	DET
gsrj-11	42	16	following	follow	VERB
gsrj-11	42	17	shh	shh	PROPN
gsrj-11	42	18	pathway	pathway	NOUN
gsrj-11	42	19	inhibitors	inhibitor	NOUN
gsrj-11	42	20	are	be	AUX
gsrj-11	42	21	potential	potential	ADJ
gsrj-11	42	22	targeted	targeted	ADJ
gsrj-11	42	23	therapeutics	therapeutic	NOUN
gsrj-11	42	24	for	for	ADP
gsrj-11	42	25	shh	shh	INTJ
gsrj-11	42	26	mb	mb	NOUN
gsrj-11	42	27	:	:	PUNCT
gsrj-11	42	28	vismodegib	vismodegib	NOUN
gsrj-11	42	29	,	,	PUNCT
gsrj-11	42	30	sonidegib	sonidegib	NOUN
gsrj-11	42	31	,	,	PUNCT
gsrj-11	42	32	glasdegib	glasdegib	NOUN
gsrj-11	42	33	,	,	PUNCT
gsrj-11	42	34	temozolomide	temozolomide	NOUN
gsrj-11	42	35	,	,	PUNCT
gsrj-11	42	36	and	and	CCONJ
gsrj-11	42	37	gant-61	gant-61	PROPN
gsrj-11	42	38	.	.	PUNCT
gsrj-11	43	1	as	as	SCONJ
gsrj-11	43	2	seen	see	VERB
gsrj-11	43	3	in	in	ADP
gsrj-11	43	4	figure	figure	NOUN
gsrj-11	43	5	2	2	NUM
gsrj-11	43	6	,	,	PUNCT
gsrj-11	43	7	they	they	PRON
gsrj-11	43	8	target	target	VERB
gsrj-11	43	9	and	and	CCONJ
gsrj-11	43	10	block	block	VERB
gsrj-11	43	11	specific	specific	ADJ
gsrj-11	43	12	parts	part	NOUN
gsrj-11	43	13	of	of	ADP
gsrj-11	43	14	the	the	DET
gsrj-11	43	15	hedgehog	hedgehog	NOUN
gsrj-11	43	16	pathway	pathway	NOUN
gsrj-11	43	17	.	.	PUNCT
gsrj-11	44	1	they	they	PRON
gsrj-11	44	2	are	be	AUX
gsrj-11	44	3	not	not	PART
gsrj-11	44	4	yet	yet	ADV
gsrj-11	44	5	approved	approve	VERB
gsrj-11	44	6	for	for	ADP
gsrj-11	44	7	treatment	treatment	NOUN
gsrj-11	44	8	for	for	ADP
gsrj-11	44	9	mb	mb	PROPN
gsrj-11	44	10	.	.	PUNCT
gsrj-11	44	11	�	�	NOUN
gsrj-11	44	12	#	#	NOUN
gsrj-11	44	13	!	!	PUNCT
gsrj-11	45	1	/,	/,	PROPN
gsrj-11	45	2	�	�	PROPN
gsrj-11	45	3	5h8	5h8	NUM
gsrj-11	45	4	�	�	PROPN
gsrj-11	45	5	$poujovfe	$poujovfe	PROPN
gsrj-11	45	6	�	�	PROPN
gsrj-11	45	7	po	po	NOUN
gsrj-11	45	8	�	�	PROPN
gsrj-11	45	9	ofyu	ofyu	PROPN
gsrj-11	45	10	�	�	PROPN
gsrj-11	45	11	qbhf	qbhf	PROPN
gsrj-11	45	12	�	�	PROPN
gsrj-11	45	13	�	�	PROPN
gsrj-11	45	14	87	87	NUM
gsrj-11	45	15	georgetown	georgetown	PROPN
gsrj-11	45	16	scientific	scientific	PROPN
gsrj-11	45	17	research	research	PROPN
gsrj-11	45	18	journal	journal	PROPN
gsrj-11	45	19	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	NOUN
gsrj-11	45	20	figure	figure	NOUN
gsrj-11	45	21	2	2	NUM
gsrj-11	45	22	.	.	PUNCT
gsrj-11	45	23	overview	overview	NOUN
gsrj-11	45	24	of	of	ADP
gsrj-11	45	25	where	where	SCONJ
gsrj-11	45	26	the	the	DET
gsrj-11	45	27	inhibitors	inhibitor	NOUN
gsrj-11	45	28	target	target	VERB
gsrj-11	45	29	the	the	DET
gsrj-11	45	30	pathway	pathway	NOUN
gsrj-11	45	31	.	.	PUNCT
gsrj-11	46	1	as	as	SCONJ
gsrj-11	46	2	shown	show	VERB
gsrj-11	46	3	,	,	PUNCT
gsrj-11	46	4	vismodegib	vismodegib	NOUN
gsrj-11	46	5	targets	target	NOUN
gsrj-11	46	6	ptch1	ptch1	PROPN
gsrj-11	46	7	and	and	CCONJ
gsrj-11	46	8	smo	smo	PROPN
gsrj-11	46	9	.	.	PROPN
gsrj-11	46	10	glasdegib	glasdegib	NOUN
gsrj-11	46	11	and	and	CCONJ
gsrj-11	46	12	sonidegib	sonidegib	NOUN
gsrj-11	46	13	are	be	AUX
gsrj-11	46	14	smo	smo	PROPN
gsrj-11	46	15	antagonists	antagonist	NOUN
gsrj-11	46	16	.	.	PUNCT
gsrj-11	47	1	gant-61	gant-61	NOUN
gsrj-11	47	2	is	be	AUX
gsrj-11	47	3	a	a	DET
gsrj-11	47	4	gli	gli	NOUN
gsrj-11	47	5	inhibitor	inhibitor	NOUN
gsrj-11	47	6	.	.	PUNCT
gsrj-11	48	1	however	however	ADV
gsrj-11	48	2	,	,	PUNCT
gsrj-11	48	3	both	both	DET
gsrj-11	48	4	vismodegib	vismodegib	NOUN
gsrj-11	48	5	and	and	CCONJ
gsrj-11	48	6	sonidegib	sonidegib	NOUN
gsrj-11	48	7	were	be	AUX
gsrj-11	48	8	approved	approve	VERB
gsrj-11	48	9	for	for	ADP
gsrj-11	48	10	metastatic	metastatic	ADJ
gsrj-11	48	11	non	non	ADJ
gsrj-11	48	12	-	-	ADJ
gsrj-11	48	13	resectable	resectable	ADJ
gsrj-11	48	14	basal	basal	NOUN
gsrj-11	48	15	cell	cell	NOUN
gsrj-11	48	16	carcinoma	carcinoma	NOUN
gsrj-11	48	17	in	in	ADP
gsrj-11	48	18	2012	2012	NUM
gsrj-11	48	19	and	and	CCONJ
gsrj-11	48	20	2015	2015	NUM
gsrj-11	48	21	,	,	PUNCT
gsrj-11	48	22	respectively	respectively	ADV
gsrj-11	48	23	.	.	PUNCT
gsrj-11	49	1	glasdegib	glasdegib	NOUN
gsrj-11	49	2	was	be	AUX
gsrj-11	49	3	approved	approve	VERB
gsrj-11	49	4	in	in	ADP
gsrj-11	49	5	2018	2018	NUM
gsrj-11	49	6	for	for	ADP
gsrj-11	49	7	acute	acute	ADJ
gsrj-11	49	8	leukemia	leukemia	NOUN
gsrj-11	49	9	treatment.6	treatment.6	PROPN
gsrj-11	49	10	vismodegib	vismodegib	PROPN
gsrj-11	49	11	is	be	AUX
gsrj-11	49	12	a	a	DET
gsrj-11	49	13	small	small	ADJ
gsrj-11	49	14	molecule	molecule	NOUN
gsrj-11	49	15	drug	drug	NOUN
gsrj-11	49	16	taken	take	VERB
gsrj-11	49	17	orally	orally	ADV
gsrj-11	49	18	.	.	PUNCT
gsrj-11	50	1	in	in	ADP
gsrj-11	50	2	regard	regard	NOUN
gsrj-11	50	3	to	to	ADP
gsrj-11	50	4	the	the	DET
gsrj-11	50	5	shh	shh	PROPN
gsrj-11	50	6	pathway	pathway	PROPN
gsrj-11	50	7	described	describe	VERB
gsrj-11	50	8	above	above	ADV
gsrj-11	50	9	,	,	PUNCT
gsrj-11	50	10	it	it	PRON
gsrj-11	50	11	interacts	interact	VERB
gsrj-11	50	12	with	with	ADP
gsrj-11	50	13	smo	smo	NOUN
gsrj-11	50	14	and	and	CCONJ
gsrj-11	50	15	ptch	ptch	VERB
gsrj-11	50	16	by	by	ADP
gsrj-11	50	17	specifically	specifically	ADV
gsrj-11	50	18	blocking	block	VERB
gsrj-11	50	19	activities	activity	NOUN
gsrj-11	50	20	of	of	ADP
gsrj-11	50	21	hedgehog	hedgehog	ADJ
gsrj-11	50	22	-	-	PUNCT
gsrj-11	50	23	ligand	ligand	ADJ
gsrj-11	50	24	cell	cell	NOUN
gsrj-11	50	25	surface	surface	NOUN
gsrj-11	50	26	receptors	receptor	NOUN
gsrj-11	50	27	ptch	ptch	VERB
gsrj-11	50	28	and/or	and/or	CCONJ
gsrj-11	50	29	smo	smo	PROPN
gsrj-11	50	30	.	.	PUNCT
gsrj-11	51	1	by	by	ADP
gsrj-11	51	2	blocking	block	VERB
gsrj-11	51	3	the	the	DET
gsrj-11	51	4	process	process	NOUN
gsrj-11	51	5	here	here	ADV
gsrj-11	51	6	,	,	PUNCT
gsrj-11	51	7	hedgehog	hedgehog	NOUN
gsrj-11	51	8	signaling	signaling	NOUN
gsrj-11	51	9	is	be	AUX
gsrj-11	51	10	suppressed	suppress	VERB
gsrj-11	51	11	.	.	PUNCT
gsrj-11	52	1	when	when	SCONJ
gsrj-11	52	2	vismodegib	vismodegib	X
gsrj-11	52	3	(	(	PUNCT
gsrj-11	52	4	also	also	ADV
gsrj-11	52	5	known	know	VERB
gsrj-11	52	6	as	as	ADP
gsrj-11	52	7	gdc-0449	gdc-0449	NOUN
gsrj-11	52	8	)	)	PUNCT
gsrj-11	52	9	blocks	block	NOUN
gsrj-11	52	10	ptch	ptch	VERB
gsrj-11	52	11	,	,	PUNCT
gsrj-11	52	12	smo	smo	PROPN
gsrj-11	52	13	can	can	AUX
gsrj-11	52	14	continue	continue	VERB
gsrj-11	52	15	to	to	PART
gsrj-11	52	16	be	be	AUX
gsrj-11	52	17	repressed	repress	VERB
gsrj-11	52	18	,	,	PUNCT
gsrj-11	52	19	and	and	CCONJ
gsrj-11	52	20	not	not	PART
gsrj-11	52	21	further	far	ADV
gsrj-11	52	22	the	the	DET
gsrj-11	52	23	cycle.9	cycle.9	PROPN
gsrj-11	52	24	vismodegib	vismodegib	PROPN
gsrj-11	52	25	acts	act	VERB
gsrj-11	52	26	as	as	ADP
gsrj-11	52	27	an	an	DET
gsrj-11	52	28	smo	smo	NOUN
gsrj-11	52	29	antagonist	antagonist	NOUN
gsrj-11	52	30	,	,	PUNCT
gsrj-11	52	31	blocking	block	VERB
gsrj-11	52	32	the	the	DET
gsrj-11	52	33	smo	smo	PROPN
gsrj-11	52	34	receptor	receptor	NOUN
gsrj-11	52	35	.	.	PUNCT
gsrj-11	53	1	this	this	PRON
gsrj-11	53	2	prevents	prevent	VERB
gsrj-11	53	3	smo	smo	NOUN
gsrj-11	53	4	from	from	ADP
gsrj-11	53	5	activating	activate	VERB
gsrj-11	53	6	the	the	DET
gsrj-11	53	7	gli	gli	NOUN
gsrj-11	53	8	zinc	zinc	NOUN
gsrj-11	53	9	finger	finger	NOUN
gsrj-11	53	10	transcription	transcription	NOUN
gsrj-11	53	11	factors	factor	NOUN
gsrj-11	53	12	,	,	PUNCT
gsrj-11	53	13	further	far	ADV
gsrj-11	53	14	inhibiting	inhibit	VERB
gsrj-11	53	15	the	the	DET
gsrj-11	53	16	pathway	pathway	NOUN
gsrj-11	53	17	.	.	PUNCT
gsrj-11	54	1	vismodegib	vismodegib	NOUN
gsrj-11	54	2	is	be	AUX
gsrj-11	54	3	also	also	ADV
gsrj-11	54	4	a	a	DET
gsrj-11	54	5	kinase	kinase	NOUN
gsrj-11	54	6	inhibitor	inhibitor	NOUN
gsrj-11	54	7	,	,	PUNCT
gsrj-11	54	8	meaning	mean	VERB
gsrj-11	54	9	that	that	SCONJ
gsrj-11	54	10	it	it	PRON
gsrj-11	54	11	inhibits	inhibit	VERB
gsrj-11	54	12	activity	activity	NOUN
gsrj-11	54	13	of	of	ADP
gsrj-11	54	14	the	the	DET
gsrj-11	54	15	enzyme	enzyme	NOUN
gsrj-11	54	16	kinase	kinase	NOUN
gsrj-11	54	17	(	(	PUNCT
gsrj-11	54	18	kinases	kinase	NOUN
gsrj-11	54	19	can	can	AUX
gsrj-11	54	20	add	add	VERB
gsrj-11	54	21	phosphate	phosphate	ADJ
gsrj-11	54	22	groups	group	NOUN
gsrj-11	54	23	to	to	ADP
gsrj-11	54	24	proteins	protein	NOUN
gsrj-11	54	25	and	and	CCONJ
gsrj-11	54	26	change	change	VERB
gsrj-11	54	27	their	their	PRON
gsrj-11	54	28	functions	function	NOUN
gsrj-11	54	29	)	)	PUNCT
gsrj-11	54	30	.	.	PUNCT
gsrj-11	55	1	in	in	ADP
gsrj-11	55	2	an	an	DET
gsrj-11	55	3	in	in	ADP
gsrj-11	55	4	vivo	vivo	NOUN
gsrj-11	55	5	study	study	NOUN
gsrj-11	55	6	,	,	PUNCT
gsrj-11	55	7	vismodegib	vismodegib	PROPN
gsrj-11	55	8	has	have	AUX
gsrj-11	55	9	been	be	AUX
gsrj-11	55	10	shown	show	VERB
gsrj-11	55	11	to	to	PART
gsrj-11	55	12	affect	affect	VERB
gsrj-11	55	13	complete	complete	ADJ
gsrj-11	55	14	tumor	tumor	NOUN
gsrj-11	55	15	regression	regression	NOUN
gsrj-11	55	16	in	in	ADP
gsrj-11	55	17	mice	mouse	NOUN
gsrj-11	55	18	with	with	ADP
gsrj-11	55	19	doses	dose	NOUN
gsrj-11	55	20	of	of	ADP
gsrj-11	55	21	12.5	12.5	NUM
gsrj-11	55	22	mg	mg	NOUN
gsrj-11	55	23	/	/	SYM
gsrj-11	55	24	kg	kg	PROPN
gsrj-11	55	25	administered	administer	VERB
gsrj-11	55	26	twice	twice	ADV
gsrj-11	55	27	per	per	ADP
gsrj-11	55	28	day.10,11	day.10,11	NOUN
gsrj-11	55	29	additionally	additionally	ADV
gsrj-11	55	30	,	,	PUNCT
gsrj-11	55	31	vismodegib	vismodegib	NOUN
gsrj-11	55	32	has	have	AUX
gsrj-11	55	33	been	be	AUX
gsrj-11	55	34	shown	show	VERB
gsrj-11	55	35	to	to	PART
gsrj-11	55	36	yield	yield	VERB
gsrj-11	55	37	vast	vast	ADJ
gsrj-11	55	38	but	but	CCONJ
gsrj-11	55	39	impermanent	impermanent	ADJ
gsrj-11	55	40	tumor	tumor	NOUN
gsrj-11	55	41	regression	regression	NOUN
gsrj-11	55	42	and	and	CCONJ
gsrj-11	55	43	relief	relief	NOUN
gsrj-11	55	44	of	of	ADP
gsrj-11	55	45	symptoms	symptom	NOUN
gsrj-11	55	46	when	when	SCONJ
gsrj-11	55	47	given	give	VERB
gsrj-11	55	48	orally	orally	ADV
gsrj-11	55	49	with	with	ADP
gsrj-11	55	50	a	a	DET
gsrj-11	55	51	dose	dose	NOUN
gsrj-11	55	52	of	of	ADP
gsrj-11	55	53	540	540	NUM
gsrj-11	55	54	mg	mg	NUM
gsrj-11	55	55	/	/	SYM
gsrj-11	55	56	day	day	NOUN
gsrj-11	55	57	for	for	ADP
gsrj-11	55	58	3	3	NUM
gsrj-11	55	59	months	month	NOUN
gsrj-11	55	60	.	.	PUNCT
gsrj-11	56	1	this	this	DET
gsrj-11	56	2	data	data	NOUN
gsrj-11	56	3	is	be	AUX
gsrj-11	56	4	important	important	ADJ
gsrj-11	56	5	in	in	ADP
gsrj-11	56	6	evaluating	evaluate	VERB
gsrj-11	56	7	the	the	DET
gsrj-11	56	8	efficacy	efficacy	NOUN
gsrj-11	56	9	of	of	ADP
gsrj-11	56	10	targeted	target	VERB
gsrj-11	56	11	inhibitors	inhibitor	NOUN
gsrj-11	56	12	to	to	ADP
gsrj-11	56	13	the	the	DET
gsrj-11	56	14	shh	shh	PROPN
gsrj-11	56	15	pathway	pathway	NOUN
gsrj-11	56	16	as	as	ADP
gsrj-11	56	17	therapeutics	therapeutic	NOUN
gsrj-11	56	18	for	for	ADP
gsrj-11	56	19	shh	shh	PROPN
gsrj-11	56	20	mb	mb	PROPN
gsrj-11	56	21	.	.	PROPN
gsrj-11	56	22	sonidegib	sonidegib	PROPN
gsrj-11	56	23	is	be	AUX
gsrj-11	56	24	also	also	ADV
gsrj-11	56	25	a	a	DET
gsrj-11	56	26	smo	smo	NOUN
gsrj-11	56	27	antagonist	antagonist	NOUN
gsrj-11	56	28	.	.	PUNCT
gsrj-11	57	1	sonidegib	sonidegib	PROPN
gsrj-11	57	2	works	work	VERB
gsrj-11	57	3	by	by	ADP
gsrj-11	57	4	penetrating	penetrate	VERB
gsrj-11	57	5	the	the	DET
gsrj-11	57	6	blood	blood	NOUN
gsrj-11	57	7	-	-	PUNCT
gsrj-11	57	8	brain	brain	NOUN
gsrj-11	57	9	barrier	barrier	NOUN
gsrj-11	57	10	and	and	CCONJ
gsrj-11	57	11	blocking	block	VERB
gsrj-11	57	12	the	the	DET
gsrj-11	57	13	smo	smo	NOUN
gsrj-11	57	14	receptor	receptor	NOUN
gsrj-11	57	15	and	and	CCONJ
gsrj-11	57	16	therefore	therefore	ADV
gsrj-11	57	17	the	the	DET
gsrj-11	57	18	shh	shh	PROPN
gsrj-11	57	19	pathway	pathway	NOUN
gsrj-11	57	20	,	,	PUNCT
gsrj-11	57	21	making	make	VERB
gsrj-11	57	22	it	it	PRON
gsrj-11	57	23	a	a	DET
gsrj-11	57	24	potentially	potentially	ADV
gsrj-11	57	25	effective	effective	ADJ
gsrj-11	57	26	treatment	treatment	NOUN
gsrj-11	57	27	for	for	ADP
gsrj-11	57	28	shh	shh	INTJ
gsrj-11	57	29	mb	mb	NOUN
gsrj-11	57	30	.	.	PUNCT
gsrj-11	58	1	it	it	PRON
gsrj-11	58	2	has	have	AUX
gsrj-11	58	3	inhibited	inhibit	VERB
gsrj-11	58	4	tumor	tumor	NOUN
gsrj-11	58	5	growth	growth	NOUN
gsrj-11	58	6	in	in	ADP
gsrj-11	58	7	mice	mouse	NOUN
gsrj-11	58	8	when	when	SCONJ
gsrj-11	58	9	administered	administer	VERB
gsrj-11	58	10	at	at	ADP
gsrj-11	58	11	5	5	NUM
gsrj-11	58	12	mg	mg	PROPN
gsrj-11	58	13	/	/	SYM
gsrj-11	58	14	kg	kg	NOUN
gsrj-11	58	15	/	/	SYM
gsrj-11	58	16	day	day	NOUN
gsrj-11	58	17	and	and	CCONJ
gsrj-11	58	18	is	be	AUX
gsrj-11	58	19	shown	show	VERB
gsrj-11	58	20	to	to	PART
gsrj-11	58	21	allow	allow	VERB
gsrj-11	58	22	for	for	ADP
gsrj-11	58	23	more	more	ADJ
gsrj-11	58	24	regression	regression	NOUN
gsrj-11	58	25	at	at	ADP
gsrj-11	58	26	higher	high	ADJ
gsrj-11	58	27	doses	dose	NOUN
gsrj-11	58	28	.	.	PUNCT
gsrj-11	59	1	however	however	ADV
gsrj-11	59	2	,	,	PUNCT
gsrj-11	59	3	these	these	PRON
gsrj-11	59	4	are	be	AUX
gsrj-11	59	5	also	also	ADV
gsrj-11	59	6	transient	transient	ADJ
gsrj-11	59	7	effects	effect	NOUN
gsrj-11	59	8	,	,	PUNCT
gsrj-11	59	9	and	and	CCONJ
gsrj-11	59	10	after	after	ADP
gsrj-11	59	11	being	be	AUX
gsrj-11	59	12	exposed	expose	VERB
gsrj-11	59	13	to	to	ADP
gsrj-11	59	14	sonidegib	sonidegib	NOUN
gsrj-11	59	15	for	for	ADP
gsrj-11	59	16	a	a	DET
gsrj-11	59	17	long	long	ADJ
gsrj-11	59	18	time	time	NOUN
gsrj-11	59	19	,	,	PUNCT
gsrj-11	59	20	it	it	PRON
gsrj-11	59	21	has	have	AUX
gsrj-11	59	22	been	be	AUX
gsrj-11	59	23	shown	show	VERB
gsrj-11	59	24	that	that	SCONJ
gsrj-11	59	25	resistance	resistance	NOUN
gsrj-11	59	26	/	/	SYM
gsrj-11	59	27	relapse	relapse	NOUN
gsrj-11	59	28	occurs	occur	VERB
gsrj-11	59	29	due	due	ADJ
gsrj-11	59	30	to	to	ADP
gsrj-11	59	31	mutations	mutation	NOUN
gsrj-11	59	32	in	in	ADP
gsrj-11	59	33	smo	smo	PROPN
gsrj-11	59	34	that	that	PRON
gsrj-11	59	35	are	be	AUX
gsrj-11	59	36	formed	form	VERB
gsrj-11	59	37	.	.	PUNCT
gsrj-11	60	1	moreover	moreover	ADV
gsrj-11	60	2	,	,	PUNCT
gsrj-11	60	3	while	while	SCONJ
gsrj-11	60	4	preclinical	preclinical	ADJ
gsrj-11	60	5	research	research	NOUN
gsrj-11	60	6	has	have	AUX
gsrj-11	60	7	demonstrated	demonstrate	VERB
gsrj-11	60	8	momentary	momentary	ADJ
gsrj-11	60	9	efficacy	efficacy	NOUN
gsrj-11	60	10	of	of	ADP
gsrj-11	60	11	sonidegib	sonidegib	NOUN
gsrj-11	60	12	in	in	ADP
gsrj-11	60	13	shh	shh	PROPN
gsrj-11	60	14	mb	mb	PROPN
gsrj-11	60	15	,	,	PUNCT
gsrj-11	60	16	the	the	DET
gsrj-11	60	17	beneficial	beneficial	ADJ
gsrj-11	60	18	effects	effect	NOUN
gsrj-11	60	19	dwindle	dwindle	VERB
gsrj-11	60	20	over	over	ADP
gsrj-11	60	21	time	time	NOUN
gsrj-11	60	22	due	due	ADP
gsrj-11	60	23	to	to	ADP
gsrj-11	60	24	smo	smo	PROPN
gsrj-11	60	25	mutations	mutation	NOUN
gsrj-11	60	26	and	and	CCONJ
gsrj-11	60	27	serve	serve	VERB
gsrj-11	60	28	as	as	ADP
gsrj-11	60	29	a	a	DET
gsrj-11	60	30	significant	significant	ADJ
gsrj-11	60	31	limitation.12	limitation.12	NOUN
gsrj-11	60	32	additionally	additionally	ADV
gsrj-11	60	33	,	,	PUNCT
gsrj-11	60	34	glasdegib	glasdegib	NOUN
gsrj-11	60	35	is	be	AUX
gsrj-11	60	36	a	a	DET
gsrj-11	60	37	smo	smo	NOUN
gsrj-11	60	38	antagonist	antagonist	NOUN
gsrj-11	60	39	.	.	PUNCT
gsrj-11	61	1	it	it	PRON
gsrj-11	61	2	functions	function	VERB
gsrj-11	61	3	due	due	ADP
gsrj-11	61	4	to	to	ADP
gsrj-11	61	5	its	its	PRON
gsrj-11	61	6	benzimidazole	benzimidazole	ADJ
gsrj-11	61	7	scaffold	scaffold	NOUN
gsrj-11	61	8	which	which	PRON
gsrj-11	61	9	has	have	AUX
gsrj-11	61	10	been	be	AUX
gsrj-11	61	11	shown	show	VERB
gsrj-11	61	12	to	to	PART
gsrj-11	61	13	be	be	AUX
gsrj-11	61	14	used	use	VERB
gsrj-11	61	15	as	as	ADP
gsrj-11	61	16	an	an	DET
gsrj-11	61	17	anticancer	anticancer	NOUN
gsrj-11	61	18	agent.13	agent.13	NOUN
gsrj-11	61	19	it	it	PRON
gsrj-11	61	20	has	have	VERB
gsrj-11	61	21	a	a	DET
gsrj-11	61	22	very	very	ADV
gsrj-11	61	23	high	high	ADJ
gsrj-11	61	24	potency	potency	NOUN
gsrj-11	61	25	,	,	PUNCT
gsrj-11	61	26	indicating	indicate	VERB
gsrj-11	61	27	that	that	SCONJ
gsrj-11	61	28	it	it	PRON
gsrj-11	61	29	may	may	AUX
gsrj-11	61	30	effectively	effectively	ADV
gsrj-11	61	31	inhibit	inhibit	VERB
gsrj-11	61	32	tumor	tumor	NOUN
gsrj-11	61	33	growth	growth	NOUN
gsrj-11	61	34	in	in	ADP
gsrj-11	61	35	shh	shh	PROPN
gsrj-11	61	36	mb	mb	PROPN
gsrj-11	61	37	.	.	PROPN
gsrj-11	61	38	as	as	SCONJ
gsrj-11	61	39	mentioned	mention	VERB
gsrj-11	61	40	before	before	ADV
gsrj-11	61	41	,	,	PUNCT
gsrj-11	61	42	it	it	PRON
gsrj-11	61	43	has	have	AUX
gsrj-11	61	44	been	be	AUX
gsrj-11	61	45	fda	fda	PROPN
gsrj-11	61	46	approved	approve	VERB
gsrj-11	61	47	along	along	ADP
gsrj-11	61	48	with	with	ADP
gsrj-11	61	49	low	low	ADJ
gsrj-11	61	50	doses	dose	NOUN
gsrj-11	61	51	of	of	ADP
gsrj-11	61	52	cytarabine	cytarabine	NOUN
gsrj-11	61	53	for	for	ADP
gsrj-11	61	54	treating	treat	VERB
gsrj-11	61	55	acute	acute	ADJ
gsrj-11	61	56	leukemia.14,15	leukemia.14,15	NOUN
gsrj-11	61	57	in	in	ADP
gsrj-11	61	58	addition	addition	NOUN
gsrj-11	61	59	to	to	ADP
gsrj-11	61	60	preclinical	preclinical	ADJ
gsrj-11	61	61	research	research	NOUN
gsrj-11	61	62	,	,	PUNCT
gsrj-11	61	63	clinical	clinical	ADJ
gsrj-11	61	64	trials	trial	NOUN
gsrj-11	61	65	have	have	AUX
gsrj-11	61	66	evaluated	evaluate	VERB
gsrj-11	61	67	the	the	DET
gsrj-11	61	68	efficacy	efficacy	NOUN
gsrj-11	61	69	of	of	ADP
gsrj-11	61	70	sonidegib	sonidegib	NOUN
gsrj-11	61	71	and	and	CCONJ
gsrj-11	61	72	vismodegib	vismodegib	NOUN
gsrj-11	61	73	at	at	ADP
gsrj-11	61	74	mitigating	mitigate	VERB
gsrj-11	61	75	mb	mb	ADP
gsrj-11	61	76	tumor	tumor	NOUN
gsrj-11	61	77	growth	growth	NOUN
gsrj-11	61	78	,	,	PUNCT
gsrj-11	61	79	as	as	ADV
gsrj-11	61	80	well	well	ADV
gsrj-11	61	81	as	as	ADP
gsrj-11	61	82	their	their	PRON
gsrj-11	61	83	safety	safety	NOUN
gsrj-11	61	84	profile	profile	NOUN
gsrj-11	61	85	.	.	PUNCT
gsrj-11	62	1	16	16	NUM
gsrj-11	62	2	-	-	SYM
gsrj-11	62	3	21	21	NUM
gsrj-11	62	4	in	in	ADP
gsrj-11	62	5	a	a	DET
gsrj-11	62	6	phase	phase	NOUN
gsrj-11	62	7	i	i	PRON
gsrj-11	62	8	trial	trial	NOUN
gsrj-11	62	9	conducted	conduct	VERB
gsrj-11	62	10	from	from	ADP
gsrj-11	62	11	2007	2007	NUM
gsrj-11	62	12	to	to	ADP
gsrj-11	62	13	2008	2008	NUM
gsrj-11	62	14	,	,	PUNCT
gsrj-11	62	15	vismodegib	vismodegib	NOUN
gsrj-11	62	16	was	be	AUX
gsrj-11	62	17	administered	administer	VERB
gsrj-11	62	18	to	to	ADP
gsrj-11	62	19	68	68	NUM
gsrj-11	62	20	patients	patient	NOUN
gsrj-11	62	21	who	who	PRON
gsrj-11	62	22	had	have	VERB
gsrj-11	62	23	refractory	refractory	NOUN
gsrj-11	62	24	,	,	PUNCT
gsrj-11	62	25	locally	locally	ADV
gsrj-11	62	26	advanced	advanced	ADJ
gsrj-11	62	27	,	,	PUNCT
gsrj-11	62	28	or	or	CCONJ
gsrj-11	62	29	metastatic	metastatic	ADJ
gsrj-11	62	30	solid	solid	ADJ
gsrj-11	62	31	tumors	tumor	NOUN
gsrj-11	62	32	caused	cause	VERB
gsrj-11	62	33	by	by	ADP
gsrj-11	62	34	aberrant	aberrant	ADJ
gsrj-11	62	35	hedgehog	hedgehog	NOUN
gsrj-11	62	36	pathway	pathway	NOUN
gsrj-11	62	37	signaling	signal	VERB
gsrj-11	62	38	.	.	PUNCT
gsrj-11	63	1	one	one	NUM
gsrj-11	63	2	of	of	ADP
gsrj-11	63	3	these	these	DET
gsrj-11	63	4	patients	patient	NOUN
gsrj-11	63	5	had	have	VERB
gsrj-11	63	6	shh	shh	INTJ
gsrj-11	63	7	mb	mb	PROPN
gsrj-11	63	8	.	.	PUNCT
gsrj-11	64	1	the	the	DET
gsrj-11	64	2	shh	shh	PROPN
gsrj-11	64	3	mb	mb	PROPN
gsrj-11	64	4	patient	patient	PROPN
gsrj-11	64	5	demonstrated	demonstrate	VERB
gsrj-11	64	6	a	a	DET
gsrj-11	64	7	partial	partial	ADJ
gsrj-11	64	8	but	but	CCONJ
gsrj-11	64	9	unconfirmed	unconfirmed	ADJ
gsrj-11	64	10	response	response	NOUN
gsrj-11	64	11	to	to	ADP
gsrj-11	64	12	increasing	increase	VERB
gsrj-11	64	13	doses	dose	NOUN
gsrj-11	64	14	of	of	ADP
gsrj-11	64	15	vismodegib	vismodegib	NOUN
gsrj-11	64	16	,	,	PUNCT
gsrj-11	64	17	as	as	ADV
gsrj-11	64	18	well	well	ADV
gsrj-11	64	19	as	as	ADP
gsrj-11	64	20	an	an	DET
gsrj-11	64	21	acceptable	acceptable	ADJ
gsrj-11	64	22	safety	safety	NOUN
gsrj-11	64	23	profile	profile	NOUN
gsrj-11	64	24	.	.	PUNCT
gsrj-11	65	1	resistance	resistance	NOUN
gsrj-11	65	2	to	to	ADP
gsrj-11	65	3	vismodegib	vismodegib	PROPN
gsrj-11	65	4	occured	occur	VERB
gsrj-11	65	5	in	in	ADP
gsrj-11	65	6	this	this	DET
gsrj-11	65	7	patient	patient	NOUN
gsrj-11	65	8	as	as	ADP
gsrj-11	65	9	a	a	DET
gsrj-11	65	10	result	result	NOUN
gsrj-11	65	11	of	of	ADP
gsrj-11	65	12	smo	smo	PROPN
gsrj-11	65	13	mutations	mutation	NOUN
gsrj-11	65	14	,	,	PUNCT
gsrj-11	65	15	revealing	reveal	VERB
gsrj-11	65	16	vismodegib	vismodegib	NOUN
gsrj-11	65	17	’s	’s	PART
gsrj-11	65	18	potential	potential	NOUN
gsrj-11	65	19	as	as	ADP
gsrj-11	65	20	a	a	DET
gsrj-11	65	21	therapy	therapy	NOUN
gsrj-11	65	22	for	for	ADP
gsrj-11	65	23	shh	shh	INTJ
gsrj-11	65	24	mb	mb	PROPN
gsrj-11	65	25	while	while	SCONJ
gsrj-11	65	26	highlighting	highlight	VERB
gsrj-11	65	27	mutations	mutation	NOUN
gsrj-11	65	28	as	as	ADP
gsrj-11	65	29	a	a	DET
gsrj-11	65	30	drawback	drawback	NOUN
gsrj-11	65	31	.	.	PUNCT
gsrj-11	66	1	this	this	DET
gsrj-11	66	2	clinical	clinical	ADJ
gsrj-11	66	3	trial	trial	NOUN
gsrj-11	66	4	is	be	AUX
gsrj-11	66	5	not	not	PART
gsrj-11	66	6	recent	recent	ADJ
gsrj-11	66	7	,	,	PUNCT
gsrj-11	66	8	however	however	ADV
gsrj-11	66	9	.	.	PUNCT
gsrj-11	67	1	much	much	ADV
gsrj-11	67	2	more	more	ADJ
gsrj-11	67	3	research	research	NOUN
gsrj-11	67	4	has	have	AUX
gsrj-11	67	5	been	be	AUX
gsrj-11	67	6	conducted	conduct	VERB
gsrj-11	67	7	on	on	ADP
gsrj-11	67	8	vismodegib	vismodegib	NOUN
gsrj-11	67	9	’s	’s	PART
gsrj-11	67	10	efficacy	efficacy	NOUN
gsrj-11	67	11	in	in	ADP
gsrj-11	67	12	shh	shh	PROPN
gsrj-11	67	13	mb	mb	ADP
gsrj-11	67	14	patients	patient	NOUN
gsrj-11	67	15	since	since	SCONJ
gsrj-11	67	16	2008	2008	NUM
gsrj-11	67	17	,	,	PUNCT
gsrj-11	67	18	producing	produce	VERB
gsrj-11	67	19	conclusions	conclusion	NOUN
gsrj-11	67	20	that	that	PRON
gsrj-11	67	21	are	be	AUX
gsrj-11	67	22	more	more	ADV
gsrj-11	67	23	revealing.17	revealing.17	ADJ
gsrj-11	67	24	a	a	DET
gsrj-11	67	25	more	more	ADV
gsrj-11	67	26	recent	recent	ADJ
gsrj-11	67	27	clinical	clinical	ADJ
gsrj-11	67	28	trial	trial	NOUN
gsrj-11	67	29	regarding	regard	VERB
gsrj-11	67	30	vismodegib	vismodegib	NOUN
gsrj-11	67	31	was	be	AUX
gsrj-11	67	32	conducted	conduct	VERB
gsrj-11	67	33	in	in	ADP
gsrj-11	67	34	2013	2013	NUM
gsrj-11	67	35	.	.	PUNCT
gsrj-11	68	1	vismodegib	vismodegib	NOUN
gsrj-11	68	2	was	be	AUX
gsrj-11	68	3	provided	provide	VERB
gsrj-11	68	4	to	to	ADP
gsrj-11	68	5	6	6	NUM
gsrj-11	68	6	patients	patient	NOUN
gsrj-11	68	7	at	at	ADP
gsrj-11	68	8	a	a	DET
gsrj-11	68	9	dose	dose	NOUN
gsrj-11	68	10	of	of	ADP
gsrj-11	68	11	85	85	NUM
gsrj-11	68	12	mg	mg	PROPN
gsrj-11	68	13	/	/	SYM
gsrj-11	68	14	m2	m2	PROPN
gsrj-11	68	15	,	,	PUNCT
gsrj-11	68	16	and	and	CCONJ
gsrj-11	68	17	7	7	NUM
gsrj-11	68	18	patients	patient	NOUN
gsrj-11	68	19	received	receive	VERB
gsrj-11	68	20	a	a	DET
gsrj-11	68	21	170mg	170mg	PROPN
gsrj-11	68	22	/	/	SYM
gsrj-11	68	23	m2	m2	PROPN
gsrj-11	68	24	dose	dose	PROPN
gsrj-11	68	25	.	.	PUNCT
gsrj-11	69	1	there	there	PRON
gsrj-11	69	2	was	be	VERB
gsrj-11	69	3	no	no	DET
gsrj-11	69	4	bone	bone	NOUN
gsrj-11	69	5	88	88	NUM
gsrj-11	69	6	georgetown	georgetown	PROPN
gsrj-11	69	7	scientific	scientific	ADJ
gsrj-11	69	8	research	research	NOUN
gsrj-11	69	9	journal	journal	NOUN
gsrj-11	69	10	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	NOUN
gsrj-11	69	11	toxicity	toxicity	NOUN
gsrj-11	69	12	documented	document	VERB
gsrj-11	69	13	from	from	ADP
gsrj-11	69	14	the	the	DET
gsrj-11	69	15	drug	drug	NOUN
gsrj-11	69	16	,	,	PUNCT
gsrj-11	69	17	although	although	SCONJ
gsrj-11	69	18	dose	dose	NOUN
gsrj-11	69	19	-	-	PUNCT
gsrj-11	69	20	limiting	limit	VERB
gsrj-11	69	21	toxicities	toxicity	NOUN
gsrj-11	69	22	did	do	AUX
gsrj-11	69	23	manifest	manif	ADJ
gsrj-11	69	24	.	.	PUNCT
gsrj-11	70	1	this	this	DET
gsrj-11	70	2	study	study	NOUN
gsrj-11	70	3	served	serve	VERB
gsrj-11	70	4	to	to	PART
gsrj-11	70	5	evaluate	evaluate	VERB
gsrj-11	70	6	the	the	DET
gsrj-11	70	7	safety	safety	NOUN
gsrj-11	70	8	,	,	PUNCT
gsrj-11	70	9	the	the	DET
gsrj-11	70	10	toxicity	toxicity	NOUN
gsrj-11	70	11	,	,	PUNCT
gsrj-11	70	12	and	and	CCONJ
gsrj-11	70	13	efficacy	efficacy	NOUN
gsrj-11	70	14	of	of	ADP
gsrj-11	70	15	vismodegib	vismodegib	NOUN
gsrj-11	70	16	in	in	ADP
gsrj-11	70	17	pediatric	pediatric	ADJ
gsrj-11	70	18	patients	patient	NOUN
gsrj-11	70	19	with	with	ADP
gsrj-11	70	20	recurrent	recurrent	NOUN
gsrj-11	70	21	or	or	CCONJ
gsrj-11	70	22	refractory	refractory	NOUN
gsrj-11	70	23	mb	mb	NOUN
gsrj-11	70	24	.	.	PUNCT
gsrj-11	71	1	ultimately	ultimately	ADV
gsrj-11	71	2	,	,	PUNCT
gsrj-11	71	3	the	the	DET
gsrj-11	71	4	study	study	NOUN
gsrj-11	71	5	showed	show	VERB
gsrj-11	71	6	that	that	SCONJ
gsrj-11	71	7	this	this	DET
gsrj-11	71	8	smo	smo	NOUN
gsrj-11	71	9	inhibitor	inhibitor	NOUN
gsrj-11	71	10	is	be	AUX
gsrj-11	71	11	safe	safe	ADJ
gsrj-11	71	12	and	and	CCONJ
gsrj-11	71	13	feasible	feasible	ADJ
gsrj-11	71	14	in	in	ADP
gsrj-11	71	15	children	child	NOUN
gsrj-11	71	16	,	,	PUNCT
gsrj-11	71	17	which	which	PRON
gsrj-11	71	18	is	be	AUX
gsrj-11	71	19	significant	significant	ADJ
gsrj-11	71	20	considering	consider	VERB
gsrj-11	71	21	the	the	DET
gsrj-11	71	22	lack	lack	NOUN
gsrj-11	71	23	of	of	ADP
gsrj-11	71	24	pediatric	pediatric	ADJ
gsrj-11	71	25	clinical	clinical	ADJ
gsrj-11	71	26	trials	trial	NOUN
gsrj-11	71	27	with	with	ADP
gsrj-11	71	28	smo	smo	PROPN
gsrj-11	71	29	inhibitors	inhibitor	NOUN
gsrj-11	71	30	.	.	PUNCT
gsrj-11	72	1	a	a	DET
gsrj-11	72	2	subsequent	subsequent	ADJ
gsrj-11	72	3	study	study	NOUN
gsrj-11	72	4	administered	administer	VERB
gsrj-11	72	5	a	a	DET
gsrj-11	72	6	phase	phase	NOUN
gsrj-11	72	7	ii	ii	NOUN
gsrj-11	72	8	dosage	dosage	NOUN
gsrj-11	72	9	to	to	ADP
gsrj-11	72	10	three	three	NUM
gsrj-11	72	11	out	out	ADP
gsrj-11	72	12	of	of	ADP
gsrj-11	72	13	seven	seven	NUM
gsrj-11	72	14	shh	shh	NOUN
gsrj-11	72	15	mb	mb	ADP
gsrj-11	72	16	patients	patient	NOUN
gsrj-11	72	17	from	from	ADP
gsrj-11	72	18	the	the	DET
gsrj-11	72	19	first	first	ADJ
gsrj-11	72	20	phase	phase	NOUN
gsrj-11	72	21	.	.	PUNCT
gsrj-11	73	1	notably	notably	ADV
gsrj-11	73	2	,	,	PUNCT
gsrj-11	73	3	antitumor	antitumor	PROPN
gsrj-11	73	4	activity	activity	NOUN
gsrj-11	73	5	was	be	AUX
gsrj-11	73	6	observed	observe	VERB
gsrj-11	73	7	in	in	ADP
gsrj-11	73	8	1	1	NUM
gsrj-11	73	9	of	of	ADP
gsrj-11	73	10	these	these	DET
gsrj-11	73	11	patients.18	patients.18	VERB
gsrj-11	73	12	these	these	DET
gsrj-11	73	13	clinical	clinical	ADJ
gsrj-11	73	14	findings	finding	NOUN
gsrj-11	73	15	suggest	suggest	VERB
gsrj-11	73	16	vismodegib	vismodegib	PROPN
gsrj-11	73	17	’s	’s	PART
gsrj-11	73	18	robust	robust	ADJ
gsrj-11	73	19	safety	safety	NOUN
gsrj-11	73	20	and	and	CCONJ
gsrj-11	73	21	efficacy	efficacy	NOUN
gsrj-11	73	22	in	in	ADP
gsrj-11	73	23	shh	shh	PROPN
gsrj-11	73	24	mb	mb	PROPN
gsrj-11	73	25	patients	patient	NOUN
gsrj-11	73	26	.	.	PUNCT
gsrj-11	74	1	in	in	ADP
gsrj-11	74	2	2	2	NUM
gsrj-11	74	3	phase	phase	NOUN
gsrj-11	74	4	ii	ii	NOUN
gsrj-11	74	5	studies	study	NOUN
gsrj-11	74	6	conducted	conduct	VERB
gsrj-11	74	7	in	in	ADP
gsrj-11	74	8	2015	2015	NUM
gsrj-11	74	9	,	,	PUNCT
gsrj-11	74	10	31	31	NUM
gsrj-11	74	11	adult	adult	NOUN
gsrj-11	74	12	patients	patient	NOUN
gsrj-11	74	13	and	and	CCONJ
gsrj-11	74	14	12	12	NUM
gsrj-11	74	15	pediatric	pediatric	ADJ
gsrj-11	74	16	patients	patient	NOUN
gsrj-11	74	17	were	be	AUX
gsrj-11	74	18	treated	treat	VERB
gsrj-11	74	19	with	with	ADP
gsrj-11	74	20	150	150	NUM
gsrj-11	74	21	-	-	SYM
gsrj-11	74	22	300	300	NUM
gsrj-11	74	23	mg	mg	PROPN
gsrj-11	74	24	/	/	SYM
gsrj-11	74	25	d	d	PROPN
gsrj-11	74	26	of	of	ADP
gsrj-11	74	27	vismodegib	vismodegib	NOUN
gsrj-11	74	28	.	.	PUNCT
gsrj-11	75	1	responses	response	NOUN
gsrj-11	75	2	were	be	AUX
gsrj-11	75	3	evaluated	evaluate	VERB
gsrj-11	75	4	with	with	ADP
gsrj-11	75	5	neuroimaging	neuroimaging	NOUN
gsrj-11	75	6	and	and	CCONJ
gsrj-11	75	7	molecular	molecular	ADJ
gsrj-11	75	8	tests	test	NOUN
gsrj-11	75	9	.	.	PUNCT
gsrj-11	76	1	protocol	protocol	NOUN
gsrj-11	76	2	defined	define	VERB
gsrj-11	76	3	response	response	NOUN
gsrj-11	76	4	outlined	outline	VERB
gsrj-11	76	5	that	that	SCONJ
gsrj-11	76	6	a	a	DET
gsrj-11	76	7	complete	complete	ADJ
gsrj-11	76	8	or	or	CCONJ
gsrj-11	76	9	partial	partial	ADJ
gsrj-11	76	10	response	response	NOUN
gsrj-11	76	11	must	must	AUX
gsrj-11	76	12	be	be	AUX
gsrj-11	76	13	sustained	sustain	VERB
gsrj-11	76	14	for	for	ADP
gsrj-11	76	15	8	8	NUM
gsrj-11	76	16	weeks	week	NOUN
gsrj-11	76	17	.	.	PUNCT
gsrj-11	77	1	a	a	DET
gsrj-11	77	2	complete	complete	ADJ
gsrj-11	77	3	response	response	NOUN
gsrj-11	77	4	was	be	AUX
gsrj-11	77	5	achieved	achieve	VERB
gsrj-11	77	6	when	when	SCONJ
gsrj-11	77	7	all	all	DET
gsrj-11	77	8	lesions	lesion	NOUN
gsrj-11	77	9	targeted	target	VERB
gsrj-11	77	10	disappeared	disappear	VERB
gsrj-11	77	11	,	,	PUNCT
gsrj-11	77	12	and	and	CCONJ
gsrj-11	77	13	a	a	DET
gsrj-11	77	14	partial	partial	ADJ
gsrj-11	77	15	response	response	NOUN
gsrj-11	77	16	was	be	AUX
gsrj-11	77	17	achieved	achieve	VERB
gsrj-11	77	18	when	when	SCONJ
gsrj-11	77	19	30	30	NUM
gsrj-11	77	20	%	%	NOUN
gsrj-11	77	21	reduction	reduction	NOUN
gsrj-11	77	22	in	in	ADP
gsrj-11	77	23	the	the	DET
gsrj-11	77	24	sum	sum	NOUN
gsrj-11	77	25	of	of	ADP
gsrj-11	77	26	the	the	DET
gsrj-11	77	27	diameter	diameter	NOUN
gsrj-11	77	28	of	of	ADP
gsrj-11	77	29	long	long	ADJ
gsrj-11	77	30	lesions	lesion	NOUN
gsrj-11	77	31	targeted	target	VERB
gsrj-11	77	32	.	.	PUNCT
gsrj-11	78	1	3	3	NUM
gsrj-11	78	2	adult	adult	NOUN
gsrj-11	78	3	patients	patient	NOUN
gsrj-11	78	4	and	and	CCONJ
gsrj-11	78	5	1	1	NUM
gsrj-11	78	6	pediatric	pediatric	ADJ
gsrj-11	78	7	patient	patient	NOUN
gsrj-11	78	8	with	with	ADP
gsrj-11	78	9	shh	shh	PROPN
gsrj-11	78	10	-	-	PUNCT
gsrj-11	78	11	mb	mb	PROPN
gsrj-11	78	12	achieved	achieve	VERB
gsrj-11	78	13	the	the	DET
gsrj-11	78	14	protocoldefined	protocoldefined	ADJ
gsrj-11	78	15	response	response	NOUN
gsrj-11	78	16	.	.	PUNCT
gsrj-11	79	1	progression	progression	NOUN
gsrj-11	79	2	-	-	PUNCT
gsrj-11	79	3	free	free	ADJ
gsrj-11	79	4	survival	survival	NOUN
gsrj-11	79	5	was	be	AUX
gsrj-11	79	6	longer	long	ADJ
gsrj-11	79	7	for	for	ADP
gsrj-11	79	8	patients	patient	NOUN
gsrj-11	79	9	with	with	ADP
gsrj-11	79	10	shh	shh	NOUN
gsrj-11	79	11	-	-	PUNCT
gsrj-11	79	12	mb	mb	PROPN
gsrj-11	79	13	than	than	SCONJ
gsrj-11	79	14	nonshh	nonshh	PROPN
gsrj-11	79	15	-	-	PUNCT
gsrj-11	79	16	mb	mb	NOUN
gsrj-11	79	17	.	.	PROPN
gsrj-11	79	18	prolonged	prolong	VERB
gsrj-11	79	19	disease	disease	NOUN
gsrj-11	79	20	stabilization	stabilization	NOUN
gsrj-11	79	21	was	be	AUX
gsrj-11	79	22	achieved	achieve	VERB
gsrj-11	79	23	in	in	ADP
gsrj-11	79	24	41	41	NUM
gsrj-11	79	25	%	%	NOUN
gsrj-11	79	26	of	of	ADP
gsrj-11	79	27	patients	patient	NOUN
gsrj-11	79	28	with	with	ADP
gsrj-11	79	29	shh	shh	NOUN
gsrj-11	79	30	-	-	PUNCT
gsrj-11	79	31	mb	mb	NOUN
gsrj-11	79	32	.	.	PUNCT
gsrj-11	80	1	it	it	PRON
gsrj-11	80	2	was	be	AUX
gsrj-11	80	3	concluded	conclude	VERB
gsrj-11	80	4	that	that	SCONJ
gsrj-11	80	5	vismodegib	vismodegib	NOUN
gsrj-11	80	6	acts	act	VERB
gsrj-11	80	7	against	against	ADP
gsrj-11	80	8	adult	adult	NOUN
gsrj-11	80	9	recurrent	recurrent	NOUN
gsrj-11	80	10	shh	shh	NOUN
gsrj-11	80	11	-	-	PROPN
gsrj-11	80	12	mb	mb	PROPN
gsrj-11	80	13	and	and	CCONJ
gsrj-11	80	14	not	not	PART
gsrj-11	80	15	non	non	ADJ
gsrj-11	80	16	-	-	ADJ
gsrj-11	80	17	shh	shh	NOUN
gsrj-11	80	18	-	-	PUNCT
gsrj-11	80	19	mb	mb	NOUN
gsrj-11	80	20	.	.	PROPN
gsrj-11	80	21	for	for	ADP
gsrj-11	80	22	pediatric	pediatric	ADJ
gsrj-11	80	23	patients	patient	NOUN
gsrj-11	80	24	,	,	PUNCT
gsrj-11	80	25	there	there	PRON
gsrj-11	80	26	was	be	VERB
gsrj-11	80	27	no	no	DET
gsrj-11	80	28	conclusion	conclusion	NOUN
gsrj-11	80	29	.	.	PUNCT
gsrj-11	81	1	it	it	PRON
gsrj-11	81	2	was	be	AUX
gsrj-11	81	3	also	also	ADV
gsrj-11	81	4	concluded	conclude	VERB
gsrj-11	81	5	that	that	SCONJ
gsrj-11	81	6	smo	smo	PROPN
gsrj-11	81	7	inhibitors	inhibitor	NOUN
gsrj-11	81	8	depend	depend	VERB
gsrj-11	81	9	on	on	ADP
gsrj-11	81	10	the	the	DET
gsrj-11	81	11	deviations	deviation	NOUN
gsrj-11	81	12	in	in	ADP
gsrj-11	81	13	the	the	DET
gsrj-11	81	14	genome	genome	NOUN
gsrj-11	81	15	of	of	ADP
gsrj-11	81	16	the	the	DET
gsrj-11	81	17	tumor.19	tumor.19	NOUN
gsrj-11	81	18	taken	take	VERB
gsrj-11	81	19	together	together	ADV
gsrj-11	81	20	,	,	PUNCT
gsrj-11	81	21	vismodegib	vismodegib	NOUN
gsrj-11	81	22	seems	seem	VERB
gsrj-11	81	23	to	to	PART
gsrj-11	81	24	work	work	VERB
gsrj-11	81	25	by	by	ADP
gsrj-11	81	26	specifically	specifically	ADV
gsrj-11	81	27	targeting	target	VERB
gsrj-11	81	28	the	the	DET
gsrj-11	81	29	shh	shh	NOUN
gsrj-11	81	30	pathway	pathway	NOUN
gsrj-11	81	31	,	,	PUNCT
gsrj-11	81	32	which	which	PRON
gsrj-11	81	33	explains	explain	VERB
gsrj-11	81	34	its	its	PRON
gsrj-11	81	35	inefficacy	inefficacy	NOUN
gsrj-11	81	36	against	against	ADP
gsrj-11	81	37	non	non	ADJ
gsrj-11	81	38	-	-	ADJ
gsrj-11	81	39	shh	shh	ADJ
gsrj-11	81	40	-	-	PUNCT
gsrj-11	81	41	mb	mb	ADJ
gsrj-11	81	42	tumors	tumor	NOUN
gsrj-11	81	43	.	.	PUNCT
gsrj-11	82	1	while	while	SCONJ
gsrj-11	82	2	this	this	DET
gsrj-11	82	3	clinical	clinical	ADJ
gsrj-11	82	4	data	datum	NOUN
gsrj-11	82	5	is	be	AUX
gsrj-11	82	6	promising	promise	VERB
gsrj-11	82	7	,	,	PUNCT
gsrj-11	82	8	vismodegib	vismodegib	NOUN
gsrj-11	82	9	needs	need	VERB
gsrj-11	82	10	to	to	PART
gsrj-11	82	11	be	be	AUX
gsrj-11	82	12	studied	study	VERB
gsrj-11	82	13	much	much	ADV
gsrj-11	82	14	more	more	ADV
gsrj-11	82	15	extensively	extensively	ADV
gsrj-11	82	16	in	in	ADP
gsrj-11	82	17	pediatric	pediatric	ADJ
gsrj-11	82	18	patients	patient	NOUN
gsrj-11	82	19	and	and	CCONJ
gsrj-11	82	20	its	its	PRON
gsrj-11	82	21	efficacy	efficacy	NOUN
gsrj-11	82	22	in	in	ADP
gsrj-11	82	23	mitigating	mitigate	VERB
gsrj-11	82	24	mutated	mutate	VERB
gsrj-11	83	1	shh	shh	INTJ
gsrj-11	83	2	mb	mb	ADP
gsrj-11	83	3	tumors	tumor	NOUN
gsrj-11	83	4	needs	need	VERB
gsrj-11	83	5	to	to	PART
gsrj-11	83	6	be	be	AUX
gsrj-11	83	7	explored	explore	VERB
gsrj-11	83	8	.	.	PUNCT
gsrj-11	84	1	in	in	ADP
gsrj-11	84	2	a	a	DET
gsrj-11	84	3	similar	similar	ADJ
gsrj-11	84	4	manner	manner	NOUN
gsrj-11	84	5	to	to	ADP
gsrj-11	84	6	vismodegib	vismodegib	NOUN
gsrj-11	84	7	,	,	PUNCT
gsrj-11	84	8	sonidegib	sonidegib	NOUN
gsrj-11	84	9	has	have	AUX
gsrj-11	84	10	also	also	ADV
gsrj-11	84	11	been	be	AUX
gsrj-11	84	12	clinically	clinically	ADV
gsrj-11	84	13	assessed	assess	VERB
gsrj-11	84	14	as	as	ADP
gsrj-11	84	15	an	an	DET
gsrj-11	84	16	inhibitor	inhibitor	NOUN
gsrj-11	84	17	of	of	ADP
gsrj-11	84	18	the	the	DET
gsrj-11	84	19	shh	shh	PROPN
gsrj-11	84	20	pathway	pathway	NOUN
gsrj-11	84	21	in	in	ADP
gsrj-11	84	22	mb	mb	ADP
gsrj-11	84	23	patients.20	patients.20	PROPN
gsrj-11	84	24	,	,	PUNCT
gsrj-11	84	25	21	21	NUM
gsrj-11	84	26	in	in	ADP
gsrj-11	84	27	2014	2014	NUM
gsrj-11	84	28	,	,	PUNCT
gsrj-11	84	29	a	a	DET
gsrj-11	84	30	phase	phase	NOUN
gsrj-11	84	31	i	i	PRON
gsrj-11	84	32	clinical	clinical	ADJ
gsrj-11	84	33	trial	trial	NOUN
gsrj-11	84	34	was	be	AUX
gsrj-11	84	35	conducted	conduct	VERB
gsrj-11	84	36	to	to	PART
gsrj-11	84	37	assess	assess	VERB
gsrj-11	84	38	the	the	DET
gsrj-11	84	39	safety	safety	NOUN
gsrj-11	84	40	and	and	CCONJ
gsrj-11	84	41	efficacy	efficacy	NOUN
gsrj-11	84	42	of	of	ADP
gsrj-11	84	43	sonidegib	sonidegib	NOUN
gsrj-11	84	44	taken	take	VERB
gsrj-11	84	45	orally	orally	ADV
gsrj-11	84	46	in	in	ADP
gsrj-11	84	47	patients	patient	NOUN
gsrj-11	84	48	with	with	ADP
gsrj-11	84	49	mb	mb	ADP
gsrj-11	84	50	and	and	CCONJ
gsrj-11	84	51	basal	basal	NOUN
gsrj-11	84	52	cell	cell	NOUN
gsrj-11	84	53	carcinoma	carcinoma	NOUN
gsrj-11	84	54	(	(	PUNCT
gsrj-11	84	55	bcc	bcc	PROPN
gsrj-11	84	56	)	)	PUNCT
gsrj-11	84	57	.	.	PUNCT
gsrj-11	85	1	the	the	DET
gsrj-11	85	2	prominent	prominent	ADJ
gsrj-11	85	3	dose	dose	NOUN
gsrj-11	85	4	-	-	PUNCT
gsrj-11	85	5	limiting	limit	VERB
gsrj-11	85	6	toxicity	toxicity	NOUN
gsrj-11	85	7	manifested	manifest	VERB
gsrj-11	85	8	as	as	ADP
gsrj-11	85	9	a	a	DET
gsrj-11	85	10	3/4	3/4	NUM
gsrj-11	85	11	increase	increase	NOUN
gsrj-11	85	12	in	in	ADP
gsrj-11	85	13	creatine	creatine	PROPN
gsrj-11	85	14	kinase	kinase	PROPN
gsrj-11	85	15	in	in	ADP
gsrj-11	85	16	blood	blood	NOUN
gsrj-11	85	17	serum	serum	NOUN
gsrj-11	85	18	,	,	PUNCT
gsrj-11	85	19	which	which	PRON
gsrj-11	85	20	developed	develop	VERB
gsrj-11	85	21	in	in	ADP
gsrj-11	85	22	18	18	NUM
gsrj-11	85	23	%	%	NOUN
gsrj-11	85	24	of	of	ADP
gsrj-11	85	25	patients	patient	NOUN
gsrj-11	85	26	.	.	PUNCT
gsrj-11	86	1	nonetheless	nonetheless	ADV
gsrj-11	86	2	,	,	PUNCT
gsrj-11	86	3	sonidegib	sonidegib	NOUN
gsrj-11	86	4	displayed	display	VERB
gsrj-11	86	5	an	an	DET
gsrj-11	86	6	adequate	adequate	ADJ
gsrj-11	86	7	safety	safety	NOUN
gsrj-11	86	8	profile	profile	NOUN
gsrj-11	86	9	and	and	CCONJ
gsrj-11	86	10	decreased	decrease	VERB
gsrj-11	86	11	expression	expression	NOUN
gsrj-11	86	12	of	of	ADP
gsrj-11	86	13	gli1	gli1	PROPN
gsrj-11	86	14	mrna	mrna	PROPN
gsrj-11	86	15	in	in	ADP
gsrj-11	86	16	a	a	DET
gsrj-11	86	17	dosedependent	dosedependent	NOUN
gsrj-11	86	18	manner.20	manner.20	PRON
gsrj-11	86	19	therefore	therefore	ADV
gsrj-11	86	20	,	,	PUNCT
gsrj-11	86	21	this	this	DET
gsrj-11	86	22	clinical	clinical	ADJ
gsrj-11	86	23	evidence	evidence	NOUN
gsrj-11	86	24	suggests	suggest	VERB
gsrj-11	86	25	sonidegib	sonidegib	NOUN
gsrj-11	86	26	’s	’s	PART
gsrj-11	86	27	safety	safety	NOUN
gsrj-11	86	28	and	and	CCONJ
gsrj-11	86	29	efficacy	efficacy	NOUN
gsrj-11	86	30	in	in	ADP
gsrj-11	86	31	curtailing	curtail	VERB
gsrj-11	86	32	mb	mb	ADP
gsrj-11	86	33	tumor	tumor	NOUN
gsrj-11	86	34	growth	growth	NOUN
gsrj-11	86	35	by	by	ADP
gsrj-11	86	36	inhibiting	inhibit	VERB
gsrj-11	86	37	progression	progression	NOUN
gsrj-11	86	38	of	of	ADP
gsrj-11	86	39	the	the	DET
gsrj-11	86	40	shh	shh	PROPN
gsrj-11	86	41	pathway	pathway	NOUN
gsrj-11	86	42	.	.	PUNCT
gsrj-11	87	1	in	in	ADP
gsrj-11	87	2	a	a	DET
gsrj-11	87	3	2017	2017	NUM
gsrj-11	87	4	phase	phase	NOUN
gsrj-11	87	5	ii	ii	NOUN
gsrj-11	87	6	trial	trial	NOUN
gsrj-11	87	7	,	,	PUNCT
gsrj-11	87	8	60	60	NUM
gsrj-11	87	9	pediatric	pediatric	ADJ
gsrj-11	87	10	patients	patient	NOUN
gsrj-11	87	11	and	and	CCONJ
gsrj-11	87	12	16	16	NUM
gsrj-11	87	13	adult	adult	NOUN
gsrj-11	87	14	patients	patient	NOUN
gsrj-11	87	15	with	with	ADP
gsrj-11	87	16	recurrent	recurrent	ADJ
gsrj-11	87	17	tumors	tumor	NOUN
gsrj-11	87	18	received	receive	VERB
gsrj-11	87	19	oral	oral	ADJ
gsrj-11	87	20	sonidegib	sonidegib	NOUN
gsrj-11	87	21	treatment	treatment	NOUN
gsrj-11	87	22	.	.	PUNCT
gsrj-11	88	1	pediatric	pediatric	ADJ
gsrj-11	88	2	patients	patient	NOUN
gsrj-11	88	3	received	receive	VERB
gsrj-11	88	4	a	a	DET
gsrj-11	88	5	680mg	680mg	PROPN
gsrj-11	88	6	/	/	SYM
gsrj-11	88	7	m2	m2	PROPN
gsrj-11	88	8	daily	daily	PROPN
gsrj-11	88	9	dose	dose	PROPN
gsrj-11	88	10	,	,	PUNCT
gsrj-11	88	11	while	while	SCONJ
gsrj-11	88	12	adults	adult	NOUN
gsrj-11	88	13	received	receive	VERB
gsrj-11	88	14	800	800	NUM
gsrj-11	88	15	mg	mg	NOUN
gsrj-11	88	16	.	.	PUNCT
gsrj-11	89	1	out	out	ADP
gsrj-11	89	2	of	of	ADP
gsrj-11	89	3	all	all	DET
gsrj-11	89	4	the	the	DET
gsrj-11	89	5	pediatric	pediatric	ADJ
gsrj-11	89	6	patients	patient	NOUN
gsrj-11	89	7	,	,	PUNCT
gsrj-11	89	8	39	39	NUM
gsrj-11	89	9	had	have	VERB
gsrj-11	89	10	mb	mb	NOUN
gsrj-11	89	11	.	.	PUNCT
gsrj-11	90	1	a	a	DET
gsrj-11	90	2	5	5	NUM
gsrj-11	90	3	-	-	PUNCT
gsrj-11	90	4	gene	gene	NOUN
gsrj-11	90	5	hh	hh	PROPN
gsrj-11	90	6	signature	signature	NOUN
gsrj-11	90	7	assay	assay	NOUN
gsrj-11	90	8	was	be	AUX
gsrj-11	90	9	conducted	conduct	VERB
gsrj-11	90	10	to	to	PART
gsrj-11	90	11	determine	determine	VERB
gsrj-11	90	12	the	the	DET
gsrj-11	90	13	genetic	genetic	ADJ
gsrj-11	90	14	driver	driver	NOUN
gsrj-11	90	15	of	of	ADP
gsrj-11	90	16	tumors	tumor	NOUN
gsrj-11	90	17	in	in	ADP
gsrj-11	90	18	complete	complete	ADJ
gsrj-11	90	19	responders	responder	NOUN
gsrj-11	90	20	,	,	PUNCT
gsrj-11	90	21	partial	partial	ADJ
gsrj-11	90	22	responders	responder	NOUN
gsrj-11	90	23	,	,	PUNCT
gsrj-11	90	24	and	and	CCONJ
gsrj-11	90	25	non	non	ADJ
gsrj-11	90	26	responders	responder	NOUN
gsrj-11	90	27	to	to	ADP
gsrj-11	90	28	sonidegib	sonidegib	PROPN
gsrj-11	90	29	treatment	treatment	NOUN
gsrj-11	90	30	.	.	PUNCT
gsrj-11	91	1	notably	notably	ADV
gsrj-11	91	2	,	,	PUNCT
gsrj-11	91	3	it	it	PRON
gsrj-11	91	4	was	be	AUX
gsrj-11	91	5	found	find	VERB
gsrj-11	91	6	that	that	SCONJ
gsrj-11	91	7	among	among	ADP
gsrj-11	91	8	the	the	DET
gsrj-11	91	9	complete	complete	ADJ
gsrj-11	91	10	responders	responder	NOUN
gsrj-11	91	11	,	,	PUNCT
gsrj-11	91	12	2	2	NUM
gsrj-11	91	13	children	child	NOUN
gsrj-11	91	14	and	and	CCONJ
gsrj-11	91	15	2	2	NUM
gsrj-11	91	16	adults	adult	NOUN
gsrj-11	91	17	,	,	PUNCT
gsrj-11	91	18	had	have	VERB
gsrj-11	91	19	shh	shh	VERB
gsrj-11	91	20	-	-	PUNCT
gsrj-11	91	21	driven	drive	VERB
gsrj-11	91	22	tumors	tumor	NOUN
gsrj-11	91	23	.	.	PUNCT
gsrj-11	92	1	this	this	DET
gsrj-11	92	2	same	same	ADJ
gsrj-11	92	3	outcome	outcome	NOUN
gsrj-11	92	4	was	be	AUX
gsrj-11	92	5	found	find	VERB
gsrj-11	92	6	in	in	ADP
gsrj-11	92	7	the	the	DET
gsrj-11	92	8	one	one	NUM
gsrj-11	92	9	partial	partial	ADJ
gsrj-11	92	10	responder	responder	NOUN
gsrj-11	92	11	.	.	PUNCT
gsrj-11	93	1	out	out	ADP
gsrj-11	93	2	of	of	ADP
gsrj-11	93	3	the	the	DET
gsrj-11	93	4	50	50	NUM
gsrj-11	93	5	non	non	NOUN
gsrj-11	93	6	-	-	NOUN
gsrj-11	93	7	responders	responder	NOUN
gsrj-11	93	8	,	,	PUNCT
gsrj-11	93	9	none	none	NOUN
gsrj-11	93	10	demonstrated	demonstrate	VERB
gsrj-11	93	11	an	an	DET
gsrj-11	93	12	shh	shh	NOUN
gsrj-11	93	13	-	-	PUNCT
gsrj-11	93	14	driven	drive	VERB
gsrj-11	93	15	tumor.21	tumor.21	NOUN
gsrj-11	93	16	this	this	PRON
gsrj-11	93	17	is	be	AUX
gsrj-11	93	18	significant	significant	ADJ
gsrj-11	93	19	because	because	SCONJ
gsrj-11	93	20	it	it	PRON
gsrj-11	93	21	indicates	indicate	VERB
gsrj-11	93	22	that	that	SCONJ
gsrj-11	93	23	sondigeib	sondigeib	PROPN
gsrj-11	93	24	shows	show	VERB
gsrj-11	93	25	efficacy	efficacy	NOUN
gsrj-11	93	26	in	in	ADP
gsrj-11	93	27	mitigating	mitigate	VERB
gsrj-11	93	28	mb	mb	ADP
gsrj-11	93	29	tumor	tumor	NOUN
gsrj-11	93	30	growth	growth	NOUN
gsrj-11	93	31	,	,	PUNCT
gsrj-11	93	32	specifically	specifically	ADV
gsrj-11	93	33	by	by	ADP
gsrj-11	93	34	inhibiting	inhibit	VERB
gsrj-11	93	35	the	the	DET
gsrj-11	93	36	shh	shh	PROPN
gsrj-11	93	37	pathway	pathway	NOUN
gsrj-11	93	38	.	.	PUNCT
gsrj-11	94	1	overall	overall	ADV
gsrj-11	94	2	,	,	PUNCT
gsrj-11	94	3	these	these	DET
gsrj-11	94	4	clinical	clinical	ADJ
gsrj-11	94	5	trials	trial	NOUN
gsrj-11	94	6	indicate	indicate	VERB
gsrj-11	94	7	that	that	SCONJ
gsrj-11	94	8	while	while	SCONJ
gsrj-11	94	9	both	both	DET
gsrj-11	94	10	vismodegib	vismodegib	NOUN
gsrj-11	94	11	and	and	CCONJ
gsrj-11	94	12	sonidegib	sonidegib	NOUN
gsrj-11	94	13	show	show	VERB
gsrj-11	94	14	substantial	substantial	ADJ
gsrj-11	94	15	promise	promise	NOUN
gsrj-11	94	16	as	as	SCONJ
gsrj-11	94	17	shh	shh	NOUN
gsrj-11	94	18	inhibitors	inhibitor	NOUN
gsrj-11	94	19	in	in	ADP
gsrj-11	94	20	mb	mb	ADP
gsrj-11	94	21	,	,	PUNCT
gsrj-11	94	22	several	several	ADJ
gsrj-11	94	23	limitations	limitation	NOUN
gsrj-11	94	24	to	to	ADP
gsrj-11	94	25	their	their	PRON
gsrj-11	94	26	efficacy	efficacy	NOUN
gsrj-11	94	27	still	still	ADV
gsrj-11	94	28	need	need	VERB
gsrj-11	94	29	to	to	PART
gsrj-11	94	30	be	be	AUX
gsrj-11	94	31	overcome	overcome	VERB
gsrj-11	94	32	.	.	PUNCT
gsrj-11	95	1	thus	thus	ADV
gsrj-11	95	2	,	,	PUNCT
gsrj-11	95	3	the	the	DET
gsrj-11	95	4	clinical	clinical	ADJ
gsrj-11	95	5	investigation	investigation	NOUN
gsrj-11	95	6	of	of	ADP
gsrj-11	95	7	other	other	ADJ
gsrj-11	95	8	potential	potential	ADJ
gsrj-11	95	9	shh	shh	NOUN
gsrj-11	95	10	inhibitors	inhibitor	NOUN
gsrj-11	95	11	is	be	AUX
gsrj-11	95	12	also	also	ADV
gsrj-11	95	13	warranted	warrant	VERB
gsrj-11	95	14	.	.	PUNCT
gsrj-11	96	1	temozolomide	temozolomide	NOUN
gsrj-11	96	2	another	another	DET
gsrj-11	96	3	shh	shh	INTJ
gsrj-11	96	4	small	small	ADJ
gsrj-11	96	5	molecule	molecule	NOUN
gsrj-11	96	6	inhibitor	inhibitor	NOUN
gsrj-11	96	7	is	be	AUX
gsrj-11	96	8	not	not	PART
gsrj-11	96	9	yet	yet	ADV
gsrj-11	96	10	approved	approve	VERB
gsrj-11	96	11	,	,	PUNCT
gsrj-11	96	12	but	but	CCONJ
gsrj-11	96	13	there	there	PRON
gsrj-11	96	14	are	be	VERB
gsrj-11	96	15	ongoing	ongoing	ADJ
gsrj-11	96	16	studies	study	NOUN
gsrj-11	96	17	about	about	ADP
gsrj-11	96	18	its	its	PRON
gsrj-11	96	19	use	use	NOUN
gsrj-11	96	20	as	as	ADP
gsrj-11	96	21	a	a	DET
gsrj-11	96	22	monotherapy	monotherapy	NOUN
gsrj-11	96	23	or	or	CCONJ
gsrj-11	96	24	in	in	ADP
gsrj-11	96	25	combination	combination	NOUN
gsrj-11	96	26	with	with	ADP
gsrj-11	96	27	vismodegib	vismodegib	NOUN
gsrj-11	96	28	.	.	PUNCT
gsrj-11	97	1	it	it	PRON
gsrj-11	97	2	functions	function	VERB
gsrj-11	97	3	by	by	ADP
gsrj-11	97	4	preventing	prevent	VERB
gsrj-11	97	5	dna	dna	ADJ
gsrj-11	97	6	duplication	duplication	NOUN
gsrj-11	97	7	in	in	ADP
gsrj-11	97	8	cells	cell	NOUN
gsrj-11	97	9	during	during	ADP
gsrj-11	97	10	proliferation	proliferation	NOUN
gsrj-11	97	11	,	,	PUNCT
gsrj-11	97	12	causing	cause	VERB
gsrj-11	97	13	cell	cell	NOUN
gsrj-11	97	14	death.22	death.22	PROPN
gsrj-11	97	15	therefore	therefore	ADV
gsrj-11	97	16	,	,	PUNCT
gsrj-11	97	17	temozolomide	temozolomide	NOUN
gsrj-11	97	18	works	work	VERB
gsrj-11	97	19	to	to	PART
gsrj-11	97	20	disrupt	disrupt	VERB
gsrj-11	97	21	division	division	NOUN
gsrj-11	97	22	of	of	ADP
gsrj-11	97	23	tumor	tumor	NOUN
gsrj-11	97	24	cells	cell	NOUN
gsrj-11	97	25	and	and	CCONJ
gsrj-11	97	26	consequently	consequently	ADV
gsrj-11	97	27	,	,	PUNCT
gsrj-11	97	28	hinders	hinder	VERB
gsrj-11	97	29	tumor	tumor	NOUN
gsrj-11	97	30	growth	growth	NOUN
gsrj-11	97	31	.	.	PUNCT
gsrj-11	98	1	though	though	SCONJ
gsrj-11	98	2	shh	shh	INTJ
gsrj-11	98	3	mb	mb	PROPN
gsrj-11	98	4	seems	seem	VERB
gsrj-11	98	5	amenable	amenable	ADJ
gsrj-11	98	6	to	to	PART
gsrj-11	98	7	temozolomide	temozolomide	VERB
gsrj-11	98	8	’s	’s	PART
gsrj-11	98	9	mechanism	mechanism	NOUN
gsrj-11	98	10	of	of	ADP
gsrj-11	98	11	action	action	NOUN
gsrj-11	98	12	,	,	PUNCT
gsrj-11	98	13	the	the	DET
gsrj-11	98	14	most	most	ADV
gsrj-11	98	15	89	89	NUM
gsrj-11	98	16	georgetown	georgetown	PROPN
gsrj-11	98	17	scientific	scientific	ADJ
gsrj-11	98	18	research	research	PROPN
gsrj-11	98	19	journal	journal	PROPN
gsrj-11	98	20	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	98	21	effective	effective	ADJ
gsrj-11	98	22	dosage	dosage	NOUN
gsrj-11	98	23	has	have	AUX
gsrj-11	98	24	not	not	PART
gsrj-11	98	25	yet	yet	ADV
gsrj-11	98	26	been	be	AUX
gsrj-11	98	27	established	establish	VERB
gsrj-11	98	28	.	.	PUNCT
gsrj-11	99	1	for	for	ADP
gsrj-11	99	2	instance	instance	NOUN
gsrj-11	99	3	,	,	PUNCT
gsrj-11	99	4	vismodegib	vismodegib	NOUN
gsrj-11	99	5	and	and	CCONJ
gsrj-11	99	6	temozolomide	temozolomide	NOUN
gsrj-11	99	7	monotherapies	monotherapie	NOUN
gsrj-11	99	8	were	be	AUX
gsrj-11	99	9	studied	study	VERB
gsrj-11	99	10	in	in	ADP
gsrj-11	99	11	a	a	DET
gsrj-11	99	12	patient	patient	NOUN
gsrj-11	99	13	with	with	ADP
gsrj-11	99	14	recurrent	recurrent	NOUN
gsrj-11	99	15	shh	shh	NOUN
gsrj-11	99	16	mb	mb	NOUN
gsrj-11	99	17	,	,	PUNCT
gsrj-11	99	18	and	and	CCONJ
gsrj-11	99	19	were	be	AUX
gsrj-11	99	20	taken	take	VERB
gsrj-11	99	21	at	at	ADP
gsrj-11	99	22	a	a	DET
gsrj-11	99	23	dose	dose	NOUN
gsrj-11	99	24	of	of	ADP
gsrj-11	99	25	150	150	NUM
gsrj-11	99	26	mg	mg	NOUN
gsrj-11	99	27	.	.	PUNCT
gsrj-11	100	1	the	the	DET
gsrj-11	100	2	patient	patient	NOUN
gsrj-11	100	3	responded	respond	VERB
gsrj-11	100	4	to	to	ADP
gsrj-11	100	5	both	both	DET
gsrj-11	100	6	vismodegib	vismodegib	NOUN
gsrj-11	100	7	and	and	CCONJ
gsrj-11	100	8	temozolomide	temozolomide	NOUN
gsrj-11	100	9	over	over	ADP
gsrj-11	100	10	a	a	DET
gsrj-11	100	11	significant	significant	ADJ
gsrj-11	100	12	period	period	NOUN
gsrj-11	100	13	of	of	ADP
gsrj-11	100	14	time	time	NOUN
gsrj-11	100	15	,	,	PUNCT
gsrj-11	100	16	though	though	SCONJ
gsrj-11	100	17	the	the	DET
gsrj-11	100	18	efficacy	efficacy	NOUN
gsrj-11	100	19	of	of	ADP
gsrj-11	100	20	both	both	DET
gsrj-11	100	21	treatments	treatment	NOUN
gsrj-11	100	22	eventually	eventually	ADV
gsrj-11	100	23	waned	wane	VERB
gsrj-11	100	24	due	due	ADP
gsrj-11	100	25	to	to	ADP
gsrj-11	100	26	drug	drug	NOUN
gsrj-11	100	27	resistance	resistance	NOUN
gsrj-11	100	28	.	.	PUNCT
gsrj-11	101	1	several	several	ADJ
gsrj-11	101	2	mutations	mutation	NOUN
gsrj-11	101	3	occurred	occur	VERB
gsrj-11	101	4	to	to	ADP
gsrj-11	101	5	smo	smo	PROPN
gsrj-11	101	6	:	:	PUNCT
gsrj-11	101	7	smo	smo	PROPN
gsrj-11	101	8	-	-	PUNCT
gsrj-11	101	9	l412p	l412p	PROPN
gsrj-11	101	10	,	,	PUNCT
gsrj-11	101	11	smo	smo	PROPN
gsrj-11	101	12	-	-	PUNCT
gsrj-11	101	13	g477l	g477l	NOUN
gsrj-11	101	14	,	,	PUNCT
gsrj-11	101	15	and	and	CCONJ
gsrj-11	101	16	pik3cah1065l	pik3cah1065l	NOUN
gsrj-11	101	17	mutations	mutation	NOUN
gsrj-11	101	18	,	,	PUNCT
gsrj-11	101	19	which	which	PRON
gsrj-11	101	20	indicates	indicate	VERB
gsrj-11	101	21	the	the	DET
gsrj-11	101	22	importance	importance	NOUN
gsrj-11	101	23	of	of	ADP
gsrj-11	101	24	a	a	DET
gsrj-11	101	25	treatment	treatment	NOUN
gsrj-11	101	26	regimen	regiman	NOUN
gsrj-11	101	27	that	that	PRON
gsrj-11	101	28	targets	target	VERB
gsrj-11	101	29	multiple	multiple	ADJ
gsrj-11	101	30	aspects	aspect	NOUN
gsrj-11	101	31	of	of	ADP
gsrj-11	101	32	the	the	DET
gsrj-11	101	33	shh	shh	PROPN
gsrj-11	101	34	pathway	pathway	NOUN
gsrj-11	101	35	.	.	PUNCT
gsrj-11	102	1	determining	determine	VERB
gsrj-11	102	2	the	the	DET
gsrj-11	102	3	optimal	optimal	ADJ
gsrj-11	102	4	dosage	dosage	NOUN
gsrj-11	102	5	of	of	ADP
gsrj-11	102	6	these	these	DET
gsrj-11	102	7	shh	shh	PROPN
gsrj-11	102	8	inhibitors	inhibitor	NOUN
gsrj-11	102	9	in	in	ADP
gsrj-11	102	10	preclinical	preclinical	ADJ
gsrj-11	102	11	studies	study	NOUN
gsrj-11	102	12	is	be	AUX
gsrj-11	102	13	critical	critical	ADJ
gsrj-11	102	14	before	before	ADP
gsrj-11	102	15	moving	move	VERB
gsrj-11	102	16	to	to	ADP
gsrj-11	102	17	clinical	clinical	ADJ
gsrj-11	102	18	trials	trial	NOUN
gsrj-11	102	19	,	,	PUNCT
gsrj-11	102	20	where	where	SCONJ
gsrj-11	102	21	patient	patient	ADJ
gsrj-11	102	22	safety	safety	NOUN
gsrj-11	102	23	is	be	AUX
gsrj-11	102	24	at	at	ADP
gsrj-11	102	25	risk	risk	NOUN
gsrj-11	102	26	.	.	PUNCT
gsrj-11	103	1	additionally	additionally	ADV
gsrj-11	103	2	,	,	PUNCT
gsrj-11	103	3	since	since	SCONJ
gsrj-11	103	4	the	the	DET
gsrj-11	103	5	benefits	benefit	NOUN
gsrj-11	103	6	of	of	ADP
gsrj-11	103	7	the	the	DET
gsrj-11	103	8	pharmaceutics	pharmaceutic	NOUN
gsrj-11	103	9	seem	seem	VERB
gsrj-11	103	10	to	to	PART
gsrj-11	103	11	dwindle	dwindle	VERB
gsrj-11	103	12	over	over	ADP
gsrj-11	103	13	time	time	NOUN
gsrj-11	103	14	,	,	PUNCT
gsrj-11	103	15	delineating	delineate	VERB
gsrj-11	103	16	time	time	NOUN
gsrj-11	103	17	of	of	ADP
gsrj-11	103	18	intervention	intervention	NOUN
gsrj-11	103	19	over	over	ADP
gsrj-11	103	20	the	the	DET
gsrj-11	103	21	course	course	NOUN
gsrj-11	103	22	of	of	ADP
gsrj-11	103	23	the	the	DET
gsrj-11	103	24	disease	disease	NOUN
gsrj-11	103	25	progression	progression	NOUN
gsrj-11	103	26	is	be	AUX
gsrj-11	103	27	also	also	ADV
gsrj-11	103	28	essential	essential	ADJ
gsrj-11	103	29	to	to	AUX
gsrj-11	103	30	better	well	ADV
gsrj-11	103	31	treating	treat	VERB
gsrj-11	103	32	patients.23	patients.23	NOUN
gsrj-11	103	33	lastly	lastly	ADV
gsrj-11	103	34	,	,	PUNCT
gsrj-11	103	35	gant-61	gant-61	PROPN
gsrj-11	103	36	is	be	AUX
gsrj-11	103	37	a	a	DET
gsrj-11	103	38	gli	gli	NOUN
gsrj-11	103	39	inhibitor	inhibitor	NOUN
gsrj-11	103	40	.	.	PUNCT
gsrj-11	104	1	inhibiting	inhibit	VERB
gsrj-11	104	2	gli	gli	NOUN
gsrj-11	104	3	in	in	ADP
gsrj-11	104	4	the	the	DET
gsrj-11	104	5	shh	shh	PROPN
gsrj-11	104	6	pathway	pathway	NOUN
gsrj-11	104	7	may	may	AUX
gsrj-11	104	8	be	be	AUX
gsrj-11	104	9	an	an	DET
gsrj-11	104	10	effective	effective	ADJ
gsrj-11	104	11	anti	anti	ADJ
gsrj-11	104	12	-	-	ADJ
gsrj-11	104	13	cancer	cancer	ADJ
gsrj-11	104	14	therapeutic	therapeutic	NOUN
gsrj-11	104	15	.	.	PUNCT
gsrj-11	105	1	it	it	PRON
gsrj-11	105	2	has	have	AUX
gsrj-11	105	3	been	be	AUX
gsrj-11	105	4	studied	study	VERB
gsrj-11	105	5	in	in	ADP
gsrj-11	105	6	daoy	daoy	ADJ
gsrj-11	105	7	cells	cell	NOUN
gsrj-11	105	8	,	,	PUNCT
gsrj-11	105	9	a	a	DET
gsrj-11	105	10	medulloblastoma	medulloblastoma	ADJ
gsrj-11	105	11	cell	cell	NOUN
gsrj-11	105	12	line	line	NOUN
gsrj-11	105	13	.	.	PUNCT
gsrj-11	106	1	the	the	DET
gsrj-11	106	2	study	study	NOUN
gsrj-11	106	3	found	find	VERB
gsrj-11	106	4	that	that	SCONJ
gsrj-11	106	5	gant-61	gant-61	NOUN
gsrj-11	106	6	succeeded	succeed	VERB
gsrj-11	106	7	at	at	ADP
gsrj-11	106	8	inhibiting	inhibit	VERB
gsrj-11	106	9	gli	gli	NOUN
gsrj-11	106	10	,	,	PUNCT
gsrj-11	106	11	a	a	DET
gsrj-11	106	12	key	key	ADJ
gsrj-11	106	13	transcription	transcription	NOUN
gsrj-11	106	14	factor	factor	NOUN
gsrj-11	106	15	in	in	ADP
gsrj-11	106	16	the	the	DET
gsrj-11	106	17	shh	shh	PROPN
gsrj-11	106	18	pathway	pathway	NOUN
gsrj-11	106	19	,	,	PUNCT
gsrj-11	106	20	downregulated	downregulate	VERB
gsrj-11	106	21	the	the	DET
gsrj-11	106	22	bcl-2	bcl-2	NOUN
gsrj-11	106	23	target	target	NOUN
gsrj-11	106	24	genes	gene	NOUN
gsrj-11	106	25	,	,	PUNCT
gsrj-11	106	26	and	and	CCONJ
gsrj-11	106	27	even	even	ADV
gsrj-11	106	28	made	make	VERB
gsrj-11	106	29	the	the	DET
gsrj-11	106	30	tumor	tumor	NOUN
gsrj-11	106	31	cells	cell	NOUN
gsrj-11	106	32	more	more	ADV
gsrj-11	106	33	sensitive	sensitive	ADJ
gsrj-11	106	34	to	to	ADP
gsrj-11	106	35	cisplatin	cisplatin	NOUN
gsrj-11	106	36	(	(	PUNCT
gsrj-11	106	37	a	a	DET
gsrj-11	106	38	chemotherapy	chemotherapy	NOUN
gsrj-11	106	39	drug).24	drug).24	NOUN
gsrj-11	106	40	this	this	PRON
gsrj-11	106	41	yielded	yield	VERB
gsrj-11	106	42	a	a	DET
gsrj-11	106	43	significant	significant	ADJ
gsrj-11	106	44	inhibition	inhibition	NOUN
gsrj-11	106	45	of	of	ADP
gsrj-11	106	46	cell	cell	NOUN
gsrj-11	106	47	proliferation	proliferation	NOUN
gsrj-11	106	48	,	,	PUNCT
gsrj-11	106	49	which	which	PRON
gsrj-11	106	50	would	would	AUX
gsrj-11	106	51	theoretically	theoretically	ADV
gsrj-11	106	52	inhibit	inhibit	VERB
gsrj-11	106	53	tumor	tumor	NOUN
gsrj-11	106	54	growth	growth	NOUN
gsrj-11	106	55	in	in	ADP
gsrj-11	106	56	vivo	vivo	NOUN
gsrj-11	106	57	.	.	PUNCT
gsrj-11	107	1	4	4	X
gsrj-11	107	2	.	.	X
gsrj-11	107	3	evaluation	evaluation	NOUN
gsrj-11	107	4	:	:	PUNCT
gsrj-11	107	5	therapeutic	therapeutic	ADJ
gsrj-11	107	6	potency	potency	NOUN
gsrj-11	107	7	of	of	ADP
gsrj-11	107	8	shh	shh	INTJ
gsrj-11	107	9	inhibitors	inhibitor	NOUN
gsrj-11	107	10	in	in	ADP
gsrj-11	107	11	shh	shh	NOUN
gsrj-11	107	12	-	-	PUNCT
gsrj-11	107	13	mb	mb	ADV
gsrj-11	107	14	targeted	target	VERB
gsrj-11	107	15	small	small	ADJ
gsrj-11	107	16	molecule	molecule	NOUN
gsrj-11	107	17	inhibitors	inhibitor	NOUN
gsrj-11	107	18	of	of	ADP
gsrj-11	107	19	the	the	DET
gsrj-11	107	20	shh	shh	PROPN
gsrj-11	107	21	pathway	pathway	NOUN
gsrj-11	107	22	have	have	AUX
gsrj-11	107	23	proven	prove	VERB
gsrj-11	107	24	to	to	PART
gsrj-11	107	25	be	be	AUX
gsrj-11	107	26	a	a	DET
gsrj-11	107	27	promising	promising	ADJ
gsrj-11	107	28	therapeutic	therapeutic	NOUN
gsrj-11	107	29	for	for	ADP
gsrj-11	107	30	shh	shh	PROPN
gsrj-11	107	31	mb	mb	NOUN
gsrj-11	107	32	.	.	PUNCT
gsrj-11	108	1	many	many	ADJ
gsrj-11	108	2	studies	study	NOUN
gsrj-11	108	3	and	and	CCONJ
gsrj-11	108	4	reviews	review	NOUN
gsrj-11	108	5	indicate	indicate	VERB
gsrj-11	108	6	that	that	SCONJ
gsrj-11	108	7	these	these	DET
gsrj-11	108	8	inhibitors	inhibitor	NOUN
gsrj-11	108	9	are	be	AUX
gsrj-11	108	10	effective	effective	ADJ
gsrj-11	108	11	at	at	ADP
gsrj-11	108	12	halting	halting	ADJ
gsrj-11	108	13	proliferation.24	proliferation.24	NOUN
gsrj-11	108	14	,	,	PUNCT
gsrj-11	108	15	25	25	NUM
gsrj-11	108	16	overall	overall	ADJ
gsrj-11	108	17	,	,	PUNCT
gsrj-11	108	18	there	there	PRON
gsrj-11	108	19	are	be	VERB
gsrj-11	108	20	three	three	NUM
gsrj-11	108	21	main	main	ADJ
gsrj-11	108	22	benefits	benefit	NOUN
gsrj-11	108	23	of	of	ADP
gsrj-11	108	24	these	these	DET
gsrj-11	108	25	inhibitors	inhibitor	NOUN
gsrj-11	108	26	that	that	PRON
gsrj-11	108	27	contribute	contribute	VERB
gsrj-11	108	28	to	to	ADP
gsrj-11	108	29	their	their	PRON
gsrj-11	108	30	efficacy	efficacy	NOUN
gsrj-11	108	31	:	:	PUNCT
gsrj-11	108	32	their	their	PRON
gsrj-11	108	33	capacity	capacity	NOUN
gsrj-11	108	34	to	to	PART
gsrj-11	108	35	directly	directly	ADV
gsrj-11	108	36	target	target	VERB
gsrj-11	108	37	the	the	DET
gsrj-11	108	38	shh	shh	PROPN
gsrj-11	108	39	pathway	pathway	NOUN
gsrj-11	108	40	,	,	PUNCT
gsrj-11	108	41	their	their	PRON
gsrj-11	108	42	infrequent	infrequent	ADJ
gsrj-11	108	43	toxicities	toxicity	NOUN
gsrj-11	108	44	,	,	PUNCT
gsrj-11	108	45	and	and	CCONJ
gsrj-11	108	46	their	their	PRON
gsrj-11	108	47	intimate	intimate	ADJ
gsrj-11	108	48	connection	connection	NOUN
gsrj-11	108	49	with	with	ADP
gsrj-11	108	50	the	the	DET
gsrj-11	108	51	shh	shh	PROPN
gsrj-11	108	52	pathway	pathway	NOUN
gsrj-11	108	53	genes	gene	NOUN
gsrj-11	108	54	.	.	PUNCT
gsrj-11	109	1	however	however	ADV
gsrj-11	109	2	,	,	PUNCT
gsrj-11	109	3	significant	significant	ADJ
gsrj-11	109	4	limitations	limitation	NOUN
gsrj-11	109	5	exist	exist	VERB
gsrj-11	109	6	.	.	PUNCT
gsrj-11	110	1	resistant	resistant	ADJ
gsrj-11	110	2	mutations	mutation	NOUN
gsrj-11	110	3	and	and	CCONJ
gsrj-11	110	4	the	the	DET
gsrj-11	110	5	heterogeneity	heterogeneity	NOUN
gsrj-11	110	6	of	of	ADP
gsrj-11	110	7	the	the	DET
gsrj-11	110	8	disease	disease	NOUN
gsrj-11	110	9	are	be	AUX
gsrj-11	110	10	two	two	NUM
gsrj-11	110	11	major	major	ADJ
gsrj-11	110	12	limitations	limitation	NOUN
gsrj-11	110	13	,	,	PUNCT
gsrj-11	110	14	and	and	CCONJ
gsrj-11	110	15	poor	poor	ADJ
gsrj-11	110	16	drug	drug	NOUN
gsrj-11	110	17	properties	property	NOUN
gsrj-11	110	18	is	be	AUX
gsrj-11	110	19	a	a	DET
gsrj-11	110	20	minor	minor	ADJ
gsrj-11	110	21	(	(	PUNCT
gsrj-11	110	22	but	but	CCONJ
gsrj-11	110	23	important	important	ADJ
gsrj-11	110	24	)	)	PUNCT
gsrj-11	110	25	limitation	limitation	NOUN
gsrj-11	110	26	.	.	PUNCT
gsrj-11	111	1	this	this	DET
gsrj-11	111	2	section	section	NOUN
gsrj-11	111	3	will	will	AUX
gsrj-11	111	4	address	address	VERB
gsrj-11	111	5	these	these	DET
gsrj-11	111	6	benefits	benefit	NOUN
gsrj-11	111	7	and	and	CCONJ
gsrj-11	111	8	limitations	limitation	NOUN
gsrj-11	111	9	.	.	PUNCT
gsrj-11	112	1	4.1	4.1	NUM
gsrj-11	112	2	precision	precision	NOUN
gsrj-11	112	3	yet	yet	CCONJ
gsrj-11	112	4	resistance	resistance	NOUN
gsrj-11	112	5	novel	novel	NOUN
gsrj-11	112	6	investigations	investigation	NOUN
gsrj-11	112	7	evaluating	evaluate	VERB
gsrj-11	112	8	the	the	DET
gsrj-11	112	9	efficacy	efficacy	NOUN
gsrj-11	112	10	of	of	ADP
gsrj-11	112	11	targeted	target	VERB
gsrj-11	112	12	inhibitor	inhibitor	NOUN
gsrj-11	112	13	therapeutics	therapeutic	NOUN
gsrj-11	112	14	in	in	ADP
gsrj-11	112	15	shh	shh	NOUN
gsrj-11	112	16	mb	mb	PROPN
gsrj-11	112	17	have	have	AUX
gsrj-11	112	18	demonstrated	demonstrate	VERB
gsrj-11	112	19	the	the	DET
gsrj-11	112	20	capacity	capacity	NOUN
gsrj-11	112	21	of	of	ADP
gsrj-11	112	22	these	these	DET
gsrj-11	112	23	inhibitors	inhibitor	NOUN
gsrj-11	112	24	to	to	PART
gsrj-11	112	25	bind	bind	VERB
gsrj-11	112	26	specifically	specifically	ADV
gsrj-11	112	27	to	to	ADP
gsrj-11	112	28	various	various	ADJ
gsrj-11	112	29	factors	factor	NOUN
gsrj-11	112	30	in	in	ADP
gsrj-11	112	31	the	the	DET
gsrj-11	112	32	shh	shh	PROPN
gsrj-11	112	33	pathway	pathway	NOUN
gsrj-11	112	34	,	,	PUNCT
gsrj-11	112	35	thereby	thereby	ADV
gsrj-11	112	36	preventing	prevent	VERB
gsrj-11	112	37	its	its	PRON
gsrj-11	112	38	progression	progression	NOUN
gsrj-11	112	39	.	.	PUNCT
gsrj-11	113	1	this	this	PRON
gsrj-11	113	2	makes	make	VERB
gsrj-11	113	3	targeted	target	VERB
gsrj-11	113	4	inhibitors	inhibitor	NOUN
gsrj-11	113	5	an	an	DET
gsrj-11	113	6	effective	effective	ADJ
gsrj-11	113	7	therapeutic	therapeutic	NOUN
gsrj-11	113	8	because	because	SCONJ
gsrj-11	113	9	it	it	PRON
gsrj-11	113	10	attacks	attack	VERB
gsrj-11	113	11	the	the	DET
gsrj-11	113	12	cancer	cancer	NOUN
gsrj-11	113	13	at	at	ADP
gsrj-11	113	14	the	the	DET
gsrj-11	113	15	heart	heart	NOUN
gsrj-11	113	16	of	of	ADP
gsrj-11	113	17	its	its	PRON
gsrj-11	113	18	mechanism	mechanism	NOUN
gsrj-11	113	19	for	for	ADP
gsrj-11	113	20	proliferation	proliferation	NOUN
gsrj-11	113	21	.	.	PUNCT
gsrj-11	114	1	poisoning	poison	VERB
gsrj-11	114	2	the	the	DET
gsrj-11	114	3	cells	cell	NOUN
gsrj-11	114	4	that	that	PRON
gsrj-11	114	5	carry	carry	VERB
gsrj-11	114	6	the	the	DET
gsrj-11	114	7	mechanism	mechanism	NOUN
gsrj-11	114	8	through	through	ADP
gsrj-11	114	9	chemotherapy	chemotherapy	NOUN
gsrj-11	114	10	,	,	PUNCT
gsrj-11	114	11	an	an	DET
gsrj-11	114	12	alternative	alternative	ADJ
gsrj-11	114	13	treatment	treatment	NOUN
gsrj-11	114	14	,	,	PUNCT
gsrj-11	114	15	is	be	AUX
gsrj-11	114	16	not	not	PART
gsrj-11	114	17	as	as	ADV
gsrj-11	114	18	precise	precise	ADJ
gsrj-11	114	19	.	.	PUNCT
gsrj-11	115	1	sonidegib	sonidegib	NOUN
gsrj-11	115	2	illustrates	illustrate	VERB
gsrj-11	115	3	this	this	PRON
gsrj-11	115	4	.	.	PUNCT
gsrj-11	116	1	mb	mb	ADP
gsrj-11	116	2	growth	growth	NOUN
gsrj-11	116	3	in	in	ADP
gsrj-11	116	4	mice	mouse	NOUN
gsrj-11	116	5	decreased	decrease	VERB
gsrj-11	116	6	by	by	ADP
gsrj-11	116	7	33	33	NUM
gsrj-11	116	8	%	%	NOUN
gsrj-11	116	9	more	more	ADJ
gsrj-11	116	10	than	than	ADP
gsrj-11	116	11	the	the	DET
gsrj-11	116	12	control	control	NOUN
gsrj-11	116	13	group	group	NOUN
gsrj-11	116	14	following	follow	VERB
gsrj-11	116	15	sonidegib	sonidegib	PROPN
gsrj-11	116	16	treatment.25	treatment.25	PROPN
gsrj-11	116	17	by	by	ADP
gsrj-11	116	18	targeting	target	VERB
gsrj-11	116	19	the	the	DET
gsrj-11	116	20	smo	smo	PROPN
gsrj-11	116	21	protein	protein	NOUN
gsrj-11	116	22	,	,	PUNCT
gsrj-11	116	23	sonidegib	sonidegib	NOUN
gsrj-11	116	24	prevented	prevent	VERB
gsrj-11	116	25	smo	smo	PROPN
gsrj-11	116	26	’s	’s	PART
gsrj-11	116	27	translocation	translocation	NOUN
gsrj-11	116	28	to	to	ADP
gsrj-11	116	29	the	the	DET
gsrj-11	116	30	primary	primary	ADJ
gsrj-11	116	31	cilium	cilium	NOUN
gsrj-11	116	32	,	,	PUNCT
gsrj-11	116	33	thereby	thereby	ADV
gsrj-11	116	34	halting	halt	VERB
gsrj-11	116	35	the	the	DET
gsrj-11	116	36	pathway	pathway	NOUN
gsrj-11	116	37	.	.	PUNCT
gsrj-11	117	1	as	as	ADP
gsrj-11	117	2	a	a	DET
gsrj-11	117	3	result	result	NOUN
gsrj-11	117	4	,	,	PUNCT
gsrj-11	117	5	tumor	tumor	NOUN
gsrj-11	117	6	progression	progression	NOUN
gsrj-11	117	7	significantly	significantly	ADV
gsrj-11	117	8	declined	decline	VERB
gsrj-11	117	9	at	at	ADP
gsrj-11	117	10	a	a	DET
gsrj-11	117	11	dose	dose	ADJ
gsrj-11	117	12	dependent	dependent	ADJ
gsrj-11	117	13	rate	rate	NOUN
gsrj-11	117	14	,	,	PUNCT
gsrj-11	117	15	indicating	indicate	VERB
gsrj-11	117	16	its	its	PRON
gsrj-11	117	17	potential	potential	NOUN
gsrj-11	117	18	for	for	ADP
gsrj-11	117	19	treating	treat	VERB
gsrj-11	117	20	shh	shh	PROPN
gsrj-11	117	21	mb.25	mb.25	PROPN
gsrj-11	117	22	another	another	DET
gsrj-11	117	23	example	example	NOUN
gsrj-11	117	24	is	be	AUX
gsrj-11	117	25	a	a	DET
gsrj-11	117	26	2016	2016	NUM
gsrj-11	117	27	study	study	NOUN
gsrj-11	117	28	examining	examine	VERB
gsrj-11	117	29	the	the	DET
gsrj-11	117	30	efficacy	efficacy	NOUN
gsrj-11	117	31	of	of	ADP
gsrj-11	117	32	gant-61	gant-61	PROPN
gsrj-11	117	33	,	,	PUNCT
gsrj-11	117	34	a	a	DET
gsrj-11	117	35	gli	gli	NOUN
gsrj-11	117	36	transcription	transcription	NOUN
gsrj-11	117	37	factor	factor	NOUN
gsrj-11	117	38	inhibitor	inhibitor	NOUN
gsrj-11	117	39	in	in	ADP
gsrj-11	117	40	shh	shh	PROPN
gsrj-11	117	41	mb	mb	PROPN
gsrj-11	117	42	.	.	PUNCT
gsrj-11	118	1	the	the	DET
gsrj-11	118	2	overexpression	overexpression	NOUN
gsrj-11	118	3	of	of	ADP
gsrj-11	118	4	this	this	DET
gsrj-11	118	5	gene	gene	NOUN
gsrj-11	118	6	is	be	AUX
gsrj-11	118	7	associated	associate	VERB
gsrj-11	118	8	with	with	ADP
gsrj-11	118	9	several	several	ADJ
gsrj-11	118	10	cancers	cancer	NOUN
gsrj-11	118	11	.	.	PUNCT
gsrj-11	119	1	in	in	ADP
gsrj-11	119	2	the	the	DET
gsrj-11	119	3	study	study	NOUN
gsrj-11	119	4	,	,	PUNCT
gsrj-11	119	5	varied	varied	ADJ
gsrj-11	119	6	concentrations	concentration	NOUN
gsrj-11	119	7	of	of	ADP
gsrj-11	119	8	gant-61	gant-61	PROPN
gsrj-11	119	9	were	be	AUX
gsrj-11	119	10	administered	administer	VERB
gsrj-11	119	11	to	to	ADP
gsrj-11	119	12	doay	doay	PROPN
gsrj-11	119	13	cells	cell	NOUN
gsrj-11	119	14	,	,	PUNCT
gsrj-11	119	15	which	which	PRON
gsrj-11	119	16	serves	serve	VERB
gsrj-11	119	17	as	as	ADP
gsrj-11	119	18	the	the	DET
gsrj-11	119	19	in	in	X
gsrj-11	119	20	vitro	vitro	X
gsrj-11	119	21	model	model	NOUN
gsrj-11	119	22	of	of	ADP
gsrj-11	119	23	mb	mb	PROPN
gsrj-11	119	24	.	.	PUNCT
gsrj-11	119	25	by	by	ADP
gsrj-11	119	26	inhibiting	inhibit	VERB
gsrj-11	119	27	gli	gli	NOUN
gsrj-11	119	28	,	,	PUNCT
gsrj-11	119	29	gant61	gant61	NOUN
gsrj-11	119	30	promoted	promote	VERB
gsrj-11	119	31	apoptosis	apoptosis	NOUN
gsrj-11	119	32	of	of	ADP
gsrj-11	119	33	the	the	DET
gsrj-11	119	34	daoy	daoy	ADJ
gsrj-11	119	35	cells	cell	NOUN
gsrj-11	119	36	and	and	CCONJ
gsrj-11	119	37	downregulated	downregulate	VERB
gsrj-11	119	38	the	the	DET
gsrj-11	119	39	bcl-2	bcl-2	PUNCT
gsrj-11	119	40	target	target	NOUN
gsrj-11	119	41	gene	gene	NOUN
gsrj-11	119	42	,	,	PUNCT
gsrj-11	119	43	substantially	substantially	ADV
gsrj-11	119	44	inhibiting	inhibit	VERB
gsrj-11	119	45	cell	cell	NOUN
gsrj-11	119	46	proliferation.24	proliferation.24	NOUN
gsrj-11	119	47	both	both	DET
gsrj-11	119	48	gli	gli	NOUN
gsrj-11	119	49	and	and	CCONJ
gsrj-11	119	50	bcl-2	bcl-2	NOUN
gsrj-11	119	51	are	be	AUX
gsrj-11	119	52	components	component	NOUN
gsrj-11	119	53	of	of	ADP
gsrj-11	119	54	the	the	DET
gsrj-11	119	55	shh	shh	PROPN
gsrj-11	119	56	pathway	pathway	NOUN
gsrj-11	119	57	,	,	PUNCT
gsrj-11	119	58	illuminating	illuminate	VERB
gsrj-11	119	59	how	how	SCONJ
gsrj-11	119	60	these	these	DET
gsrj-11	119	61	inhibitors	inhibitor	NOUN
gsrj-11	119	62	attack	attack	VERB
gsrj-11	119	63	the	the	DET
gsrj-11	119	64	mb	mb	NOUN
gsrj-11	119	65	cancer	cancer	NOUN
gsrj-11	119	66	at	at	ADP
gsrj-11	119	67	the	the	DET
gsrj-11	119	68	site	site	NOUN
gsrj-11	119	69	of	of	ADP
gsrj-11	119	70	tumor	tumor	NOUN
gsrj-11	119	71	initiation	initiation	NOUN
gsrj-11	119	72	.	.	PUNCT
gsrj-11	120	1	in	in	ADP
gsrj-11	120	2	summary	summary	NOUN
gsrj-11	120	3	,	,	PUNCT
gsrj-11	120	4	the	the	DET
gsrj-11	120	5	examples	example	NOUN
gsrj-11	120	6	of	of	ADP
gsrj-11	120	7	sonidegib	sonidegib	NOUN
gsrj-11	120	8	and	and	CCONJ
gsrj-11	120	9	gant-61	gant-61	PROPN
gsrj-11	120	10	illustrate	illustrate	VERB
gsrj-11	120	11	that	that	SCONJ
gsrj-11	120	12	shh	shh	PROPN
gsrj-11	120	13	targeted	target	VERB
gsrj-11	120	14	inhibitors	inhibitor	NOUN
gsrj-11	120	15	are	be	AUX
gsrj-11	120	16	effective	effective	ADJ
gsrj-11	120	17	because	because	SCONJ
gsrj-11	120	18	they	they	PRON
gsrj-11	120	19	target	target	VERB
gsrj-11	120	20	the	the	DET
gsrj-11	120	21	mb	mb	NOUN
gsrj-11	120	22	cancer	cancer	NOUN
gsrj-11	120	23	at	at	ADP
gsrj-11	120	24	its	its	PRON
gsrj-11	120	25	source	source	NOUN
gsrj-11	120	26	:	:	PUNCT
gsrj-11	120	27	the	the	DET
gsrj-11	120	28	shh	shh	PROPN
gsrj-11	120	29	pathway	pathway	NOUN
gsrj-11	120	30	.	.	PUNCT
gsrj-11	121	1	90	90	NUM
gsrj-11	121	2	georgetown	georgetown	PROPN
gsrj-11	121	3	scientific	scientific	ADJ
gsrj-11	121	4	research	research	NOUN
gsrj-11	121	5	journal	journal	NOUN
gsrj-11	121	6	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	NOUN
gsrj-11	121	7	although	although	SCONJ
gsrj-11	121	8	the	the	DET
gsrj-11	121	9	targeting	target	VERB
gsrj-11	121	10	nature	nature	NOUN
gsrj-11	121	11	of	of	ADP
gsrj-11	121	12	small	small	ADJ
gsrj-11	121	13	molecule	molecule	NOUN
gsrj-11	121	14	inhibitors	inhibitor	NOUN
gsrj-11	121	15	is	be	AUX
gsrj-11	121	16	a	a	DET
gsrj-11	121	17	significant	significant	ADJ
gsrj-11	121	18	benefit	benefit	NOUN
gsrj-11	121	19	,	,	PUNCT
gsrj-11	121	20	mutations	mutation	NOUN
gsrj-11	121	21	in	in	ADP
gsrj-11	121	22	the	the	DET
gsrj-11	121	23	shh	shh	PROPN
gsrj-11	121	24	pathway	pathway	NOUN
gsrj-11	121	25	genes	gene	NOUN
gsrj-11	121	26	often	often	ADV
gsrj-11	121	27	lead	lead	VERB
gsrj-11	121	28	to	to	ADP
gsrj-11	121	29	resistance	resistance	NOUN
gsrj-11	121	30	.	.	PUNCT
gsrj-11	122	1	these	these	DET
gsrj-11	122	2	mutations	mutation	NOUN
gsrj-11	122	3	create	create	VERB
gsrj-11	122	4	proteins	protein	NOUN
gsrj-11	122	5	in	in	ADP
gsrj-11	122	6	the	the	DET
gsrj-11	122	7	shh	shh	PROPN
gsrj-11	122	8	pathway	pathway	NOUN
gsrj-11	122	9	that	that	PRON
gsrj-11	122	10	interfere	interfere	VERB
gsrj-11	122	11	with	with	ADP
gsrj-11	122	12	the	the	DET
gsrj-11	122	13	inhibitors	inhibitor	NOUN
gsrj-11	122	14	’	'	PUNCT
gsrj-11	122	15	effects	effect	NOUN
gsrj-11	122	16	,	,	PUNCT
gsrj-11	122	17	rendering	render	VERB
gsrj-11	122	18	them	they	PRON
gsrj-11	122	19	ineffective	ineffective	ADJ
gsrj-11	122	20	at	at	ADP
gsrj-11	122	21	halting	halt	VERB
gsrj-11	122	22	tumor	tumor	NOUN
gsrj-11	122	23	growth	growth	NOUN
gsrj-11	122	24	.	.	PUNCT
gsrj-11	123	1	for	for	ADP
gsrj-11	123	2	example	example	NOUN
gsrj-11	123	3	,	,	PUNCT
gsrj-11	123	4	multiple	multiple	ADJ
gsrj-11	123	5	sources	source	NOUN
gsrj-11	123	6	reveal	reveal	VERB
gsrj-11	123	7	that	that	SCONJ
gsrj-11	123	8	smo	smo	PROPN
gsrj-11	123	9	point	point	NOUN
gsrj-11	123	10	mutations	mutation	NOUN
gsrj-11	123	11	result	result	VERB
gsrj-11	123	12	in	in	ADP
gsrj-11	123	13	proteins	protein	NOUN
gsrj-11	123	14	that	that	PRON
gsrj-11	123	15	do	do	AUX
gsrj-11	123	16	not	not	PART
gsrj-11	123	17	allow	allow	VERB
gsrj-11	123	18	for	for	ADP
gsrj-11	123	19	inhibitor	inhibitor	NOUN
gsrj-11	123	20	binding.1,6	binding.1,6	PROPN
gsrj-11	123	21	overall	overall	ADJ
gsrj-11	123	22	,	,	PUNCT
gsrj-11	123	23	patterns	pattern	NOUN
gsrj-11	123	24	in	in	ADP
gsrj-11	123	25	current	current	ADJ
gsrj-11	123	26	literature	literature	NOUN
gsrj-11	123	27	indicate	indicate	VERB
gsrj-11	123	28	that	that	SCONJ
gsrj-11	123	29	smo	smo	PROPN
gsrj-11	123	30	,	,	PUNCT
gsrj-11	123	31	sufu	sufu	X
gsrj-11	123	32	,	,	PUNCT
gsrj-11	123	33	gli2	gli2	NOUN
gsrj-11	123	34	,	,	PUNCT
gsrj-11	123	35	and	and	CCONJ
gsrj-11	123	36	mycn	mycn	NOUN
gsrj-11	123	37	are	be	AUX
gsrj-11	123	38	the	the	DET
gsrj-11	123	39	genes	gene	NOUN
gsrj-11	123	40	that	that	PRON
gsrj-11	123	41	primarily	primarily	ADV
gsrj-11	123	42	experience	experience	VERB
gsrj-11	123	43	inappropriate	inappropriate	ADJ
gsrj-11	123	44	amplifications	amplification	NOUN
gsrj-11	123	45	or	or	CCONJ
gsrj-11	123	46	mutations	mutation	NOUN
gsrj-11	123	47	resulting	result	VERB
gsrj-11	123	48	in	in	ADP
gsrj-11	123	49	resistant	resistant	ADJ
gsrj-11	123	50	effects	effect	NOUN
gsrj-11	123	51	.	.	PUNCT
gsrj-11	124	1	patterns	pattern	NOUN
gsrj-11	124	2	in	in	ADP
gsrj-11	124	3	these	these	DET
gsrj-11	124	4	mutations	mutation	NOUN
gsrj-11	124	5	and	and	CCONJ
gsrj-11	124	6	how	how	SCONJ
gsrj-11	124	7	each	each	DET
gsrj-11	124	8	mutation	mutation	NOUN
gsrj-11	124	9	results	result	VERB
gsrj-11	124	10	in	in	ADP
gsrj-11	124	11	resistance	resistance	NOUN
gsrj-11	124	12	is	be	AUX
gsrj-11	124	13	still	still	ADV
gsrj-11	124	14	unclear	unclear	ADJ
gsrj-11	124	15	,	,	PUNCT
gsrj-11	124	16	but	but	CCONJ
gsrj-11	124	17	multiple	multiple	ADJ
gsrj-11	124	18	studies	study	NOUN
gsrj-11	124	19	report	report	VERB
gsrj-11	124	20	that	that	SCONJ
gsrj-11	124	21	sufu	sufu	PROPN
gsrj-11	124	22	,	,	PUNCT
gsrj-11	124	23	gli2	gli2	NOUN
gsrj-11	124	24	,	,	PUNCT
gsrj-11	124	25	and	and	CCONJ
gsrj-11	124	26	mycn	mycn	NOUN
gsrj-11	124	27	are	be	AUX
gsrj-11	124	28	all	all	ADV
gsrj-11	124	29	downstream	downstream	ADJ
gsrj-11	124	30	from	from	ADP
gsrj-11	124	31	smo.1	smo.1	PROPN
gsrj-11	124	32	,	,	PUNCT
gsrj-11	124	33	19	19	NUM
gsrj-11	124	34	,	,	PUNCT
gsrj-11	124	35	26	26	NUM
gsrj-11	124	36	for	for	ADP
gsrj-11	124	37	example	example	NOUN
gsrj-11	124	38	,	,	PUNCT
gsrj-11	124	39	one	one	NUM
gsrj-11	124	40	clinical	clinical	ADJ
gsrj-11	124	41	trial	trial	NOUN
gsrj-11	124	42	found	find	VERB
gsrj-11	124	43	that	that	SCONJ
gsrj-11	124	44	patients	patient	NOUN
gsrj-11	124	45	with	with	ADP
gsrj-11	124	46	the	the	DET
gsrj-11	124	47	downstream	downstream	ADJ
gsrj-11	124	48	genes	gene	NOUN
gsrj-11	124	49	did	do	AUX
gsrj-11	124	50	not	not	PART
gsrj-11	124	51	respond	respond	VERB
gsrj-11	124	52	to	to	ADP
gsrj-11	124	53	smo	smo	PROPN
gsrj-11	124	54	antagonists	antagonist	NOUN
gsrj-11	124	55	at	at	ADV
gsrj-11	124	56	all	all	ADV
gsrj-11	124	57	or	or	CCONJ
gsrj-11	124	58	initially	initially	ADV
gsrj-11	124	59	responded	respond	VERB
gsrj-11	124	60	to	to	ADP
gsrj-11	124	61	the	the	DET
gsrj-11	124	62	antagonists	antagonist	NOUN
gsrj-11	124	63	but	but	CCONJ
gsrj-11	124	64	later	later	ADV
gsrj-11	124	65	experienced	experience	VERB
gsrj-11	124	66	recurrence.26	recurrence.26	VERB
gsrj-11	124	67	conversely	conversely	ADV
gsrj-11	124	68	,	,	PUNCT
gsrj-11	124	69	this	this	DET
gsrj-11	124	70	clinical	clinical	ADJ
gsrj-11	124	71	trial	trial	NOUN
gsrj-11	124	72	and	and	CCONJ
gsrj-11	124	73	a	a	DET
gsrj-11	124	74	separate	separate	ADJ
gsrj-11	124	75	clinical	clinical	ADJ
gsrj-11	124	76	trial	trial	NOUN
gsrj-11	124	77	found	find	VERB
gsrj-11	124	78	that	that	SCONJ
gsrj-11	124	79	shh	shh	PROPN
gsrj-11	124	80	mb	mb	ADP
gsrj-11	124	81	patients	patient	NOUN
gsrj-11	124	82	with	with	ADP
gsrj-11	124	83	mutations	mutation	NOUN
gsrj-11	124	84	in	in	ADP
gsrj-11	124	85	the	the	DET
gsrj-11	124	86	upstream	upstream	ADJ
gsrj-11	124	87	ptch1	ptch1	PROPN
gsrj-11	124	88	gene	gene	NOUN
gsrj-11	124	89	did	do	AUX
gsrj-11	124	90	respond	respond	VERB
gsrj-11	124	91	to	to	ADP
gsrj-11	124	92	the	the	DET
gsrj-11	124	93	inhibitors.19	inhibitors.19	NOUN
gsrj-11	124	94	,	,	PUNCT
gsrj-11	124	95	26	26	NUM
gsrj-11	124	96	these	these	DET
gsrj-11	124	97	variable	variable	ADJ
gsrj-11	124	98	clinical	clinical	ADJ
gsrj-11	124	99	responses	response	NOUN
gsrj-11	124	100	are	be	AUX
gsrj-11	124	101	due	due	ADJ
gsrj-11	124	102	to	to	ADP
gsrj-11	124	103	the	the	DET
gsrj-11	124	104	heterogeneity	heterogeneity	NOUN
gsrj-11	124	105	of	of	ADP
gsrj-11	124	106	the	the	DET
gsrj-11	124	107	disease	disease	NOUN
gsrj-11	124	108	and	and	CCONJ
gsrj-11	124	109	mutations	mutation	NOUN
gsrj-11	124	110	that	that	PRON
gsrj-11	124	111	lead	lead	VERB
gsrj-11	124	112	to	to	ADP
gsrj-11	124	113	resistance.23	resistance.23	NOUN
gsrj-11	124	114	,	,	PUNCT
gsrj-11	124	115	26	26	NUM
gsrj-11	124	116	furthermore	furthermore	ADV
gsrj-11	124	117	,	,	PUNCT
gsrj-11	124	118	a	a	DET
gsrj-11	124	119	pattern	pattern	NOUN
gsrj-11	124	120	in	in	ADP
gsrj-11	124	121	clinical	clinical	ADJ
gsrj-11	124	122	trials	trial	NOUN
gsrj-11	124	123	has	have	AUX
gsrj-11	124	124	emerged	emerge	VERB
gsrj-11	124	125	where	where	SCONJ
gsrj-11	124	126	shh	shh	PROPN
gsrj-11	124	127	mb	mb	PROPN
gsrj-11	124	128	patients	patient	NOUN
gsrj-11	124	129	’	'	PUNCT
gsrj-11	124	130	tumors	tumor	NOUN
gsrj-11	124	131	will	will	AUX
gsrj-11	124	132	initially	initially	ADV
gsrj-11	124	133	shrink	shrink	VERB
gsrj-11	124	134	,	,	PUNCT
gsrj-11	124	135	only	only	ADV
gsrj-11	124	136	to	to	PART
gsrj-11	124	137	be	be	AUX
gsrj-11	124	138	followed	follow	VERB
gsrj-11	124	139	with	with	ADP
gsrj-11	124	140	recurrent	recurrent	ADJ
gsrj-11	124	141	growth.6	growth.6	NOUN
gsrj-11	124	142	,	,	PUNCT
gsrj-11	124	143	26	26	NUM
gsrj-11	124	144	,	,	PUNCT
gsrj-11	124	145	27	27	NUM
gsrj-11	124	146	these	these	DET
gsrj-11	124	147	patterns	pattern	NOUN
gsrj-11	124	148	are	be	AUX
gsrj-11	124	149	supported	support	VERB
gsrj-11	124	150	by	by	ADP
gsrj-11	124	151	in	in	ADP
gsrj-11	124	152	vitro	vitro	X
gsrj-11	124	153	experimentation	experimentation	NOUN
gsrj-11	124	154	.	.	PUNCT
gsrj-11	125	1	inhibitors	inhibitor	NOUN
gsrj-11	125	2	such	such	ADJ
gsrj-11	125	3	as	as	ADP
gsrj-11	125	4	sonidegib	sonidegib	NOUN
gsrj-11	125	5	and	and	CCONJ
gsrj-11	125	6	novel	novel	ADJ
gsrj-11	125	7	artemisinin	artemisinin	NOUN
gsrj-11	125	8	derivatives	derivative	NOUN
gsrj-11	125	9	significantly	significantly	ADV
gsrj-11	125	10	halted	halt	VERB
gsrj-11	125	11	mb	mb	ADP
gsrj-11	125	12	proliferation	proliferation	NOUN
gsrj-11	125	13	during	during	ADP
gsrj-11	125	14	early	early	ADJ
gsrj-11	125	15	stages	stage	NOUN
gsrj-11	125	16	of	of	ADP
gsrj-11	125	17	experimentation	experimentation	NOUN
gsrj-11	125	18	but	but	CCONJ
gsrj-11	125	19	were	be	AUX
gsrj-11	125	20	unable	unable	ADJ
gsrj-11	125	21	to	to	PART
gsrj-11	125	22	overcome	overcome	VERB
gsrj-11	125	23	resistant	resistant	ADJ
gsrj-11	125	24	mutations	mutation	NOUN
gsrj-11	125	25	that	that	PRON
gsrj-11	125	26	led	lead	VERB
gsrj-11	125	27	to	to	PART
gsrj-11	125	28	recurrent	recurrent	VERB
gsrj-11	125	29	proliferation.12	proliferation.12	NOUN
gsrj-11	125	30	,	,	PUNCT
gsrj-11	125	31	28	28	NUM
gsrj-11	125	32	-	-	SYM
gsrj-11	125	33	30	30	NUM
gsrj-11	125	34	it	it	PRON
gsrj-11	125	35	should	should	AUX
gsrj-11	125	36	be	be	AUX
gsrj-11	125	37	noted	note	VERB
gsrj-11	125	38	that	that	SCONJ
gsrj-11	125	39	not	not	PART
gsrj-11	125	40	all	all	PRON
gsrj-11	125	41	of	of	ADP
gsrj-11	125	42	the	the	DET
gsrj-11	125	43	sources	source	NOUN
gsrj-11	125	44	agree	agree	VERB
gsrj-11	125	45	on	on	ADP
gsrj-11	125	46	which	which	PRON
gsrj-11	125	47	gene	gene	NOUN
gsrj-11	125	48	mutations	mutation	NOUN
gsrj-11	125	49	result	result	VERB
gsrj-11	125	50	in	in	ADP
gsrj-11	125	51	resistance	resistance	NOUN
gsrj-11	125	52	.	.	PUNCT
gsrj-11	126	1	most	most	ADJ
gsrj-11	126	2	sources	source	NOUN
gsrj-11	126	3	comment	comment	VERB
gsrj-11	126	4	on	on	ADP
gsrj-11	126	5	sufu	sufu	PROPN
gsrj-11	126	6	,	,	PUNCT
gsrj-11	126	7	gli2	gli2	NOUN
gsrj-11	126	8	,	,	PUNCT
gsrj-11	126	9	and	and	CCONJ
gsrj-11	126	10	mycn	mycn	NOUN
gsrj-11	126	11	,	,	PUNCT
gsrj-11	126	12	but	but	CCONJ
gsrj-11	126	13	one	one	NUM
gsrj-11	126	14	review	review	NOUN
gsrj-11	126	15	also	also	ADV
gsrj-11	126	16	discusses	discuss	VERB
gsrj-11	126	17	truncations	truncation	NOUN
gsrj-11	126	18	of	of	ADP
gsrj-11	126	19	gli1	gli1	NOUN
gsrj-11	126	20	,	,	PUNCT
gsrj-11	126	21	amplifications	amplification	NOUN
gsrj-11	126	22	of	of	ADP
gsrj-11	126	23	gli2	gli2	PROPN
gsrj-11	126	24	,	,	PUNCT
gsrj-11	126	25	cyclin	cyclin	NOUN
gsrj-11	126	26	d1	d1	NOUN
gsrj-11	126	27	,	,	PUNCT
gsrj-11	126	28	and	and	CCONJ
gsrj-11	126	29	upregulation	upregulation	NOUN
gsrj-11	126	30	of	of	ADP
gsrj-11	126	31	the	the	DET
gsrj-11	126	32	atp	atp	NOUN
gsrj-11	126	33	binding	bind	VERB
gsrj-11	126	34	cassette	cassette	NOUN
gsrj-11	126	35	transporter	transporter	NOUN
gsrj-11	126	36	p	p	NOUN
gsrj-11	126	37	-	-	PUNCT
gsrj-11	126	38	glycoprotein	glycoprotein	NOUN
gsrj-11	126	39	substrate	substrate	NOUN
gsrj-11	126	40	.	.	PUNCT
gsrj-11	127	1	given	give	VERB
gsrj-11	127	2	that	that	SCONJ
gsrj-11	127	3	the	the	DET
gsrj-11	127	4	other	other	ADJ
gsrj-11	127	5	sources	source	NOUN
gsrj-11	127	6	did	do	AUX
gsrj-11	127	7	not	not	PART
gsrj-11	127	8	mention	mention	VERB
gsrj-11	127	9	these	these	DET
gsrj-11	127	10	mutations	mutation	NOUN
gsrj-11	127	11	,	,	PUNCT
gsrj-11	127	12	it	it	PRON
gsrj-11	127	13	is	be	AUX
gsrj-11	127	14	unclear	unclear	ADJ
gsrj-11	127	15	whether	whether	SCONJ
gsrj-11	127	16	they	they	PRON
gsrj-11	127	17	pose	pose	VERB
gsrj-11	127	18	a	a	DET
gsrj-11	127	19	significant	significant	ADJ
gsrj-11	127	20	limitation	limitation	NOUN
gsrj-11	127	21	.	.	PUNCT
gsrj-11	128	1	overall	overall	ADJ
gsrj-11	128	2	,	,	PUNCT
gsrj-11	128	3	resistant	resistant	ADJ
gsrj-11	128	4	mutations	mutation	NOUN
gsrj-11	128	5	pose	pose	VERB
gsrj-11	128	6	a	a	DET
gsrj-11	128	7	serious	serious	ADJ
gsrj-11	128	8	limitation	limitation	NOUN
gsrj-11	128	9	to	to	ADP
gsrj-11	128	10	the	the	DET
gsrj-11	128	11	efficacy	efficacy	NOUN
gsrj-11	128	12	of	of	ADP
gsrj-11	128	13	the	the	DET
gsrj-11	128	14	inhibitors	inhibitor	NOUN
gsrj-11	128	15	because	because	SCONJ
gsrj-11	128	16	they	they	PRON
gsrj-11	128	17	undo	undo	VERB
gsrj-11	128	18	the	the	DET
gsrj-11	128	19	exact	exact	ADJ
gsrj-11	128	20	mechanism	mechanism	NOUN
gsrj-11	128	21	used	use	VERB
gsrj-11	128	22	to	to	PART
gsrj-11	128	23	halt	halt	VERB
gsrj-11	128	24	proliferation	proliferation	NOUN
gsrj-11	128	25	of	of	ADP
gsrj-11	128	26	the	the	DET
gsrj-11	128	27	mb	mb	PROPN
gsrj-11	128	28	cells	cell	NOUN
gsrj-11	128	29	.	.	PUNCT
gsrj-11	129	1	more	more	ADJ
gsrj-11	129	2	research	research	NOUN
gsrj-11	129	3	is	be	AUX
gsrj-11	129	4	needed	need	VERB
gsrj-11	129	5	to	to	PART
gsrj-11	129	6	clarify	clarify	VERB
gsrj-11	129	7	which	which	DET
gsrj-11	129	8	mutations	mutation	NOUN
gsrj-11	129	9	most	most	ADV
gsrj-11	129	10	contribute	contribute	VERB
gsrj-11	129	11	to	to	ADP
gsrj-11	129	12	resistance	resistance	NOUN
gsrj-11	129	13	and	and	CCONJ
gsrj-11	129	14	how	how	SCONJ
gsrj-11	129	15	they	they	PRON
gsrj-11	129	16	do	do	VERB
gsrj-11	129	17	so	so	ADV
gsrj-11	129	18	.	.	PUNCT
gsrj-11	130	1	however	however	ADV
gsrj-11	130	2	,	,	PUNCT
gsrj-11	130	3	the	the	DET
gsrj-11	130	4	following	follow	VERB
gsrj-11	130	5	additional	additional	ADJ
gsrj-11	130	6	benefits	benefit	NOUN
gsrj-11	130	7	of	of	ADP
gsrj-11	130	8	shh	shh	PROPN
gsrj-11	130	9	inhibitors	inhibitor	NOUN
gsrj-11	130	10	still	still	ADV
gsrj-11	130	11	make	make	VERB
gsrj-11	130	12	these	these	DET
gsrj-11	130	13	therapeutics	therapeutic	NOUN
gsrj-11	130	14	a	a	DET
gsrj-11	130	15	promising	promising	ADJ
gsrj-11	130	16	option	option	NOUN
gsrj-11	130	17	.	.	PUNCT
gsrj-11	131	1	4.2	4.2	NUM
gsrj-11	131	2	less	less	ADV
gsrj-11	131	3	toxic	toxic	ADJ
gsrj-11	131	4	yet	yet	CCONJ
gsrj-11	131	5	less	less	ADV
gsrj-11	131	6	stable	stable	ADJ
gsrj-11	131	7	notable	notable	ADJ
gsrj-11	131	8	advancements	advancement	NOUN
gsrj-11	131	9	have	have	AUX
gsrj-11	131	10	revealed	reveal	VERB
gsrj-11	131	11	that	that	SCONJ
gsrj-11	131	12	targeted	target	VERB
gsrj-11	131	13	inhibitor	inhibitor	NOUN
gsrj-11	131	14	therapeutics	therapeutic	NOUN
gsrj-11	131	15	of	of	ADP
gsrj-11	131	16	shh	shh	INTJ
gsrj-11	131	17	mb	mb	PROPN
gsrj-11	131	18	are	be	AUX
gsrj-11	131	19	much	much	ADV
gsrj-11	131	20	less	less	ADV
gsrj-11	131	21	invasive	invasive	ADJ
gsrj-11	131	22	and	and	CCONJ
gsrj-11	131	23	toxic	toxic	ADJ
gsrj-11	131	24	than	than	ADP
gsrj-11	131	25	the	the	DET
gsrj-11	131	26	current	current	ADJ
gsrj-11	131	27	standardized	standardized	ADJ
gsrj-11	131	28	treatment	treatment	NOUN
gsrj-11	131	29	.	.	PUNCT
gsrj-11	132	1	a	a	DET
gsrj-11	132	2	2010	2010	NUM
gsrj-11	132	3	investigation	investigation	NOUN
gsrj-11	132	4	demonstrated	demonstrate	VERB
gsrj-11	132	5	that	that	SCONJ
gsrj-11	132	6	shh	shh	PROPN
gsrj-11	132	7	inhibitors	inhibitor	NOUN
gsrj-11	132	8	are	be	AUX
gsrj-11	132	9	an	an	DET
gsrj-11	132	10	effective	effective	ADJ
gsrj-11	132	11	mode	mode	NOUN
gsrj-11	132	12	of	of	ADP
gsrj-11	132	13	treatment	treatment	NOUN
gsrj-11	132	14	for	for	ADP
gsrj-11	132	15	other	other	ADJ
gsrj-11	132	16	shh	shh	ADJ
gsrj-11	132	17	-	-	ADJ
gsrj-11	132	18	dependent	dependent	ADJ
gsrj-11	132	19	cancers	cancer	NOUN
gsrj-11	132	20	,	,	PUNCT
gsrj-11	132	21	such	such	ADJ
gsrj-11	132	22	as	as	ADP
gsrj-11	132	23	basal	basal	ADJ
gsrj-11	132	24	cellular	cellular	ADJ
gsrj-11	132	25	carcinoma	carcinoma	NOUN
gsrj-11	132	26	,	,	PUNCT
gsrj-11	132	27	lung	lung	NOUN
gsrj-11	132	28	cancer	cancer	NOUN
gsrj-11	132	29	,	,	PUNCT
gsrj-11	132	30	and	and	CCONJ
gsrj-11	132	31	liver	liver	NOUN
gsrj-11	132	32	cancer.31	cancer.31	NOUN
gsrj-11	132	33	since	since	SCONJ
gsrj-11	132	34	2015	2015	NUM
gsrj-11	132	35	,	,	PUNCT
gsrj-11	132	36	shh	shh	NOUN
gsrj-11	132	37	inhibitors	inhibitor	NOUN
gsrj-11	132	38	have	have	AUX
gsrj-11	132	39	been	be	AUX
gsrj-11	132	40	a	a	DET
gsrj-11	132	41	validated	validate	VERB
gsrj-11	132	42	treatment	treatment	NOUN
gsrj-11	132	43	option	option	NOUN
gsrj-11	132	44	,	,	PUNCT
gsrj-11	132	45	specifically	specifically	ADV
gsrj-11	132	46	for	for	ADP
gsrj-11	132	47	treating	treat	VERB
gsrj-11	132	48	metastatic	metastatic	ADJ
gsrj-11	132	49	or	or	CCONJ
gsrj-11	132	50	locally	locally	ADV
gsrj-11	132	51	advanced	advanced	ADJ
gsrj-11	132	52	non	non	ADJ
gsrj-11	132	53	-	-	ADJ
gsrj-11	132	54	resectable	resectable	ADJ
gsrj-11	132	55	basal	basal	ADJ
gsrj-11	132	56	cellular	cellular	ADJ
gsrj-11	132	57	carcinoma.25	carcinoma.25	NOUN
gsrj-11	132	58	therefore	therefore	ADV
gsrj-11	132	59	,	,	PUNCT
gsrj-11	132	60	shh	shh	PROPN
gsrj-11	132	61	inhibitors	inhibitor	NOUN
gsrj-11	132	62	demonstrate	demonstrate	VERB
gsrj-11	132	63	rehabilitative	rehabilitative	ADJ
gsrj-11	132	64	potential	potential	NOUN
gsrj-11	132	65	in	in	ADP
gsrj-11	132	66	shh	shh	PROPN
gsrj-11	132	67	mb	mb	PROPN
gsrj-11	132	68	,	,	PUNCT
gsrj-11	132	69	which	which	PRON
gsrj-11	132	70	is	be	AUX
gsrj-11	132	71	driven	drive	VERB
gsrj-11	132	72	by	by	ADP
gsrj-11	132	73	aberrations	aberration	NOUN
gsrj-11	132	74	in	in	ADP
gsrj-11	132	75	the	the	DET
gsrj-11	132	76	shh	shh	PROPN
gsrj-11	132	77	pathway	pathway	NOUN
gsrj-11	132	78	.	.	PUNCT
gsrj-11	133	1	administration	administration	NOUN
gsrj-11	133	2	of	of	ADP
gsrj-11	133	3	shh	shh	PROPN
gsrj-11	133	4	inhibitors	inhibitor	NOUN
gsrj-11	133	5	have	have	AUX
gsrj-11	133	6	been	be	AUX
gsrj-11	133	7	shown	show	VERB
gsrj-11	133	8	as	as	ADP
gsrj-11	133	9	safe	safe	ADJ
gsrj-11	133	10	with	with	ADP
gsrj-11	133	11	limited	limited	ADJ
gsrj-11	133	12	adverse	adverse	ADJ
gsrj-11	133	13	effects	effect	NOUN
gsrj-11	133	14	,	,	PUNCT
gsrj-11	133	15	as	as	SCONJ
gsrj-11	133	16	indicated	indicate	VERB
gsrj-11	133	17	by	by	ADP
gsrj-11	133	18	its	its	PRON
gsrj-11	133	19	clinical	clinical	ADJ
gsrj-11	133	20	approval	approval	NOUN
gsrj-11	133	21	for	for	ADP
gsrj-11	133	22	basal	basal	ADJ
gsrj-11	133	23	cell	cell	NOUN
gsrj-11	133	24	carcinoma	carcinoma	NOUN
gsrj-11	133	25	.	.	PUNCT
gsrj-11	134	1	moreover	moreover	ADV
gsrj-11	134	2	,	,	PUNCT
gsrj-11	134	3	these	these	DET
gsrj-11	134	4	inhibitors	inhibitor	NOUN
gsrj-11	134	5	’	'	PUNCT
gsrj-11	134	6	low	low	ADJ
gsrj-11	134	7	toxicity	toxicity	NOUN
gsrj-11	134	8	and	and	CCONJ
gsrj-11	134	9	limited	limited	ADJ
gsrj-11	134	10	invasiveness	invasiveness	NOUN
gsrj-11	134	11	suggest	suggest	VERB
gsrj-11	134	12	its	its	PRON
gsrj-11	134	13	greater	great	ADJ
gsrj-11	134	14	therapeutic	therapeutic	ADJ
gsrj-11	134	15	capacity	capacity	NOUN
gsrj-11	134	16	in	in	ADP
gsrj-11	134	17	comparison	comparison	NOUN
gsrj-11	134	18	with	with	ADP
gsrj-11	134	19	current	current	ADJ
gsrj-11	134	20	standardized	standardized	ADJ
gsrj-11	134	21	treatment	treatment	NOUN
gsrj-11	134	22	.	.	PUNCT
gsrj-11	135	1	for	for	ADP
gsrj-11	135	2	example	example	NOUN
gsrj-11	135	3	,	,	PUNCT
gsrj-11	135	4	vismodegib	vismodegib	NOUN
gsrj-11	135	5	and	and	CCONJ
gsrj-11	135	6	temozolomide	temozolomide	NOUN
gsrj-11	135	7	have	have	AUX
gsrj-11	135	8	exhibited	exhibit	VERB
gsrj-11	135	9	a	a	DET
gsrj-11	135	10	promising	promising	ADJ
gsrj-11	135	11	safety	safety	NOUN
gsrj-11	135	12	index	index	NOUN
gsrj-11	135	13	in	in	ADP
gsrj-11	135	14	recent	recent	ADJ
gsrj-11	135	15	investigations	investigation	NOUN
gsrj-11	135	16	.	.	PUNCT
gsrj-11	136	1	one	one	NUM
gsrj-11	136	2	vismodegib	vismodegib	NOUN
gsrj-11	136	3	clinical	clinical	ADJ
gsrj-11	136	4	trial	trial	NOUN
gsrj-11	136	5	found	find	VERB
gsrj-11	136	6	that	that	SCONJ
gsrj-11	136	7	the	the	DET
gsrj-11	136	8	patients	patient	NOUN
gsrj-11	136	9	revealed	reveal	VERB
gsrj-11	136	10	a	a	DET
gsrj-11	136	11	low	low	ADJ
gsrj-11	136	12	toxicity	toxicity	NOUN
gsrj-11	136	13	profile	profile	NOUN
gsrj-11	136	14	and	and	CCONJ
gsrj-11	136	15	that	that	SCONJ
gsrj-11	136	16	none	none	NOUN
gsrj-11	136	17	of	of	ADP
gsrj-11	136	18	the	the	DET
gsrj-11	136	19	patients	patient	NOUN
gsrj-11	136	20	withdrew	withdraw	VERB
gsrj-11	136	21	from	from	ADP
gsrj-11	136	22	the	the	DET
gsrj-11	136	23	clinical	clinical	ADJ
gsrj-11	136	24	trial	trial	NOUN
gsrj-11	136	25	because	because	SCONJ
gsrj-11	136	26	of	of	ADP
gsrj-11	136	27	toxicity.19	toxicity.19	NOUN
gsrj-11	136	28	another	another	DET
gsrj-11	136	29	clinical	clinical	ADJ
gsrj-11	136	30	trial	trial	NOUN
gsrj-11	136	31	found	find	VERB
gsrj-11	136	32	that	that	SCONJ
gsrj-11	136	33	a	a	DET
gsrj-11	136	34	16year	16year	NUM
gsrj-11	136	35	old	old	ADJ
gsrj-11	136	36	patient	patient	NOUN
gsrj-11	136	37	suffering	suffering	NOUN
gsrj-11	136	38	from	from	ADP
gsrj-11	136	39	shh	shh	PROPN
gsrj-11	136	40	mb	mb	PROPN
gsrj-11	136	41	exhibited	exhibit	VERB
gsrj-11	136	42	a	a	DET
gsrj-11	136	43	steady	steady	ADJ
gsrj-11	136	44	response	response	NOUN
gsrj-11	136	45	to	to	ADP
gsrj-11	136	46	vismodegib	vismodegib	NOUN
gsrj-11	136	47	and	and	CCONJ
gsrj-11	136	48	temozolomide	temozolomide	NOUN
gsrj-11	136	49	with	with	ADP
gsrj-11	136	50	limited	limited	ADJ
gsrj-11	136	51	adverse	adverse	ADJ
gsrj-11	136	52	effects	effect	NOUN
gsrj-11	136	53	.	.	PUNCT
gsrj-11	137	1	although	although	SCONJ
gsrj-11	137	2	the	the	DET
gsrj-11	137	3	benefits	benefit	NOUN
gsrj-11	137	4	eventually	eventually	ADV
gsrj-11	137	5	declined	decline	VERB
gsrj-11	137	6	due	due	ADP
gsrj-11	137	7	to	to	ADP
gsrj-11	137	8	mutations	mutation	NOUN
gsrj-11	137	9	,	,	PUNCT
gsrj-11	137	10	this	this	DET
gsrj-11	137	11	study	study	NOUN
gsrj-11	137	12	demonstrates	demonstrate	VERB
gsrj-11	137	13	that	that	SCONJ
gsrj-11	137	14	adverse	adverse	ADJ
gsrj-11	137	15	events	event	NOUN
gsrj-11	137	16	were	be	AUX
gsrj-11	137	17	not	not	PART
gsrj-11	137	18	due	due	ADJ
gsrj-11	137	19	to	to	ADP
gsrj-11	137	20	toxicity	toxicity	NOUN
gsrj-11	137	21	.	.	PUNCT
gsrj-11	138	1	23	23	NUM
gsrj-11	139	1	nonetheless	nonetheless	ADV
gsrj-11	139	2	,	,	PUNCT
gsrj-11	139	3	surgical	surgical	ADJ
gsrj-11	139	4	resection	resection	NOUN
gsrj-11	139	5	and	and	CCONJ
gsrj-11	139	6	subsequent	subsequent	ADJ
gsrj-11	139	7	radiation	radiation	NOUN
gsrj-11	139	8	and	and	CCONJ
gsrj-11	139	9	91	91	NUM
gsrj-11	139	10	georgetown	georgetown	NOUN
gsrj-11	139	11	scientific	scientific	PROPN
gsrj-11	139	12	research	research	PROPN
gsrj-11	139	13	journal	journal	PROPN
gsrj-11	139	14	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	139	15	chemotherapy	chemotherapy	NOUN
gsrj-11	139	16	are	be	AUX
gsrj-11	139	17	still	still	ADV
gsrj-11	139	18	the	the	DET
gsrj-11	139	19	most	most	ADV
gsrj-11	139	20	prevalent	prevalent	ADJ
gsrj-11	139	21	treatment	treatment	NOUN
gsrj-11	139	22	regimen	regiman	NOUN
gsrj-11	139	23	for	for	ADP
gsrj-11	139	24	all	all	DET
gsrj-11	139	25	mb	mb	ADP
gsrj-11	139	26	subtypes	subtype	NOUN
gsrj-11	139	27	.	.	PUNCT
gsrj-11	140	1	given	give	VERB
gsrj-11	140	2	that	that	SCONJ
gsrj-11	140	3	the	the	DET
gsrj-11	140	4	invasive	invasive	ADJ
gsrj-11	140	5	nature	nature	NOUN
gsrj-11	140	6	of	of	ADP
gsrj-11	140	7	radiation	radiation	NOUN
gsrj-11	140	8	and	and	CCONJ
gsrj-11	140	9	chemotherapy	chemotherapy	NOUN
gsrj-11	140	10	often	often	ADV
gsrj-11	140	11	generate	generate	VERB
gsrj-11	140	12	chronic	chronic	ADJ
gsrj-11	140	13	cytotoxic	cytotoxic	ADJ
gsrj-11	140	14	effects	effect	NOUN
gsrj-11	140	15	and	and	CCONJ
gsrj-11	140	16	tumor	tumor	NOUN
gsrj-11	140	17	recurrence	recurrence	NOUN
gsrj-11	140	18	,	,	PUNCT
gsrj-11	140	19	inhibitors	inhibitor	NOUN
gsrj-11	140	20	are	be	AUX
gsrj-11	140	21	a	a	DET
gsrj-11	140	22	promising	promising	ADJ
gsrj-11	140	23	alternative	alternative	NOUN
gsrj-11	140	24	.	.	PUNCT
gsrj-11	141	1	although	although	SCONJ
gsrj-11	141	2	this	this	DET
gsrj-11	141	3	data	data	NOUN
gsrj-11	141	4	indicates	indicate	VERB
gsrj-11	141	5	that	that	SCONJ
gsrj-11	141	6	inhibitors	inhibitor	NOUN
gsrj-11	141	7	improve	improve	VERB
gsrj-11	141	8	upon	upon	SCONJ
gsrj-11	141	9	the	the	DET
gsrj-11	141	10	standard	standard	ADJ
gsrj-11	141	11	treatment	treatment	NOUN
gsrj-11	141	12	regimen	regiman	NOUN
gsrj-11	141	13	for	for	ADP
gsrj-11	141	14	shh	shh	INTJ
gsrj-11	141	15	mb	mb	NOUN
gsrj-11	141	16	in	in	ADP
gsrj-11	141	17	terms	term	NOUN
gsrj-11	141	18	of	of	ADP
gsrj-11	141	19	toxicity	toxicity	NOUN
gsrj-11	141	20	and	and	CCONJ
gsrj-11	141	21	invasiveness	invasiveness	NOUN
gsrj-11	141	22	,	,	PUNCT
gsrj-11	141	23	evidence	evidence	NOUN
gsrj-11	141	24	suggests	suggest	VERB
gsrj-11	141	25	that	that	SCONJ
gsrj-11	141	26	developing	develop	VERB
gsrj-11	141	27	inhibitors	inhibitor	NOUN
gsrj-11	141	28	without	without	ADP
gsrj-11	141	29	these	these	DET
gsrj-11	141	30	cytotoxic	cytotoxic	ADJ
gsrj-11	141	31	effects	effect	NOUN
gsrj-11	141	32	and	and	CCONJ
gsrj-11	141	33	optimal	optimal	ADJ
gsrj-11	141	34	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	141	35	properties	property	NOUN
gsrj-11	141	36	has	have	AUX
gsrj-11	141	37	posed	pose	VERB
gsrj-11	141	38	a	a	DET
gsrj-11	141	39	challenge	challenge	NOUN
gsrj-11	141	40	.	.	PUNCT
gsrj-11	142	1	for	for	ADP
gsrj-11	142	2	example	example	NOUN
gsrj-11	142	3	,	,	PUNCT
gsrj-11	142	4	two	two	NUM
gsrj-11	142	5	shh	shh	NOUN
gsrj-11	142	6	pathway	pathway	NOUN
gsrj-11	142	7	inhibitors	inhibitor	NOUN
gsrj-11	142	8	that	that	PRON
gsrj-11	142	9	resulted	result	VERB
gsrj-11	142	10	in	in	ADP
gsrj-11	142	11	negative	negative	ADJ
gsrj-11	142	12	consequences	consequence	NOUN
gsrj-11	142	13	are	be	AUX
gsrj-11	142	14	cyclopamine	cyclopamine	ADJ
gsrj-11	142	15	and	and	CCONJ
gsrj-11	142	16	hhantag	hhantag	NOUN
gsrj-11	142	17	:	:	PUNCT
gsrj-11	142	18	cyclopamine	cyclopamine	PROPN
gsrj-11	142	19	generated	generate	VERB
gsrj-11	142	20	cytotoxic	cytotoxic	ADJ
gsrj-11	142	21	effects	effect	NOUN
gsrj-11	142	22	in	in	ADP
gsrj-11	142	23	healthy	healthy	ADJ
gsrj-11	142	24	cells	cell	NOUN
gsrj-11	142	25	and	and	CCONJ
gsrj-11	142	26	a	a	DET
gsrj-11	142	27	preclinical	preclinical	ADJ
gsrj-11	142	28	study	study	NOUN
gsrj-11	142	29	of	of	ADP
gsrj-11	142	30	hhantag	hhantag	NOUN
gsrj-11	142	31	resulted	result	VERB
gsrj-11	142	32	in	in	ADP
gsrj-11	142	33	permanent	permanent	ADJ
gsrj-11	142	34	developmental	developmental	ADJ
gsrj-11	142	35	defects	defect	NOUN
gsrj-11	142	36	in	in	ADP
gsrj-11	142	37	the	the	DET
gsrj-11	142	38	bones	bone	NOUN
gsrj-11	142	39	of	of	ADP
gsrj-11	142	40	the	the	DET
gsrj-11	142	41	mouse	mouse	NOUN
gsrj-11	142	42	models.32	models.32	VERB
gsrj-11	142	43	,	,	PUNCT
gsrj-11	142	44	33	33	NUM
gsrj-11	142	45	given	give	VERB
gsrj-11	142	46	that	that	SCONJ
gsrj-11	142	47	shh	shh	PROPN
gsrj-11	142	48	is	be	AUX
gsrj-11	142	49	a	a	DET
gsrj-11	142	50	pathway	pathway	NOUN
gsrj-11	142	51	critical	critical	ADJ
gsrj-11	142	52	for	for	ADP
gsrj-11	142	53	development	development	NOUN
gsrj-11	142	54	,	,	PUNCT
gsrj-11	142	55	the	the	DET
gsrj-11	142	56	latter	latter	ADJ
gsrj-11	142	57	study	study	NOUN
gsrj-11	142	58	has	have	AUX
gsrj-11	142	59	raised	raise	VERB
gsrj-11	142	60	concerns	concern	NOUN
gsrj-11	142	61	about	about	ADP
gsrj-11	142	62	the	the	DET
gsrj-11	142	63	use	use	NOUN
gsrj-11	142	64	of	of	ADP
gsrj-11	142	65	shh	shh	INTJ
gsrj-11	142	66	inhibitors	inhibitor	NOUN
gsrj-11	142	67	in	in	ADP
gsrj-11	142	68	infants	infant	NOUN
gsrj-11	142	69	and	and	CCONJ
gsrj-11	142	70	young	young	ADJ
gsrj-11	142	71	children	child	NOUN
gsrj-11	142	72	.	.	PUNCT
gsrj-11	143	1	cyclopamine	cyclopamine	PROPN
gsrj-11	143	2	also	also	ADV
gsrj-11	143	3	had	have	VERB
gsrj-11	143	4	poor	poor	ADJ
gsrj-11	143	5	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	143	6	properties	property	NOUN
gsrj-11	143	7	,	,	PUNCT
gsrj-11	143	8	another	another	DET
gsrj-11	143	9	limitation	limitation	NOUN
gsrj-11	143	10	of	of	ADP
gsrj-11	143	11	shh	shh	INTJ
gsrj-11	143	12	mb	mb	ADJ
gsrj-11	143	13	inhibitors	inhibitor	NOUN
gsrj-11	143	14	.	.	PUNCT
gsrj-11	144	1	adequate	adequate	ADJ
gsrj-11	144	2	concentration	concentration	NOUN
gsrj-11	144	3	and	and	CCONJ
gsrj-11	144	4	stability	stability	NOUN
gsrj-11	144	5	in	in	ADP
gsrj-11	144	6	circulation	circulation	NOUN
gsrj-11	144	7	are	be	AUX
gsrj-11	144	8	two	two	NUM
gsrj-11	144	9	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	144	10	properties	property	NOUN
gsrj-11	144	11	that	that	PRON
gsrj-11	144	12	have	have	AUX
gsrj-11	144	13	been	be	AUX
gsrj-11	144	14	commented	comment	VERB
gsrj-11	144	15	on	on	ADP
gsrj-11	144	16	in	in	ADP
gsrj-11	144	17	the	the	DET
gsrj-11	144	18	literature	literature	NOUN
gsrj-11	144	19	.	.	PUNCT
gsrj-11	145	1	for	for	ADP
gsrj-11	145	2	example	example	NOUN
gsrj-11	145	3	,	,	PUNCT
gsrj-11	145	4	rat	rat	NOUN
gsrj-11	145	5	livers	liver	NOUN
gsrj-11	145	6	cleared	clear	VERB
gsrj-11	145	7	away	away	ADV
gsrj-11	145	8	nphenylbenzamide	nphenylbenzamide	ADV
gsrj-11	145	9	too	too	ADV
gsrj-11	145	10	quickly	quickly	ADV
gsrj-11	145	11	,	,	PUNCT
gsrj-11	145	12	preventing	prevent	VERB
gsrj-11	145	13	adequate	adequate	ADJ
gsrj-11	145	14	concentration	concentration	NOUN
gsrj-11	145	15	.	.	PUNCT
gsrj-11	146	1	this	this	PRON
gsrj-11	146	2	ended	end	VERB
gsrj-11	146	3	its	its	PRON
gsrj-11	146	4	testing	testing	NOUN
gsrj-11	146	5	although	although	SCONJ
gsrj-11	146	6	it	it	PRON
gsrj-11	146	7	was	be	AUX
gsrj-11	146	8	initially	initially	ADV
gsrj-11	146	9	promising.34	promising.34	VERB
gsrj-11	146	10	other	other	ADJ
gsrj-11	146	11	examples	example	NOUN
gsrj-11	146	12	are	be	AUX
gsrj-11	146	13	gant-61	gant-61	PROPN
gsrj-11	146	14	and	and	CCONJ
gsrj-11	146	15	vismodegib	vismodegib	NOUN
gsrj-11	146	16	.	.	PUNCT
gsrj-11	147	1	gant61	gant61	PROPN
gsrj-11	147	2	has	have	AUX
gsrj-11	147	3	proven	prove	VERB
gsrj-11	147	4	effective	effective	ADJ
gsrj-11	147	5	in	in	ADP
gsrj-11	147	6	vitro	vitro	X
gsrj-11	147	7	but	but	CCONJ
gsrj-11	147	8	is	be	AUX
gsrj-11	147	9	less	less	ADV
gsrj-11	147	10	stable	stable	ADJ
gsrj-11	147	11	than	than	ADP
gsrj-11	147	12	its	its	PRON
gsrj-11	147	13	gant-58	gant-58	PROPN
gsrj-11	147	14	alternative	alternative	NOUN
gsrj-11	147	15	under	under	ADP
gsrj-11	147	16	physiological	physiological	ADJ
gsrj-11	147	17	conditions.35	conditions.35	NOUN
gsrj-11	147	18	vismodegib	vismodegib	NOUN
gsrj-11	147	19	has	have	AUX
gsrj-11	147	20	demonstrated	demonstrate	VERB
gsrj-11	147	21	encouraging	encourage	VERB
gsrj-11	147	22	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	147	23	characteristics	characteristic	NOUN
gsrj-11	147	24	in	in	ADP
gsrj-11	147	25	animal	animal	NOUN
gsrj-11	147	26	models	model	NOUN
gsrj-11	147	27	,	,	PUNCT
gsrj-11	147	28	but	but	CCONJ
gsrj-11	147	29	its	its	PRON
gsrj-11	147	30	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	147	31	properties	property	NOUN
gsrj-11	147	32	can	can	AUX
gsrj-11	147	33	also	also	ADV
gsrj-11	147	34	be	be	AUX
gsrj-11	147	35	improved	improve	VERB
gsrj-11	147	36	upon	upon	SCONJ
gsrj-11	147	37	.	.	PUNCT
gsrj-11	148	1	an	an	DET
gsrj-11	148	2	in	in	ADP
gsrj-11	148	3	vivo	vivo	NOUN
gsrj-11	148	4	study	study	NOUN
gsrj-11	148	5	demonstrated	demonstrate	VERB
gsrj-11	148	6	that	that	SCONJ
gsrj-11	148	7	these	these	DET
gsrj-11	148	8	properties	property	NOUN
gsrj-11	148	9	can	can	AUX
gsrj-11	148	10	be	be	AUX
gsrj-11	148	11	further	far	ADV
gsrj-11	148	12	bolstered	bolster	VERB
gsrj-11	148	13	when	when	SCONJ
gsrj-11	148	14	hydrogen	hydrogen	NOUN
gsrj-11	148	15	ions	ion	NOUN
gsrj-11	148	16	in	in	ADP
gsrj-11	148	17	the	the	DET
gsrj-11	148	18	active	active	ADJ
gsrj-11	148	19	sites	site	NOUN
gsrj-11	148	20	are	be	AUX
gsrj-11	148	21	replaced	replace	VERB
gsrj-11	148	22	with	with	ADP
gsrj-11	148	23	deuterium	deuterium	NOUN
gsrj-11	148	24	.	.	PUNCT
gsrj-11	149	1	this	this	PRON
gsrj-11	149	2	allowed	allow	VERB
gsrj-11	149	3	for	for	ADP
gsrj-11	149	4	sustained	sustained	ADJ
gsrj-11	149	5	benefits	benefit	NOUN
gsrj-11	149	6	at	at	ADP
gsrj-11	149	7	lower	low	ADJ
gsrj-11	149	8	doses.36	doses.36	NOUN
gsrj-11	149	9	overall	overall	ADV
gsrj-11	149	10	,	,	PUNCT
gsrj-11	149	11	although	although	SCONJ
gsrj-11	149	12	poor	poor	ADJ
gsrj-11	149	13	drug	drug	NOUN
gsrj-11	149	14	properties	property	NOUN
gsrj-11	149	15	are	be	AUX
gsrj-11	149	16	important	important	ADJ
gsrj-11	149	17	limitations	limitation	NOUN
gsrj-11	149	18	,	,	PUNCT
gsrj-11	149	19	literature	literature	NOUN
gsrj-11	149	20	suggests	suggest	VERB
gsrj-11	149	21	that	that	SCONJ
gsrj-11	149	22	they	they	PRON
gsrj-11	149	23	are	be	AUX
gsrj-11	149	24	not	not	PART
gsrj-11	149	25	as	as	ADV
gsrj-11	149	26	significant	significant	ADJ
gsrj-11	149	27	as	as	ADP
gsrj-11	149	28	genetic	genetic	ADJ
gsrj-11	149	29	based	base	VERB
gsrj-11	149	30	limitations	limitation	NOUN
gsrj-11	149	31	such	such	ADJ
gsrj-11	149	32	as	as	ADP
gsrj-11	149	33	resistant	resistant	ADJ
gsrj-11	149	34	mutations	mutation	NOUN
gsrj-11	149	35	and	and	CCONJ
gsrj-11	149	36	heterogeneity	heterogeneity	NOUN
gsrj-11	149	37	.	.	PUNCT
gsrj-11	150	1	most	most	ADJ
gsrj-11	150	2	of	of	ADP
gsrj-11	150	3	the	the	DET
gsrj-11	150	4	sources	source	NOUN
gsrj-11	150	5	analyzed	analyze	VERB
gsrj-11	150	6	did	do	AUX
gsrj-11	150	7	not	not	PART
gsrj-11	150	8	comment	comment	VERB
gsrj-11	150	9	extensively	extensively	ADV
gsrj-11	150	10	on	on	ADP
gsrj-11	150	11	the	the	DET
gsrj-11	150	12	cytotoxicity	cytotoxicity	NOUN
gsrj-11	150	13	and	and	CCONJ
gsrj-11	150	14	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	150	15	properties	property	NOUN
gsrj-11	150	16	,	,	PUNCT
gsrj-11	150	17	if	if	SCONJ
gsrj-11	150	18	at	at	ADV
gsrj-11	150	19	all	all	ADV
gsrj-11	150	20	.	.	PUNCT
gsrj-11	151	1	these	these	DET
gsrj-11	151	2	challenges	challenge	NOUN
gsrj-11	151	3	should	should	AUX
gsrj-11	151	4	be	be	AUX
gsrj-11	151	5	addressed	address	VERB
gsrj-11	151	6	,	,	PUNCT
gsrj-11	151	7	however	however	ADV
gsrj-11	151	8	,	,	PUNCT
gsrj-11	151	9	as	as	SCONJ
gsrj-11	151	10	the	the	DET
gsrj-11	151	11	development	development	NOUN
gsrj-11	151	12	of	of	ADP
gsrj-11	151	13	novel	novel	ADJ
gsrj-11	151	14	shh	shh	NOUN
gsrj-11	151	15	inhibitors	inhibitor	NOUN
gsrj-11	151	16	progresses	progress	VERB
gsrj-11	151	17	.	.	PUNCT
gsrj-11	152	1	4.3	4.3	NUM
gsrj-11	152	2	genetic	genetic	ADJ
gsrj-11	152	3	connections	connection	NOUN
gsrj-11	152	4	yet	yet	CCONJ
gsrj-11	152	5	persistent	persistent	ADJ
gsrj-11	152	6	heterogeneity	heterogeneity	NOUN
gsrj-11	152	7	recent	recent	ADJ
gsrj-11	152	8	developments	development	NOUN
gsrj-11	152	9	in	in	ADP
gsrj-11	152	10	the	the	DET
gsrj-11	152	11	use	use	NOUN
gsrj-11	152	12	of	of	ADP
gsrj-11	152	13	shh	shh	NOUN
gsrj-11	152	14	inhibitors	inhibitor	NOUN
gsrj-11	152	15	have	have	AUX
gsrj-11	152	16	also	also	ADV
gsrj-11	152	17	elucidated	elucidate	VERB
gsrj-11	152	18	connections	connection	NOUN
gsrj-11	152	19	between	between	ADP
gsrj-11	152	20	the	the	DET
gsrj-11	152	21	genetics	genetic	NOUN
gsrj-11	152	22	of	of	ADP
gsrj-11	152	23	the	the	DET
gsrj-11	152	24	disease	disease	NOUN
gsrj-11	152	25	and	and	CCONJ
gsrj-11	152	26	the	the	DET
gsrj-11	152	27	efficacy	efficacy	NOUN
gsrj-11	152	28	of	of	ADP
gsrj-11	152	29	inhibitors	inhibitor	NOUN
gsrj-11	152	30	.	.	PUNCT
gsrj-11	153	1	these	these	DET
gsrj-11	153	2	connections	connection	NOUN
gsrj-11	153	3	have	have	AUX
gsrj-11	153	4	allowed	allow	VERB
gsrj-11	153	5	researchers	researcher	NOUN
gsrj-11	153	6	to	to	PART
gsrj-11	153	7	craft	craft	VERB
gsrj-11	153	8	treatment	treatment	NOUN
gsrj-11	153	9	regimens	regimen	NOUN
gsrj-11	153	10	that	that	PRON
gsrj-11	153	11	target	target	VERB
gsrj-11	153	12	specific	specific	ADJ
gsrj-11	153	13	genetic	genetic	ADJ
gsrj-11	153	14	mutations	mutation	NOUN
gsrj-11	153	15	,	,	PUNCT
gsrj-11	153	16	bolstering	bolster	VERB
gsrj-11	153	17	their	their	PRON
gsrj-11	153	18	efficacy	efficacy	NOUN
gsrj-11	153	19	.	.	PUNCT
gsrj-11	154	1	in	in	ADP
gsrj-11	154	2	2015	2015	NUM
gsrj-11	154	3	,	,	PUNCT
gsrj-11	154	4	a	a	DET
gsrj-11	154	5	clinical	clinical	ADJ
gsrj-11	154	6	study	study	NOUN
gsrj-11	154	7	reported	report	VERB
gsrj-11	154	8	results	result	NOUN
gsrj-11	154	9	from	from	ADP
gsrj-11	154	10	two	two	NUM
gsrj-11	154	11	phase	phase	NOUN
gsrj-11	154	12	ii	ii	NOUN
gsrj-11	154	13	trials	trial	NOUN
gsrj-11	154	14	that	that	PRON
gsrj-11	154	15	evaluated	evaluate	VERB
gsrj-11	154	16	the	the	DET
gsrj-11	154	17	safety	safety	NOUN
gsrj-11	154	18	and	and	CCONJ
gsrj-11	154	19	efficacy	efficacy	NOUN
gsrj-11	154	20	of	of	ADP
gsrj-11	154	21	vismodegib	vismodegib	NOUN
gsrj-11	154	22	in	in	ADP
gsrj-11	154	23	patients	patient	NOUN
gsrj-11	154	24	with	with	ADP
gsrj-11	154	25	recurrent	recurrent	NOUN
gsrj-11	154	26	or	or	CCONJ
gsrj-11	154	27	refractory	refractory	NOUN
gsrj-11	154	28	shh	shh	NOUN
gsrj-11	154	29	mb.19	mb.19	VERB
gsrj-11	154	30	it	it	PRON
gsrj-11	154	31	was	be	AUX
gsrj-11	154	32	found	find	VERB
gsrj-11	154	33	that	that	SCONJ
gsrj-11	154	34	the	the	DET
gsrj-11	154	35	position	position	NOUN
gsrj-11	154	36	of	of	ADP
gsrj-11	154	37	the	the	DET
gsrj-11	154	38	genomic	genomic	ADJ
gsrj-11	154	39	deviation	deviation	NOUN
gsrj-11	154	40	in	in	ADP
gsrj-11	154	41	relation	relation	NOUN
gsrj-11	154	42	to	to	ADP
gsrj-11	154	43	smo	smo	PROPN
gsrj-11	154	44	and	and	CCONJ
gsrj-11	154	45	ptch1	ptch1	PROPN
gsrj-11	154	46	were	be	AUX
gsrj-11	154	47	predictors	predictor	NOUN
gsrj-11	154	48	of	of	ADP
gsrj-11	154	49	the	the	DET
gsrj-11	154	50	response	response	NOUN
gsrj-11	154	51	to	to	ADP
gsrj-11	154	52	smo	smo	PROPN
gsrj-11	154	53	inhibitor	inhibitor	NOUN
gsrj-11	154	54	activity	activity	NOUN
gsrj-11	154	55	.	.	PUNCT
gsrj-11	155	1	both	both	CCONJ
gsrj-11	155	2	the	the	DET
gsrj-11	155	3	transgressions	transgression	NOUN
gsrj-11	155	4	of	of	ADP
gsrj-11	155	5	smo	smo	PROPN
gsrj-11	155	6	and	and	CCONJ
gsrj-11	155	7	ptch1	ptch1	PROPN
gsrj-11	155	8	culminated	culminate	VERB
gsrj-11	155	9	in	in	ADP
gsrj-11	155	10	favorable	favorable	ADJ
gsrj-11	155	11	outcomes	outcome	NOUN
gsrj-11	155	12	with	with	ADP
gsrj-11	155	13	respect	respect	NOUN
gsrj-11	155	14	to	to	ADP
gsrj-11	155	15	attenuating	attenuate	VERB
gsrj-11	155	16	tumor	tumor	NOUN
gsrj-11	155	17	progression	progression	NOUN
gsrj-11	155	18	.	.	PUNCT
gsrj-11	156	1	this	this	DET
gsrj-11	156	2	discovery	discovery	NOUN
gsrj-11	156	3	is	be	AUX
gsrj-11	156	4	critical	critical	ADJ
gsrj-11	156	5	because	because	SCONJ
gsrj-11	156	6	it	it	PRON
gsrj-11	156	7	demonstrates	demonstrate	VERB
gsrj-11	156	8	that	that	SCONJ
gsrj-11	156	9	knowing	know	VERB
gsrj-11	156	10	the	the	DET
gsrj-11	156	11	genetic	genetic	ADJ
gsrj-11	156	12	basis	basis	NOUN
gsrj-11	156	13	of	of	ADP
gsrj-11	156	14	the	the	DET
gsrj-11	156	15	patients	patient	NOUN
gsrj-11	156	16	’	'	PUNCT
gsrj-11	156	17	shh	shh	PROPN
gsrj-11	156	18	mb	mb	ADP
gsrj-11	156	19	tumor	tumor	NOUN
gsrj-11	156	20	can	can	AUX
gsrj-11	156	21	predict	predict	VERB
gsrj-11	156	22	whether	whether	SCONJ
gsrj-11	156	23	or	or	CCONJ
gsrj-11	156	24	not	not	PART
gsrj-11	156	25	they	they	PRON
gsrj-11	156	26	respond	respond	VERB
gsrj-11	156	27	favorably	favorably	ADV
gsrj-11	156	28	to	to	ADP
gsrj-11	156	29	the	the	DET
gsrj-11	156	30	inhibitor	inhibitor	NOUN
gsrj-11	156	31	.	.	PUNCT
gsrj-11	157	1	secondly	secondly	ADV
gsrj-11	157	2	,	,	PUNCT
gsrj-11	157	3	it	it	PRON
gsrj-11	157	4	was	be	AUX
gsrj-11	157	5	discovered	discover	VERB
gsrj-11	157	6	that	that	SCONJ
gsrj-11	157	7	robust	robust	ADJ
gsrj-11	157	8	p53	p53	NOUN
gsrj-11	157	9	diffuse	diffuse	NOUN
gsrj-11	157	10	staining	stain	VERB
gsrj-11	157	11	in	in	ADP
gsrj-11	157	12	shh	shh	PROPN
gsrj-11	157	13	mb	mb	PROPN
gsrj-11	157	14	was	be	AUX
gsrj-11	157	15	associated	associate	VERB
gsrj-11	157	16	with	with	ADP
gsrj-11	157	17	a	a	DET
gsrj-11	157	18	substantially	substantially	ADV
gsrj-11	157	19	less	less	ADV
gsrj-11	157	20	significant	significant	ADJ
gsrj-11	157	21	response	response	NOUN
gsrj-11	157	22	to	to	ADP
gsrj-11	157	23	the	the	DET
gsrj-11	157	24	inhibition	inhibition	NOUN
gsrj-11	157	25	of	of	ADP
gsrj-11	157	26	smo	smo	PROPN
gsrj-11	157	27	.	.	PUNCT
gsrj-11	158	1	the	the	DET
gsrj-11	158	2	mechanism	mechanism	NOUN
gsrj-11	158	3	underlying	underlie	VERB
gsrj-11	158	4	this	this	DET
gsrj-11	158	5	finding	finding	NOUN
gsrj-11	158	6	is	be	AUX
gsrj-11	158	7	not	not	PART
gsrj-11	158	8	yet	yet	ADV
gsrj-11	158	9	understood	understand	VERB
gsrj-11	158	10	because	because	SCONJ
gsrj-11	158	11	the	the	DET
gsrj-11	158	12	relationship	relationship	NOUN
gsrj-11	158	13	between	between	ADP
gsrj-11	158	14	p53	p53	NOUN
gsrj-11	158	15	and	and	CCONJ
gsrj-11	158	16	smo	smo	NOUN
gsrj-11	158	17	is	be	AUX
gsrj-11	158	18	unclear	unclear	ADJ
gsrj-11	158	19	.	.	PUNCT
gsrj-11	159	1	however	however	ADV
gsrj-11	159	2	,	,	PUNCT
gsrj-11	159	3	results	result	NOUN
gsrj-11	159	4	indicated	indicate	VERB
gsrj-11	159	5	that	that	SCONJ
gsrj-11	159	6	mutations	mutation	NOUN
gsrj-11	159	7	of	of	ADP
gsrj-11	159	8	this	this	DET
gsrj-11	159	9	protein	protein	NOUN
gsrj-11	159	10	generate	generate	NOUN
gsrj-11	159	11	chromothripsis	chromothripsis	NOUN
gsrj-11	159	12	,	,	PUNCT
gsrj-11	159	13	where	where	SCONJ
gsrj-11	159	14	thousands	thousand	NOUN
gsrj-11	159	15	of	of	ADP
gsrj-11	159	16	chromosomal	chromosomal	ADJ
gsrj-11	159	17	rearrangements	rearrangement	NOUN
gsrj-11	159	18	occur	occur	VERB
gsrj-11	159	19	,	,	PUNCT
gsrj-11	159	20	possibly	possibly	ADV
gsrj-11	159	21	upregulating	upregulate	VERB
gsrj-11	159	22	the	the	DET
gsrj-11	159	23	expression	expression	NOUN
gsrj-11	159	24	of	of	ADP
gsrj-11	159	25	shh	shh	NOUN
gsrj-11	159	26	signaling	signal	VERB
gsrj-11	159	27	oncogenes.37	oncogenes.37	NOUN
gsrj-11	159	28	with	with	ADP
gsrj-11	159	29	this	this	DET
gsrj-11	159	30	information	information	NOUN
gsrj-11	159	31	,	,	PUNCT
gsrj-11	159	32	paired	pair	VERB
gsrj-11	159	33	with	with	ADP
gsrj-11	159	34	the	the	DET
gsrj-11	159	35	relationship	relationship	NOUN
gsrj-11	159	36	between	between	ADP
gsrj-11	159	37	p53	p53	NOUN
gsrj-11	159	38	and	and	CCONJ
gsrj-11	159	39	smo	smo	NOUN
gsrj-11	159	40	that	that	PRON
gsrj-11	159	41	still	still	ADV
gsrj-11	159	42	requires	require	VERB
gsrj-11	159	43	further	further	ADJ
gsrj-11	159	44	investigation	investigation	NOUN
gsrj-11	159	45	,	,	PUNCT
gsrj-11	159	46	it	it	PRON
gsrj-11	159	47	is	be	AUX
gsrj-11	159	48	concluded	conclude	VERB
gsrj-11	159	49	that	that	SCONJ
gsrj-11	159	50	alterations	alteration	NOUN
gsrj-11	159	51	to	to	ADP
gsrj-11	159	52	the	the	DET
gsrj-11	159	53	p53	p53	NOUN
gsrj-11	159	54	protein	protein	NOUN
gsrj-11	159	55	expression	expression	NOUN
gsrj-11	159	56	may	may	AUX
gsrj-11	159	57	be	be	AUX
gsrj-11	159	58	correlated	correlate	VERB
gsrj-11	159	59	with	with	ADP
gsrj-11	159	60	anomalous	anomalous	ADJ
gsrj-11	159	61	smo	smo	NOUN
gsrj-11	159	62	activity.19	activity.19	ADV
gsrj-11	159	63	moreover	moreover	ADV
gsrj-11	159	64	,	,	PUNCT
gsrj-11	159	65	inhibitors	inhibitor	NOUN
gsrj-11	159	66	that	that	PRON
gsrj-11	159	67	can	can	AUX
gsrj-11	159	68	mitigate	mitigate	VERB
gsrj-11	159	69	both	both	PRON
gsrj-11	159	70	p53	p53	NOUN
gsrj-11	159	71	and	and	CCONJ
gsrj-11	159	72	smo	smo	PROPN
gsrj-11	159	73	aberrancy	aberrancy	NOUN
gsrj-11	159	74	,	,	PUNCT
gsrj-11	159	75	which	which	PRON
gsrj-11	159	76	are	be	AUX
gsrj-11	159	77	driven	drive	VERB
gsrj-11	159	78	by	by	ADP
gsrj-11	159	79	genetic	genetic	ADJ
gsrj-11	159	80	mutations	mutation	NOUN
gsrj-11	159	81	,	,	PUNCT
gsrj-11	159	82	serve	serve	VERB
gsrj-11	159	83	as	as	ADP
gsrj-11	159	84	a	a	DET
gsrj-11	159	85	potential	potential	ADJ
gsrj-11	159	86	therapeutic	therapeutic	ADJ
gsrj-11	159	87	strategy	strategy	NOUN
gsrj-11	159	88	for	for	ADP
gsrj-11	159	89	shh	shh	INTJ
gsrj-11	159	90	mb	mb	PROPN
gsrj-11	159	91	.	.	PUNCT
gsrj-11	160	1	this	this	PRON
gsrj-11	160	2	underscores	underscore	VERB
gsrj-11	160	3	the	the	DET
gsrj-11	160	4	92	92	NUM
gsrj-11	160	5	georgetown	georgetown	NOUN
gsrj-11	160	6	scientific	scientific	ADJ
gsrj-11	160	7	research	research	PROPN
gsrj-11	160	8	journal	journal	PROPN
gsrj-11	160	9	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	160	10	relationship	relationship	NOUN
gsrj-11	160	11	between	between	ADP
gsrj-11	160	12	shh	shh	INTJ
gsrj-11	160	13	mb	mb	PROPN
gsrj-11	160	14	’s	’s	PART
gsrj-11	160	15	genetics	genetic	NOUN
gsrj-11	160	16	and	and	CCONJ
gsrj-11	160	17	efficacy	efficacy	NOUN
gsrj-11	160	18	of	of	ADP
gsrj-11	160	19	inhibitors	inhibitor	NOUN
gsrj-11	160	20	.	.	PUNCT
gsrj-11	161	1	a	a	DET
gsrj-11	161	2	third	third	ADJ
gsrj-11	161	3	key	key	ADJ
gsrj-11	161	4	finding	finding	NOUN
gsrj-11	161	5	from	from	ADP
gsrj-11	161	6	this	this	DET
gsrj-11	161	7	study	study	NOUN
gsrj-11	161	8	was	be	AUX
gsrj-11	161	9	the	the	DET
gsrj-11	161	10	delineation	delineation	NOUN
gsrj-11	161	11	of	of	ADP
gsrj-11	161	12	the	the	DET
gsrj-11	161	13	target	target	NOUN
gsrj-11	161	14	population	population	NOUN
gsrj-11	161	15	for	for	ADP
gsrj-11	161	16	vismodegib	vismodegib	NOUN
gsrj-11	161	17	therapy	therapy	NOUN
gsrj-11	161	18	,	,	PUNCT
gsrj-11	161	19	which	which	PRON
gsrj-11	161	20	was	be	AUX
gsrj-11	161	21	conducted	conduct	VERB
gsrj-11	161	22	via	via	ADP
gsrj-11	161	23	complete	complete	ADJ
gsrj-11	161	24	molecular	molecular	ADJ
gsrj-11	161	25	profiling	profiling	NOUN
gsrj-11	161	26	of	of	ADP
gsrj-11	161	27	shh	shh	PROPN
gsrj-11	161	28	mbs	mb	NOUN
gsrj-11	161	29	.	.	PUNCT
gsrj-11	162	1	the	the	DET
gsrj-11	162	2	evidence	evidence	NOUN
gsrj-11	162	3	obtained	obtain	VERB
gsrj-11	162	4	demonstrated	demonstrate	VERB
gsrj-11	162	5	the	the	DET
gsrj-11	162	6	importance	importance	NOUN
gsrj-11	162	7	of	of	ADP
gsrj-11	162	8	distinguishing	distinguish	VERB
gsrj-11	162	9	shh	shh	INTJ
gsrj-11	162	10	mbs	mb	NOUN
gsrj-11	162	11	that	that	PRON
gsrj-11	162	12	are	be	AUX
gsrj-11	162	13	driven	drive	VERB
gsrj-11	162	14	by	by	ADP
gsrj-11	162	15	mutations	mutation	NOUN
gsrj-11	162	16	downstream	downstream	ADJ
gsrj-11	162	17	in	in	ADP
gsrj-11	162	18	the	the	DET
gsrj-11	162	19	shh	shh	PROPN
gsrj-11	162	20	pathway	pathway	NOUN
gsrj-11	162	21	,	,	PUNCT
gsrj-11	162	22	which	which	PRON
gsrj-11	162	23	are	be	AUX
gsrj-11	162	24	not	not	PART
gsrj-11	162	25	amenable	amenable	ADJ
gsrj-11	162	26	to	to	ADP
gsrj-11	162	27	the	the	DET
gsrj-11	162	28	inhibition	inhibition	NOUN
gsrj-11	162	29	of	of	ADP
gsrj-11	162	30	smo	smo	PROPN
gsrj-11	162	31	.	.	PUNCT
gsrj-11	163	1	this	this	PRON
gsrj-11	163	2	serves	serve	VERB
gsrj-11	163	3	as	as	ADP
gsrj-11	163	4	a	a	DET
gsrj-11	163	5	significant	significant	ADJ
gsrj-11	163	6	milestone	milestone	NOUN
gsrj-11	163	7	because	because	SCONJ
gsrj-11	163	8	it	it	PRON
gsrj-11	163	9	suggests	suggest	VERB
gsrj-11	163	10	the	the	DET
gsrj-11	163	11	need	need	NOUN
gsrj-11	163	12	for	for	ADP
gsrj-11	163	13	novel	novel	ADJ
gsrj-11	163	14	inhibitor	inhibitor	NOUN
gsrj-11	163	15	therapeutics	therapeutic	NOUN
gsrj-11	163	16	that	that	PRON
gsrj-11	163	17	target	target	VERB
gsrj-11	163	18	different	different	ADJ
gsrj-11	163	19	proteins	protein	NOUN
gsrj-11	163	20	of	of	ADP
gsrj-11	163	21	the	the	DET
gsrj-11	163	22	pathway	pathway	NOUN
gsrj-11	163	23	while	while	SCONJ
gsrj-11	163	24	underscoring	underscore	VERB
gsrj-11	163	25	that	that	DET
gsrj-11	163	26	inhibitor	inhibitor	NOUN
gsrj-11	163	27	efficacy	efficacy	NOUN
gsrj-11	163	28	has	have	VERB
gsrj-11	163	29	genetic	genetic	ADJ
gsrj-11	163	30	connections	connection	NOUN
gsrj-11	163	31	.	.	PUNCT
gsrj-11	164	1	this	this	PRON
gsrj-11	164	2	emphasizes	emphasize	VERB
gsrj-11	164	3	the	the	DET
gsrj-11	164	4	importance	importance	NOUN
gsrj-11	164	5	of	of	ADP
gsrj-11	164	6	further	far	ADV
gsrj-11	164	7	delineating	delineate	VERB
gsrj-11	164	8	the	the	DET
gsrj-11	164	9	genetic	genetic	ADJ
gsrj-11	164	10	basis	basis	NOUN
gsrj-11	164	11	of	of	ADP
gsrj-11	164	12	shh	shh	INTJ
gsrj-11	164	13	mb	mb	NOUN
gsrj-11	164	14	in	in	ADP
gsrj-11	164	15	order	order	NOUN
gsrj-11	164	16	to	to	PART
gsrj-11	164	17	provide	provide	VERB
gsrj-11	164	18	more	more	ADV
gsrj-11	164	19	effective	effective	ADJ
gsrj-11	164	20	individualized	individualized	ADJ
gsrj-11	164	21	therapies	therapy	NOUN
gsrj-11	164	22	.	.	PUNCT
gsrj-11	165	1	although	although	SCONJ
gsrj-11	165	2	there	there	PRON
gsrj-11	165	3	are	be	VERB
gsrj-11	165	4	useful	useful	ADJ
gsrj-11	165	5	connections	connection	NOUN
gsrj-11	165	6	between	between	ADP
gsrj-11	165	7	inhibitor	inhibitor	NOUN
gsrj-11	165	8	efficacy	efficacy	NOUN
gsrj-11	165	9	and	and	CCONJ
gsrj-11	165	10	disease	disease	NOUN
gsrj-11	165	11	genetics	genetic	NOUN
gsrj-11	165	12	,	,	PUNCT
gsrj-11	165	13	not	not	PART
gsrj-11	165	14	all	all	PRON
gsrj-11	165	15	of	of	ADP
gsrj-11	165	16	the	the	DET
gsrj-11	165	17	shh	shh	PROPN
gsrj-11	165	18	mb	mb	PROPN
gsrj-11	165	19	genes	gene	NOUN
gsrj-11	165	20	have	have	AUX
gsrj-11	165	21	been	be	AUX
gsrj-11	165	22	discovered	discover	VERB
gsrj-11	165	23	and	and	CCONJ
gsrj-11	165	24	important	important	ADJ
gsrj-11	165	25	patterns	pattern	NOUN
gsrj-11	165	26	in	in	ADP
gsrj-11	165	27	expression	expression	NOUN
gsrj-11	165	28	have	have	VERB
gsrj-11	165	29	yet	yet	ADV
gsrj-11	165	30	to	to	PART
gsrj-11	165	31	be	be	AUX
gsrj-11	165	32	identified	identify	VERB
gsrj-11	165	33	.	.	PUNCT
gsrj-11	166	1	much	much	ADJ
gsrj-11	166	2	of	of	ADP
gsrj-11	166	3	the	the	DET
gsrj-11	166	4	literature	literature	NOUN
gsrj-11	166	5	describes	describe	VERB
gsrj-11	166	6	shh	shh	INTJ
gsrj-11	166	7	mb	mb	NOUN
gsrj-11	166	8	as	as	ADP
gsrj-11	166	9	a	a	DET
gsrj-11	166	10	heterogeneous	heterogeneous	ADJ
gsrj-11	166	11	disease	disease	NOUN
gsrj-11	166	12	,	,	PUNCT
gsrj-11	166	13	meaning	mean	VERB
gsrj-11	166	14	that	that	SCONJ
gsrj-11	166	15	different	different	ADJ
gsrj-11	166	16	genes	gene	NOUN
gsrj-11	166	17	are	be	AUX
gsrj-11	166	18	associated	associate	VERB
gsrj-11	166	19	with	with	ADP
gsrj-11	166	20	tumor	tumor	NOUN
gsrj-11	166	21	growth	growth	NOUN
gsrj-11	166	22	across	across	ADP
gsrj-11	166	23	patients	patient	NOUN
gsrj-11	166	24	.	.	PUNCT
gsrj-11	167	1	there	there	PRON
gsrj-11	167	2	is	be	VERB
gsrj-11	167	3	evidence	evidence	NOUN
gsrj-11	167	4	for	for	ADP
gsrj-11	167	5	this	this	PRON
gsrj-11	167	6	in	in	ADP
gsrj-11	167	7	the	the	DET
gsrj-11	167	8	variability	variability	NOUN
gsrj-11	167	9	of	of	ADP
gsrj-11	167	10	responses	response	NOUN
gsrj-11	167	11	to	to	ADP
gsrj-11	167	12	inhibitors	inhibitor	NOUN
gsrj-11	167	13	.	.	PUNCT
gsrj-11	168	1	for	for	ADP
gsrj-11	168	2	example	example	NOUN
gsrj-11	168	3	,	,	PUNCT
gsrj-11	168	4	two	two	NUM
gsrj-11	168	5	adult	adult	NOUN
gsrj-11	168	6	males	male	NOUN
gsrj-11	168	7	suffering	suffer	VERB
gsrj-11	168	8	from	from	ADP
gsrj-11	168	9	shh	shh	PROPN
gsrj-11	168	10	mb	mb	PROPN
gsrj-11	168	11	had	have	VERB
gsrj-11	168	12	extremely	extremely	ADV
gsrj-11	168	13	different	different	ADJ
gsrj-11	168	14	responses	response	NOUN
gsrj-11	168	15	to	to	ADP
gsrj-11	168	16	vismodegib	vismodegib	NOUN
gsrj-11	168	17	.	.	PUNCT
gsrj-11	169	1	one	one	NUM
gsrj-11	169	2	had	have	VERB
gsrj-11	169	3	a	a	DET
gsrj-11	169	4	very	very	ADV
gsrj-11	169	5	favorable	favorable	ADJ
gsrj-11	169	6	response	response	NOUN
gsrj-11	169	7	while	while	SCONJ
gsrj-11	169	8	the	the	DET
gsrj-11	169	9	other	other	ADJ
gsrj-11	169	10	developed	develop	VERB
gsrj-11	169	11	resistance	resistance	NOUN
gsrj-11	169	12	multiple	multiple	ADJ
gsrj-11	169	13	times	time	NOUN
gsrj-11	169	14	.	.	PUNCT
gsrj-11	170	1	furthermore	furthermore	ADV
gsrj-11	170	2	,	,	PUNCT
gsrj-11	170	3	the	the	DET
gsrj-11	170	4	second	second	ADJ
gsrj-11	170	5	adult	adult	NOUN
gsrj-11	170	6	male	male	NOUN
gsrj-11	170	7	even	even	ADV
gsrj-11	170	8	had	have	VERB
gsrj-11	170	9	a	a	DET
gsrj-11	170	10	genetic	genetic	ADJ
gsrj-11	170	11	profiling	profiling	NOUN
gsrj-11	170	12	more	more	ADV
gsrj-11	170	13	similar	similar	ADJ
gsrj-11	170	14	to	to	ADP
gsrj-11	170	15	the	the	DET
gsrj-11	170	16	childhood	childhood	ADJ
gsrj-11	170	17	version	version	NOUN
gsrj-11	170	18	of	of	ADP
gsrj-11	170	19	the	the	DET
gsrj-11	170	20	disease	disease	NOUN
gsrj-11	170	21	,	,	PUNCT
gsrj-11	170	22	making	make	VERB
gsrj-11	170	23	it	it	PRON
gsrj-11	170	24	difficult	difficult	ADJ
gsrj-11	170	25	to	to	PART
gsrj-11	170	26	predict	predict	VERB
gsrj-11	170	27	how	how	SCONJ
gsrj-11	170	28	he	he	PRON
gsrj-11	170	29	would	would	AUX
gsrj-11	170	30	respond	respond	VERB
gsrj-11	170	31	to	to	ADP
gsrj-11	170	32	the	the	DET
gsrj-11	170	33	treatment.27	treatment.27	PROPN
gsrj-11	170	34	this	this	DET
gsrj-11	170	35	highlights	highlight	VERB
gsrj-11	170	36	the	the	DET
gsrj-11	170	37	complexity	complexity	NOUN
gsrj-11	170	38	of	of	ADP
gsrj-11	170	39	the	the	DET
gsrj-11	170	40	disease	disease	NOUN
gsrj-11	170	41	’s	’s	PART
gsrj-11	170	42	genetic	genetic	ADJ
gsrj-11	170	43	basis	basis	NOUN
gsrj-11	170	44	and	and	CCONJ
gsrj-11	170	45	suggests	suggest	VERB
gsrj-11	170	46	that	that	SCONJ
gsrj-11	170	47	there	there	PRON
gsrj-11	170	48	are	be	VERB
gsrj-11	170	49	subgroups	subgroup	NOUN
gsrj-11	170	50	of	of	ADP
gsrj-11	170	51	shh	shh	INTJ
gsrj-11	170	52	mb	mb	PROPN
gsrj-11	170	53	based	base	VERB
gsrj-11	170	54	on	on	ADP
gsrj-11	170	55	combinations	combination	NOUN
gsrj-11	170	56	of	of	ADP
gsrj-11	170	57	affected	affected	ADJ
gsrj-11	170	58	genes	gene	NOUN
gsrj-11	170	59	.	.	PUNCT
gsrj-11	171	1	however	however	ADV
gsrj-11	171	2	,	,	PUNCT
gsrj-11	171	3	these	these	DET
gsrj-11	171	4	nuances	nuance	NOUN
gsrj-11	171	5	are	be	AUX
gsrj-11	171	6	still	still	ADV
gsrj-11	171	7	unclear	unclear	ADJ
gsrj-11	171	8	because	because	SCONJ
gsrj-11	171	9	it	it	PRON
gsrj-11	171	10	is	be	AUX
gsrj-11	171	11	a	a	DET
gsrj-11	171	12	rare	rare	ADJ
gsrj-11	171	13	cancer	cancer	NOUN
gsrj-11	171	14	;	;	PUNCT
gsrj-11	171	15	more	more	ADJ
gsrj-11	171	16	patients	patient	NOUN
gsrj-11	171	17	are	be	AUX
gsrj-11	171	18	required	require	VERB
gsrj-11	171	19	to	to	PART
gsrj-11	171	20	detect	detect	VERB
gsrj-11	171	21	patterns	pattern	NOUN
gsrj-11	171	22	with	with	ADP
gsrj-11	171	23	certainty	certainty	PROPN
gsrj-11	171	24	.	.	PUNCT
gsrj-11	172	1	this	this	PRON
gsrj-11	172	2	makes	make	VERB
gsrj-11	172	3	it	it	PRON
gsrj-11	172	4	difficult	difficult	ADJ
gsrj-11	172	5	for	for	SCONJ
gsrj-11	172	6	researchers	researcher	NOUN
gsrj-11	172	7	to	to	PART
gsrj-11	172	8	develop	develop	VERB
gsrj-11	172	9	effective	effective	ADJ
gsrj-11	172	10	inhibitors	inhibitor	NOUN
gsrj-11	172	11	and	and	CCONJ
gsrj-11	172	12	assign	assign	VERB
gsrj-11	172	13	patients	patient	NOUN
gsrj-11	172	14	to	to	ADP
gsrj-11	172	15	optimal	optimal	ADJ
gsrj-11	172	16	clinical	clinical	ADJ
gsrj-11	172	17	trials.6	trials.6	NOUN
gsrj-11	172	18	furthermore	furthermore	ADV
gsrj-11	172	19	,	,	PUNCT
gsrj-11	172	20	some	some	DET
gsrj-11	172	21	genes	gene	NOUN
gsrj-11	172	22	might	might	AUX
gsrj-11	172	23	even	even	ADV
gsrj-11	172	24	be	be	AUX
gsrj-11	172	25	better	well	ADV
gsrj-11	172	26	suited	suit	VERB
gsrj-11	172	27	for	for	ADP
gsrj-11	172	28	use	use	NOUN
gsrj-11	172	29	as	as	ADP
gsrj-11	172	30	a	a	DET
gsrj-11	172	31	diagnostic	diagnostic	ADJ
gsrj-11	172	32	tool	tool	NOUN
gsrj-11	172	33	while	while	SCONJ
gsrj-11	172	34	other	other	ADJ
gsrj-11	172	35	genes	gene	NOUN
gsrj-11	172	36	(	(	PUNCT
gsrj-11	172	37	such	such	ADJ
gsrj-11	172	38	as	as	ADP
gsrj-11	172	39	gli	gli	NOUN
gsrj-11	172	40	)	)	PUNCT
gsrj-11	172	41	have	have	AUX
gsrj-11	172	42	shown	show	VERB
gsrj-11	172	43	promising	promising	ADJ
gsrj-11	172	44	results	result	NOUN
gsrj-11	172	45	as	as	ADP
gsrj-11	172	46	a	a	DET
gsrj-11	172	47	therapeutic	therapeutic	ADJ
gsrj-11	172	48	target.24	target.24	NOUN
gsrj-11	172	49	overall	overall	ADV
gsrj-11	172	50	,	,	PUNCT
gsrj-11	172	51	the	the	DET
gsrj-11	172	52	heterogeneity	heterogeneity	NOUN
gsrj-11	172	53	of	of	ADP
gsrj-11	172	54	shh	shh	INTJ
gsrj-11	172	55	mb	mb	PROPN
gsrj-11	172	56	limits	limit	VERB
gsrj-11	172	57	the	the	DET
gsrj-11	172	58	efficacy	efficacy	NOUN
gsrj-11	172	59	of	of	ADP
gsrj-11	172	60	inhibitors	inhibitor	NOUN
gsrj-11	172	61	in	in	SCONJ
gsrj-11	172	62	that	that	SCONJ
gsrj-11	172	63	they	they	PRON
gsrj-11	172	64	might	might	AUX
gsrj-11	172	65	not	not	PART
gsrj-11	172	66	target	target	VERB
gsrj-11	172	67	the	the	DET
gsrj-11	172	68	pathway	pathway	NOUN
gsrj-11	172	69	optimally	optimally	ADV
gsrj-11	172	70	in	in	ADP
gsrj-11	172	71	each	each	DET
gsrj-11	172	72	patient	patient	NOUN
gsrj-11	172	73	.	.	PUNCT
gsrj-11	173	1	fortunately	fortunately	ADV
gsrj-11	173	2	,	,	PUNCT
gsrj-11	173	3	studies	study	NOUN
gsrj-11	173	4	have	have	AUX
gsrj-11	173	5	successfully	successfully	ADV
gsrj-11	173	6	identified	identify	VERB
gsrj-11	173	7	preliminary	preliminary	ADJ
gsrj-11	173	8	patterns	pattern	NOUN
gsrj-11	173	9	of	of	ADP
gsrj-11	173	10	tumor	tumor	NOUN
gsrj-11	173	11	-	-	PUNCT
gsrj-11	173	12	inducing	induce	VERB
gsrj-11	173	13	gene	gene	NOUN
gsrj-11	173	14	expression	expression	NOUN
gsrj-11	173	15	in	in	ADP
gsrj-11	173	16	shh	shh	NOUN
gsrj-11	173	17	mb	mb	ADP
gsrj-11	173	18	patients	patient	NOUN
gsrj-11	173	19	using	use	VERB
gsrj-11	173	20	transcriptome	transcriptome	ADJ
gsrj-11	173	21	sequencing	sequence	VERB
gsrj-11	173	22	and	and	CCONJ
gsrj-11	173	23	whole	whole	ADJ
gsrj-11	173	24	genome	genome	NOUN
gsrj-11	173	25	analysis	analysis	NOUN
gsrj-11	173	26	.	.	PUNCT
gsrj-11	174	1	these	these	DET
gsrj-11	174	2	studies	study	NOUN
gsrj-11	174	3	have	have	AUX
gsrj-11	174	4	found	find	VERB
gsrj-11	174	5	that	that	SCONJ
gsrj-11	174	6	there	there	PRON
gsrj-11	174	7	are	be	VERB
gsrj-11	174	8	patterns	pattern	NOUN
gsrj-11	174	9	across	across	ADP
gsrj-11	174	10	age	age	NOUN
gsrj-11	174	11	groups.1,26	groups.1,26	NOUN
gsrj-11	174	12	one	one	NUM
gsrj-11	174	13	study	study	NOUN
gsrj-11	174	14	found	find	VERB
gsrj-11	174	15	that	that	SCONJ
gsrj-11	174	16	infants	infant	NOUN
gsrj-11	174	17	,	,	PUNCT
gsrj-11	174	18	children	child	NOUN
gsrj-11	174	19	,	,	PUNCT
gsrj-11	174	20	and	and	CCONJ
gsrj-11	174	21	adults	adult	NOUN
gsrj-11	174	22	had	have	VERB
gsrj-11	174	23	instances	instance	NOUN
gsrj-11	174	24	of	of	ADP
gsrj-11	174	25	ptch1	ptch1	NOUN
gsrj-11	174	26	mutations	mutation	NOUN
gsrj-11	174	27	,	,	PUNCT
gsrj-11	174	28	only	only	ADV
gsrj-11	174	29	infants	infant	NOUN
gsrj-11	174	30	had	have	VERB
gsrj-11	174	31	the	the	DET
gsrj-11	174	32	sufu	sufu	NOUN
gsrj-11	174	33	mutations	mutation	NOUN
gsrj-11	174	34	,	,	PUNCT
gsrj-11	174	35	and	and	CCONJ
gsrj-11	174	36	only	only	ADV
gsrj-11	174	37	adults	adult	NOUN
gsrj-11	174	38	had	have	VERB
gsrj-11	174	39	smo	smo	PROPN
gsrj-11	174	40	mutations	mutation	NOUN
gsrj-11	174	41	.	.	PUNCT
gsrj-11	175	1	mutations	mutation	NOUN
gsrj-11	175	2	in	in	ADP
gsrj-11	175	3	sufu	sufu	PROPN
gsrj-11	175	4	,	,	PUNCT
gsrj-11	175	5	gli2	gli2	NOUN
gsrj-11	175	6	,	,	PUNCT
gsrj-11	175	7	and	and	CCONJ
gsrj-11	175	8	mycn	mycn	NOUN
gsrj-11	175	9	genes	gene	NOUN
gsrj-11	175	10	have	have	AUX
gsrj-11	175	11	shown	show	VERB
gsrj-11	175	12	primary	primary	ADJ
gsrj-11	175	13	resistance	resistance	NOUN
gsrj-11	175	14	to	to	ADP
gsrj-11	175	15	smo	smo	PROPN
gsrj-11	175	16	inhibition.26	inhibition.26	PROPN
gsrj-11	175	17	this	this	PRON
gsrj-11	175	18	suggests	suggest	VERB
gsrj-11	175	19	that	that	SCONJ
gsrj-11	175	20	patients	patient	NOUN
gsrj-11	175	21	in	in	ADP
gsrj-11	175	22	clinical	clinical	ADJ
gsrj-11	175	23	trials	trial	NOUN
gsrj-11	175	24	should	should	AUX
gsrj-11	175	25	be	be	AUX
gsrj-11	175	26	assigned	assign	VERB
gsrj-11	175	27	inhibitors	inhibitor	NOUN
gsrj-11	175	28	according	accord	VERB
gsrj-11	175	29	to	to	ADP
gsrj-11	175	30	age	age	NOUN
gsrj-11	175	31	,	,	PUNCT
gsrj-11	175	32	and	and	CCONJ
gsrj-11	175	33	that	that	SCONJ
gsrj-11	175	34	genetic	genetic	ADJ
gsrj-11	175	35	sequencing	sequencing	NOUN
gsrj-11	175	36	of	of	ADP
gsrj-11	175	37	shh	shh	INTJ
gsrj-11	175	38	mbs	mb	NOUN
gsrj-11	175	39	should	should	AUX
gsrj-11	175	40	be	be	AUX
gsrj-11	175	41	a	a	DET
gsrj-11	175	42	part	part	NOUN
gsrj-11	175	43	of	of	ADP
gsrj-11	175	44	the	the	DET
gsrj-11	175	45	treatment	treatment	NOUN
gsrj-11	175	46	planning	planning	NOUN
gsrj-11	175	47	process	process	NOUN
gsrj-11	175	48	.	.	PUNCT
gsrj-11	176	1	ultimately	ultimately	ADV
gsrj-11	176	2	,	,	PUNCT
gsrj-11	176	3	a	a	DET
gsrj-11	176	4	better	well	ADJ
gsrj-11	176	5	understanding	understanding	NOUN
gsrj-11	176	6	of	of	ADP
gsrj-11	176	7	the	the	DET
gsrj-11	176	8	responsible	responsible	ADJ
gsrj-11	176	9	genes	gene	NOUN
gsrj-11	176	10	is	be	AUX
gsrj-11	176	11	still	still	ADV
gsrj-11	176	12	needed	need	VERB
gsrj-11	176	13	.	.	PUNCT
gsrj-11	177	1	overall	overall	ADV
gsrj-11	177	2	,	,	PUNCT
gsrj-11	177	3	the	the	DET
gsrj-11	177	4	potential	potential	NOUN
gsrj-11	177	5	of	of	ADP
gsrj-11	177	6	shh	shh	PROPN
gsrj-11	177	7	inhibitors	inhibitor	NOUN
gsrj-11	177	8	makes	make	VERB
gsrj-11	177	9	them	they	PRON
gsrj-11	177	10	a	a	DET
gsrj-11	177	11	promising	promising	ADJ
gsrj-11	177	12	therapeutic	therapeutic	NOUN
gsrj-11	177	13	for	for	ADP
gsrj-11	177	14	shh	shh	INTJ
gsrj-11	177	15	mb	mb	PROPN
gsrj-11	177	16	in	in	ADP
gsrj-11	177	17	the	the	DET
gsrj-11	177	18	clinical	clinical	ADJ
gsrj-11	177	19	setting	setting	NOUN
gsrj-11	177	20	,	,	PUNCT
gsrj-11	177	21	despite	despite	SCONJ
gsrj-11	177	22	their	their	PRON
gsrj-11	177	23	limitations	limitation	NOUN
gsrj-11	177	24	.	.	PUNCT
gsrj-11	178	1	future	future	ADJ
gsrj-11	178	2	research	research	NOUN
gsrj-11	178	3	must	must	AUX
gsrj-11	178	4	address	address	VERB
gsrj-11	178	5	these	these	DET
gsrj-11	178	6	limitations	limitation	NOUN
gsrj-11	178	7	if	if	SCONJ
gsrj-11	178	8	the	the	DET
gsrj-11	178	9	inhibitors	inhibitor	NOUN
gsrj-11	178	10	are	be	AUX
gsrj-11	178	11	to	to	PART
gsrj-11	178	12	be	be	AUX
gsrj-11	178	13	approved	approve	VERB
gsrj-11	178	14	for	for	ADP
gsrj-11	178	15	clinical	clinical	ADJ
gsrj-11	178	16	use	use	NOUN
gsrj-11	178	17	.	.	PUNCT
gsrj-11	179	1	however	however	ADV
gsrj-11	179	2	,	,	PUNCT
gsrj-11	179	3	the	the	DET
gsrj-11	179	4	promise	promise	NOUN
gsrj-11	179	5	of	of	ADP
gsrj-11	179	6	these	these	DET
gsrj-11	179	7	inhibitors	inhibitor	NOUN
gsrj-11	179	8	warrants	warrant	VERB
gsrj-11	179	9	the	the	DET
gsrj-11	179	10	investment	investment	NOUN
gsrj-11	179	11	of	of	ADP
gsrj-11	179	12	such	such	ADJ
gsrj-11	179	13	research	research	NOUN
gsrj-11	179	14	.	.	PUNCT
gsrj-11	180	1	given	give	VERB
gsrj-11	180	2	how	how	SCONJ
gsrj-11	180	3	they	they	PRON
gsrj-11	180	4	have	have	AUX
gsrj-11	180	5	improved	improve	VERB
gsrj-11	180	6	upon	upon	SCONJ
gsrj-11	180	7	the	the	DET
gsrj-11	180	8	standard	standard	ADJ
gsrj-11	180	9	treatment	treatment	NOUN
gsrj-11	180	10	regimen	regiman	NOUN
gsrj-11	180	11	for	for	ADP
gsrj-11	180	12	shh	shh	INTJ
gsrj-11	180	13	mb	mb	PROPN
gsrj-11	180	14	,	,	PUNCT
gsrj-11	180	15	small	small	ADJ
gsrj-11	180	16	molecule	molecule	NOUN
gsrj-11	180	17	inhibitors	inhibitor	NOUN
gsrj-11	180	18	of	of	ADP
gsrj-11	180	19	the	the	DET
gsrj-11	180	20	shh	shh	PROPN
gsrj-11	180	21	pathway	pathway	NOUN
gsrj-11	180	22	are	be	AUX
gsrj-11	180	23	likely	likely	ADJ
gsrj-11	180	24	the	the	DET
gsrj-11	180	25	future	future	NOUN
gsrj-11	180	26	of	of	ADP
gsrj-11	180	27	shh	shh	INTJ
gsrj-11	180	28	mb	mb	PROPN
gsrj-11	180	29	treatment	treatment	NOUN
gsrj-11	180	30	.	.	PUNCT
gsrj-11	181	1	93	93	NUM
gsrj-11	181	2	georgetown	georgetown	PROPN
gsrj-11	181	3	scientific	scientific	PROPN
gsrj-11	181	4	research	research	NOUN
gsrj-11	181	5	journal	journal	NOUN
gsrj-11	181	6	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	181	7	5	5	NUM
gsrj-11	181	8	.	.	PUNCT
gsrj-11	181	9	further	further	ADJ
gsrj-11	181	10	research	research	NOUN
gsrj-11	181	11	needed	need	VERB
gsrj-11	181	12	the	the	DET
gsrj-11	181	13	current	current	ADJ
gsrj-11	181	14	limitations	limitation	NOUN
gsrj-11	181	15	of	of	ADP
gsrj-11	181	16	shh	shh	INTJ
gsrj-11	181	17	inhibitors	inhibitor	NOUN
gsrj-11	181	18	in	in	ADP
gsrj-11	181	19	shh	shh	INTJ
gsrj-11	181	20	mb	mb	PART
gsrj-11	181	21	illuminate	illuminate	VERB
gsrj-11	181	22	crucial	crucial	ADJ
gsrj-11	181	23	areas	area	NOUN
gsrj-11	181	24	of	of	ADP
gsrj-11	181	25	future	future	ADJ
gsrj-11	181	26	research	research	NOUN
gsrj-11	181	27	.	.	PUNCT
gsrj-11	182	1	first	first	ADJ
gsrj-11	182	2	,	,	PUNCT
gsrj-11	182	3	optimal	optimal	ADJ
gsrj-11	182	4	dosage	dosage	NOUN
gsrj-11	182	5	and	and	CCONJ
gsrj-11	182	6	timing	timing	NOUN
gsrj-11	182	7	of	of	ADP
gsrj-11	182	8	intervention	intervention	NOUN
gsrj-11	182	9	need	need	VERB
gsrj-11	182	10	to	to	PART
gsrj-11	182	11	be	be	AUX
gsrj-11	182	12	established	establish	VERB
gsrj-11	182	13	.	.	PUNCT
gsrj-11	183	1	in	in	ADP
gsrj-11	183	2	a	a	DET
gsrj-11	183	3	case	case	NOUN
gsrj-11	183	4	study	study	NOUN
gsrj-11	183	5	,	,	PUNCT
gsrj-11	183	6	vismodegib	vismodegib	NOUN
gsrj-11	183	7	and	and	CCONJ
gsrj-11	183	8	temozolomide	temozolomide	NOUN
gsrj-11	183	9	were	be	AUX
gsrj-11	183	10	taken	take	VERB
gsrj-11	183	11	at	at	ADP
gsrj-11	183	12	a	a	DET
gsrj-11	183	13	dose	dose	NOUN
gsrj-11	183	14	of	of	ADP
gsrj-11	183	15	150	150	NUM
gsrj-11	183	16	mg	mg	NUM
gsrj-11	183	17	.	.	PUNCT
gsrj-11	184	1	the	the	DET
gsrj-11	184	2	therapeutic	therapeutic	ADJ
gsrj-11	184	3	benefits	benefit	NOUN
gsrj-11	184	4	of	of	ADP
gsrj-11	184	5	both	both	DET
gsrj-11	184	6	inhibitors	inhibitor	NOUN
gsrj-11	184	7	dwindled	dwindle	VERB
gsrj-11	184	8	as	as	SCONJ
gsrj-11	184	9	mutations	mutation	NOUN
gsrj-11	184	10	arose	arise	VERB
gsrj-11	184	11	.	.	PUNCT
gsrj-11	185	1	the	the	DET
gsrj-11	185	2	new	new	ADJ
gsrj-11	185	3	tumors	tumor	NOUN
gsrj-11	185	4	that	that	PRON
gsrj-11	185	5	formed	form	VERB
gsrj-11	185	6	varied	varied	ADJ
gsrj-11	185	7	genetically	genetically	ADV
gsrj-11	185	8	from	from	ADP
gsrj-11	185	9	the	the	DET
gsrj-11	185	10	initial	initial	ADJ
gsrj-11	185	11	tumor	tumor	NOUN
gsrj-11	185	12	.	.	PUNCT
gsrj-11	186	1	following	follow	VERB
gsrj-11	186	2	failure	failure	NOUN
gsrj-11	186	3	of	of	ADP
gsrj-11	186	4	those	those	DET
gsrj-11	186	5	treatments	treatment	NOUN
gsrj-11	186	6	,	,	PUNCT
gsrj-11	186	7	sonidegib	sonidegib	NOUN
gsrj-11	186	8	was	be	AUX
gsrj-11	186	9	taken	take	VERB
gsrj-11	186	10	at	at	ADP
gsrj-11	186	11	a	a	DET
gsrj-11	186	12	dose	dose	NOUN
gsrj-11	186	13	of	of	ADP
gsrj-11	186	14	400	400	NUM
gsrj-11	186	15	mg	mg	PROPN
gsrj-11	186	16	,	,	PUNCT
gsrj-11	186	17	which	which	PRON
gsrj-11	186	18	resulted	result	VERB
gsrj-11	186	19	in	in	ADP
gsrj-11	186	20	the	the	DET
gsrj-11	186	21	need	need	NOUN
gsrj-11	186	22	for	for	ADP
gsrj-11	186	23	emergency	emergency	NOUN
gsrj-11	186	24	surgery.23	surgery.23	NOUN
gsrj-11	186	25	therefore	therefore	ADV
gsrj-11	186	26	,	,	PUNCT
gsrj-11	186	27	optimizing	optimize	VERB
gsrj-11	186	28	dosage	dosage	NOUN
gsrj-11	186	29	and	and	CCONJ
gsrj-11	186	30	timing	timing	NOUN
gsrj-11	186	31	of	of	ADP
gsrj-11	186	32	intervention	intervention	NOUN
gsrj-11	186	33	are	be	AUX
gsrj-11	186	34	crucial	crucial	ADJ
gsrj-11	186	35	for	for	ADP
gsrj-11	186	36	translating	translate	VERB
gsrj-11	186	37	preclinical	preclinical	ADJ
gsrj-11	186	38	findings	finding	NOUN
gsrj-11	186	39	to	to	ADP
gsrj-11	186	40	clinical	clinical	ADJ
gsrj-11	186	41	practice	practice	NOUN
gsrj-11	186	42	.	.	PUNCT
gsrj-11	187	1	importantly	importantly	ADV
gsrj-11	187	2	,	,	PUNCT
gsrj-11	187	3	optimal	optimal	ADJ
gsrj-11	187	4	timing	timing	NOUN
gsrj-11	187	5	and	and	CCONJ
gsrj-11	187	6	dosage	dosage	NOUN
gsrj-11	187	7	of	of	ADP
gsrj-11	187	8	inhibitor	inhibitor	NOUN
gsrj-11	187	9	treatment	treatment	NOUN
gsrj-11	187	10	should	should	AUX
gsrj-11	187	11	be	be	AUX
gsrj-11	187	12	examined	examine	VERB
gsrj-11	187	13	for	for	ADP
gsrj-11	187	14	both	both	CCONJ
gsrj-11	187	15	pediatric	pediatric	ADJ
gsrj-11	187	16	and	and	CCONJ
gsrj-11	187	17	adult	adult	NOUN
gsrj-11	187	18	patients	patient	NOUN
gsrj-11	187	19	,	,	PUNCT
gsrj-11	187	20	especially	especially	ADV
gsrj-11	187	21	since	since	SCONJ
gsrj-11	187	22	clinical	clinical	ADJ
gsrj-11	187	23	trials	trial	NOUN
gsrj-11	187	24	with	with	ADP
gsrj-11	187	25	pediatric	pediatric	ADJ
gsrj-11	187	26	shh	shh	NOUN
gsrj-11	187	27	mb	mb	PROPN
gsrj-11	187	28	subjects	subject	NOUN
gsrj-11	187	29	are	be	AUX
gsrj-11	187	30	lacking	lack	VERB
gsrj-11	187	31	.	.	PUNCT
gsrj-11	188	1	compared	compare	VERB
gsrj-11	188	2	to	to	ADP
gsrj-11	188	3	the	the	DET
gsrj-11	188	4	standard	standard	ADJ
gsrj-11	188	5	treatment	treatment	NOUN
gsrj-11	188	6	regimen	regiman	NOUN
gsrj-11	188	7	for	for	ADP
gsrj-11	188	8	shh	shh	INTJ
gsrj-11	188	9	mb	mb	X
gsrj-11	188	10	(	(	PUNCT
gsrj-11	188	11	radiation	radiation	NOUN
gsrj-11	188	12	,	,	PUNCT
gsrj-11	188	13	chemotherapy	chemotherapy	NOUN
gsrj-11	188	14	,	,	PUNCT
gsrj-11	188	15	and	and	CCONJ
gsrj-11	188	16	surgery	surgery	NOUN
gsrj-11	188	17	)	)	PUNCT
gsrj-11	188	18	,	,	PUNCT
gsrj-11	188	19	shh	shh	NOUN
gsrj-11	188	20	inhibitors	inhibitor	NOUN
gsrj-11	188	21	demonstrate	demonstrate	VERB
gsrj-11	188	22	greater	great	ADJ
gsrj-11	188	23	therapeutic	therapeutic	ADJ
gsrj-11	188	24	promise	promise	NOUN
gsrj-11	188	25	.	.	PUNCT
gsrj-11	189	1	nevertheless	nevertheless	ADV
gsrj-11	189	2	,	,	PUNCT
gsrj-11	189	3	future	future	ADJ
gsrj-11	189	4	research	research	NOUN
gsrj-11	189	5	should	should	AUX
gsrj-11	189	6	focus	focus	VERB
gsrj-11	189	7	on	on	ADP
gsrj-11	189	8	improving	improve	VERB
gsrj-11	189	9	the	the	DET
gsrj-11	189	10	efficacy	efficacy	NOUN
gsrj-11	189	11	of	of	ADP
gsrj-11	189	12	these	these	DET
gsrj-11	189	13	inhibitor	inhibitor	NOUN
gsrj-11	189	14	therapeutics	therapeutic	NOUN
gsrj-11	189	15	to	to	PART
gsrj-11	189	16	combat	combat	VERB
gsrj-11	189	17	resistant	resistant	ADJ
gsrj-11	189	18	mutations	mutation	NOUN
gsrj-11	189	19	.	.	PUNCT
gsrj-11	190	1	resistance	resistance	NOUN
gsrj-11	190	2	to	to	ADP
gsrj-11	190	3	both	both	DET
gsrj-11	190	4	smo	smo	PROPN
gsrj-11	190	5	antagonists	antagonist	NOUN
gsrj-11	190	6	and	and	CCONJ
gsrj-11	190	7	inhibitors	inhibitor	NOUN
gsrj-11	190	8	of	of	ADP
gsrj-11	190	9	ptch	ptch	NOUN
gsrj-11	190	10	frequently	frequently	ADV
gsrj-11	190	11	develop	develop	VERB
gsrj-11	190	12	in	in	ADP
gsrj-11	190	13	patients	patient	NOUN
gsrj-11	190	14	,	,	PUNCT
gsrj-11	190	15	which	which	PRON
gsrj-11	190	16	can	can	AUX
gsrj-11	190	17	exacerbate	exacerbate	VERB
gsrj-11	190	18	tumor	tumor	NOUN
gsrj-11	190	19	growth	growth	NOUN
gsrj-11	190	20	and	and	CCONJ
gsrj-11	190	21	spur	spur	VERB
gsrj-11	190	22	other	other	ADJ
gsrj-11	190	23	adverse	adverse	ADJ
gsrj-11	190	24	events	event	NOUN
gsrj-11	190	25	.	.	PUNCT
gsrj-11	191	1	moreover	moreover	ADV
gsrj-11	191	2	,	,	PUNCT
gsrj-11	191	3	more	more	ADV
gsrj-11	191	4	downstream	downstream	ADJ
gsrj-11	191	5	inhibitors	inhibitor	NOUN
gsrj-11	191	6	of	of	ADP
gsrj-11	191	7	the	the	DET
gsrj-11	191	8	shh	shh	PROPN
gsrj-11	191	9	pathway	pathway	NOUN
gsrj-11	191	10	,	,	PUNCT
gsrj-11	191	11	such	such	ADJ
gsrj-11	191	12	as	as	ADP
gsrj-11	191	13	gli	gli	NOUN
gsrj-11	191	14	inhibitors	inhibitor	NOUN
gsrj-11	191	15	,	,	PUNCT
gsrj-11	191	16	should	should	AUX
gsrj-11	191	17	be	be	AUX
gsrj-11	191	18	explored	explore	VERB
gsrj-11	191	19	in	in	ADP
gsrj-11	191	20	studies	study	NOUN
gsrj-11	191	21	.	.	PUNCT
gsrj-11	192	1	investigation	investigation	NOUN
gsrj-11	192	2	into	into	ADP
gsrj-11	192	3	various	various	ADJ
gsrj-11	192	4	shh	shh	NOUN
gsrj-11	192	5	inhibitors	inhibitor	NOUN
gsrj-11	192	6	is	be	AUX
gsrj-11	192	7	also	also	ADV
gsrj-11	192	8	critical	critical	ADJ
gsrj-11	192	9	for	for	ADP
gsrj-11	192	10	treatment	treatment	NOUN
gsrj-11	192	11	of	of	ADP
gsrj-11	192	12	shh	shh	INTJ
gsrj-11	192	13	mb	mb	NOUN
gsrj-11	192	14	in	in	ADP
gsrj-11	192	15	pediatric	pediatric	ADJ
gsrj-11	192	16	patients	patient	NOUN
gsrj-11	192	17	,	,	PUNCT
gsrj-11	192	18	as	as	SCONJ
gsrj-11	192	19	shh	shh	NOUN
gsrj-11	192	20	mb	mb	X
gsrj-11	192	21	in	in	ADP
gsrj-11	192	22	the	the	DET
gsrj-11	192	23	pediatric	pediatric	ADJ
gsrj-11	192	24	setting	setting	NOUN
gsrj-11	192	25	most	most	ADV
gsrj-11	192	26	often	often	ADV
gsrj-11	192	27	occurs	occur	VERB
gsrj-11	192	28	due	due	ADJ
gsrj-11	192	29	to	to	ADP
gsrj-11	192	30	genetic	genetic	ADJ
gsrj-11	192	31	mutations	mutation	NOUN
gsrj-11	192	32	downstream	downstream	ADJ
gsrj-11	192	33	of	of	ADP
gsrj-11	192	34	smo	smo	NOUN
gsrj-11	192	35	in	in	ADP
gsrj-11	192	36	the	the	DET
gsrj-11	192	37	pathway.26	pathway.26	NOUN
gsrj-11	192	38	it	it	PRON
gsrj-11	192	39	is	be	AUX
gsrj-11	192	40	also	also	ADV
gsrj-11	192	41	important	important	ADJ
gsrj-11	192	42	to	to	PART
gsrj-11	192	43	consider	consider	VERB
gsrj-11	192	44	the	the	DET
gsrj-11	192	45	use	use	NOUN
gsrj-11	192	46	of	of	ADP
gsrj-11	192	47	combination	combination	NOUN
gsrj-11	192	48	inhibitor	inhibitor	NOUN
gsrj-11	192	49	therapies	therapy	NOUN
gsrj-11	192	50	for	for	ADP
gsrj-11	192	51	shh	shh	INTJ
gsrj-11	192	52	mb	mb	PROPN
gsrj-11	192	53	.	.	PROPN
gsrj-11	193	1	since	since	SCONJ
gsrj-11	193	2	the	the	DET
gsrj-11	193	3	efficacy	efficacy	NOUN
gsrj-11	193	4	of	of	ADP
gsrj-11	193	5	shh	shh	PROPN
gsrj-11	193	6	inhibitors	inhibitor	NOUN
gsrj-11	193	7	,	,	PUNCT
gsrj-11	193	8	such	such	ADJ
gsrj-11	193	9	as	as	ADP
gsrj-11	193	10	vismodegib	vismodegib	NOUN
gsrj-11	193	11	,	,	PUNCT
gsrj-11	193	12	may	may	AUX
gsrj-11	193	13	diminish	diminish	VERB
gsrj-11	193	14	over	over	ADP
gsrj-11	193	15	time	time	NOUN
gsrj-11	193	16	due	due	ADP
gsrj-11	193	17	to	to	ADP
gsrj-11	193	18	drug	drug	NOUN
gsrj-11	193	19	resistance	resistance	NOUN
gsrj-11	193	20	,	,	PUNCT
gsrj-11	193	21	synergistic	synergistic	ADJ
gsrj-11	193	22	inhibitor	inhibitor	NOUN
gsrj-11	193	23	treatment	treatment	NOUN
gsrj-11	193	24	with	with	ADP
gsrj-11	193	25	other	other	ADJ
gsrj-11	193	26	therapies	therapy	NOUN
gsrj-11	193	27	may	may	AUX
gsrj-11	193	28	elicit	elicit	VERB
gsrj-11	193	29	a	a	DET
gsrj-11	193	30	more	more	ADV
gsrj-11	193	31	robust	robust	ADJ
gsrj-11	193	32	rehabilitative	rehabilitative	ADJ
gsrj-11	193	33	response	response	NOUN
gsrj-11	193	34	.	.	PUNCT
gsrj-11	194	1	it	it	PRON
gsrj-11	194	2	may	may	AUX
gsrj-11	194	3	be	be	AUX
gsrj-11	194	4	beneficial	beneficial	ADJ
gsrj-11	194	5	to	to	PART
gsrj-11	194	6	target	target	VERB
gsrj-11	194	7	both	both	CCONJ
gsrj-11	194	8	the	the	DET
gsrj-11	194	9	shh	shh	PROPN
gsrj-11	194	10	pathway	pathway	NOUN
gsrj-11	194	11	and	and	CCONJ
gsrj-11	194	12	other	other	ADJ
gsrj-11	194	13	pathways	pathway	NOUN
gsrj-11	194	14	that	that	PRON
gsrj-11	194	15	interact	interact	VERB
gsrj-11	194	16	with	with	ADP
gsrj-11	194	17	shh	shh	INTJ
gsrj-11	194	18	signaling	signal	VERB
gsrj-11	194	19	,	,	PUNCT
gsrj-11	194	20	such	such	ADJ
gsrj-11	194	21	as	as	ADP
gsrj-11	194	22	p53	p53	NOUN
gsrj-11	194	23	,	,	PUNCT
gsrj-11	194	24	camp	camp	NOUN
gsrj-11	194	25	,	,	PUNCT
gsrj-11	194	26	atoh1	atoh1	NOUN
gsrj-11	194	27	,	,	PUNCT
gsrj-11	194	28	boc	boc	NOUN
gsrj-11	194	29	,	,	PUNCT
gsrj-11	194	30	cxcl12	cxcl12	ADJ
gsrj-11	194	31	,	,	PUNCT
gsrj-11	194	32	cxcr4	cxcr4	NOUN
gsrj-11	194	33	,	,	PUNCT
gsrj-11	194	34	and	and	CCONJ
gsrj-11	194	35	pi3k.1,19	pi3k.1,19	NOUN
gsrj-11	194	36	for	for	ADP
gsrj-11	194	37	example	example	NOUN
gsrj-11	194	38	,	,	PUNCT
gsrj-11	194	39	though	though	SCONJ
gsrj-11	194	40	the	the	DET
gsrj-11	194	41	interaction	interaction	NOUN
gsrj-11	194	42	between	between	ADP
gsrj-11	194	43	p53	p53	NOUN
gsrj-11	194	44	and	and	CCONJ
gsrj-11	194	45	the	the	DET
gsrj-11	194	46	shh	shh	PROPN
gsrj-11	194	47	pathway	pathway	NOUN
gsrj-11	194	48	remains	remain	VERB
gsrj-11	194	49	unclear	unclear	ADJ
gsrj-11	194	50	,	,	PUNCT
gsrj-11	194	51	an	an	DET
gsrj-11	194	52	in	in	ADP
gsrj-11	194	53	vivo	vivo	NOUN
gsrj-11	194	54	study	study	NOUN
gsrj-11	194	55	found	find	VERB
gsrj-11	194	56	that	that	SCONJ
gsrj-11	194	57	development	development	NOUN
gsrj-11	194	58	of	of	ADP
gsrj-11	194	59	mb	mb	ADV
gsrj-11	194	60	increased	increase	VERB
gsrj-11	194	61	from	from	ADP
gsrj-11	194	62	14	14	NUM
gsrj-11	194	63	%	%	NOUN
gsrj-11	194	64	to	to	ADP
gsrj-11	194	65	more	more	ADJ
gsrj-11	194	66	than	than	ADP
gsrj-11	194	67	95	95	NUM
gsrj-11	194	68	%	%	NOUN
gsrj-11	194	69	when	when	SCONJ
gsrj-11	194	70	ptch	ptch	NOUN
gsrj-11	194	71	loss	loss	NOUN
gsrj-11	194	72	was	be	AUX
gsrj-11	194	73	coupled	couple	VERB
gsrj-11	194	74	with	with	ADP
gsrj-11	194	75	p53	p53	NOUN
gsrj-11	194	76	loss.38	loss.38	NOUN
gsrj-11	194	77	moreover	moreover	ADV
gsrj-11	194	78	,	,	PUNCT
gsrj-11	194	79	administration	administration	NOUN
gsrj-11	194	80	of	of	ADP
gsrj-11	194	81	shh	shh	PROPN
gsrj-11	194	82	inhibitors	inhibitor	NOUN
gsrj-11	194	83	with	with	ADP
gsrj-11	194	84	p53	p53	NOUN
gsrj-11	194	85	mediators	mediator	NOUN
gsrj-11	194	86	should	should	AUX
gsrj-11	194	87	be	be	AUX
gsrj-11	194	88	explored	explore	VERB
gsrj-11	194	89	as	as	ADP
gsrj-11	194	90	a	a	DET
gsrj-11	194	91	putative	putative	ADJ
gsrj-11	194	92	combination	combination	NOUN
gsrj-11	194	93	therapy	therapy	NOUN
gsrj-11	194	94	for	for	ADP
gsrj-11	194	95	shh	shh	PROPN
gsrj-11	194	96	mb	mb	PROPN
gsrj-11	194	97	.	.	PUNCT
gsrj-11	194	98	additionally	additionally	ADV
gsrj-11	194	99	,	,	PUNCT
gsrj-11	194	100	cholesterol	cholesterol	NOUN
gsrj-11	194	101	homeostasis	homeostasis	NOUN
gsrj-11	194	102	may	may	AUX
gsrj-11	194	103	contribute	contribute	VERB
gsrj-11	194	104	to	to	ADP
gsrj-11	194	105	the	the	DET
gsrj-11	194	106	overactivation	overactivation	NOUN
gsrj-11	194	107	of	of	ADP
gsrj-11	194	108	the	the	DET
gsrj-11	194	109	shh	shh	PROPN
gsrj-11	194	110	pathway	pathway	NOUN
gsrj-11	194	111	and	and	CCONJ
gsrj-11	194	112	so	so	ADV
gsrj-11	194	113	,	,	PUNCT
gsrj-11	194	114	modulated	modulate	VERB
gsrj-11	194	115	inhibitor	inhibitor	NOUN
gsrj-11	194	116	therapies	therapy	NOUN
gsrj-11	194	117	that	that	PRON
gsrj-11	194	118	can	can	AUX
gsrj-11	194	119	also	also	ADV
gsrj-11	194	120	obstruct	obstruct	VERB
gsrj-11	194	121	cholesterol	cholesterol	NOUN
gsrj-11	194	122	regulation	regulation	NOUN
gsrj-11	194	123	may	may	AUX
gsrj-11	194	124	serve	serve	VERB
gsrj-11	194	125	as	as	ADP
gsrj-11	194	126	an	an	DET
gsrj-11	194	127	important	important	ADJ
gsrj-11	194	128	area	area	NOUN
gsrj-11	194	129	of	of	ADP
gsrj-11	194	130	future	future	ADJ
gsrj-11	194	131	research	research	NOUN
gsrj-11	194	132	.	.	PUNCT
gsrj-11	195	1	indeed	indeed	ADV
gsrj-11	195	2	,	,	PUNCT
gsrj-11	195	3	a	a	DET
gsrj-11	195	4	recent	recent	ADJ
gsrj-11	195	5	milestone	milestone	NOUN
gsrj-11	195	6	investigation	investigation	NOUN
gsrj-11	195	7	not	not	PART
gsrj-11	195	8	only	only	ADV
gsrj-11	195	9	demonstrated	demonstrate	VERB
gsrj-11	195	10	that	that	SCONJ
gsrj-11	195	11	lipid	lipid	NOUN
gsrj-11	195	12	-	-	PUNCT
gsrj-11	195	13	based	base	VERB
gsrj-11	195	14	nanoparticles	nanoparticle	NOUN
gsrj-11	195	15	effectively	effectively	ADV
gsrj-11	195	16	crossed	cross	VERB
gsrj-11	195	17	the	the	DET
gsrj-11	195	18	blood	blood	NOUN
gsrj-11	195	19	brain	brain	NOUN
gsrj-11	195	20	barrier	barrier	NOUN
gsrj-11	195	21	and	and	CCONJ
gsrj-11	195	22	delivered	deliver	VERB
gsrj-11	195	23	the	the	DET
gsrj-11	195	24	therapeutic	therapeutic	ADJ
gsrj-11	195	25	cargo	cargo	NOUN
gsrj-11	195	26	to	to	ADP
gsrj-11	195	27	the	the	DET
gsrj-11	195	28	tumor	tumor	NOUN
gsrj-11	195	29	site	site	NOUN
gsrj-11	195	30	,	,	PUNCT
gsrj-11	195	31	but	but	CCONJ
gsrj-11	195	32	also	also	ADV
gsrj-11	195	33	effluxed	effluxe	VERB
gsrj-11	195	34	cholesterol	cholesterol	NOUN
gsrj-11	195	35	from	from	ADP
gsrj-11	195	36	the	the	DET
gsrj-11	195	37	cytosol	cytosol	NOUN
gsrj-11	195	38	of	of	ADP
gsrj-11	195	39	tumor	tumor	NOUN
gsrj-11	195	40	cells.39	cells.39	VERB
gsrj-11	195	41	lower	low	ADJ
gsrj-11	195	42	levels	level	NOUN
gsrj-11	195	43	of	of	ADP
gsrj-11	195	44	cytoplasmic	cytoplasmic	ADJ
gsrj-11	195	45	cholesterol	cholesterol	NOUN
gsrj-11	195	46	94	94	NUM
gsrj-11	195	47	georgetown	georgetown	PROPN
gsrj-11	195	48	scientific	scientific	PROPN
gsrj-11	195	49	research	research	PROPN
gsrj-11	195	50	journal	journal	PROPN
gsrj-11	195	51	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	195	52	generated	generate	VERB
gsrj-11	195	53	cytotoxic	cytotoxic	ADJ
gsrj-11	195	54	effects	effect	NOUN
gsrj-11	195	55	in	in	ADP
gsrj-11	195	56	the	the	DET
gsrj-11	195	57	shh	shh	PROPN
gsrj-11	195	58	mb	mb	PROPN
gsrj-11	195	59	cells	cell	NOUN
gsrj-11	195	60	.	.	PUNCT
gsrj-11	196	1	moreover	moreover	ADV
gsrj-11	196	2	,	,	PUNCT
gsrj-11	196	3	the	the	DET
gsrj-11	196	4	use	use	NOUN
gsrj-11	196	5	of	of	ADP
gsrj-11	196	6	lipid	lipid	NOUN
gsrj-11	196	7	-	-	PUNCT
gsrj-11	196	8	based	base	VERB
gsrj-11	196	9	nanoparticles	nanoparticle	NOUN
gsrj-11	196	10	to	to	PART
gsrj-11	196	11	carry	carry	VERB
gsrj-11	196	12	targeted	target	VERB
gsrj-11	196	13	inhibitor	inhibitor	NOUN
gsrj-11	196	14	therapeutics	therapeutic	NOUN
gsrj-11	196	15	may	may	AUX
gsrj-11	196	16	bolster	bolster	VERB
gsrj-11	196	17	the	the	DET
gsrj-11	196	18	efficacy	efficacy	NOUN
gsrj-11	196	19	of	of	ADP
gsrj-11	196	20	these	these	DET
gsrj-11	196	21	pharmaceuticals	pharmaceutical	NOUN
gsrj-11	196	22	and	and	CCONJ
gsrj-11	196	23	reduce	reduce	VERB
gsrj-11	196	24	the	the	DET
gsrj-11	196	25	drug	drug	NOUN
gsrj-11	196	26	dosage	dosage	NOUN
gsrj-11	196	27	needed	need	VERB
gsrj-11	196	28	to	to	PART
gsrj-11	196	29	elicit	elicit	VERB
gsrj-11	196	30	a	a	DET
gsrj-11	196	31	response	response	NOUN
gsrj-11	196	32	.	.	PUNCT
gsrj-11	197	1	lastly	lastly	ADV
gsrj-11	197	2	,	,	PUNCT
gsrj-11	197	3	the	the	DET
gsrj-11	197	4	pathological	pathological	ADJ
gsrj-11	197	5	mechanisms	mechanism	NOUN
gsrj-11	197	6	of	of	ADP
gsrj-11	197	7	shh	shh	INTJ
gsrj-11	197	8	mb	mb	PROPN
gsrj-11	197	9	are	be	AUX
gsrj-11	197	10	still	still	ADV
gsrj-11	197	11	largely	largely	ADV
gsrj-11	197	12	unknown	unknown	ADJ
gsrj-11	197	13	due	due	ADJ
gsrj-11	197	14	to	to	ADP
gsrj-11	197	15	substantial	substantial	ADJ
gsrj-11	197	16	molecular	molecular	ADJ
gsrj-11	197	17	heterogeneity	heterogeneity	NOUN
gsrj-11	197	18	in	in	ADP
gsrj-11	197	19	these	these	DET
gsrj-11	197	20	tumors	tumor	NOUN
gsrj-11	197	21	.	.	PUNCT
gsrj-11	198	1	there	there	PRON
gsrj-11	198	2	are	be	VERB
gsrj-11	198	3	still	still	ADV
gsrj-11	198	4	a	a	DET
gsrj-11	198	5	multitude	multitude	NOUN
gsrj-11	198	6	of	of	ADP
gsrj-11	198	7	genes	gene	NOUN
gsrj-11	198	8	that	that	PRON
gsrj-11	198	9	drive	drive	VERB
gsrj-11	198	10	this	this	DET
gsrj-11	198	11	tumor	tumor	NOUN
gsrj-11	198	12	that	that	PRON
gsrj-11	198	13	have	have	AUX
gsrj-11	198	14	not	not	PART
gsrj-11	198	15	yet	yet	ADV
gsrj-11	198	16	been	be	AUX
gsrj-11	198	17	identified	identify	VERB
gsrj-11	198	18	,	,	PUNCT
gsrj-11	198	19	making	make	VERB
gsrj-11	198	20	it	it	PRON
gsrj-11	198	21	difficult	difficult	ADJ
gsrj-11	198	22	to	to	PART
gsrj-11	198	23	determine	determine	VERB
gsrj-11	198	24	which	which	DET
gsrj-11	198	25	inhibitor	inhibitor	NOUN
gsrj-11	198	26	therapeutic	therapeutic	ADJ
gsrj-11	198	27	would	would	AUX
gsrj-11	198	28	be	be	AUX
gsrj-11	198	29	most	most	ADJ
gsrj-11	198	30	effective.6	effective.6	NOUN
gsrj-11	198	31	among	among	ADP
gsrj-11	198	32	infants	infant	NOUN
gsrj-11	198	33	,	,	PUNCT
gsrj-11	198	34	children	child	NOUN
gsrj-11	198	35	,	,	PUNCT
gsrj-11	198	36	and	and	CCONJ
gsrj-11	198	37	adult	adult	NOUN
gsrj-11	198	38	patients	patient	NOUN
gsrj-11	198	39	,	,	PUNCT
gsrj-11	198	40	the	the	DET
gsrj-11	198	41	genetic	genetic	ADJ
gsrj-11	198	42	basis	basis	NOUN
gsrj-11	198	43	of	of	ADP
gsrj-11	198	44	the	the	DET
gsrj-11	198	45	tumor	tumor	NOUN
gsrj-11	198	46	differs	differ	VERB
gsrj-11	198	47	significantly	significantly	ADV
gsrj-11	198	48	.	.	PUNCT
gsrj-11	199	1	future	future	ADJ
gsrj-11	199	2	investigations	investigation	NOUN
gsrj-11	199	3	should	should	AUX
gsrj-11	199	4	focus	focus	VERB
gsrj-11	199	5	on	on	ADP
gsrj-11	199	6	further	far	ADV
gsrj-11	199	7	elucidating	elucidate	VERB
gsrj-11	199	8	the	the	DET
gsrj-11	199	9	genetic	genetic	ADJ
gsrj-11	199	10	basis	basis	NOUN
gsrj-11	199	11	of	of	ADP
gsrj-11	199	12	shh	shh	INTJ
gsrj-11	199	13	mb	mb	PROPN
gsrj-11	199	14	tumors	tumor	NOUN
gsrj-11	199	15	to	to	PART
gsrj-11	199	16	determine	determine	VERB
gsrj-11	199	17	whether	whether	SCONJ
gsrj-11	199	18	there	there	PRON
gsrj-11	199	19	is	be	VERB
gsrj-11	199	20	an	an	DET
gsrj-11	199	21	agedependent	agedependent	ADJ
gsrj-11	199	22	factor	factor	NOUN
gsrj-11	199	23	underlying	underlie	VERB
gsrj-11	199	24	the	the	DET
gsrj-11	199	25	molecular	molecular	ADJ
gsrj-11	199	26	disparities	disparity	NOUN
gsrj-11	199	27	.	.	PUNCT
gsrj-11	200	1	therefore	therefore	ADV
gsrj-11	200	2	,	,	PUNCT
gsrj-11	200	3	individualized	individualized	ADJ
gsrj-11	200	4	targeted	target	VERB
gsrj-11	200	5	treatment	treatment	NOUN
gsrj-11	200	6	aiming	aim	VERB
gsrj-11	200	7	to	to	PART
gsrj-11	200	8	alleviate	alleviate	VERB
gsrj-11	200	9	the	the	DET
gsrj-11	200	10	specific	specific	ADJ
gsrj-11	200	11	aberration	aberration	NOUN
gsrj-11	200	12	in	in	ADP
gsrj-11	200	13	the	the	DET
gsrj-11	200	14	shh	shh	PROPN
gsrj-11	200	15	pathway	pathway	NOUN
gsrj-11	200	16	is	be	AUX
gsrj-11	200	17	critical	critical	ADJ
gsrj-11	200	18	for	for	ADP
gsrj-11	200	19	formulating	formulate	VERB
gsrj-11	200	20	the	the	DET
gsrj-11	200	21	most	most	ADV
gsrj-11	200	22	effective	effective	ADJ
gsrj-11	200	23	treatment	treatment	NOUN
gsrj-11	200	24	of	of	ADP
gsrj-11	200	25	shh	shh	INTJ
gsrj-11	200	26	mb	mb	NOUN
gsrj-11	200	27	in	in	ADP
gsrj-11	200	28	both	both	CCONJ
gsrj-11	200	29	pediatric	pediatric	ADJ
gsrj-11	200	30	and	and	CCONJ
gsrj-11	200	31	adult	adult	NOUN
gsrj-11	200	32	patients	patient	NOUN
gsrj-11	200	33	.	.	PUNCT
gsrj-11	201	1	all	all	ADV
gsrj-11	201	2	in	in	ADP
gsrj-11	201	3	all	all	PRON
gsrj-11	201	4	,	,	PUNCT
gsrj-11	201	5	extensive	extensive	ADJ
gsrj-11	201	6	genetic	genetic	ADJ
gsrj-11	201	7	profiling	profiling	NOUN
gsrj-11	201	8	of	of	ADP
gsrj-11	201	9	shh	shh	PROPN
gsrj-11	201	10	mb	mb	PROPN
gsrj-11	201	11	tumors	tumors	PROPN
gsrj-11	201	12	serves	serve	VERB
gsrj-11	201	13	as	as	ADP
gsrj-11	201	14	a	a	DET
gsrj-11	201	15	pivotal	pivotal	ADJ
gsrj-11	201	16	area	area	NOUN
gsrj-11	201	17	of	of	ADP
gsrj-11	201	18	future	future	ADJ
gsrj-11	201	19	research	research	NOUN
gsrj-11	201	20	.	.	PUNCT
gsrj-11	202	1	6	6	X
gsrj-11	202	2	.	.	X
gsrj-11	202	3	summary	summary	NOUN
gsrj-11	202	4	in	in	ADP
gsrj-11	202	5	summary	summary	NOUN
gsrj-11	202	6	,	,	PUNCT
gsrj-11	202	7	in	in	ADP
gsrj-11	202	8	understanding	understand	VERB
gsrj-11	202	9	the	the	DET
gsrj-11	202	10	shh	shh	NOUN
gsrj-11	202	11	pathway	pathway	NOUN
gsrj-11	202	12	and	and	CCONJ
gsrj-11	202	13	inhibitors	inhibitor	NOUN
gsrj-11	202	14	vismodegib	vismodegib	NOUN
gsrj-11	202	15	,	,	PUNCT
gsrj-11	202	16	sonidegib	sonidegib	NOUN
gsrj-11	202	17	,	,	PUNCT
gsrj-11	202	18	glasdegib	glasdegib	NOUN
gsrj-11	202	19	,	,	PUNCT
gsrj-11	202	20	temozolomide	temozolomide	NOUN
gsrj-11	202	21	,	,	PUNCT
gsrj-11	202	22	and	and	CCONJ
gsrj-11	202	23	gant-61	gant-61	PROPN
gsrj-11	202	24	,	,	PUNCT
gsrj-11	202	25	benefits	benefit	NOUN
gsrj-11	202	26	as	as	ADV
gsrj-11	202	27	well	well	ADV
gsrj-11	202	28	as	as	ADP
gsrj-11	202	29	limitations	limitation	NOUN
gsrj-11	202	30	were	be	AUX
gsrj-11	202	31	exposed	expose	VERB
gsrj-11	202	32	.	.	PUNCT
gsrj-11	203	1	drug	drug	NOUN
gsrj-11	203	2	resistance	resistance	NOUN
gsrj-11	203	3	due	due	ADP
gsrj-11	203	4	to	to	ADP
gsrj-11	203	5	smo	smo	PROPN
gsrj-11	203	6	mutations	mutation	NOUN
gsrj-11	203	7	,	,	PUNCT
gsrj-11	203	8	molecular	molecular	ADJ
gsrj-11	203	9	heterogeneity	heterogeneity	NOUN
gsrj-11	203	10	,	,	PUNCT
gsrj-11	203	11	and	and	CCONJ
gsrj-11	203	12	poor	poor	ADJ
gsrj-11	203	13	drug	drug	NOUN
gsrj-11	203	14	properties	property	NOUN
gsrj-11	203	15	were	be	AUX
gsrj-11	203	16	discussed	discuss	VERB
gsrj-11	203	17	.	.	PUNCT
gsrj-11	204	1	gaps	gap	NOUN
gsrj-11	204	2	in	in	ADP
gsrj-11	204	3	knowledge	knowledge	NOUN
gsrj-11	204	4	for	for	ADP
gsrj-11	204	5	future	future	ADJ
gsrj-11	204	6	research	research	NOUN
gsrj-11	204	7	include	include	VERB
gsrj-11	204	8	establishing	establish	VERB
gsrj-11	204	9	a	a	DET
gsrj-11	204	10	more	more	ADV
gsrj-11	204	11	thorough	thorough	ADJ
gsrj-11	204	12	understanding	understanding	NOUN
gsrj-11	204	13	of	of	ADP
gsrj-11	204	14	the	the	DET
gsrj-11	204	15	genetic	genetic	ADJ
gsrj-11	204	16	basis	basis	NOUN
gsrj-11	204	17	of	of	ADP
gsrj-11	204	18	the	the	DET
gsrj-11	204	19	disease	disease	NOUN
gsrj-11	204	20	,	,	PUNCT
gsrj-11	204	21	determining	determine	VERB
gsrj-11	204	22	optimal	optimal	ADJ
gsrj-11	204	23	dosage	dosage	NOUN
gsrj-11	204	24	of	of	ADP
gsrj-11	204	25	the	the	DET
gsrj-11	204	26	inhibitors	inhibitor	NOUN
gsrj-11	204	27	,	,	PUNCT
gsrj-11	204	28	as	as	ADV
gsrj-11	204	29	well	well	ADV
gsrj-11	204	30	as	as	ADP
gsrj-11	204	31	time	time	NOUN
gsrj-11	204	32	of	of	ADP
gsrj-11	204	33	intervention	intervention	NOUN
gsrj-11	204	34	,	,	PUNCT
gsrj-11	204	35	pathological	pathological	ADJ
gsrj-11	204	36	mechanisms	mechanism	NOUN
gsrj-11	204	37	,	,	PUNCT
gsrj-11	204	38	and	and	CCONJ
gsrj-11	204	39	synergistic	synergistic	ADJ
gsrj-11	204	40	treatments	treatment	NOUN
gsrj-11	204	41	to	to	PART
gsrj-11	204	42	improve	improve	VERB
gsrj-11	204	43	efficacy	efficacy	NOUN
gsrj-11	204	44	.	.	PUNCT
gsrj-11	205	1	in	in	ADP
gsrj-11	205	2	conclusion	conclusion	NOUN
gsrj-11	205	3	,	,	PUNCT
gsrj-11	205	4	targeted	target	VERB
gsrj-11	205	5	inhibitors	inhibitor	NOUN
gsrj-11	205	6	of	of	ADP
gsrj-11	205	7	the	the	DET
gsrj-11	205	8	shh	shh	PROPN
gsrj-11	205	9	pathway	pathway	NOUN
gsrj-11	205	10	are	be	AUX
gsrj-11	205	11	a	a	DET
gsrj-11	205	12	promising	promising	ADJ
gsrj-11	205	13	treatment	treatment	NOUN
gsrj-11	205	14	method	method	NOUN
gsrj-11	205	15	,	,	PUNCT
gsrj-11	205	16	though	though	SCONJ
gsrj-11	205	17	there	there	PRON
gsrj-11	205	18	are	be	VERB
gsrj-11	205	19	limitations	limitation	NOUN
gsrj-11	205	20	that	that	PRON
gsrj-11	205	21	must	must	AUX
gsrj-11	205	22	be	be	AUX
gsrj-11	205	23	further	far	ADV
gsrj-11	205	24	explored	explore	VERB
gsrj-11	205	25	to	to	PART
gsrj-11	205	26	improve	improve	VERB
gsrj-11	205	27	the	the	DET
gsrj-11	205	28	efficacy	efficacy	NOUN
gsrj-11	205	29	and	and	CCONJ
gsrj-11	205	30	safety	safety	NOUN
gsrj-11	205	31	as	as	ADP
gsrj-11	205	32	a	a	DET
gsrj-11	205	33	therapeutic	therapeutic	ADJ
gsrj-11	205	34	treatment	treatment	NOUN
gsrj-11	205	35	for	for	ADP
gsrj-11	205	36	sonic	sonic	ADJ
gsrj-11	205	37	hedgehog	hedgehog	ADJ
gsrj-11	205	38	medulloblastoma	medulloblastoma	NOUN
gsrj-11	205	39	.	.	PUNCT
gsrj-11	206	1	acknowledgements	acknowledgement	NOUN
gsrj-11	206	2	we	we	PRON
gsrj-11	206	3	acknowledge	acknowledge	VERB
gsrj-11	206	4	the	the	DET
gsrj-11	206	5	nhs	nhs	PROPN
gsrj-11	206	6	and	and	CCONJ
gsrj-11	206	7	dr	dr	PROPN
gsrj-11	206	8	.	.	PROPN
gsrj-11	206	9	tilan	tilan	PROPN
gsrj-11	206	10	.	.	PUNCT
gsrj-11	207	1	references	reference	NOUN
gsrj-11	207	2	1	1	NUM
gsrj-11	207	3	.	.	PUNCT
gsrj-11	208	1	huang	huang	PROPN
gsrj-11	208	2	,	,	PUNCT
gsrj-11	208	3	s.	s.	PROPN
gsrj-11	208	4	y.	y.	PROPN
gsrj-11	208	5	,	,	PUNCT
gsrj-11	208	6	&	&	CCONJ
gsrj-11	208	7	yang	yang	PROPN
gsrj-11	208	8	,	,	PUNCT
gsrj-11	208	9	j.	j.	PROPN
gsrj-11	208	10	y.	y.	PROPN
gsrj-11	208	11	(	(	PUNCT
gsrj-11	208	12	2015	2015	NUM
gsrj-11	208	13	)	)	PUNCT
gsrj-11	208	14	.	.	PUNCT
gsrj-11	209	1	targeting	target	VERB
gsrj-11	209	2	the	the	DET
gsrj-11	209	3	hedgehog	hedgehog	ADJ
gsrj-11	209	4	pathway	pathway	NOUN
gsrj-11	209	5	in	in	ADP
gsrj-11	209	6	pediatric	pediatric	ADJ
gsrj-11	209	7	medulloblastoma	medulloblastoma	NOUN
gsrj-11	209	8	.	.	PUNCT
gsrj-11	210	1	cancers	cancer	NOUN
gsrj-11	210	2	,	,	PUNCT
gsrj-11	210	3	7(4	7(4	NUM
gsrj-11	210	4	)	)	PUNCT
gsrj-11	210	5	,	,	PUNCT
gsrj-11	210	6	2110	2110	NUM
gsrj-11	210	7	-	-	SYM
gsrj-11	210	8	2123	2123	NUM
gsrj-11	210	9	.	.	PUNCT
gsrj-11	211	1	https://doi.org/10.3390/cancers7040880	https://doi.org/10.3390/cancers7040880	PROPN
gsrj-11	211	2	2	2	NUM
gsrj-11	211	3	.	.	PUNCT
gsrj-11	212	1	majd	majd	PROPN
gsrj-11	212	2	,	,	PUNCT
gsrj-11	212	3	n.	n.	PROPN
gsrj-11	212	4	,	,	PUNCT
gsrj-11	212	5	&	&	CCONJ
gsrj-11	212	6	penas	penas	PROPN
gsrj-11	212	7	-	-	PUNCT
gsrj-11	212	8	prado	prado	PROPN
gsrj-11	212	9	,	,	PUNCT
gsrj-11	212	10	m.	m.	NOUN
gsrj-11	212	11	(	(	PUNCT
gsrj-11	212	12	2019	2019	NUM
gsrj-11	212	13	)	)	PUNCT
gsrj-11	212	14	.	.	PUNCT
gsrj-11	213	1	updates	update	NOUN
gsrj-11	213	2	on	on	ADP
gsrj-11	213	3	management	management	NOUN
gsrj-11	213	4	of	of	ADP
gsrj-11	213	5	adult	adult	NOUN
gsrj-11	213	6	medulloblastoma	medulloblastoma	NOUN
gsrj-11	213	7	.	.	PUNCT
gsrj-11	214	1	current	current	ADJ
gsrj-11	214	2	treatment	treatment	NOUN
gsrj-11	214	3	options	option	NOUN
gsrj-11	214	4	in	in	ADP
gsrj-11	214	5	oncology	oncology	NOUN
gsrj-11	214	6	,	,	PUNCT
gsrj-11	214	7	20(8	20(8	NOUN
gsrj-11	214	8	)	)	PUNCT
gsrj-11	214	9	,	,	PUNCT
gsrj-11	214	10	1	1	NUM
gsrj-11	214	11	-	-	SYM
gsrj-11	214	12	24	24	NUM
gsrj-11	214	13	.	.	PUNCT
gsrj-11	214	14	https://doi.org/10.1007/s11864-019-0663-0	https://doi.org/10.1007/s11864-019-0663-0	NOUN
gsrj-11	214	15	3	3	NUM
gsrj-11	214	16	.	.	PUNCT
gsrj-11	215	1	the	the	DET
gsrj-11	215	2	university	university	PROPN
gsrj-11	215	3	of	of	ADP
gsrj-11	215	4	texas	texas	PROPN
gsrj-11	215	5	md	md	PROPN
gsrj-11	215	6	anderson	anderson	PROPN
gsrj-11	215	7	cancer	cancer	PROPN
gsrj-11	215	8	center	center	PROPN
gsrj-11	215	9	.	.	PUNCT
gsrj-11	216	1	medulloblastoma	medulloblastoma	NOUN
gsrj-11	216	2	.	.	PUNCT
gsrj-11	217	1	https://www.mdanderson.org/cancertypes/medulloblastoma.html	https://www.mdanderson.org/cancertypes/medulloblastoma.html	PUNCT
gsrj-11	217	2	.	.	PUNCT
gsrj-11	218	1	4	4	X
gsrj-11	218	2	.	.	X
gsrj-11	218	3	northcott	northcott	PROPN
gsrj-11	218	4	,	,	PUNCT
gsrj-11	218	5	p.	p.	NOUN
gsrj-11	218	6	a.	a.	PROPN
gsrj-11	218	7	,	,	PUNCT
gsrj-11	218	8	buchhalter	buchhalter	PROPN
gsrj-11	218	9	,	,	PUNCT
gsrj-11	218	10	i.	i.	PROPN
gsrj-11	218	11	,	,	PUNCT
gsrj-11	218	12	morrissy	morrissy	PROPN
gsrj-11	218	13	,	,	PUNCT
gsrj-11	218	14	a.	a.	PROPN
gsrj-11	218	15	s.	s.	PROPN
gsrj-11	218	16	,	,	PUNCT
gsrj-11	218	17	hovestadt	hovestadt	NOUN
gsrj-11	218	18	,	,	PUNCT
gsrj-11	218	19	v.	v.	ADP
gsrj-11	218	20	,	,	PUNCT
gsrj-11	218	21	weischenfeldt	weischenfeldt	PROPN
gsrj-11	218	22	,	,	PUNCT
gsrj-11	218	23	j.	j.	PROPN
gsrj-11	218	24	,	,	PUNCT
gsrj-11	218	25	ehrenberger	ehrenberger	NOUN
gsrj-11	218	26	,	,	PUNCT
gsrj-11	218	27	t.	t.	PROPN
gsrj-11	218	28	,	,	PUNCT
gsrj-11	218	29	...	...	PUNCT
gsrj-11	218	30	&	&	CCONJ
gsrj-11	218	31	lichter	lichter	PROPN
gsrj-11	218	32	,	,	PUNCT
gsrj-11	218	33	p.	p.	NOUN
gsrj-11	218	34	(	(	PUNCT
gsrj-11	218	35	2017	2017	NUM
gsrj-11	218	36	)	)	PUNCT
gsrj-11	218	37	.	.	PUNCT
gsrj-11	219	1	the	the	DET
gsrj-11	219	2	whole	whole	ADJ
gsrj-11	219	3	-	-	PUNCT
gsrj-11	219	4	genome	genome	NOUN
gsrj-11	219	5	landscape	landscape	NOUN
gsrj-11	219	6	of	of	ADP
gsrj-11	219	7	medulloblastoma	medulloblastoma	ADJ
gsrj-11	219	8	subtypes	subtype	NOUN
gsrj-11	219	9	.	.	PUNCT
gsrj-11	220	1	nature	nature	NOUN
gsrj-11	220	2	,	,	PUNCT
gsrj-11	220	3	547(7663	547(7663	NUM
gsrj-11	220	4	)	)	PUNCT
gsrj-11	220	5	,	,	PUNCT
gsrj-11	220	6	311	311	NUM
gsrj-11	220	7	-	-	SYM
gsrj-11	220	8	317	317	NUM
gsrj-11	220	9	.	.	PUNCT
gsrj-11	220	10	https://doi.org/10.1038/nature22973	https://doi.org/10.1038/nature22973	PROPN
gsrj-11	220	11	5	5	NUM
gsrj-11	220	12	.	.	PUNCT
gsrj-11	220	13	millard	millard	PROPN
gsrj-11	220	14	,	,	PUNCT
gsrj-11	220	15	n.	n.	PROPN
gsrj-11	220	16	e.	e.	PROPN
gsrj-11	220	17	,	,	PUNCT
gsrj-11	220	18	&	&	CCONJ
gsrj-11	220	19	de	de	PROPN
gsrj-11	220	20	braganca	braganca	PROPN
gsrj-11	220	21	,	,	PUNCT
gsrj-11	220	22	k.	k.	PROPN
gsrj-11	220	23	c.	c.	PROPN
gsrj-11	220	24	(	(	PUNCT
gsrj-11	220	25	2016	2016	NUM
gsrj-11	220	26	)	)	PUNCT
gsrj-11	220	27	.	.	PUNCT
gsrj-11	221	1	medulloblastoma	medulloblastoma	NOUN
gsrj-11	221	2	.	.	PUNCT
gsrj-11	222	1	journal	journal	PROPN
gsrj-11	222	2	of	of	ADP
gsrj-11	222	3	child	child	NOUN
gsrj-11	222	4	neurology	neurology	NOUN
gsrj-11	222	5	,	,	PUNCT
gsrj-11	222	6	31(12	31(12	NUM
gsrj-11	222	7	)	)	PUNCT
gsrj-11	222	8	,	,	PUNCT
gsrj-11	222	9	1341	1341	NUM
gsrj-11	222	10	-	-	SYM
gsrj-11	222	11	1353	1353	NUM
gsrj-11	222	12	.	.	PUNCT
gsrj-11	223	1	https://doi.org/0.1177/0883073815600866	https://doi.org/0.1177/0883073815600866	PROPN
gsrj-11	223	2	6	6	NUM
gsrj-11	223	3	.	.	PUNCT
gsrj-11	224	1	liu	liu	PROPN
gsrj-11	224	2	,	,	PUNCT
gsrj-11	224	3	x.	x.	NOUN
gsrj-11	224	4	,	,	PUNCT
gsrj-11	224	5	ding	ding	NOUN
gsrj-11	224	6	,	,	PUNCT
gsrj-11	224	7	c.	c.	PROPN
gsrj-11	224	8	,	,	PUNCT
gsrj-11	224	9	tan	tan	PROPN
gsrj-11	224	10	,	,	PUNCT
gsrj-11	224	11	w.	w.	PROPN
gsrj-11	224	12	,	,	PUNCT
gsrj-11	224	13	&	&	CCONJ
gsrj-11	224	14	zhang	zhang	PROPN
gsrj-11	224	15	,	,	PUNCT
gsrj-11	224	16	a.	a.	PROPN
gsrj-11	224	17	(	(	PUNCT
gsrj-11	224	18	2020	2020	NUM
gsrj-11	224	19	)	)	PUNCT
gsrj-11	224	20	.	.	PUNCT
gsrj-11	225	1	medulloblastoma	medulloblastoma	ADJ
gsrj-11	225	2	:	:	PUNCT
gsrj-11	225	3	molecular	molecular	ADJ
gsrj-11	225	4	understanding	understanding	NOUN
gsrj-11	225	5	,	,	PUNCT
gsrj-11	225	6	treatment	treatment	NOUN
gsrj-11	225	7	evolution	evolution	NOUN
gsrj-11	225	8	,	,	PUNCT
gsrj-11	225	9	and	and	CCONJ
gsrj-11	225	10	new	new	ADJ
gsrj-11	225	11	developments	development	NOUN
gsrj-11	225	12	.	.	PUNCT
gsrj-11	226	1	pharmacology	pharmacology	NOUN
gsrj-11	226	2	&	&	CCONJ
gsrj-11	226	3	therapeutics	therapeutic	NOUN
gsrj-11	226	4	,	,	PUNCT
gsrj-11	226	5	210	210	NUM
gsrj-11	226	6	,	,	PUNCT
gsrj-11	226	7	107516	107516	NUM
gsrj-11	226	8	.	.	PUNCT
gsrj-11	227	1	https://doi.org/10.1016/j.pharmthera	https://doi.org/10.1016/j.pharmthera	PROPN
gsrj-11	227	2	.	.	PUNCT
gsrj-11	228	1	2020.107516	2020.107516	NUM
gsrj-11	228	2	.	.	PUNCT
gsrj-11	229	1	sari	sari	PROPN
gsrj-11	229	2	,	,	PUNCT
gsrj-11	229	3	i.	i.	PROPN
gsrj-11	229	4	n.	n.	PROPN
gsrj-11	229	5	,	,	PUNCT
gsrj-11	229	6	phi	phi	NOUN
gsrj-11	229	7	,	,	PUNCT
gsrj-11	229	8	l.	l.	PROPN
gsrj-11	229	9	t.	t.	PROPN
gsrj-11	229	10	h.	h.	PROPN
gsrj-11	229	11	,	,	PUNCT
gsrj-11	229	12	jun	jun	PROPN
gsrj-11	229	13	,	,	PUNCT
gsrj-11	229	14	n.	n.	PROPN
gsrj-11	229	15	,	,	PUNCT
gsrj-11	229	16	wijaya	wijaya	PROPN
gsrj-11	229	17	,	,	PUNCT
gsrj-11	229	18	y.	y.	PROPN
gsrj-11	229	19	t.	t.	PROPN
gsrj-11	229	20	,	,	PUNCT
gsrj-11	229	21	lee	lee	PROPN
gsrj-11	229	22	,	,	PUNCT
gsrj-11	229	23	s.	s.	PROPN
gsrj-11	229	24	,	,	PUNCT
gsrj-11	229	25	&	&	CCONJ
gsrj-11	229	26	kwon	kwon	PROPN
gsrj-11	229	27	,	,	PUNCT
gsrj-11	229	28	h.	h.	PROPN
gsrj-11	229	29	y.	y.	PROPN
gsrj-11	229	30	(	(	PUNCT
gsrj-11	229	31	2018	2018	NUM
gsrj-11	229	32	)	)	PUNCT
gsrj-11	229	33	.	.	PUNCT
gsrj-11	230	1	hedgehog	hedgehog	PROPN
gsrj-11	230	2	signaling	signal	VERB
gsrj-11	230	3	in	in	ADP
gsrj-11	230	4	cancer	cancer	NOUN
gsrj-11	230	5	:	:	PUNCT
gsrj-11	230	6	a	a	DET
gsrj-11	230	7	prospective	prospective	ADJ
gsrj-11	230	8	therapeutic	therapeutic	ADJ
gsrj-11	230	9	target	target	NOUN
gsrj-11	230	10	for	for	ADP
gsrj-11	230	11	eradicating	eradicate	VERB
gsrj-11	230	12	cancer	cancer	NOUN
gsrj-11	230	13	stem	stem	NOUN
gsrj-11	230	14	cells	cell	NOUN
gsrj-11	230	15	.	.	PUNCT
gsrj-11	231	1	cells	cell	NOUN
gsrj-11	231	2	,	,	PUNCT
gsrj-11	231	3	7(11	7(11	NUM
gsrj-11	231	4	)	)	PUNCT
gsrj-11	231	5	,	,	PUNCT
gsrj-11	231	6	208	208	NUM
gsrj-11	231	7	.	.	PUNCT
gsrj-11	232	1	https://doi	https://doi	X
gsrj-11	232	2	.	.	PUNCT
gsrj-11	232	3	org/10.3390	org/10.3390	PROPN
gsrj-11	232	4	/	/	SYM
gsrj-11	232	5	cells7110208	cells7110208	PROPN
gsrj-11	232	6	.	.	PUNCT
gsrj-11	233	1	shimada	shimada	PROPN
gsrj-11	233	2	,	,	PUNCT
gsrj-11	233	3	i.	i.	PROPN
gsrj-11	233	4	s.	s.	PROPN
gsrj-11	233	5	,	,	PUNCT
gsrj-11	233	6	hwang	hwang	PROPN
gsrj-11	233	7	,	,	PUNCT
gsrj-11	233	8	s.	s.	PROPN
gsrj-11	233	9	h.	h.	PROPN
gsrj-11	233	10	,	,	PUNCT
gsrj-11	233	11	somatilaka	somatilaka	PROPN
gsrj-11	233	12	,	,	PUNCT
gsrj-11	233	13	b.	b.	PROPN
gsrj-11	233	14	n.	n.	PROPN
gsrj-11	233	15	,	,	PUNCT
gsrj-11	233	16	wang	wang	PROPN
gsrj-11	233	17	,	,	PUNCT
gsrj-11	233	18	x.	x.	PROPN
gsrj-11	233	19	,	,	PUNCT
gsrj-11	233	20	skowron	skowron	PROPN
gsrj-11	233	21	,	,	PUNCT
gsrj-11	233	22	p.	p.	NOUN
gsrj-11	233	23	,	,	PUNCT
gsrj-11	233	24	kim	kim	PROPN
gsrj-11	233	25	,	,	PUNCT
gsrj-11	233	26	j.	j.	PROPN
gsrj-11	233	27	,	,	PUNCT
gsrj-11	233	28	...	...	PUNCT
gsrj-11	233	29	&	&	CCONJ
gsrj-11	233	30	mukhopadhyay	mukhopadhyay	PROPN
gsrj-11	233	31	,	,	PUNCT
gsrj-11	233	32	s.	s.	PROPN
gsrj-11	233	33	(	(	PUNCT
gsrj-11	233	34	2018	2018	NUM
gsrj-11	233	35	)	)	PUNCT
gsrj-11	233	36	.	.	PUNCT
gsrj-11	234	1	basal	basal	PROPN
gsrj-11	234	2	suppression	suppression	NOUN
gsrj-11	234	3	of	of	ADP
gsrj-11	234	4	the	the	DET
gsrj-11	234	5	sonic	sonic	ADJ
gsrj-11	234	6	hedgehog	hedgehog	NOUN
gsrj-11	234	7	pathway	pathway	NOUN
gsrj-11	234	8	by	by	ADP
gsrj-11	234	9	the	the	DET
gsrj-11	234	10	g95	g95	PROPN
gsrj-11	234	11	georgetown	georgetown	PROPN
gsrj-11	234	12	scientific	scientific	PROPN
gsrj-11	234	13	research	research	PROPN
gsrj-11	234	14	journal	journal	PROPN
gsrj-11	234	15	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	234	16	protein	protein	NOUN
gsrj-11	234	17	-	-	PUNCT
gsrj-11	234	18	coupled	couple	VERB
gsrj-11	234	19	-	-	PUNCT
gsrj-11	234	20	receptor	receptor	NOUN
gsrj-11	234	21	gpr161	gpr161	NOUN
gsrj-11	234	22	restricts	restrict	VERB
gsrj-11	234	23	medulloblastoma	medulloblastoma	ADJ
gsrj-11	234	24	pathogenesis	pathogenesis	NOUN
gsrj-11	234	25	.	.	PUNCT
gsrj-11	235	1	cell	cell	NOUN
gsrj-11	235	2	reports	report	NOUN
gsrj-11	235	3	,	,	PUNCT
gsrj-11	235	4	22(5	22(5	NOUN
gsrj-11	235	5	)	)	PUNCT
gsrj-11	235	6	,	,	PUNCT
gsrj-11	235	7	1169	1169	NUM
gsrj-11	235	8	-	-	SYM
gsrj-11	235	9	1184	1184	NUM
gsrj-11	235	10	.	.	PUNCT
gsrj-11	236	1	https://doi.org/10.1016/j.celrep.2018.01.018	https://doi.org/10.1016/j.celrep.2018.01.018	NOUN
gsrj-11	236	2	.	.	PUNCT
gsrj-11	237	1	national	national	ADJ
gsrj-11	237	2	center	center	NOUN
gsrj-11	237	3	for	for	ADP
gsrj-11	237	4	biotechnology	biotechnology	NOUN
gsrj-11	237	5	information	information	NOUN
gsrj-11	237	6	(	(	PUNCT
gsrj-11	237	7	2021	2021	NUM
gsrj-11	237	8	)	)	PUNCT
gsrj-11	237	9	.	.	PUNCT
gsrj-11	238	1	pubchem	pubchem	NOUN
gsrj-11	238	2	compound	compound	NOUN
gsrj-11	238	3	summary	summary	NOUN
gsrj-11	238	4	for	for	ADP
gsrj-11	238	5	cid	cid	PROPN
gsrj-11	238	6	24776445	24776445	NUM
gsrj-11	238	7	,	,	PUNCT
gsrj-11	238	8	vismodegib	vismodegib	NOUN
gsrj-11	238	9	.	.	PUNCT
gsrj-11	239	1	retrieved	retrieve	VERB
gsrj-11	239	2	february	february	PROPN
gsrj-11	239	3	4	4	NUM
gsrj-11	239	4	,	,	PUNCT
gsrj-11	239	5	2021	2021	NUM
gsrj-11	239	6	from	from	ADP
gsrj-11	239	7	https://pubchem.ncbi.nlm.nih.gov/comp	https://pubchem.ncbi.nlm.nih.gov/comp	ADJ
gsrj-11	239	8	ound	ound	PROPN
gsrj-11	239	9	/	/	SYM
gsrj-11	239	10	vismodegib	vismodegib	NOUN
gsrj-11	239	11	.	.	PUNCT
gsrj-11	240	1	1	1	X
gsrj-11	240	2	.	.	PUNCT
gsrj-11	241	1	dlugosz	dlugosz	NOUN
gsrj-11	241	2	,	,	PUNCT
gsrj-11	241	3	a.	a.	NOUN
gsrj-11	241	4	,	,	PUNCT
gsrj-11	241	5	agrawal	agrawal	PROPN
gsrj-11	241	6	,	,	PUNCT
gsrj-11	241	7	s.	s.	PROPN
gsrj-11	241	8	,	,	PUNCT
gsrj-11	241	9	&	&	CCONJ
gsrj-11	241	10	kirkpatrick	kirkpatrick	PROPN
gsrj-11	241	11	,	,	PUNCT
gsrj-11	241	12	p.	p.	NOUN
gsrj-11	241	13	(	(	PUNCT
gsrj-11	241	14	2012	2012	NUM
gsrj-11	241	15	)	)	PUNCT
gsrj-11	241	16	.	.	PUNCT
gsrj-11	242	1	vismodegib	vismodegib	NOUN
gsrj-11	242	2	.	.	PUNCT
gsrj-11	243	1	nature	nature	NOUN
gsrj-11	243	2	reviews	review	VERB
gsrj-11	243	3	drug	drug	NOUN
gsrj-11	243	4	discovery	discovery	NOUN
gsrj-11	243	5	,	,	PUNCT
gsrj-11	243	6	11(6	11(6	NUM
gsrj-11	243	7	)	)	PUNCT
gsrj-11	243	8	,	,	PUNCT
gsrj-11	243	9	437	437	NUM
gsrj-11	243	10	.	.	PUNCT
gsrj-11	244	1	https://doi.org/10.1038/nrd3753	https://doi.org/10.1038/nrd3753	NOUN
gsrj-11	244	2	.	.	PROPN
gsrj-11	244	3	11	11	NUM
gsrj-11	244	4	.	.	X
gsrj-11	245	1	gould	gould	PROPN
gsrj-11	245	2	,	,	PUNCT
gsrj-11	245	3	s.	s.	PROPN
gsrj-11	245	4	e.	e.	PROPN
gsrj-11	245	5	,	,	PUNCT
gsrj-11	245	6	low	low	PROPN
gsrj-11	245	7	,	,	PUNCT
gsrj-11	245	8	j.	j.	PROPN
gsrj-11	245	9	a.	a.	PROPN
gsrj-11	245	10	,	,	PUNCT
gsrj-11	245	11	marsters	marsters	PROPN
gsrj-11	245	12	jr	jr	PROPN
gsrj-11	245	13	,	,	PUNCT
gsrj-11	245	14	j.	j.	PROPN
gsrj-11	245	15	c.	c.	PROPN
gsrj-11	245	16	,	,	PUNCT
gsrj-11	245	17	robarge	robarge	NOUN
gsrj-11	245	18	,	,	PUNCT
gsrj-11	245	19	k.	k.	PROPN
gsrj-11	245	20	,	,	PUNCT
gsrj-11	245	21	rubin	rubin	PROPN
gsrj-11	245	22	,	,	PUNCT
gsrj-11	245	23	l.	l.	PROPN
gsrj-11	245	24	l.	l.	PROPN
gsrj-11	245	25	,	,	PUNCT
gsrj-11	245	26	de	de	PROPN
gsrj-11	245	27	sauvage	sauvage	PROPN
gsrj-11	245	28	,	,	PUNCT
gsrj-11	245	29	f.	f.	PROPN
gsrj-11	245	30	j.	j.	PROPN
gsrj-11	245	31	,	,	PUNCT
gsrj-11	245	32	...	...	PUNCT
gsrj-11	245	33	&	&	CCONJ
gsrj-11	245	34	yauch	yauch	PROPN
gsrj-11	245	35	,	,	PUNCT
gsrj-11	245	36	r.	r.	PROPN
gsrj-11	245	37	l.	l.	PROPN
gsrj-11	245	38	(	(	PUNCT
gsrj-11	245	39	2014	2014	NUM
gsrj-11	245	40	)	)	PUNCT
gsrj-11	245	41	.	.	PUNCT
gsrj-11	246	1	discovery	discovery	NOUN
gsrj-11	246	2	and	and	CCONJ
gsrj-11	246	3	preclinical	preclinical	ADJ
gsrj-11	246	4	development	development	NOUN
gsrj-11	246	5	of	of	ADP
gsrj-11	246	6	vismodegib	vismodegib	NOUN
gsrj-11	246	7	.	.	PUNCT
gsrj-11	247	1	expert	expert	ADJ
gsrj-11	247	2	opinion	opinion	NOUN
gsrj-11	247	3	on	on	ADP
gsrj-11	247	4	drug	drug	NOUN
gsrj-11	247	5	discovery	discovery	NOUN
gsrj-11	247	6	,	,	PUNCT
gsrj-11	247	7	9(8	9(8	NUM
gsrj-11	247	8	)	)	PUNCT
gsrj-11	247	9	,	,	PUNCT
gsrj-11	247	10	969	969	NUM
gsrj-11	247	11	-	-	SYM
gsrj-11	247	12	984	984	NUM
gsrj-11	247	13	.	.	PUNCT
gsrj-11	248	1	https://doi.org/10.1517/17460441.2014.92081	https://doi.org/10.1517/17460441.2014.92081	PROPN
gsrj-11	248	2	6	6	NUM
gsrj-11	248	3	12	12	NUM
gsrj-11	248	4	.	.	PUNCT
gsrj-11	248	5	atwood	atwood	PROPN
gsrj-11	248	6	,	,	PUNCT
gsrj-11	248	7	s.	s.	PROPN
gsrj-11	248	8	x.	x.	PROPN
gsrj-11	248	9	,	,	PUNCT
gsrj-11	248	10	sarin	sarin	NOUN
gsrj-11	248	11	,	,	PUNCT
gsrj-11	248	12	k.	k.	PROPN
gsrj-11	248	13	y.	y.	PROPN
gsrj-11	248	14	,	,	PUNCT
gsrj-11	248	15	whitson	whitson	PROPN
gsrj-11	248	16	,	,	PUNCT
gsrj-11	248	17	r.	r.	PROPN
gsrj-11	248	18	j.	j.	PROPN
gsrj-11	248	19	,	,	PUNCT
gsrj-11	248	20	li	li	PROPN
gsrj-11	248	21	,	,	PUNCT
gsrj-11	248	22	j.	j.	PROPN
gsrj-11	248	23	r.	r.	PROPN
gsrj-11	248	24	,	,	PUNCT
gsrj-11	248	25	kim	kim	PROPN
gsrj-11	248	26	,	,	PUNCT
gsrj-11	248	27	g.	g.	PROPN
gsrj-11	248	28	,	,	PUNCT
gsrj-11	248	29	rezaee	rezaee	PROPN
gsrj-11	248	30	,	,	PUNCT
gsrj-11	248	31	m.	m.	NOUN
gsrj-11	248	32	,	,	PUNCT
gsrj-11	248	33	...	...	PUNCT
gsrj-11	248	34	&	&	CCONJ
gsrj-11	248	35	tang	tang	PROPN
gsrj-11	248	36	,	,	PUNCT
gsrj-11	248	37	j.	j.	PROPN
gsrj-11	248	38	y.	y.	PROPN
gsrj-11	248	39	(	(	PUNCT
gsrj-11	248	40	2015	2015	NUM
gsrj-11	248	41	)	)	PUNCT
gsrj-11	248	42	.	.	PUNCT
gsrj-11	249	1	smoothened	smoothen	VERB
gsrj-11	249	2	variants	variant	NOUN
gsrj-11	249	3	explain	explain	VERB
gsrj-11	249	4	the	the	DET
gsrj-11	249	5	majority	majority	NOUN
gsrj-11	249	6	of	of	ADP
gsrj-11	249	7	drug	drug	NOUN
gsrj-11	249	8	resistance	resistance	NOUN
gsrj-11	249	9	in	in	ADP
gsrj-11	249	10	basal	basal	ADJ
gsrj-11	249	11	cell	cell	NOUN
gsrj-11	249	12	carcinoma	carcinoma	NOUN
gsrj-11	249	13	.	.	PUNCT
gsrj-11	250	1	cancer	cancer	NOUN
gsrj-11	250	2	cell	cell	NOUN
gsrj-11	250	3	,	,	PUNCT
gsrj-11	250	4	27(3	27(3	NUM
gsrj-11	250	5	)	)	PUNCT
gsrj-11	250	6	,	,	PUNCT
gsrj-11	250	7	342	342	NUM
gsrj-11	250	8	-	-	SYM
gsrj-11	250	9	353	353	NUM
gsrj-11	250	10	.	.	PUNCT
gsrj-11	250	11	https://doi.org/10.1016/j.ccell.2015.02.002	https://doi.org/10.1016/j.ccell.2015.02.002	NOUN
gsrj-11	250	12	13	13	NUM
gsrj-11	250	13	.	.	PUNCT
gsrj-11	251	1	munchhof	munchhof	NOUN
gsrj-11	251	2	,	,	PUNCT
gsrj-11	251	3	m.	m.	NOUN
gsrj-11	251	4	j.	j.	PROPN
gsrj-11	251	5	,	,	PUNCT
gsrj-11	251	6	li	li	PROPN
gsrj-11	251	7	,	,	PUNCT
gsrj-11	251	8	q.	q.	PROPN
gsrj-11	251	9	,	,	PUNCT
gsrj-11	251	10	shavnya	shavnya	PROPN
gsrj-11	251	11	,	,	PUNCT
gsrj-11	251	12	a.	a.	NOUN
gsrj-11	251	13	,	,	PUNCT
gsrj-11	251	14	borzillo	borzillo	NOUN
gsrj-11	251	15	,	,	PUNCT
gsrj-11	251	16	g.	g.	PROPN
gsrj-11	251	17	v.	v.	PROPN
gsrj-11	251	18	,	,	PUNCT
gsrj-11	251	19	boyden	boyden	PROPN
gsrj-11	251	20	,	,	PUNCT
gsrj-11	251	21	t.	t.	PROPN
gsrj-11	251	22	l.	l.	PROPN
gsrj-11	251	23	,	,	PUNCT
gsrj-11	251	24	jones	jones	PROPN
gsrj-11	251	25	,	,	PUNCT
gsrj-11	251	26	c.	c.	PROPN
gsrj-11	251	27	s.	s.	PROPN
gsrj-11	251	28	,	,	PUNCT
gsrj-11	251	29	...	...	PUNCT
gsrj-11	251	30	&	&	CCONJ
gsrj-11	251	31	tkalcevic	tkalcevic	PROPN
gsrj-11	251	32	,	,	PUNCT
gsrj-11	251	33	g.	g.	PROPN
gsrj-11	251	34	t.	t.	PROPN
gsrj-11	251	35	(	(	PUNCT
gsrj-11	251	36	2012	2012	NUM
gsrj-11	251	37	)	)	PUNCT
gsrj-11	251	38	.	.	PUNCT
gsrj-11	252	1	discovery	discovery	NOUN
gsrj-11	252	2	of	of	ADP
gsrj-11	252	3	pf04449913	pf04449913	PROPN
gsrj-11	252	4	,	,	PUNCT
gsrj-11	252	5	a	a	DET
gsrj-11	252	6	potent	potent	ADJ
gsrj-11	252	7	and	and	CCONJ
gsrj-11	252	8	orally	orally	ADV
gsrj-11	252	9	bioavailable	bioavailable	ADJ
gsrj-11	252	10	inhibitor	inhibitor	NOUN
gsrj-11	252	11	of	of	ADP
gsrj-11	252	12	smoothened	smoothen	VERB
gsrj-11	252	13	.	.	PUNCT
gsrj-11	253	1	acs	acs	PROPN
gsrj-11	253	2	medicinal	medicinal	ADJ
gsrj-11	253	3	chemistry	chemistry	NOUN
gsrj-11	253	4	letters	letter	NOUN
gsrj-11	253	5	,	,	PUNCT
gsrj-11	253	6	3(2	3(2	NUM
gsrj-11	253	7	)	)	PUNCT
gsrj-11	253	8	,	,	PUNCT
gsrj-11	253	9	106	106	NUM
gsrj-11	253	10	-	-	SYM
gsrj-11	253	11	111	111	NUM
gsrj-11	253	12	.	.	PUNCT
gsrj-11	254	1	https://doi.org/10.1021/ml2002423	https://doi.org/10.1021/ml2002423	NOUN
gsrj-11	254	2	14	14	NUM
gsrj-11	254	3	.	.	PUNCT
gsrj-11	255	1	fukushima	fukushima	PROPN
gsrj-11	255	2	,	,	PUNCT
gsrj-11	255	3	n.	n.	PROPN
gsrj-11	255	4	,	,	PUNCT
gsrj-11	255	5	minami	minami	PROPN
gsrj-11	255	6	,	,	PUNCT
gsrj-11	255	7	y.	y.	PROPN
gsrj-11	255	8	,	,	PUNCT
gsrj-11	255	9	kakiuchi	kakiuchi	PROPN
gsrj-11	255	10	,	,	PUNCT
gsrj-11	255	11	s.	s.	PROPN
gsrj-11	255	12	,	,	PUNCT
gsrj-11	255	13	kuwatsuka	kuwatsuka	PROPN
gsrj-11	255	14	,	,	PUNCT
gsrj-11	255	15	y.	y.	PROPN
gsrj-11	255	16	,	,	PUNCT
gsrj-11	255	17	hayakawa	hayakawa	PROPN
gsrj-11	255	18	,	,	PUNCT
gsrj-11	255	19	f.	f.	PROPN
gsrj-11	255	20	,	,	PUNCT
gsrj-11	255	21	jamieson	jamieson	PROPN
gsrj-11	255	22	,	,	PUNCT
gsrj-11	255	23	c.	c.	PROPN
gsrj-11	255	24	,	,	PUNCT
gsrj-11	255	25	...	...	PUNCT
gsrj-11	255	26	&	&	CCONJ
gsrj-11	255	27	naoe	naoe	PROPN
gsrj-11	255	28	,	,	PUNCT
gsrj-11	255	29	t.	t.	PROPN
gsrj-11	255	30	(	(	PUNCT
gsrj-11	255	31	2016	2016	NUM
gsrj-11	255	32	)	)	PUNCT
gsrj-11	255	33	.	.	PUNCT
gsrj-11	256	1	small!molecule	small!molecule	ADJ
gsrj-11	256	2	hedgehog	hedgehog	NOUN
gsrj-11	256	3	inhibitor	inhibitor	NOUN
gsrj-11	256	4	attenuates	attenuate	VERB
gsrj-11	256	5	the	the	DET
gsrj-11	256	6	leukemia!initiation	leukemia!initiation	NOUN
gsrj-11	256	7	potential	potential	NOUN
gsrj-11	256	8	of	of	ADP
gsrj-11	256	9	acute	acute	ADJ
gsrj-11	256	10	myeloid	myeloid	ADJ
gsrj-11	256	11	leukemia	leukemia	NOUN
gsrj-11	256	12	cells	cell	NOUN
gsrj-11	256	13	.	.	PUNCT
gsrj-11	257	1	cancer	cancer	NOUN
gsrj-11	257	2	science	science	NOUN
gsrj-11	257	3	,	,	PUNCT
gsrj-11	257	4	107(10	107(10	NUM
gsrj-11	257	5	)	)	PUNCT
gsrj-11	257	6	,	,	PUNCT
gsrj-11	257	7	1422	1422	NUM
gsrj-11	257	8	-	-	SYM
gsrj-11	257	9	1429	1429	NUM
gsrj-11	257	10	.	.	PUNCT
gsrj-11	258	1	https://doi.org/10.1111/cas.13019	https://doi.org/10.1111/cas.13019	ADV
gsrj-11	258	2	15	15	NUM
gsrj-11	258	3	.	.	PUNCT
gsrj-11	259	1	wolska	wolska	NOUN
gsrj-11	259	2	-	-	PUNCT
gsrj-11	259	3	washer	washer	NOUN
gsrj-11	259	4	,	,	PUNCT
gsrj-11	259	5	a.	a.	NOUN
gsrj-11	259	6	,	,	PUNCT
gsrj-11	259	7	&	&	CCONJ
gsrj-11	259	8	robak	robak	NOUN
gsrj-11	259	9	,	,	PUNCT
gsrj-11	259	10	t.	t.	PROPN
gsrj-11	259	11	(	(	PUNCT
gsrj-11	259	12	2019	2019	NUM
gsrj-11	259	13	)	)	PUNCT
gsrj-11	259	14	.	.	PUNCT
gsrj-11	260	1	glasdegib	glasdegib	NOUN
gsrj-11	260	2	in	in	ADP
gsrj-11	260	3	the	the	DET
gsrj-11	260	4	treatment	treatment	NOUN
gsrj-11	260	5	of	of	ADP
gsrj-11	260	6	acute	acute	ADJ
gsrj-11	260	7	myeloid	myeloid	ADJ
gsrj-11	260	8	leukemia	leukemia	NOUN
gsrj-11	260	9	.	.	PUNCT
gsrj-11	261	1	future	future	ADJ
gsrj-11	261	2	oncology	oncology	NOUN
gsrj-11	261	3	,	,	PUNCT
gsrj-11	261	4	15(28	15(28	NUM
gsrj-11	261	5	)	)	PUNCT
gsrj-11	261	6	,	,	PUNCT
gsrj-11	261	7	3219	3219	NUM
gsrj-11	261	8	-	-	SYM
gsrj-11	261	9	3232	3232	NUM
gsrj-11	261	10	.	.	PUNCT
gsrj-11	261	11	https://doi.org/10.2217/fon-2019-0171	https://doi.org/10.2217/fon-2019-0171	PROPN
gsrj-11	261	12	16	16	NUM
gsrj-11	261	13	.	.	PUNCT
gsrj-11	262	1	li	li	PROPN
gsrj-11	262	2	,	,	PUNCT
gsrj-11	262	3	y.	y.	PROPN
gsrj-11	262	4	,	,	PUNCT
gsrj-11	262	5	song	song	NOUN
gsrj-11	262	6	,	,	PUNCT
gsrj-11	262	7	q.	q.	PROPN
gsrj-11	262	8	,	,	PUNCT
gsrj-11	262	9	&	&	CCONJ
gsrj-11	262	10	day	day	PROPN
gsrj-11	262	11	,	,	PUNCT
gsrj-11	262	12	b.	b.	PROPN
gsrj-11	262	13	w.	w.	PROPN
gsrj-11	262	14	(	(	PUNCT
gsrj-11	262	15	2019	2019	NUM
gsrj-11	262	16	)	)	PUNCT
gsrj-11	262	17	.	.	PUNCT
gsrj-11	263	1	phase	phase	NOUN
gsrj-11	263	2	i	i	PRON
gsrj-11	263	3	and	and	CCONJ
gsrj-11	263	4	phase	phase	NOUN
gsrj-11	263	5	ii	ii	PROPN
gsrj-11	263	6	sonidegib	sonidegib	NOUN
gsrj-11	263	7	and	and	CCONJ
gsrj-11	263	8	vismodegib	vismodegib	VERB
gsrj-11	263	9	clinical	clinical	ADJ
gsrj-11	263	10	trials	trial	NOUN
gsrj-11	263	11	for	for	ADP
gsrj-11	263	12	the	the	DET
gsrj-11	263	13	treatment	treatment	NOUN
gsrj-11	263	14	of	of	ADP
gsrj-11	263	15	paediatric	paediatric	ADJ
gsrj-11	263	16	and	and	CCONJ
gsrj-11	263	17	adult	adult	NOUN
gsrj-11	263	18	mb	mb	NOUN
gsrj-11	263	19	patients	patient	NOUN
gsrj-11	263	20	:	:	PUNCT
gsrj-11	263	21	a	a	DET
gsrj-11	263	22	systemic	systemic	ADJ
gsrj-11	263	23	review	review	NOUN
gsrj-11	263	24	and	and	CCONJ
gsrj-11	263	25	meta	meta	ADJ
gsrj-11	263	26	-	-	PUNCT
gsrj-11	263	27	analysis	analysis	NOUN
gsrj-11	263	28	.	.	PUNCT
gsrj-11	264	1	acta	acta	PROPN
gsrj-11	264	2	neuropathologica	neuropathologica	PROPN
gsrj-11	264	3	communications	communications	PROPN
gsrj-11	264	4	,	,	PUNCT
gsrj-11	264	5	7(1	7(1	NUM
gsrj-11	264	6	)	)	PUNCT
gsrj-11	264	7	,	,	PUNCT
gsrj-11	264	8	1	1	NUM
gsrj-11	264	9	-	-	SYM
gsrj-11	264	10	8	8	NUM
gsrj-11	264	11	.	.	PUNCT
gsrj-11	265	1	https://doi.org/10.1186/s40478-019-0773-8	https://doi.org/10.1186/s40478-019-0773-8	NOUN
gsrj-11	265	2	1	1	NUM
gsrj-11	265	3	.	.	PUNCT
gsrj-11	266	1	lorusso	lorusso	PROPN
gsrj-11	266	2	,	,	PUNCT
gsrj-11	266	3	p.	p.	NOUN
gsrj-11	266	4	m.	m.	NOUN
gsrj-11	266	5	,	,	PUNCT
gsrj-11	266	6	rudin	rudin	PROPN
gsrj-11	266	7	,	,	PUNCT
gsrj-11	266	8	c.	c.	PROPN
gsrj-11	266	9	m.	m.	PROPN
gsrj-11	266	10	,	,	PUNCT
gsrj-11	266	11	reddy	reddy	PROPN
gsrj-11	266	12	,	,	PUNCT
gsrj-11	266	13	j.	j.	PROPN
gsrj-11	266	14	c.	c.	PROPN
gsrj-11	266	15	,	,	PUNCT
gsrj-11	266	16	tibes	tibe	NOUN
gsrj-11	266	17	,	,	PUNCT
gsrj-11	266	18	r.	r.	PROPN
gsrj-11	266	19	,	,	PUNCT
gsrj-11	266	20	weiss	weiss	PROPN
gsrj-11	266	21	,	,	PUNCT
gsrj-11	266	22	g.	g.	PROPN
gsrj-11	266	23	j.	j.	PROPN
gsrj-11	266	24	,	,	PUNCT
gsrj-11	266	25	borad	borad	PROPN
gsrj-11	266	26	,	,	PUNCT
gsrj-11	266	27	m.	m.	NOUN
gsrj-11	266	28	j.	j.	PROPN
gsrj-11	266	29	,	,	PUNCT
gsrj-11	266	30	...	...	PUNCT
gsrj-11	266	31	&	&	CCONJ
gsrj-11	266	32	von	von	PROPN
gsrj-11	266	33	hoff	hoff	PROPN
gsrj-11	266	34	,	,	PUNCT
gsrj-11	266	35	d.	d.	PROPN
gsrj-11	266	36	d.	d.	PROPN
gsrj-11	266	37	(	(	PUNCT
gsrj-11	266	38	2011	2011	NUM
gsrj-11	266	39	)	)	PUNCT
gsrj-11	266	40	.	.	PUNCT
gsrj-11	267	1	phase	phase	NOUN
gsrj-11	267	2	i	i	PRON
gsrj-11	267	3	trial	trial	NOUN
gsrj-11	267	4	of	of	ADP
gsrj-11	267	5	hedgehog	hedgehog	PROPN
gsrj-11	267	6	pathway	pathway	NOUN
gsrj-11	267	7	inhibitor	inhibitor	NOUN
gsrj-11	267	8	vismodegib	vismodegib	PROPN
gsrj-11	267	9	(	(	PUNCT
gsrj-11	267	10	gdc-0449	gdc-0449	NOUN
gsrj-11	267	11	)	)	PUNCT
gsrj-11	267	12	in	in	ADP
gsrj-11	267	13	patients	patient	NOUN
gsrj-11	267	14	with	with	ADP
gsrj-11	267	15	refractory	refractory	NOUN
gsrj-11	267	16	,	,	PUNCT
gsrj-11	267	17	locally	locally	ADV
gsrj-11	267	18	advanced	advanced	ADJ
gsrj-11	267	19	or	or	CCONJ
gsrj-11	267	20	metastatic	metastatic	ADJ
gsrj-11	267	21	solid	solid	ADJ
gsrj-11	267	22	tumors	tumor	NOUN
gsrj-11	267	23	.	.	PUNCT
gsrj-11	268	1	clinical	clinical	ADJ
gsrj-11	268	2	cancer	cancer	NOUN
gsrj-11	268	3	research	research	NOUN
gsrj-11	268	4	,	,	PUNCT
gsrj-11	268	5	17(8	17(8	NUM
gsrj-11	268	6	)	)	PUNCT
gsrj-11	268	7	,	,	PUNCT
gsrj-11	268	8	25022511	25022511	NUM
gsrj-11	268	9	.	.	PUNCT
gsrj-11	269	1	https://doi.org/10.1158/10780432.ccr-10-2745	https://doi.org/10.1158/10780432.ccr-10-2745	NOUN
gsrj-11	269	2	.	.	PUNCT
gsrj-11	270	1	1	1	NUM
gsrj-11	270	2	.	.	PUNCT
gsrj-11	271	1	gajjar	gajjar	NOUN
gsrj-11	271	2	,	,	PUNCT
gsrj-11	271	3	a.	a.	PROPN
gsrj-11	271	4	,	,	PUNCT
gsrj-11	271	5	stewart	stewart	PROPN
gsrj-11	271	6	,	,	PUNCT
gsrj-11	271	7	c.	c.	PROPN
gsrj-11	271	8	f.	f.	PROPN
gsrj-11	271	9	,	,	PUNCT
gsrj-11	271	10	ellison	ellison	PROPN
gsrj-11	271	11	,	,	PUNCT
gsrj-11	271	12	d.	d.	PROPN
gsrj-11	271	13	w.	w.	PROPN
gsrj-11	271	14	,	,	PUNCT
gsrj-11	271	15	kaste	kaste	PROPN
gsrj-11	271	16	,	,	PUNCT
gsrj-11	271	17	s.	s.	PROPN
gsrj-11	271	18	,	,	PUNCT
gsrj-11	271	19	kun	kun	PROPN
gsrj-11	271	20	,	,	PUNCT
gsrj-11	271	21	l.	l.	PROPN
gsrj-11	271	22	e.	e.	PROPN
gsrj-11	271	23	,	,	PUNCT
gsrj-11	271	24	packer	packer	PROPN
gsrj-11	271	25	,	,	PUNCT
gsrj-11	271	26	r.	r.	PROPN
gsrj-11	271	27	j.	j.	PROPN
gsrj-11	271	28	,	,	PUNCT
gsrj-11	271	29	...	...	PUNCT
gsrj-11	271	30	&	&	CCONJ
gsrj-11	271	31	curran	curran	PROPN
gsrj-11	271	32	,	,	PUNCT
gsrj-11	271	33	t.	t.	PROPN
gsrj-11	271	34	(	(	PUNCT
gsrj-11	271	35	2013	2013	NUM
gsrj-11	271	36	)	)	PUNCT
gsrj-11	271	37	.	.	PUNCT
gsrj-11	272	1	phase	phase	NOUN
gsrj-11	272	2	i	i	PRON
gsrj-11	272	3	study	study	VERB
gsrj-11	272	4	of	of	ADP
gsrj-11	272	5	vismodegib	vismodegib	NOUN
gsrj-11	272	6	in	in	ADP
gsrj-11	272	7	children	child	NOUN
gsrj-11	272	8	with	with	ADP
gsrj-11	272	9	recurrent	recurrent	NOUN
gsrj-11	272	10	or	or	CCONJ
gsrj-11	272	11	refractory	refractory	NOUN
gsrj-11	272	12	medulloblastoma	medulloblastoma	NOUN
gsrj-11	272	13	:	:	PUNCT
gsrj-11	272	14	a	a	DET
gsrj-11	272	15	pediatric	pediatric	ADJ
gsrj-11	272	16	brain	brain	NOUN
gsrj-11	272	17	tumor	tumor	PROPN
gsrj-11	272	18	consortium	consortium	PROPN
gsrj-11	272	19	study	study	NOUN
gsrj-11	272	20	.	.	PUNCT
gsrj-11	273	1	clinical	clinical	ADJ
gsrj-11	273	2	cancer	cancer	NOUN
gsrj-11	273	3	research	research	NOUN
gsrj-11	273	4	,	,	PUNCT
gsrj-11	273	5	19(22	19(22	NUM
gsrj-11	273	6	)	)	PUNCT
gsrj-11	273	7	,	,	PUNCT
gsrj-11	273	8	6305	6305	NUM
gsrj-11	273	9	-	-	SYM
gsrj-11	273	10	6312	6312	NUM
gsrj-11	273	11	.	.	PUNCT
gsrj-11	274	1	https://doi.org/10.1158/1078-0432.ccr-131425	https://doi.org/10.1158/1078-0432.ccr-131425	X
gsrj-11	275	1	.	.	NOUN
gsrj-11	275	2	1	1	NUM
gsrj-11	275	3	.	.	PUNCT
gsrj-11	276	1	robinson	robinson	PROPN
gsrj-11	276	2	,	,	PUNCT
gsrj-11	276	3	g.	g.	PROPN
gsrj-11	276	4	w.	w.	PROPN
gsrj-11	276	5	,	,	PUNCT
gsrj-11	276	6	orr	orr	PROPN
gsrj-11	276	7	,	,	PUNCT
gsrj-11	276	8	b.	b.	PROPN
gsrj-11	276	9	a.	a.	PROPN
gsrj-11	276	10	,	,	PUNCT
gsrj-11	276	11	wu	wu	PROPN
gsrj-11	276	12	,	,	PUNCT
gsrj-11	276	13	g.	g.	PROPN
gsrj-11	276	14	,	,	PUNCT
gsrj-11	276	15	gururangan	gururangan	PROPN
gsrj-11	276	16	,	,	PUNCT
gsrj-11	276	17	s.	s.	PROPN
gsrj-11	276	18	,	,	PUNCT
gsrj-11	276	19	lin	lin	PROPN
gsrj-11	276	20	,	,	PUNCT
gsrj-11	276	21	t.	t.	PROPN
gsrj-11	276	22	,	,	PUNCT
gsrj-11	276	23	qaddoumi	qaddoumi	PROPN
gsrj-11	276	24	,	,	PUNCT
gsrj-11	276	25	i.	i.	PROPN
gsrj-11	276	26	,	,	PUNCT
gsrj-11	276	27	...	...	PUNCT
gsrj-11	276	28	&	&	CCONJ
gsrj-11	276	29	gajjar	gajjar	PROPN
gsrj-11	276	30	,	,	PUNCT
gsrj-11	276	31	a.	a.	NOUN
gsrj-11	276	32	(	(	PUNCT
gsrj-11	276	33	2015	2015	NUM
gsrj-11	276	34	)	)	PUNCT
gsrj-11	276	35	.	.	PUNCT
gsrj-11	277	1	vismodegib	vismodegib	PROPN
gsrj-11	277	2	exerts	exert	VERB
gsrj-11	277	3	targeted	target	VERB
gsrj-11	277	4	efficacy	efficacy	NOUN
gsrj-11	277	5	against	against	ADP
gsrj-11	277	6	recurrent	recurrent	ADJ
gsrj-11	277	7	sonic	sonic	ADJ
gsrj-11	277	8	hedgehog	hedgehog	NOUN
gsrj-11	277	9	–	–	PUNCT
gsrj-11	277	10	subgroup	subgroup	NOUN
gsrj-11	277	11	medulloblastoma	medulloblastoma	NOUN
gsrj-11	277	12	:	:	PUNCT
gsrj-11	277	13	results	result	NOUN
gsrj-11	277	14	from	from	ADP
gsrj-11	277	15	phase	phase	NOUN
gsrj-11	277	16	ii	ii	PROPN
gsrj-11	277	17	pediatric	pediatric	ADJ
gsrj-11	277	18	brain	brain	NOUN
gsrj-11	277	19	tumor	tumor	PROPN
gsrj-11	277	20	consortium	consortium	PROPN
gsrj-11	277	21	studies	study	NOUN
gsrj-11	277	22	pbtc-025b	pbtc-025b	PROPN
gsrj-11	277	23	and	and	CCONJ
gsrj-11	277	24	pbtc-032	pbtc-032	NOUN
gsrj-11	277	25	.	.	PUNCT
gsrj-11	278	1	journal	journal	NOUN
gsrj-11	278	2	of	of	ADP
gsrj-11	278	3	clinical	clinical	ADJ
gsrj-11	278	4	oncology	oncology	NOUN
gsrj-11	278	5	,	,	PUNCT
gsrj-11	278	6	33(24	33(24	NUM
gsrj-11	278	7	)	)	PUNCT
gsrj-11	278	8	,	,	PUNCT
gsrj-11	278	9	2646.https://doi.org/10.1200/jco.2014.60.15	2646.https://doi.org/10.1200/jco.2014.60.15	PRON
gsrj-11	278	10	91	91	NUM
gsrj-11	278	11	.	.	NOUN
gsrj-11	278	12	2	2	NUM
gsrj-11	278	13	.	.	PUNCT
gsrj-11	279	1	rodon	rodon	PROPN
gsrj-11	279	2	,	,	PUNCT
gsrj-11	279	3	j.	j.	PROPN
gsrj-11	279	4	,	,	PUNCT
gsrj-11	279	5	tawbi	tawbi	PROPN
gsrj-11	279	6	,	,	PUNCT
gsrj-11	279	7	h.	h.	PROPN
gsrj-11	279	8	a.	a.	PROPN
gsrj-11	279	9	,	,	PUNCT
gsrj-11	279	10	thomas	thomas	PROPN
gsrj-11	279	11	,	,	PUNCT
gsrj-11	279	12	a.	a.	PROPN
gsrj-11	279	13	l.	l.	PROPN
gsrj-11	279	14	,	,	PUNCT
gsrj-11	279	15	stoller	stoller	PROPN
gsrj-11	279	16	,	,	PUNCT
gsrj-11	279	17	r.	r.	PROPN
gsrj-11	279	18	g.	g.	PROPN
gsrj-11	279	19	,	,	PUNCT
gsrj-11	279	20	turtschi	turtschi	NOUN
gsrj-11	279	21	,	,	PUNCT
gsrj-11	279	22	c.	c.	PROPN
gsrj-11	279	23	p.	p.	PROPN
gsrj-11	279	24	,	,	PUNCT
gsrj-11	279	25	baselga	baselga	PROPN
gsrj-11	279	26	,	,	PUNCT
gsrj-11	279	27	j.	j.	PROPN
gsrj-11	279	28	,	,	PUNCT
gsrj-11	279	29	...	...	PUNCT
gsrj-11	279	30	&	&	CCONJ
gsrj-11	279	31	mita	mita	PROPN
gsrj-11	279	32	,	,	PUNCT
gsrj-11	279	33	a.	a.	PROPN
gsrj-11	279	34	c.	c.	PROPN
gsrj-11	279	35	(	(	PUNCT
gsrj-11	279	36	2014	2014	NUM
gsrj-11	279	37	)	)	PUNCT
gsrj-11	279	38	.	.	PUNCT
gsrj-11	280	1	a	a	DET
gsrj-11	280	2	phase	phase	NOUN
gsrj-11	280	3	i	i	PRON
gsrj-11	280	4	,	,	PUNCT
gsrj-11	280	5	multicenter	multicenter	NOUN
gsrj-11	280	6	,	,	PUNCT
gsrj-11	280	7	open	open	ADJ
gsrj-11	280	8	-	-	PUNCT
gsrj-11	280	9	label	label	NOUN
gsrj-11	280	10	,	,	PUNCT
gsrj-11	280	11	first	first	ADJ
gsrj-11	280	12	-	-	PUNCT
gsrj-11	280	13	in	in	ADP
gsrj-11	280	14	-	-	PUNCT
gsrj-11	280	15	human	human	NOUN
gsrj-11	280	16	,	,	PUNCT
gsrj-11	280	17	dose	dose	NOUN
gsrj-11	280	18	-	-	PUNCT
gsrj-11	280	19	escalation	escalation	NOUN
gsrj-11	280	20	study	study	NOUN
gsrj-11	280	21	of	of	ADP
gsrj-11	280	22	the	the	DET
gsrj-11	280	23	oral	oral	ADJ
gsrj-11	280	24	smoothened	smoothen	VERB
gsrj-11	280	25	inhibitor	inhibitor	NOUN
gsrj-11	280	26	sonidegib	sonidegib	NOUN
gsrj-11	280	27	(	(	PUNCT
gsrj-11	280	28	lde225	lde225	PROPN
gsrj-11	280	29	)	)	PUNCT
gsrj-11	280	30	in	in	ADP
gsrj-11	280	31	patients	patient	NOUN
gsrj-11	280	32	with	with	ADP
gsrj-11	280	33	advanced	advanced	ADJ
gsrj-11	280	34	solid	solid	ADJ
gsrj-11	280	35	tumors	tumor	NOUN
gsrj-11	280	36	.	.	PUNCT
gsrj-11	281	1	clinical	clinical	ADJ
gsrj-11	281	2	cancer	cancer	NOUN
gsrj-11	281	3	research	research	NOUN
gsrj-11	281	4	,	,	PUNCT
gsrj-11	281	5	20(7	20(7	NUM
gsrj-11	281	6	)	)	PUNCT
gsrj-11	281	7	,	,	PUNCT
gsrj-11	281	8	1900	1900	NUM
gsrj-11	281	9	-	-	SYM
gsrj-11	281	10	1909	1909	NUM
gsrj-11	281	11	.	.	PUNCT
gsrj-11	282	1	https://doi.org/10.1158/1078-0432.ccr-131710	https://doi.org/10.1158/1078-0432.ccr-131710	ADJ
gsrj-11	282	2	.	.	PROPN
gsrj-11	282	3	96	96	NUM
gsrj-11	282	4	georgetown	georgetown	PROPN
gsrj-11	282	5	scientific	scientific	PROPN
gsrj-11	282	6	research	research	PROPN
gsrj-11	282	7	journal	journal	NOUN
gsrj-11	282	8	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	282	9	21	21	NUM
gsrj-11	282	10	.	.	PUNCT
gsrj-11	283	1	kieran	kieran	PROPN
gsrj-11	283	2	,	,	PUNCT
gsrj-11	283	3	m.	m.	PROPN
gsrj-11	283	4	w.	w.	PROPN
gsrj-11	283	5	,	,	PUNCT
gsrj-11	283	6	chisholm	chisholm	PROPN
gsrj-11	283	7	,	,	PUNCT
gsrj-11	283	8	j.	j.	PROPN
gsrj-11	283	9	,	,	PUNCT
gsrj-11	283	10	casanova	casanova	PROPN
gsrj-11	283	11	,	,	PUNCT
gsrj-11	283	12	m.	m.	NOUN
gsrj-11	283	13	,	,	PUNCT
gsrj-11	283	14	brandes	brande	NOUN
gsrj-11	283	15	,	,	PUNCT
gsrj-11	283	16	a.	a.	NOUN
gsrj-11	283	17	a.	a.	PROPN
gsrj-11	283	18	,	,	PUNCT
gsrj-11	283	19	aerts	aert	NOUN
gsrj-11	283	20	,	,	PUNCT
gsrj-11	283	21	i.	i.	NOUN
gsrj-11	283	22	,	,	PUNCT
gsrj-11	283	23	bouffet	bouffet	NOUN
gsrj-11	283	24	,	,	PUNCT
gsrj-11	283	25	e.	e.	PROPN
gsrj-11	283	26	,	,	PUNCT
gsrj-11	283	27	...	...	PUNCT
gsrj-11	283	28	&	&	CCONJ
gsrj-11	283	29	geoerger	geoerger	PROPN
gsrj-11	283	30	,	,	PUNCT
gsrj-11	283	31	b.	b.	PROPN
gsrj-11	283	32	(	(	PUNCT
gsrj-11	283	33	2017	2017	NUM
gsrj-11	283	34	)	)	PUNCT
gsrj-11	283	35	.	.	PUNCT
gsrj-11	284	1	phase	phase	NOUN
gsrj-11	284	2	i	i	PRON
gsrj-11	284	3	study	study	VERB
gsrj-11	284	4	of	of	ADP
gsrj-11	284	5	oral	oral	ADJ
gsrj-11	284	6	sonidegib	sonidegib	NOUN
gsrj-11	284	7	(	(	PUNCT
gsrj-11	284	8	lde225	lde225	PROPN
gsrj-11	284	9	)	)	PUNCT
gsrj-11	284	10	in	in	ADP
gsrj-11	284	11	pediatric	pediatric	ADJ
gsrj-11	284	12	brain	brain	NOUN
gsrj-11	284	13	and	and	CCONJ
gsrj-11	284	14	solid	solid	ADJ
gsrj-11	284	15	tumors	tumor	NOUN
gsrj-11	284	16	and	and	CCONJ
gsrj-11	284	17	a	a	DET
gsrj-11	284	18	phase	phase	NOUN
gsrj-11	284	19	ii	ii	NOUN
gsrj-11	284	20	study	study	NOUN
gsrj-11	284	21	in	in	ADP
gsrj-11	284	22	children	child	NOUN
gsrj-11	284	23	and	and	CCONJ
gsrj-11	284	24	adults	adult	NOUN
gsrj-11	284	25	with	with	ADP
gsrj-11	284	26	relapsed	relapse	VERB
gsrj-11	284	27	medulloblastoma	medulloblastoma	NOUN
gsrj-11	284	28	.	.	PUNCT
gsrj-11	285	1	neuro	neuro	NOUN
gsrj-11	285	2	-	-	PUNCT
gsrj-11	285	3	oncology	oncology	NOUN
gsrj-11	285	4	,	,	PUNCT
gsrj-11	285	5	19(11	19(11	NUM
gsrj-11	285	6	)	)	PUNCT
gsrj-11	285	7	,	,	PUNCT
gsrj-11	285	8	1542	1542	NUM
gsrj-11	285	9	-	-	SYM
gsrj-11	285	10	1552	1552	NUM
gsrj-11	285	11	.	.	PUNCT
gsrj-11	286	1	https://doi.org/10.1093/neuonc/nox109	https://doi.org/10.1093/neuonc/nox109	NOUN
gsrj-11	286	2	.	.	PUNCT
gsrj-11	287	1	22	22	NUM
gsrj-11	287	2	.	.	PUNCT
gsrj-11	288	1	wang	wang	PROPN
gsrj-11	288	2	,	,	PUNCT
gsrj-11	288	3	c.	c.	PROPN
gsrj-11	288	4	,	,	PUNCT
gsrj-11	288	5	wu	wu	PROPN
gsrj-11	288	6	,	,	PUNCT
gsrj-11	288	7	h.	h.	PROPN
gsrj-11	288	8	,	,	PUNCT
gsrj-11	288	9	evron	evron	PROPN
gsrj-11	288	10	,	,	PUNCT
gsrj-11	288	11	t.	t.	PROPN
gsrj-11	288	12	,	,	PUNCT
gsrj-11	288	13	vardy	vardy	NOUN
gsrj-11	288	14	,	,	PUNCT
gsrj-11	288	15	e.	e.	PROPN
gsrj-11	288	16	,	,	PUNCT
gsrj-11	288	17	han	han	PROPN
gsrj-11	288	18	,	,	PUNCT
gsrj-11	288	19	g.	g.	PROPN
gsrj-11	288	20	w.	w.	PROPN
gsrj-11	288	21	,	,	PUNCT
gsrj-11	288	22	huang	huang	PROPN
gsrj-11	288	23	,	,	PUNCT
gsrj-11	288	24	x.	x.	PROPN
gsrj-11	288	25	p.	p.	PROPN
gsrj-11	288	26	,	,	PUNCT
gsrj-11	288	27	...	...	PUNCT
gsrj-11	288	28	&	&	CCONJ
gsrj-11	288	29	stevens	stevens	PROPN
gsrj-11	288	30	,	,	PUNCT
gsrj-11	288	31	r.	r.	PROPN
gsrj-11	288	32	c.	c.	PROPN
gsrj-11	288	33	(	(	PUNCT
gsrj-11	288	34	2014	2014	NUM
gsrj-11	288	35	)	)	PUNCT
gsrj-11	288	36	.	.	PUNCT
gsrj-11	289	1	structural	structural	ADJ
gsrj-11	289	2	basis	basis	NOUN
gsrj-11	289	3	for	for	ADP
gsrj-11	289	4	smoothened	smoothen	VERB
gsrj-11	289	5	receptor	receptor	NOUN
gsrj-11	289	6	modulation	modulation	NOUN
gsrj-11	289	7	and	and	CCONJ
gsrj-11	289	8	chemoresistance	chemoresistance	NOUN
gsrj-11	289	9	to	to	PART
gsrj-11	289	10	anticancer	anticancer	NOUN
gsrj-11	289	11	drugs	drug	NOUN
gsrj-11	289	12	.	.	PUNCT
gsrj-11	290	1	nature	nature	NOUN
gsrj-11	290	2	communications	communication	NOUN
gsrj-11	290	3	,	,	PUNCT
gsrj-11	290	4	5(1	5(1	NUM
gsrj-11	290	5	)	)	PUNCT
gsrj-11	290	6	,	,	PUNCT
gsrj-11	290	7	1	1	NUM
gsrj-11	290	8	-	-	SYM
gsrj-11	290	9	11	11	NUM
gsrj-11	290	10	.	.	PUNCT
gsrj-11	291	1	https://doi.org/10.1038/ncomms5355	https://doi.org/10.1038/ncomms5355	PROPN
gsrj-11	291	2	.	.	PUNCT
gsrj-11	292	1	23	23	NUM
gsrj-11	292	2	.	.	X
gsrj-11	292	3	petrirena	petrirena	NOUN
gsrj-11	292	4	,	,	PUNCT
gsrj-11	292	5	g.	g.	PROPN
gsrj-11	292	6	j.	j.	PROPN
gsrj-11	292	7	,	,	PUNCT
gsrj-11	292	8	masliah	masliah	PROPN
gsrj-11	292	9	-	-	PUNCT
gsrj-11	292	10	planchon	planchon	PROPN
gsrj-11	292	11	,	,	PUNCT
gsrj-11	292	12	j.	j.	PROPN
gsrj-11	292	13	,	,	PUNCT
gsrj-11	292	14	sala	sala	PROPN
gsrj-11	292	15	,	,	PUNCT
gsrj-11	292	16	q.	q.	PROPN
gsrj-11	292	17	,	,	PUNCT
gsrj-11	292	18	pourroy	pourroy	PROPN
gsrj-11	292	19	,	,	PUNCT
gsrj-11	292	20	b.	b.	PROPN
gsrj-11	292	21	,	,	PUNCT
gsrj-11	292	22	frappaz	frappaz	PROPN
gsrj-11	292	23	,	,	PUNCT
gsrj-11	292	24	d.	d.	PROPN
gsrj-11	292	25	,	,	PUNCT
gsrj-11	292	26	tabouret	tabouret	PROPN
gsrj-11	292	27	,	,	PUNCT
gsrj-11	292	28	e.	e.	PROPN
gsrj-11	292	29	,	,	PUNCT
gsrj-11	292	30	...	...	PUNCT
gsrj-11	292	31	&	&	CCONJ
gsrj-11	292	32	padovani	padovani	PROPN
gsrj-11	292	33	,	,	PUNCT
gsrj-11	292	34	l.	l.	PROPN
gsrj-11	292	35	(	(	PUNCT
gsrj-11	292	36	2018	2018	NUM
gsrj-11	292	37	)	)	PUNCT
gsrj-11	292	38	.	.	PUNCT
gsrj-11	293	1	recurrent	recurrent	ADJ
gsrj-11	293	2	extraneural	extraneural	ADJ
gsrj-11	293	3	sonic	sonic	ADJ
gsrj-11	293	4	hedgehog	hedgehog	NOUN
gsrj-11	293	5	medulloblastoma	medulloblastoma	NOUN
gsrj-11	293	6	exhibiting	exhibit	VERB
gsrj-11	293	7	sustained	sustained	ADJ
gsrj-11	293	8	response	response	NOUN
gsrj-11	293	9	to	to	ADP
gsrj-11	293	10	vismodegib	vismodegib	NOUN
gsrj-11	293	11	and	and	CCONJ
gsrj-11	293	12	temozolomide	temozolomide	NOUN
gsrj-11	293	13	monotherapies	monotherapie	NOUN
gsrj-11	293	14	and	and	CCONJ
gsrj-11	293	15	intermetastatic	intermetastatic	ADJ
gsrj-11	293	16	molecular	molecular	ADJ
gsrj-11	293	17	heterogeneity	heterogeneity	NOUN
gsrj-11	293	18	at	at	ADP
gsrj-11	293	19	progression	progression	NOUN
gsrj-11	293	20	.	.	PUNCT
gsrj-11	294	1	oncotarget	oncotarget	NOUN
gsrj-11	294	2	,	,	PUNCT
gsrj-11	294	3	9(11	9(11	NUM
gsrj-11	294	4	)	)	PUNCT
gsrj-11	294	5	,	,	PUNCT
gsrj-11	294	6	10175	10175	NUM
gsrj-11	294	7	.	.	PUNCT
gsrj-11	295	1	https://doi.org/10.18632/oncotarget.23699	https://doi.org/10.18632/oncotarget.23699	PROPN
gsrj-11	295	2	.	.	PUNCT
gsrj-11	296	1	24	24	NUM
gsrj-11	296	2	.	.	PUNCT
gsrj-11	297	1	lin	lin	PROPN
gsrj-11	297	2	,	,	PUNCT
gsrj-11	297	3	z.	z.	PROPN
gsrj-11	297	4	,	,	PUNCT
gsrj-11	297	5	li	li	PROPN
gsrj-11	297	6	,	,	PUNCT
gsrj-11	297	7	s.	s.	PROPN
gsrj-11	297	8	,	,	PUNCT
gsrj-11	297	9	sheng	sheng	PROPN
gsrj-11	297	10	,	,	PUNCT
gsrj-11	297	11	h.	h.	PROPN
gsrj-11	297	12	,	,	PUNCT
gsrj-11	297	13	cai	cai	PROPN
gsrj-11	297	14	,	,	PUNCT
gsrj-11	297	15	m.	m.	NOUN
gsrj-11	297	16	,	,	PUNCT
gsrj-11	297	17	ma	ma	PROPN
gsrj-11	297	18	,	,	PUNCT
gsrj-11	297	19	l.	l.	PROPN
gsrj-11	297	20	y.	y.	PROPN
gsrj-11	297	21	s.	s.	PROPN
gsrj-11	297	22	,	,	PUNCT
gsrj-11	297	23	hu	hu	PROPN
gsrj-11	297	24	,	,	PUNCT
gsrj-11	297	25	l.	l.	PROPN
gsrj-11	297	26	,	,	PUNCT
gsrj-11	297	27	...	...	PUNCT
gsrj-11	297	28	&	&	CCONJ
gsrj-11	297	29	zhang	zhang	PROPN
gsrj-11	297	30	,	,	PUNCT
gsrj-11	297	31	n.	n.	PROPN
gsrj-11	297	32	(	(	PUNCT
gsrj-11	297	33	2016	2016	NUM
gsrj-11	297	34	)	)	PUNCT
gsrj-11	297	35	.	.	PUNCT
gsrj-11	298	1	suppression	suppression	NOUN
gsrj-11	298	2	of	of	ADP
gsrj-11	298	3	gli	gli	NOUN
gsrj-11	298	4	sensitizes	sensitize	VERB
gsrj-11	298	5	medulloblastoma	medulloblastoma	NOUN
gsrj-11	298	6	cells	cell	NOUN
gsrj-11	298	7	to	to	ADP
gsrj-11	298	8	mitochondriamediated	mitochondriamediate	VERB
gsrj-11	298	9	apoptosis	apoptosis	NOUN
gsrj-11	298	10	.	.	PUNCT
gsrj-11	299	1	journal	journal	PROPN
gsrj-11	299	2	of	of	ADP
gsrj-11	299	3	cancer	cancer	NOUN
gsrj-11	299	4	research	research	NOUN
gsrj-11	299	5	and	and	CCONJ
gsrj-11	299	6	clinical	clinical	ADJ
gsrj-11	299	7	oncology	oncology	NOUN
gsrj-11	299	8	,	,	PUNCT
gsrj-11	299	9	142(12	142(12	NUM
gsrj-11	299	10	)	)	PUNCT
gsrj-11	299	11	,	,	PUNCT
gsrj-11	299	12	2469	2469	NUM
gsrj-11	299	13	-	-	SYM
gsrj-11	299	14	2478	2478	NUM
gsrj-11	299	15	.	.	PUNCT
gsrj-11	300	1	https://doi.org/10.1007/s00432-016-2241-1	https://doi.org/10.1007/s00432-016-2241-1	NUM
gsrj-11	300	2	.	.	PUNCT
gsrj-11	301	1	25	25	NUM
gsrj-11	301	2	.	.	PUNCT
gsrj-11	302	1	pan	pan	PROPN
gsrj-11	302	2	,	,	PUNCT
gsrj-11	302	3	s.	s.	PROPN
gsrj-11	302	4	,	,	PUNCT
gsrj-11	302	5	wu	wu	PROPN
gsrj-11	302	6	,	,	PUNCT
gsrj-11	302	7	x.	x.	PROPN
gsrj-11	302	8	,	,	PUNCT
gsrj-11	302	9	jiang	jiang	PROPN
gsrj-11	302	10	,	,	PUNCT
gsrj-11	302	11	j.	j.	PROPN
gsrj-11	302	12	,	,	PUNCT
gsrj-11	302	13	gao	gao	PROPN
gsrj-11	302	14	,	,	PUNCT
gsrj-11	302	15	w.	w.	PROPN
gsrj-11	302	16	,	,	PUNCT
gsrj-11	302	17	wan	wan	PROPN
gsrj-11	302	18	,	,	PUNCT
gsrj-11	302	19	y.	y.	PROPN
gsrj-11	302	20	,	,	PUNCT
gsrj-11	302	21	cheng	cheng	PROPN
gsrj-11	302	22	,	,	PUNCT
gsrj-11	302	23	d.	d.	PROPN
gsrj-11	302	24	,	,	PUNCT
gsrj-11	302	25	...	...	PUNCT
gsrj-11	302	26	&	&	CCONJ
gsrj-11	302	27	dorsch	dorsch	PROPN
gsrj-11	302	28	,	,	PUNCT
gsrj-11	302	29	m.	m.	NOUN
gsrj-11	302	30	(	(	PUNCT
gsrj-11	302	31	2010	2010	NUM
gsrj-11	302	32	)	)	PUNCT
gsrj-11	302	33	.	.	PUNCT
gsrj-11	303	1	discovery	discovery	NOUN
gsrj-11	303	2	of	of	ADP
gsrj-11	303	3	nvp	nvp	PROPN
gsrj-11	303	4	-	-	PUNCT
gsrj-11	303	5	lde225	lde225	PROPN
gsrj-11	303	6	,	,	PUNCT
gsrj-11	303	7	a	a	DET
gsrj-11	303	8	potent	potent	ADJ
gsrj-11	303	9	and	and	CCONJ
gsrj-11	303	10	selective	selective	ADJ
gsrj-11	303	11	smoothened	smoothen	VERB
gsrj-11	303	12	antagonist	antagonist	NOUN
gsrj-11	303	13	.	.	PUNCT
gsrj-11	304	1	acs	acs	PROPN
gsrj-11	304	2	medicinal	medicinal	ADJ
gsrj-11	304	3	chemistry	chemistry	NOUN
gsrj-11	304	4	letters	letter	NOUN
gsrj-11	304	5	,	,	PUNCT
gsrj-11	304	6	1(3	1(3	NUM
gsrj-11	304	7	)	)	PUNCT
gsrj-11	304	8	,	,	PUNCT
gsrj-11	304	9	130	130	NUM
gsrj-11	304	10	-	-	SYM
gsrj-11	304	11	134	134	NUM
gsrj-11	304	12	.	.	PUNCT
gsrj-11	305	1	https://doi.org/10.1021/ml1000307	https://doi.org/10.1021/ml1000307	X
gsrj-11	305	2	.	.	PROPN
gsrj-11	305	3	26	26	NUM
gsrj-11	305	4	.	.	PUNCT
gsrj-11	306	1	kool	kool	NOUN
gsrj-11	306	2	,	,	PUNCT
gsrj-11	306	3	m.	m.	NOUN
gsrj-11	306	4	,	,	PUNCT
gsrj-11	306	5	jones	jones	PROPN
gsrj-11	306	6	,	,	PUNCT
gsrj-11	306	7	d.	d.	PROPN
gsrj-11	306	8	t.	t.	PROPN
gsrj-11	306	9	,	,	PUNCT
gsrj-11	306	10	jäger	jäger	PROPN
gsrj-11	306	11	,	,	PUNCT
gsrj-11	306	12	n.	n.	PROPN
gsrj-11	306	13	,	,	PUNCT
gsrj-11	306	14	northcott	northcott	PROPN
gsrj-11	306	15	,	,	PUNCT
gsrj-11	306	16	p.	p.	PROPN
gsrj-11	306	17	a.	a.	PROPN
gsrj-11	306	18	,	,	PUNCT
gsrj-11	306	19	pugh	pugh	PROPN
gsrj-11	306	20	,	,	PUNCT
gsrj-11	306	21	t.	t.	PROPN
gsrj-11	306	22	j.	j.	PROPN
gsrj-11	306	23	,	,	PUNCT
gsrj-11	306	24	hovestadt	hovestadt	NOUN
gsrj-11	306	25	,	,	PUNCT
gsrj-11	306	26	v.	v.	ADV
gsrj-11	306	27	,	,	PUNCT
gsrj-11	306	28	...	...	PUNCT
gsrj-11	306	29	&	&	CCONJ
gsrj-11	306	30	pfister	pfister	PROPN
gsrj-11	306	31	,	,	PUNCT
gsrj-11	306	32	s.	s.	PROPN
gsrj-11	306	33	m.	m.	PROPN
gsrj-11	306	34	(	(	PUNCT
gsrj-11	306	35	2014	2014	NUM
gsrj-11	306	36	)	)	PUNCT
gsrj-11	306	37	.	.	PUNCT
gsrj-11	307	1	genome	genome	NOUN
gsrj-11	307	2	sequencing	sequencing	NOUN
gsrj-11	307	3	of	of	ADP
gsrj-11	307	4	shh	shh	INTJ
gsrj-11	307	5	medulloblastoma	medulloblastoma	PROPN
gsrj-11	307	6	predicts	predict	VERB
gsrj-11	307	7	genotype	genotype	NOUN
gsrj-11	307	8	-	-	PUNCT
gsrj-11	307	9	related	relate	VERB
gsrj-11	307	10	response	response	NOUN
gsrj-11	307	11	to	to	ADP
gsrj-11	307	12	smoothened	smoothen	VERB
gsrj-11	307	13	inhibition	inhibition	NOUN
gsrj-11	307	14	.	.	PUNCT
gsrj-11	308	1	cancer	cancer	NOUN
gsrj-11	308	2	cell	cell	NOUN
gsrj-11	308	3	,	,	PUNCT
gsrj-11	308	4	25(3	25(3	NUM
gsrj-11	308	5	)	)	PUNCT
gsrj-11	308	6	,	,	PUNCT
gsrj-11	308	7	393	393	NUM
gsrj-11	308	8	-	-	SYM
gsrj-11	308	9	405	405	NUM
gsrj-11	308	10	.	.	PUNCT
gsrj-11	309	1	https://doi.org/10.1016/j.ccr.2014.02.004	https://doi.org/10.1016/j.ccr.2014.02.004	NOUN
gsrj-11	309	2	.	.	PROPN
gsrj-11	310	1	2	2	NUM
gsrj-11	310	2	.	.	PUNCT
gsrj-11	311	1	lou	lou	PROPN
gsrj-11	311	2	,	,	PUNCT
gsrj-11	311	3	e.	e.	PROPN
gsrj-11	311	4	,	,	PUNCT
gsrj-11	311	5	nelson	nelson	PROPN
gsrj-11	311	6	,	,	PUNCT
gsrj-11	311	7	a.	a.	PROPN
gsrj-11	311	8	c.	c.	PROPN
gsrj-11	311	9	,	,	PUNCT
gsrj-11	311	10	&	&	CCONJ
gsrj-11	311	11	kool	kool	PROPN
gsrj-11	311	12	,	,	PUNCT
gsrj-11	311	13	m.	m.	NOUN
gsrj-11	311	14	(	(	PUNCT
gsrj-11	311	15	2019	2019	NUM
gsrj-11	311	16	)	)	PUNCT
gsrj-11	311	17	.	.	PUNCT
gsrj-11	312	1	differential	differential	ADJ
gsrj-11	312	2	response	response	NOUN
gsrj-11	312	3	of	of	ADP
gsrj-11	312	4	shh	shh	NOUN
gsrj-11	312	5	-	-	PUNCT
gsrj-11	312	6	expressing	express	VERB
gsrj-11	312	7	adult	adult	NOUN
gsrj-11	312	8	medulloblastomas	medulloblastoma	NOUN
gsrj-11	312	9	to	to	ADP
gsrj-11	312	10	the	the	DET
gsrj-11	312	11	sonic	sonic	ADJ
gsrj-11	312	12	hedgehog	hedgehog	PROPN
gsrj-11	312	13	inhibitor	inhibitor	NOUN
gsrj-11	312	14	vismodegib	vismodegib	NOUN
gsrj-11	312	15	:	:	PUNCT
gsrj-11	312	16	whole	whole	ADJ
gsrj-11	312	17	-	-	PUNCT
gsrj-11	312	18	genome	genome	NOUN
gsrj-11	312	19	analysis	analysis	NOUN
gsrj-11	312	20	.	.	PUNCT
gsrj-11	313	1	cancer	cancer	NOUN
gsrj-11	313	2	biology	biology	NOUN
gsrj-11	313	3	&	&	CCONJ
gsrj-11	313	4	therapy	therapy	NOUN
gsrj-11	313	5	,	,	PUNCT
gsrj-11	313	6	20(11	20(11	NUM
gsrj-11	313	7	)	)	PUNCT
gsrj-11	313	8	,	,	PUNCT
gsrj-11	313	9	1398	1398	NUM
gsrj-11	313	10	-	-	SYM
gsrj-11	313	11	1402	1402	NUM
gsrj-11	313	12	.	.	PUNCT
gsrj-11	314	1	https://doi.org/10.1080/15384047.2019.16470	https://doi.org/10.1080/15384047.2019.16470	PROPN
gsrj-11	315	1	57	57	NUM
gsrj-11	315	2	.	.	NOUN
gsrj-11	315	3	2	2	NUM
gsrj-11	315	4	.	.	PUNCT
gsrj-11	316	1	casey	casey	PROPN
gsrj-11	316	2	,	,	PUNCT
gsrj-11	316	3	d.	d.	PROPN
gsrj-11	316	4	,	,	PUNCT
gsrj-11	316	5	demko	demko	PROPN
gsrj-11	316	6	,	,	PUNCT
gsrj-11	316	7	s.	s.	PROPN
gsrj-11	316	8	,	,	PUNCT
gsrj-11	316	9	shord	shord	NOUN
gsrj-11	316	10	,	,	PUNCT
gsrj-11	316	11	s.	s.	PROPN
gsrj-11	316	12	,	,	PUNCT
gsrj-11	316	13	zhao	zhao	PROPN
gsrj-11	316	14	,	,	PUNCT
gsrj-11	316	15	h.	h.	PROPN
gsrj-11	316	16	,	,	PUNCT
gsrj-11	316	17	chen	chen	PROPN
gsrj-11	316	18	,	,	PUNCT
gsrj-11	316	19	h.	h.	PROPN
gsrj-11	316	20	,	,	PUNCT
gsrj-11	316	21	he	he	PRON
gsrj-11	316	22	,	,	PUNCT
gsrj-11	316	23	k.	k.	PROPN
gsrj-11	316	24	,	,	PUNCT
gsrj-11	316	25	...	...	PUNCT
gsrj-11	316	26	&	&	CCONJ
gsrj-11	316	27	pazdur	pazdur	PROPN
gsrj-11	316	28	,	,	PUNCT
gsrj-11	316	29	r.	r.	PROPN
gsrj-11	316	30	(	(	PUNCT
gsrj-11	316	31	2017	2017	NUM
gsrj-11	316	32	)	)	PUNCT
gsrj-11	316	33	.	.	PUNCT
gsrj-11	317	1	fda	fda	PROPN
gsrj-11	317	2	approval	approval	PROPN
gsrj-11	317	3	summary	summary	NOUN
gsrj-11	317	4	:	:	PUNCT
gsrj-11	317	5	sonidegib	sonidegib	NOUN
gsrj-11	317	6	for	for	ADP
gsrj-11	317	7	locally	locally	ADV
gsrj-11	317	8	advanced	advance	VERB
gsrj-11	317	9	basal	basal	NOUN
gsrj-11	317	10	cell	cell	NOUN
gsrj-11	317	11	carcinoma	carcinoma	NOUN
gsrj-11	317	12	.	.	PUNCT
gsrj-11	318	1	clinical	clinical	ADJ
gsrj-11	318	2	cancer	cancer	NOUN
gsrj-11	318	3	research	research	NOUN
gsrj-11	318	4	,	,	PUNCT
gsrj-11	318	5	23(10	23(10	NUM
gsrj-11	318	6	)	)	PUNCT
gsrj-11	318	7	,	,	PUNCT
gsrj-11	318	8	2377	2377	NUM
gsrj-11	318	9	-	-	SYM
gsrj-11	318	10	2381	2381	NUM
gsrj-11	318	11	.	.	PUNCT
gsrj-11	319	1	https://doi.org/10.1158/1078-0432.ccr-162051	https://doi.org/10.1158/1078-0432.ccr-162051	PROPN
gsrj-11	319	2	.	.	PROPN
gsrj-11	319	3	2	2	NUM
gsrj-11	319	4	.	.	PUNCT
gsrj-11	320	1	danial	danial	PROPN
gsrj-11	320	2	,	,	PUNCT
gsrj-11	320	3	c.	c.	NOUN
gsrj-11	320	4	,	,	PUNCT
gsrj-11	320	5	sarin	sarin	NOUN
gsrj-11	320	6	,	,	PUNCT
gsrj-11	320	7	k.	k.	PROPN
gsrj-11	320	8	y.	y.	PROPN
gsrj-11	320	9	,	,	PUNCT
gsrj-11	320	10	oro	oro	PROPN
gsrj-11	320	11	,	,	PUNCT
gsrj-11	320	12	a.	a.	PROPN
gsrj-11	320	13	e.	e.	PROPN
gsrj-11	320	14	,	,	PUNCT
gsrj-11	320	15	&	&	CCONJ
gsrj-11	320	16	chang	chang	PROPN
gsrj-11	320	17	,	,	PUNCT
gsrj-11	320	18	a.	a.	PROPN
gsrj-11	320	19	l.	l.	PROPN
gsrj-11	320	20	s.	s.	PROPN
gsrj-11	320	21	(	(	PUNCT
gsrj-11	320	22	2016	2016	NUM
gsrj-11	320	23	)	)	PUNCT
gsrj-11	320	24	.	.	PUNCT
gsrj-11	321	1	an	an	DET
gsrj-11	321	2	investigator	investigator	NOUN
gsrj-11	321	3	-	-	PUNCT
gsrj-11	321	4	initiated	initiate	VERB
gsrj-11	321	5	open	open	ADJ
gsrj-11	321	6	-	-	PUNCT
gsrj-11	321	7	label	label	NOUN
gsrj-11	321	8	trial	trial	NOUN
gsrj-11	321	9	of	of	ADP
gsrj-11	321	10	sonidegib	sonidegib	NOUN
gsrj-11	321	11	in	in	ADP
gsrj-11	321	12	advanced	advanced	ADJ
gsrj-11	321	13	basal	basal	NOUN
gsrj-11	321	14	cell	cell	NOUN
gsrj-11	321	15	carcinoma	carcinoma	NOUN
gsrj-11	321	16	patients	patient	NOUN
gsrj-11	321	17	resistant	resistant	ADJ
gsrj-11	321	18	to	to	ADP
gsrj-11	321	19	vismodegib	vismodegib	NOUN
gsrj-11	321	20	.	.	PUNCT
gsrj-11	322	1	clinical	clinical	ADJ
gsrj-11	322	2	cancer	cancer	NOUN
gsrj-11	322	3	research	research	NOUN
gsrj-11	322	4	,	,	PUNCT
gsrj-11	322	5	22(6	22(6	NUM
gsrj-11	322	6	)	)	PUNCT
gsrj-11	322	7	,	,	PUNCT
gsrj-11	322	8	1325	1325	NUM
gsrj-11	322	9	-	-	SYM
gsrj-11	322	10	1329	1329	NUM
gsrj-11	322	11	.	.	PUNCT
gsrj-11	323	1	https://doi.org/10.1158/10780432.ccr-15-1588	https://doi.org/10.1158/10780432.ccr-15-1588	PROPN
gsrj-11	323	2	.	.	PROPN
gsrj-11	323	3	3	3	NUM
gsrj-11	323	4	.	.	PUNCT
gsrj-11	324	1	liu	liu	PROPN
gsrj-11	324	2	,	,	PUNCT
gsrj-11	324	3	g.	g.	PROPN
gsrj-11	324	4	,	,	PUNCT
gsrj-11	324	5	xue	xue	PROPN
gsrj-11	324	6	,	,	PUNCT
gsrj-11	324	7	d.	d.	PROPN
gsrj-11	324	8	,	,	PUNCT
gsrj-11	324	9	yang	yang	PROPN
gsrj-11	324	10	,	,	PUNCT
gsrj-11	324	11	j.	j.	PROPN
gsrj-11	324	12	,	,	PUNCT
gsrj-11	324	13	wang	wang	PROPN
gsrj-11	324	14	,	,	PUNCT
gsrj-11	324	15	j.	j.	PROPN
gsrj-11	324	16	,	,	PUNCT
gsrj-11	324	17	liu	liu	PROPN
gsrj-11	324	18	,	,	PUNCT
gsrj-11	324	19	x.	x.	PROPN
gsrj-11	324	20	,	,	PUNCT
gsrj-11	324	21	huang	huang	PROPN
gsrj-11	324	22	,	,	PUNCT
gsrj-11	324	23	w.	w.	PROPN
gsrj-11	324	24	,	,	PUNCT
gsrj-11	324	25	...	...	PUNCT
gsrj-11	324	26	&	&	CCONJ
gsrj-11	324	27	zhang	zhang	PROPN
gsrj-11	324	28	,	,	PUNCT
gsrj-11	324	29	a.	a.	PROPN
gsrj-11	324	30	(	(	PUNCT
gsrj-11	324	31	2016	2016	NUM
gsrj-11	324	32	)	)	PUNCT
gsrj-11	324	33	.	.	PUNCT
gsrj-11	325	1	design	design	NOUN
gsrj-11	325	2	,	,	PUNCT
gsrj-11	325	3	synthesis	synthesis	NOUN
gsrj-11	325	4	,	,	PUNCT
gsrj-11	325	5	and	and	CCONJ
gsrj-11	325	6	pharmacological	pharmacological	ADJ
gsrj-11	325	7	evaluation	evaluation	NOUN
gsrj-11	325	8	of	of	ADP
gsrj-11	325	9	2-(2	2-(2	PROPN
gsrj-11	325	10	,	,	PUNCT
gsrj-11	325	11	5	5	NUM
gsrj-11	325	12	-	-	SYM
gsrj-11	325	13	dimethyl-5	dimethyl-5	NUM
gsrj-11	325	14	,	,	PUNCT
gsrj-11	325	15	6	6	NUM
gsrj-11	325	16	,	,	PUNCT
gsrj-11	325	17	7	7	NUM
gsrj-11	325	18	,	,	PUNCT
gsrj-11	325	19	8tetrahydroquinolin-8	8tetrahydroquinolin-8	NUM
gsrj-11	325	20	-	-	PUNCT
gsrj-11	325	21	yl)-n	yl)-n	ADJ
gsrj-11	325	22	-	-	PUNCT
gsrj-11	325	23	aryl	aryl	NOUN
gsrj-11	325	24	propanamides	propanamide	NOUN
gsrj-11	325	25	as	as	SCONJ
gsrj-11	325	26	novel	novel	NOUN
gsrj-11	325	27	smoothened	smoothen	VERB
gsrj-11	325	28	(	(	PUNCT
gsrj-11	325	29	smo	smo	PROPN
gsrj-11	325	30	)	)	PUNCT
gsrj-11	325	31	antagonists	antagonist	NOUN
gsrj-11	325	32	.	.	PUNCT
gsrj-11	326	1	journal	journal	NOUN
gsrj-11	326	2	of	of	ADP
gsrj-11	326	3	medicinal	medicinal	ADJ
gsrj-11	326	4	chemistry	chemistry	NOUN
gsrj-11	326	5	,	,	PUNCT
gsrj-11	326	6	59(24	59(24	NUM
gsrj-11	326	7	)	)	PUNCT
gsrj-11	326	8	,	,	PUNCT
gsrj-11	326	9	11050	11050	NUM
gsrj-11	326	10	-	-	SYM
gsrj-11	326	11	11068	11068	NUM
gsrj-11	326	12	.	.	PUNCT
gsrj-11	327	1	https://doi.org/10.1021/acs.jmedchem.6b0124	https://doi.org/10.1021/acs.jmedchem.6b0124	VERB
gsrj-11	328	1	7	7	NUM
gsrj-11	328	2	.	.	PROPN
gsrj-11	328	3	31	31	NUM
gsrj-11	328	4	.	.	PUNCT
gsrj-11	329	1	peukert	peukert	NOUN
gsrj-11	329	2	,	,	PUNCT
gsrj-11	329	3	s.	s.	PROPN
gsrj-11	329	4	,	,	PUNCT
gsrj-11	329	5	&	&	CCONJ
gsrj-11	329	6	miller!moslin	miller!moslin	PROPN
gsrj-11	329	7	,	,	PUNCT
gsrj-11	329	8	k.	k.	PROPN
gsrj-11	329	9	(	(	PUNCT
gsrj-11	329	10	2010	2010	NUM
gsrj-11	329	11	)	)	PUNCT
gsrj-11	329	12	.	.	PUNCT
gsrj-11	330	1	small!molecule	small!molecule	ADJ
gsrj-11	330	2	inhibitors	inhibitor	NOUN
gsrj-11	330	3	of	of	ADP
gsrj-11	330	4	the	the	DET
gsrj-11	330	5	hedgehog	hedgehog	NOUN
gsrj-11	330	6	signaling	signal	VERB
gsrj-11	330	7	pathway	pathway	NOUN
gsrj-11	330	8	as	as	ADP
gsrj-11	330	9	cancer	cancer	NOUN
gsrj-11	330	10	therapeutics	therapeutic	NOUN
gsrj-11	330	11	.	.	PUNCT
gsrj-11	331	1	chemmedchem	chemmedchem	PROPN
gsrj-11	331	2	:	:	PUNCT
gsrj-11	332	1	chemistry	chemistry	NOUN
gsrj-11	332	2	enabling	enable	VERB
gsrj-11	332	3	drug	drug	NOUN
gsrj-11	332	4	discovery	discovery	NOUN
gsrj-11	332	5	,	,	PUNCT
gsrj-11	332	6	5(4	5(4	NUM
gsrj-11	332	7	)	)	PUNCT
gsrj-11	332	8	,	,	PUNCT
gsrj-11	332	9	500	500	NUM
gsrj-11	332	10	-	-	SYM
gsrj-11	332	11	512	512	NUM
gsrj-11	332	12	.	.	PUNCT
gsrj-11	333	1	https://doi.org/	https://doi.org/	NOUN
gsrj-11	333	2	10.1002	10.1002	NUM
gsrj-11	333	3	/	/	SYM
gsrj-11	333	4	cmdc.201000011	cmdc.201000011	PROPN
gsrj-11	333	5	32	32	NUM
gsrj-11	333	6	.	.	PUNCT
gsrj-11	334	1	iovine	iovine	PROPN
gsrj-11	334	2	,	,	PUNCT
gsrj-11	334	3	v.	v.	PROPN
gsrj-11	334	4	,	,	PUNCT
gsrj-11	334	5	mori	mori	PROPN
gsrj-11	334	6	,	,	PUNCT
gsrj-11	334	7	m.	m.	NOUN
gsrj-11	334	8	,	,	PUNCT
gsrj-11	334	9	calcaterra	calcaterra	PROPN
gsrj-11	334	10	,	,	PUNCT
gsrj-11	334	11	a.	a.	NOUN
gsrj-11	334	12	,	,	PUNCT
gsrj-11	334	13	berardozzi	berardozzi	NOUN
gsrj-11	334	14	,	,	PUNCT
gsrj-11	334	15	s.	s.	PROPN
gsrj-11	334	16	,	,	PUNCT
gsrj-11	334	17	&	&	CCONJ
gsrj-11	334	18	botta	botta	PROPN
gsrj-11	334	19	,	,	PUNCT
gsrj-11	334	20	b.	b.	PROPN
gsrj-11	334	21	(	(	PUNCT
gsrj-11	334	22	2016	2016	NUM
gsrj-11	334	23	)	)	PUNCT
gsrj-11	334	24	.	.	PUNCT
gsrj-11	335	1	one	one	NUM
gsrj-11	335	2	hundred	hundred	NUM
gsrj-11	335	3	faces	face	NOUN
gsrj-11	335	4	of	of	ADP
gsrj-11	335	5	cyclopamine	cyclopamine	NOUN
gsrj-11	335	6	.	.	PUNCT
gsrj-11	336	1	current	current	ADJ
gsrj-11	336	2	pharmaceutical	pharmaceutical	ADJ
gsrj-11	336	3	design	design	NOUN
gsrj-11	336	4	,	,	PUNCT
gsrj-11	336	5	22(12	22(12	NUM
gsrj-11	336	6	)	)	PUNCT
gsrj-11	336	7	,	,	PUNCT
gsrj-11	336	8	1658	1658	NUM
gsrj-11	336	9	-	-	SYM
gsrj-11	336	10	1681	1681	NUM
gsrj-11	336	11	.	.	PUNCT
gsrj-11	337	1	https://doi.org/	https://doi.org/	VERB
gsrj-11	337	2	10.2174/1381612822666160112130157	10.2174/1381612822666160112130157	NUM
gsrj-11	337	3	.	.	PUNCT
gsrj-11	338	1	97	97	NUM
gsrj-11	338	2	georgetown	georgetown	PROPN
gsrj-11	338	3	scientific	scientific	PROPN
gsrj-11	338	4	research	research	NOUN
gsrj-11	338	5	journal	journal	PROPN
gsrj-11	338	6	https://doi.org/10.48091/atjh8708	https://doi.org/10.48091/atjh8708	PROPN
gsrj-11	338	7	33	33	NUM
gsrj-11	338	8	.	.	PUNCT
gsrj-11	339	1	kimura	kimura	PROPN
gsrj-11	339	2	,	,	PUNCT
gsrj-11	339	3	h.	h.	PROPN
gsrj-11	339	4	,	,	PUNCT
gsrj-11	339	5	ng	ng	PROPN
gsrj-11	339	6	,	,	PUNCT
gsrj-11	339	7	j.	j.	PROPN
gsrj-11	339	8	m.	m.	PROPN
gsrj-11	339	9	,	,	PUNCT
gsrj-11	339	10	&	&	CCONJ
gsrj-11	339	11	curran	curran	PROPN
gsrj-11	339	12	,	,	PUNCT
gsrj-11	339	13	t.	t.	PROPN
gsrj-11	339	14	(	(	PUNCT
gsrj-11	339	15	2008	2008	NUM
gsrj-11	339	16	)	)	PUNCT
gsrj-11	339	17	.	.	PUNCT
gsrj-11	340	1	transient	transient	ADJ
gsrj-11	340	2	inhibition	inhibition	NOUN
gsrj-11	340	3	of	of	ADP
gsrj-11	340	4	the	the	DET
gsrj-11	340	5	hedgehog	hedgehog	ADJ
gsrj-11	340	6	pathway	pathway	NOUN
gsrj-11	340	7	in	in	ADP
gsrj-11	340	8	young	young	ADJ
gsrj-11	340	9	mice	mouse	NOUN
gsrj-11	340	10	causes	cause	VERB
gsrj-11	340	11	permanent	permanent	ADJ
gsrj-11	340	12	defects	defect	NOUN
gsrj-11	340	13	in	in	ADP
gsrj-11	340	14	bone	bone	NOUN
gsrj-11	340	15	structure	structure	NOUN
gsrj-11	340	16	.	.	PUNCT
gsrj-11	341	1	cancer	cancer	NOUN
gsrj-11	341	2	cell	cell	NOUN
gsrj-11	341	3	,	,	PUNCT
gsrj-11	341	4	13(3	13(3	NUM
gsrj-11	341	5	)	)	PUNCT
gsrj-11	341	6	,	,	PUNCT
gsrj-11	341	7	249	249	NUM
gsrj-11	341	8	-	-	SYM
gsrj-11	341	9	260	260	NUM
gsrj-11	341	10	.	.	PUNCT
gsrj-11	342	1	https://doi.org/10.1016/j.ccr.2008.01.027	https://doi.org/10.1016/j.ccr.2008.01.027	X
gsrj-11	342	2	.	.	PUNCT
gsrj-11	343	1	34	34	NUM
gsrj-11	343	2	.	.	PUNCT
gsrj-11	343	3	romer	romer	PROPN
gsrj-11	343	4	,	,	PUNCT
gsrj-11	343	5	j.	j.	PROPN
gsrj-11	343	6	t.	t.	PROPN
gsrj-11	343	7	,	,	PUNCT
gsrj-11	343	8	kimura	kimura	PROPN
gsrj-11	343	9	,	,	PUNCT
gsrj-11	343	10	h.	h.	PROPN
gsrj-11	343	11	,	,	PUNCT
gsrj-11	343	12	magdaleno	magdaleno	PROPN
gsrj-11	343	13	,	,	PUNCT
gsrj-11	343	14	s.	s.	PROPN
gsrj-11	343	15	,	,	PUNCT
gsrj-11	343	16	sasai	sasai	PROPN
gsrj-11	343	17	,	,	PUNCT
gsrj-11	343	18	k.	k.	PROPN
gsrj-11	343	19	,	,	PUNCT
gsrj-11	343	20	fuller	full	ADJ
gsrj-11	343	21	,	,	PUNCT
gsrj-11	343	22	c.	c.	NOUN
gsrj-11	343	23	,	,	PUNCT
gsrj-11	343	24	baines	baine	NOUN
gsrj-11	343	25	,	,	PUNCT
gsrj-11	343	26	h.	h.	PROPN
gsrj-11	343	27	,	,	PUNCT
gsrj-11	343	28	...	...	PUNCT
gsrj-11	343	29	&	&	CCONJ
gsrj-11	343	30	curran	curran	PROPN
gsrj-11	343	31	,	,	PUNCT
gsrj-11	343	32	t.	t.	PROPN
gsrj-11	343	33	(	(	PUNCT
gsrj-11	343	34	2004	2004	NUM
gsrj-11	343	35	)	)	PUNCT
gsrj-11	343	36	.	.	PUNCT
gsrj-11	344	1	suppression	suppression	NOUN
gsrj-11	344	2	of	of	ADP
gsrj-11	344	3	the	the	DET
gsrj-11	344	4	shh	shh	PROPN
gsrj-11	344	5	pathway	pathway	NOUN
gsrj-11	344	6	using	use	VERB
gsrj-11	344	7	a	a	DET
gsrj-11	344	8	small	small	ADJ
gsrj-11	344	9	molecule	molecule	NOUN
gsrj-11	344	10	inhibitor	inhibitor	NOUN
gsrj-11	344	11	eliminates	eliminate	VERB
gsrj-11	344	12	medulloblastoma	medulloblastoma	NOUN
gsrj-11	344	13	in	in	ADP
gsrj-11	344	14	ptc1+/	ptc1+/	NOUN
gsrj-11	344	15	!	!	PUNCT
gsrj-11	344	16	p53!/	p53!/	NUM
gsrj-11	344	17	!	!	PUNCT
gsrj-11	345	1	mice	mouse	NOUN
gsrj-11	345	2	.	.	PUNCT
gsrj-11	346	1	cancer	cancer	NOUN
gsrj-11	346	2	cell	cell	NOUN
gsrj-11	346	3	,	,	PUNCT
gsrj-11	346	4	6(3	6(3	NUM
gsrj-11	346	5	)	)	PUNCT
gsrj-11	346	6	,	,	PUNCT
gsrj-11	346	7	229	229	NUM
gsrj-11	346	8	-	-	SYM
gsrj-11	346	9	240	240	NUM
gsrj-11	346	10	.	.	PUNCT
gsrj-11	347	1	https://doi.org/10.1016/j.ccr.2004.08.019	https://doi.org/10.1016/j.ccr.2004.08.019	X
gsrj-11	347	2	.	.	PUNCT
gsrj-11	348	1	35	35	NUM
gsrj-11	348	2	.	.	X
gsrj-11	349	1	agyeman	agyeman	PROPN
gsrj-11	349	2	,	,	PUNCT
gsrj-11	349	3	a.	a.	PROPN
gsrj-11	349	4	,	,	PUNCT
gsrj-11	349	5	jha	jha	PROPN
gsrj-11	349	6	,	,	PUNCT
gsrj-11	349	7	b.	b.	PROPN
gsrj-11	349	8	k.	k.	PROPN
gsrj-11	349	9	,	,	PUNCT
gsrj-11	349	10	mazumdar	mazumdar	NOUN
gsrj-11	349	11	,	,	PUNCT
gsrj-11	349	12	t.	t.	PROPN
gsrj-11	349	13	,	,	PUNCT
gsrj-11	349	14	&	&	CCONJ
gsrj-11	349	15	houghton	houghton	PROPN
gsrj-11	349	16	,	,	PUNCT
gsrj-11	349	17	j.	j.	PROPN
gsrj-11	349	18	a.	a.	PROPN
gsrj-11	349	19	(	(	PUNCT
gsrj-11	349	20	2014	2014	NUM
gsrj-11	349	21	)	)	PUNCT
gsrj-11	349	22	.	.	PUNCT
gsrj-11	350	1	mode	mode	NOUN
gsrj-11	350	2	and	and	CCONJ
gsrj-11	350	3	specificity	specificity	NOUN
gsrj-11	350	4	of	of	ADP
gsrj-11	350	5	binding	bind	VERB
gsrj-11	350	6	of	of	ADP
gsrj-11	350	7	the	the	DET
gsrj-11	350	8	small	small	ADJ
gsrj-11	350	9	molecule	molecule	NOUN
gsrj-11	350	10	gant61	gant61	NOUN
gsrj-11	350	11	to	to	ADP
gsrj-11	350	12	gli	gli	NOUN
gsrj-11	350	13	determines	determine	NOUN
gsrj-11	350	14	inhibition	inhibition	NOUN
gsrj-11	350	15	of	of	ADP
gsrj-11	350	16	gli	gli	NOUN
gsrj-11	350	17	-	-	ADJ
gsrj-11	350	18	dna	dna	ADJ
gsrj-11	350	19	binding	binding	NOUN
gsrj-11	350	20	.	.	PUNCT
gsrj-11	351	1	oncotarget	oncotarget	NOUN
gsrj-11	351	2	,	,	PUNCT
gsrj-11	351	3	5(12	5(12	NUM
gsrj-11	351	4	)	)	PUNCT
gsrj-11	351	5	,	,	PUNCT
gsrj-11	351	6	4492	4492	NUM
gsrj-11	351	7	.	.	PUNCT
gsrj-11	352	1	https://doi.org/10.18632/oncotarget.2046	https://doi.org/10.18632/oncotarget.2046	PROPN
gsrj-11	352	2	36	36	NUM
gsrj-11	352	3	.	.	PUNCT
gsrj-11	353	1	wang	wang	PROPN
gsrj-11	353	2	,	,	PUNCT
gsrj-11	353	3	f.	f.	PROPN
gsrj-11	353	4	,	,	PUNCT
gsrj-11	353	5	jiang	jiang	PROPN
gsrj-11	353	6	,	,	PUNCT
gsrj-11	353	7	h.	h.	PROPN
gsrj-11	353	8	,	,	PUNCT
gsrj-11	353	9	deng	deng	PROPN
gsrj-11	353	10	,	,	PUNCT
gsrj-11	353	11	y.	y.	PROPN
gsrj-11	353	12	,	,	PUNCT
gsrj-11	353	13	yu	yu	PROPN
gsrj-11	353	14	,	,	PUNCT
gsrj-11	353	15	j.	j.	PROPN
gsrj-11	353	16	,	,	PUNCT
gsrj-11	353	17	zhan	zhan	PROPN
gsrj-11	353	18	,	,	PUNCT
gsrj-11	353	19	m.	m.	NOUN
gsrj-11	353	20	,	,	PUNCT
gsrj-11	353	21	zhao	zhao	PROPN
gsrj-11	353	22	,	,	PUNCT
gsrj-11	353	23	l.	l.	PROPN
gsrj-11	353	24	,	,	PUNCT
gsrj-11	353	25	&	&	CCONJ
gsrj-11	353	26	chen	chen	PROPN
gsrj-11	353	27	,	,	PUNCT
gsrj-11	353	28	y.	y.	PROPN
gsrj-11	353	29	(	(	PUNCT
gsrj-11	353	30	2018	2018	NUM
gsrj-11	353	31	)	)	PUNCT
gsrj-11	353	32	.	.	PUNCT
gsrj-11	354	1	design	design	NOUN
gsrj-11	354	2	,	,	PUNCT
gsrj-11	354	3	synthesis	synthesis	NOUN
gsrj-11	354	4	and	and	CCONJ
gsrj-11	354	5	biological	biological	ADJ
gsrj-11	354	6	evaluation	evaluation	NOUN
gsrj-11	354	7	of	of	ADP
gsrj-11	354	8	deuterated	deuterate	VERB
gsrj-11	354	9	vismodegib	vismodegib	NOUN
gsrj-11	354	10	for	for	ADP
gsrj-11	354	11	improving	improve	VERB
gsrj-11	354	12	pharmacokinetic	pharmacokinetic	ADJ
gsrj-11	354	13	properties	property	NOUN
gsrj-11	354	14	.	.	PUNCT
gsrj-11	355	1	bioorganic	bioorganic	PROPN
gsrj-11	355	2	&	&	CCONJ
gsrj-11	355	3	medicinal	medicinal	ADJ
gsrj-11	355	4	chemistry	chemistry	NOUN
gsrj-11	355	5	letters	letter	NOUN
gsrj-11	355	6	,	,	PUNCT
gsrj-11	355	7	28(14	28(14	NOUN
gsrj-11	355	8	)	)	PUNCT
gsrj-11	355	9	,	,	PUNCT
gsrj-11	355	10	2399	2399	NUM
gsrj-11	355	11	-	-	SYM
gsrj-11	355	12	2402	2402	NUM
gsrj-11	355	13	.	.	PUNCT
gsrj-11	356	1	https://doi.org/10.1016/j.bmcl.2018.06.025	https://doi.org/10.1016/j.bmcl.2018.06.025	PROPN
gsrj-11	356	2	.	.	PROPN
gsrj-11	357	1	3	3	NUM
gsrj-11	357	2	.	.	PUNCT
gsrj-11	357	3	forment	forment	PROPN
gsrj-11	357	4	,	,	PUNCT
gsrj-11	357	5	j.	j.	PROPN
gsrj-11	357	6	v.	v.	PROPN
gsrj-11	357	7	,	,	PUNCT
gsrj-11	357	8	kaidi	kaidi	PROPN
gsrj-11	357	9	,	,	PUNCT
gsrj-11	357	10	a.	a.	NOUN
gsrj-11	357	11	,	,	PUNCT
gsrj-11	357	12	&	&	CCONJ
gsrj-11	357	13	jackson	jackson	PROPN
gsrj-11	357	14	,	,	PUNCT
gsrj-11	357	15	s.	s.	PROPN
gsrj-11	357	16	p.	p.	PROPN
gsrj-11	357	17	(	(	PUNCT
gsrj-11	357	18	2012	2012	NUM
gsrj-11	357	19	)	)	PUNCT
gsrj-11	357	20	.	.	PUNCT
gsrj-11	358	1	chromothripsis	chromothripsis	NOUN
gsrj-11	358	2	and	and	CCONJ
gsrj-11	358	3	cancer	cancer	NOUN
gsrj-11	358	4	:	:	PUNCT
gsrj-11	358	5	causes	cause	NOUN
gsrj-11	358	6	and	and	CCONJ
gsrj-11	358	7	consequences	consequence	NOUN
gsrj-11	358	8	of	of	ADP
gsrj-11	358	9	chromosome	chromosome	NOUN
gsrj-11	358	10	shattering	shattering	NOUN
gsrj-11	358	11	.	.	PUNCT
gsrj-11	359	1	nature	nature	NOUN
gsrj-11	359	2	reviews	review	VERB
gsrj-11	359	3	cancer	cancer	NOUN
gsrj-11	359	4	,	,	PUNCT
gsrj-11	359	5	12(10	12(10	NUM
gsrj-11	359	6	)	)	PUNCT
gsrj-11	359	7	,	,	PUNCT
gsrj-11	359	8	663	663	NUM
gsrj-11	359	9	-	-	SYM
gsrj-11	359	10	670	670	NUM
gsrj-11	359	11	.	.	PUNCT
gsrj-11	360	1	https://doi.org/10.1038/nrc3352	https://doi.org/10.1038/nrc3352	PROPN
gsrj-11	360	2	.	.	PROPN
gsrj-11	360	3	3	3	NUM
gsrj-11	360	4	.	.	PUNCT
gsrj-11	361	1	wetmore	wetmore	PROPN
gsrj-11	361	2	,	,	PUNCT
gsrj-11	361	3	c.	c.	PROPN
gsrj-11	361	4	,	,	PUNCT
gsrj-11	361	5	eberhart	eberhart	PROPN
gsrj-11	361	6	,	,	PUNCT
gsrj-11	361	7	d.	d.	PROPN
gsrj-11	361	8	e.	e.	PROPN
gsrj-11	361	9	,	,	PUNCT
gsrj-11	361	10	&	&	CCONJ
gsrj-11	361	11	curran	curran	PROPN
gsrj-11	361	12	,	,	PUNCT
gsrj-11	361	13	t.	t.	PROPN
gsrj-11	361	14	(	(	PUNCT
gsrj-11	361	15	2001	2001	NUM
gsrj-11	361	16	)	)	PUNCT
gsrj-11	361	17	.	.	PUNCT
gsrj-11	362	1	loss	loss	NOUN
gsrj-11	362	2	of	of	ADP
gsrj-11	362	3	p53	p53	NOUN
gsrj-11	362	4	but	but	CCONJ
gsrj-11	362	5	not	not	PART
gsrj-11	362	6	arf	arf	NOUN
gsrj-11	362	7	accelerates	accelerate	VERB
gsrj-11	362	8	medulloblastoma	medulloblastoma	ADJ
gsrj-11	362	9	in	in	ADP
gsrj-11	362	10	mice	mouse	NOUN
gsrj-11	362	11	heterozygous	heterozygous	ADJ
gsrj-11	362	12	for	for	ADP
gsrj-11	362	13	patched	patch	VERB
gsrj-11	362	14	.	.	PUNCT
gsrj-11	363	1	cancer	cancer	NOUN
gsrj-11	363	2	research	research	PROPN
gsrj-11	363	3	,	,	PUNCT
gsrj-11	363	4	61(2	61(2	NUM
gsrj-11	363	5	)	)	PUNCT
gsrj-11	363	6	,	,	PUNCT
gsrj-11	363	7	513	513	NUM
gsrj-11	363	8	-	-	SYM
gsrj-11	363	9	516	516	NUM
gsrj-11	363	10	.	.	NUM
gsrj-11	363	11	3	3	NUM
gsrj-11	363	12	.	.	PUNCT
gsrj-11	364	1	kim	kim	PROPN
gsrj-11	364	2	,	,	PUNCT
gsrj-11	364	3	j.	j.	PROPN
gsrj-11	364	4	,	,	PUNCT
gsrj-11	364	5	dey	dey	PROPN
gsrj-11	364	6	,	,	PUNCT
gsrj-11	364	7	a.	a.	NOUN
gsrj-11	364	8	,	,	PUNCT
gsrj-11	364	9	malhotra	malhotra	PROPN
gsrj-11	364	10	,	,	PUNCT
gsrj-11	364	11	a.	a.	PROPN
gsrj-11	364	12	,	,	PUNCT
gsrj-11	364	13	liu	liu	PROPN
gsrj-11	364	14	,	,	PUNCT
gsrj-11	364	15	j.	j.	PROPN
gsrj-11	364	16	,	,	PUNCT
gsrj-11	364	17	ahn	ahn	PROPN
gsrj-11	364	18	,	,	PUNCT
gsrj-11	364	19	s.	s.	PROPN
gsrj-11	364	20	i.	i.	PROPN
gsrj-11	364	21	,	,	PUNCT
gsrj-11	364	22	sei	sei	PROPN
gsrj-11	364	23	,	,	PUNCT
gsrj-11	364	24	y.	y.	PROPN
gsrj-11	364	25	j.	j.	PROPN
gsrj-11	364	26	,	,	PUNCT
gsrj-11	364	27	...	...	PUNCT
gsrj-11	364	28	&	&	CCONJ
gsrj-11	364	29	kim	kim	PROPN
gsrj-11	364	30	,	,	PUNCT
gsrj-11	364	31	y.	y.	PROPN
gsrj-11	364	32	(	(	PUNCT
gsrj-11	364	33	2020	2020	NUM
gsrj-11	364	34	)	)	PUNCT
gsrj-11	364	35	.	.	PUNCT
gsrj-11	365	1	engineered	engineer	VERB
gsrj-11	365	2	biomimetic	biomimetic	ADJ
gsrj-11	365	3	nanoparticle	nanoparticle	NOUN
gsrj-11	365	4	for	for	ADP
gsrj-11	365	5	dual	dual	ADJ
gsrj-11	365	6	targeting	targeting	NOUN
gsrj-11	365	7	of	of	ADP
gsrj-11	365	8	the	the	DET
gsrj-11	365	9	cancer	cancer	NOUN
gsrj-11	365	10	stem	stem	NOUN
gsrj-11	365	11	-	-	PUNCT
gsrj-11	365	12	like	like	ADJ
gsrj-11	365	13	cell	cell	NOUN
gsrj-11	365	14	population	population	NOUN
gsrj-11	365	15	in	in	ADP
gsrj-11	365	16	sonic	sonic	ADJ
gsrj-11	365	17	hedgehog	hedgehog	ADJ
gsrj-11	365	18	medulloblastoma	medulloblastoma	NOUN
gsrj-11	365	19	.	.	PUNCT
gsrj-11	366	1	proceedings	proceeding	NOUN
gsrj-11	366	2	of	of	ADP
gsrj-11	366	3	the	the	DET
gsrj-11	366	4	national	national	PROPN
gsrj-11	366	5	academy	academy	PROPN
gsrj-11	366	6	of	of	ADP
gsrj-11	366	7	sciences	sciences	PROPN
gsrj-11	366	8	,	,	PUNCT
gsrj-11	366	9	117(39	117(39	NUM
gsrj-11	366	10	)	)	PUNCT
gsrj-11	366	11	,	,	PUNCT
gsrj-11	366	12	24205	24205	NUM
gsrj-11	366	13	-	-	SYM
gsrj-11	366	14	24212	24212	NUM
gsrj-11	366	15	.	.	PUNCT
gsrj-11	367	1	https://doi.org/10.1073/pnas.1911229117	https://doi.org/10.1073/pnas.1911229117	NOUN
gsrj-11	367	2	98	98	NUM
gsrj-11	367	3	biological	biological	ADJ
gsrj-11	367	4	and	and	CCONJ
gsrj-11	367	5	physical	physical	ADJ
gsrj-11	367	6	interactions	interaction	NOUN
gsrj-11	367	7	at	at	ADP
gsrj-11	367	8	local	local	ADJ
gsrj-11	367	9	ocean	ocean	NOUN
gsrj-11	367	10	scales	scale	NOUN
gsrj-11	367	11	:	:	PUNCT
gsrj-11	367	12	coupled	couple	VERB
gsrj-11	367	13	systems	system	NOUN
gsrj-11	367	14	determinants	determinant	NOUN
gsrj-11	367	15	of	of	ADP
gsrj-11	367	16	hepatocellular	hepatocellular	ADJ
gsrj-11	367	17	carcinoma	carcinoma	NOUN
gsrj-11	367	18	in	in	ADP
gsrj-11	367	19	the	the	DET
gsrj-11	367	20	united	united	PROPN
gsrj-11	367	21	states	states	PROPN
gsrj-11	367	22	:	:	PUNCT
gsrj-11	367	23	differences	difference	NOUN
gsrj-11	367	24	in	in	ADP
gsrj-11	367	25	risk	risk	NOUN
gsrj-11	367	26	factor	factor	NOUN
gsrj-11	367	27	and	and	CCONJ
gsrj-11	367	28	geneti	geneti	VERB
gsrj-11	367	29	the	the	DET
gsrj-11	367	30	preventative	preventative	ADJ
gsrj-11	367	31	and	and	CCONJ
gsrj-11	367	32	healing	healing	NOUN
gsrj-11	367	33	properties	property	NOUN
gsrj-11	367	34	of	of	ADP
gsrj-11	367	35	performing	perform	VERB
gsrj-11	367	36	arts	art	NOUN
gsrj-11	367	37	in	in	ADP
gsrj-11	367	38	female	female	ADJ
gsrj-11	367	39	genital	genital	ADJ
gsrj-11	367	40	mutilation	mutilation	NOUN
gsrj-11	367	41	policy	policy	NOUN
gsrj-11	367	42	brief	brief	NOUN
gsrj-11	367	43	:	:	PUNCT
gsrj-11	367	44	comparison	comparison	NOUN
gsrj-11	367	45	and	and	CCONJ
gsrj-11	367	46	recommendations	recommendation	NOUN
gsrj-11	367	47	for	for	ADP
gsrj-11	367	48	state	state	NOUN
gsrj-11	367	49	covid-19	covid-19	PROPN
gsrj-11	367	50	responses	response	NOUN
gsrj-11	367	51	of	of	ADP
gsrj-11	367	52	new	new	PROPN
gsrj-11	367	53	mexico	mexico	PROPN
gsrj-11	367	54	and	and	CCONJ
gsrj-11	367	55	utah	utah	PROPN
gsrj-11	367	56	interplay	interplay	NOUN
gsrj-11	367	57	of	of	ADP
gsrj-11	367	58	nicotine	nicotine	NOUN
gsrj-11	367	59	and	and	CCONJ
gsrj-11	367	60	social	social	ADJ
gsrj-11	367	61	stress	stress	NOUN
gsrj-11	367	62	mediate	mediate	VERB
gsrj-11	367	63	dopaminergic	dopaminergic	ADJ
gsrj-11	367	64	neuron	neuron	NOUN
gsrj-11	367	65	firing	fire	VERB
gsrj-11	367	66	in	in	ADP
gsrj-11	367	67	the	the	DET
gsrj-11	367	68	ventral	ventral	ADJ
gsrj-11	367	69	tegmental	tegmental	NOUN
gsrj-11	367	70	evaluating	evaluate	VERB
gsrj-11	367	71	the	the	DET
gsrj-11	367	72	efficacy	efficacy	NOUN
gsrj-11	367	73	of	of	ADP
gsrj-11	367	74	targeted	target	VERB
gsrj-11	367	75	inhibitor	inhibitor	NOUN
gsrj-11	367	76	therapeutics	therapeutic	NOUN
gsrj-11	367	77	for	for	ADP
gsrj-11	367	78	sonic	sonic	ADJ
gsrj-11	367	79	hedgehog	hedgehog	ADJ
gsrj-11	367	80	medulloblastoma	medulloblastoma	NOUN
gsrj-11	367	81	:	:	PUNCT
gsrj-11	367	82	signi	signi	ADJ
gsrj-11	367	83	refractory	refractory	NOUN
gsrj-11	367	84	epilepsy	epilepsy	NOUN
gsrj-11	367	85	:	:	PUNCT
gsrj-11	367	86	mechanisms	mechanism	NOUN
gsrj-11	367	87	of	of	ADP
gsrj-11	367	88	pharmacoresistance	pharmacoresistance	ADJ
gsrj-11	367	89	table	table	NOUN
gsrj-11	367	90	of	of	ADP
gsrj-11	367	91	contents	content	NOUN